

Summary Tables by Market Group, Health Area, Country and Product

POPULATION SERVICES INTERNATIONAL
CYPs, Cases, and Deaths by Market Group
1/2019 - 12/2019

	<u>New HIV Infections</u>	<u>STI Deaths</u>	<u>PWID Deaths</u>	<u>TB Deaths</u>	<u>CYP*</u>	<u>Maternal Deaths</u>	<u>Unintended Pregnancies</u>	<u>Malaria Deaths</u>	<u>Diarrhea Deaths</u>	<u>Pneumonia Deaths</u>	<u>Cervical Cancer Death</u>	<u>Sum of All Deaths</u>
Acceleration Market Group	41,942	-	-	3,129	3,382,778	4,670	1,501,143	1,085	564	123	3	26,663
Anglophone Africa Market Group	95,551	23	-	5	4,012,517	4,161	1,661,065	803	144	-	55	40,258
Franco/Lusophone Africa Market Gro	10,209	4	-	-	1,811,247	2,577	726,890	8,990	456	-	-	27,282
Latin America & Asia Market Group	4,244	-	48	2,195	4,186,405	1,947	1,591,750	3	78	-	-	14,232
Foundation Market Group	3,394	2	-	677	1,600,475	1,878	625,204	61,220	239	881	2	77,362
Social Enterprise	18,683	-	-	-	1,233,886	1,234	431,636	-	313	-	-	3,788
Total	174,022	30	48	6,006	16,227,308	16,468	6,537,688	72,101	1,795	1,004	60	189,585

* Using USAID CYP conversion factors

POPULATION SERVICES INTERNATIONAL
Monthly DALY Report by Market Group
Period: 12
Year: 2019

	DALY 12/2019	YTD DALY 2018	YTD DALY 2019	Percentage Change	Percentage of Category	Annual DALY Target	Percentage of Target Achieved
GRAND TOTAL	4,188,251	26,150,430	21,995,933	(16%)		24,036,878	92%
Acceleration Market Group	361,126	4,677,485	3,642,740	(22%)	100%	4,096,068	89%
Modern Contraception	147,656	1,354,750	1,601,669	18%	44%	1,305,027	123%
HIV & STIs	189,765	2,922,876	1,720,293	(41)%	47%	2,388,411	72%
Malaria	6,406	130,182	76,803	(41)%	2%	116,230	66%
Maternal, Newborn, and Child H	8,885	40,594	54,374	34%	1%	62,513	87%
Non-communicable diseases	2	70	73	3%	0%	73	100%
Nutrition	-	249	-	(100)%	0%	-	0%
Safe Abortion	1,918	131,766	93,163	(29)%	3%	119,871	78%
Tuberculosis	6,292	88,122	84,817	(4)%	2%	94,197	90%
WASH	202	8,877	11,548	30%	0%	9,747	118%
Anglophone Africa Market Group	508,500	8,737,057	7,098,951	(19%)	100%	6,838,586	104%
Modern Contraception	298,541	3,574,876	3,190,057	(11)%	45%	3,168,819	101%
HIV & STIs	206,969	4,895,700	3,817,645	(22)%	54%	3,592,960	106%
Malaria	-	228,768	56,590	(75)%	1%	35,727	158%
Maternal, Newborn, and Child H	116	6,418	2,171	(66)%	0%	4,132	53%
Non-communicable diseases	7	306	1,457	376%	0%	264	552%
Safe Abortion	2,326	22,753	23,148	2%	0%	25,618	90%
Tuberculosis	24	300	284	(5)%	0%	626	45%
WASH	516	7,937	7,599	(4)%	0%	10,440	73%
Franco/Lusophone Africa Market Group	715,759	2,498,201	2,625,497	5%	100%	2,722,253	96%
Modern Contraception	136,838	1,231,563	1,411,435	15%	54%	1,242,892	114%
HIV & STIs	56,098	461,736	413,494	(10)%	16%	543,046	76%
Malaria	519,356	719,056	741,889	3%	28%	868,795	85%
Maternal, Newborn, and Child H	178	58,996	19,576	(67)%	1%	37,043	53%
Non-communicable diseases	-	6	2	(67)%	0%	-	0%
Nutrition	-	-	-	0%	0%	-	0%
Safe Abortion	2,137	18,987	24,828	31%	1%	18,447	135%
WASH	1,152	7,857	14,274	82%	1%	12,029	119%
Latin America & Asia Market Group	92,055	1,215,801	1,278,619	5%	100%	1,133,232	113%
Modern Contraception	65,432	803,569	906,992	13%	71%	873,063	104%
HIV & STIs	11,285	232,104	195,435	(16)%	15%	214,953	91%
Malaria	20	2,386	243	(90)%	0%	424	57%
Maternal, Newborn, and Child H	176	5,860	6,929	18%	1%	1,827	379%
Non-communicable diseases	-	-	-	0%	0%	-	0%
Nutrition	6	-	25	0%	0%	-	0%
Safe Abortion	4,660	52,617	51,016	(3)%	4%	42,896	119%
Tuberculosis	10,475	119,106	117,936	(1)%	9%	38	310,703%
WASH	-	160	43	(73)%	0%	30	142%
Foundation Market Group	2,386,388	7,586,885	6,338,408	(16%)	100%	7,584,880	84%
Modern Contraception	101,601	863,324	1,033,128	20%	16%	949,254	109%
HIV & STIs	36,955	212,797	175,730	(17)%	3%	146,629	120%
Malaria	2,229,425	5,638,477	4,864,942	(14)%	77%	6,242,139	78%
Maternal, Newborn, and Child H	13,876	673,037	123,714	(82)%	2%	92,588	134%
Non-communicable diseases	4	61	48	(21)%	0%	210	23%
Nutrition	3,085	104,340	86,897	(17)%	1%	103,209	84%
Safe Abortion	1,438	11,120	13,857	25%	0%	14,822	93%
Tuberculosis	-	76,671	38,021	(50)%	1%	34,091	112%
WASH	4	7,057	2,072	(71)%	0%	1,936	107%

POPULATION SERVICES INTERNATIONAL
Monthly DALY Report by Market Group
Period: 12
Year: 2019

	DALY 12/2019	YTD DALY 2018	YTD DALY 2019	Percentage Change	Percentage of Category	Annual DALY Target	Percentage of Target Achieved
Social Enterprise	124,424	1,433,239	1,011,719	(29%)	100%	1,661,860	61%
Modern Contraception	17,849	340,352	208,723	(39)%	21%	376,521	55%
HIV & STIs	103,293	963,709	722,562	(25)%	71%	1,103,405	65%
Maternal, Newborn, and Child H	(76)	22,965	27,074	18%	3%	26,486	102%
Nutrition	21	337	241	(29)%	0%	381	63%
Safe Abortion	3,337	105,875	53,118	(50)%	5%	155,067	34%
Other	-	-	-	0%	0%	-	0%
Inactive	-	1,762	0	(100%)	-%	-	-%
Modern Contraception	-	1,520	-	(100)%	0%	-	0%
HIV & STIs	-	242	-	(100)%	0%	-	0%

POPULATION SERVICES INTERNATIONAL
Monthly DALY Report by Health Area
Period: 12
Year: 2019

	DALY 12/2019	YTD DALY 2018	YTD DALY 2019	Percentage Change	Percentage of Category	Annual DALY Target	Percentage of Target Achieved
GRAND TOTAL	4,188,251	26,150,430	21,995,933	(16)%		24,036,878	92%
Modern Contraception	767,916	8,169,954	8,352,003	2%	100%	7,915,576	106 %
Acceleration Market Group	147,656	1,354,750	1,601,669	18%	19 %	1,305,027	123%
Anglophone Africa Market Group	298,541	3,574,876	3,190,057	(11)%	38 %	3,168,819	101%
Franco/Lusophone Africa Market Group	136,838	1,231,563	1,411,435	15%	17 %	1,242,892	114%
Latin America & Asia Market Group	65,432	803,569	906,992	13%	11 %	873,063	104%
Foundation Market Group	101,601	863,324	1,033,128	20%	12 %	949,254	109%
Social Enterprise	17,849	340,352	208,723	(39)%	2 %	376,521	55%
Inactive	-	1,520	-	(100)%	0 %	-	0%
HIV & STIs	604,365	9,689,164	7,045,159	(27)%	100%	7,989,404	88 %
Acceleration Market Group	189,765	2,922,876	1,720,293	(41)%	24 %	2,388,411	72%
Anglophone Africa Market Group	206,969	4,895,700	3,817,645	(22)%	54 %	3,592,960	106%
Franco/Lusophone Africa Market Group	56,098	461,736	413,494	(10)%	6 %	543,046	76%
Latin America & Asia Market Group	11,285	232,104	195,435	(16)%	3 %	214,953	91%
Foundation Market Group	36,955	212,797	175,730	(17)%	2 %	146,629	120%
Social Enterprise	103,293	963,709	722,562	(25)%	10 %	1,103,405	65%
Inactive	-	242	-	(100)%	0 %	-	0%
Malaria	2,755,208	6,718,869	5,740,466	(15)%	100%	7,263,315	79 %
Acceleration Market Group	6,406	130,182	76,803	(41)%	1 %	116,230	66%
Anglophone Africa Market Group	-	228,768	56,590	(75)%	1 %	35,727	158%
Franco/Lusophone Africa Market Group	519,356	719,056	741,889	3%	13 %	868,795	85%
Latin America & Asia Market Group	20	2,386	243	(90)%	0 %	424	57%
Foundation Market Group	2,229,425	5,638,477	4,864,942	(14)%	85 %	6,242,139	78%
Maternal, Newborn, and Child Health	23,156	807,869	233,837	(71)%	100%	224,590	104 %
Acceleration Market Group	8,885	40,594	54,374	34%	23 %	62,513	87%
Anglophone Africa Market Group	116	6,418	2,171	(66)%	1 %	4,132	53%
Franco/Lusophone Africa Market Group	178	58,996	19,576	(67)%	8 %	37,043	53%
Latin America & Asia Market Group	176	5,860	6,929	18%	3 %	1,827	379%
Foundation Market Group	13,876	673,037	123,714	(82)%	53 %	92,588	134%
Social Enterprise	(76)	22,965	27,074	18%	12 %	26,486	102%
Non-communicable diseases	14	443	1,579	257%	100%	547	289 %
Acceleration Market Group	2	70	73	3%	5 %	73	100%
Anglophone Africa Market Group	7	306	1,457	376%	92 %	264	552%
Franco/Lusophone Africa Market Group	-	6	2	(67)%	0 %	-	0%
Latin America & Asia Market Group	-	-	-	0%	0 %	-	0%
Foundation Market Group	4	61	48	(21)%	3 %	210	23%
Nutrition	3,111	104,927	87,163	(17)%	100%	103,591	84 %
Acceleration Market Group	-	249	-	(100)%	0 %	-	0%
Franco/Lusophone Africa Market Group	-	-	-	0%	0 %	-	0%
Latin America & Asia Market Group	6	-	25	0%	0 %	-	0%
Foundation Market Group	3,085	104,340	86,897	(17)%	100 %	103,209	84%
Social Enterprise	21	337	241	(29)%	0 %	381	63%
Safe Abortion	15,816	343,119	259,132	(24)%	100%	376,721	69 %
Acceleration Market Group	1,918	131,766	93,163	(29)%	36 %	119,871	78%
Anglophone Africa Market Group	2,326	22,753	23,148	2%	9 %	25,618	90%
Franco/Lusophone Africa Market Group	2,137	18,987	24,828	31%	10 %	18,447	135%
Latin America & Asia Market Group	4,660	52,617	51,016	(3)%	20 %	42,896	119%
Foundation Market Group	1,438	11,120	13,857	25%	5 %	14,822	93%
Social Enterprise	3,337	105,875	53,118	(50)%	20 %	155,067	34%

POPULATION SERVICES INTERNATIONAL
Monthly DALY Report by Health Area
Period: 12
Year: 2019

	DALY 12/2019	YTD DALY 2018	YTD DALY 2019	Percentage Change	Percentage of Category	Annual DALY Target	Percentage of Target Achieved
Tuberculosis	16,792	284,198	241,059	(15)%	100%	128,952	187 %
Acceleration Market Group	6,292	88,122	84,817	(4)%	35 %	94,197	90%
Anglophone Africa Market Group	24	300	284	(5)%	0 %	626	45%
Latin America & Asia Market Group	10,475	119,106	117,936	(1)%	49 %	38	310,703%
Foundation Market Group	-	76,671	38,021	(50)%	16 %	34,091	112%
WASH	1,874	31,888	35,536	11%	100%	34,182	104 %
Acceleration Market Group	202	8,877	11,548	30%	32 %	9,747	118%
Anglophone Africa Market Group	516	7,937	7,599	(4)%	21 %	10,440	73%
Franco/Lusophone Africa Market Group	1,152	7,857	14,274	82%	40 %	12,029	119%
Latin America & Asia Market Group	-	160	43	(73)%	0 %	30	142%
Foundation Market Group	4	7,057	2,072	(71)%	6 %	1,936	107%
Other	-	-	-	0%	0%	-	0 %
Social Enterprise	-	-	-	0%	0 %	-	0%

POPULATION SERVICES INTERNATIONAL
Monthly DALY Report by Country
Period: 12
Year: 2019

	DALY 12/2019	YTD DALY 2018	YTD DALY 2019	Percentage Change	Percentage of Category	Annual DALY Target	Percentage of Target Achieved
GRAND TOTAL	4,188,251	26,150,430	21,995,933	(16%)		24,036,878	92%
Acceleration Market Group	361,126	4,677,485	3,642,740	(22%)	100%	4,096,068	89%
India	50,798	181,428	299,908	65 %	8%	151,017	199%
Modern Contraception	50,798	175,412	291,926	66%	8%	142,343	205 %
Non-communicable diseases	-	-	-	0%	0%	-	0 %
Tuberculosis	-	-	-	0%	0%	1,677	0 %
WASH	-	6,017	7,982	33%	0%	6,997	114 %
Kenya	129,685	2,114,656	1,610,141	(24)%	44%	2,352,036	68%
Modern Contraception	46,810	536,784	634,129	18%	17%	579,992	109 %
HIV & STIs	69,247	1,454,845	900,739	(38)%	25%	1,646,645	55 %
Malaria	5,538	93,015	39,504	(58)%	1%	75,807	52 %
Maternal, Newborn, and Child Health	7,888	27,111	32,163	19%	1%	46,781	69 %
Non-communicable diseases	-	56	40	(29)%	0%	63	63 %
Tuberculosis	-	-	-	0%	0%	-	0 %
WASH	202	2,845	3,566	25%	0%	2,750	130 %
Myanmar	21,002	282,568	301,075	7 %	8%	317,773	95%
Modern Contraception	7,378	70,471	74,428	6%	2%	81,594	91 %
HIV & STIs	5,465	73,048	82,287	13%	2%	87,494	94 %
Malaria	868	37,167	37,299	0%	1%	40,423	92 %
Maternal, Newborn, and Child Health	997	13,483	22,210	65%	1%	15,733	141 %
Non-communicable diseases	2	15	33	125%	0%	10	333 %
Nutrition	-	249	-	(100)%	0%	-	0 %
Tuberculosis	6,292	88,122	84,817	(4)%	2%	92,520	92 %
WASH	-	15	-	(100)%	0%	-	0 %
Nigeria	10,312	40,908	112,654	175 %	3%	-	-%
Modern Contraception	10,312	32,064	112,654	251%	3%	-	0 %
HIV & STIs	-	8,844	-	(100)%	0%	-	0 %
PSI Nigeria	34,276	620,137	581,695	(6)%	16%	620,328	94%
Modern Contraception	32,359	488,371	488,531	0%	13%	500,457	98 %
Safe Abortion	1,918	131,766	93,163	(29)%	3%	119,871	78 %
South Africa	115,053	1,437,788	737,267	(49)%	20%	654,913	113%
Modern Contraception	-	51,649	-	(100)%	0%	641	0 %
HIV & STIs	115,053	1,386,139	737,267	(47)%	20%	654,272	113 %
Anglophone Africa Market Group	508,500	8,737,057	7,098,951	(19)%	100%	6,838,586	104%
Ethiopia	26,391	270,640	165,192	(39)%	2%	144,850	114%
Modern Contraception	8,820	90,177	53,642	(41)%	1%	47,793	112 %
HIV & STIs	17,090	176,544	105,510	(40)%	1%	89,820	117 %
Malaria	-	-	1	0%	0%	-	0 %
Non-communicable diseases	-	-	-	0%	0%	-	0 %
Tuberculosis	-	-	-	0%	0%	-	0 %
WASH	481	3,919	6,039	54%	0%	7,237	83 %
Ghana	-	170,301	69,948	(59)%	1%	97,820	72%
Modern Contraception	-	170,186	69,858	(59)%	1%	95,927	73 %
HIV & STIs	-	64	-	(100)%	0%	1,792	0 %
WASH	-	51	90	76%	0%	101	89 %
Lesotho	3,807	469,110	59,567	(87)%	1%	34,799	171%

POPULATION SERVICES INTERNATIONAL
Monthly DALY Report by Country
Period: 12
Year: 2019

	DALY 12/2019	YTD DALY 2018	YTD DALY 2019	Percentage Change	Percentage of Category	Annual DALY Target	Percentage of Target Achieved
Modern Contraception	286	40,199	5,791	(86)%	0%	3,516	165 %
HIV & STIs	3,497	428,660	53,492	(88)%	1%	30,657	174 %
Non-communicable diseases	-	-	-	0%	0%	-	0 %
Tuberculosis	24	252	284	13%	0%	626	45 %
Malawi	43,825	1,186,609	1,161,833	(2)%	16%	1,170,485	99%
Modern Contraception	20,276	527,237	521,296	(1)%	7%	578,870	90 %
HIV & STIs	23,549	656,727	635,862	(3)%	9%	588,683	108 %
Malaria	-	2,142	4,503	110%	0%	2,818	160 %
Non-communicable diseases	-	-	-	0%	0%	-	0 %
WASH	-	502	172	(66)%	0%	113	152 %
Namibia	-	-	2,252	- %	-%	-	-%
Modern Contraception	-	-	242	0%	0%	-	0 %
HIV & STIs	-	-	2,011	0%	0%	-	0 %
PSI Uganda	223,703	1,524,598	1,675,134	10 %	24%	1,617,541	104%
Modern Contraception	215,931	1,472,215	1,625,215	10%	23%	1,561,294	104 %
HIV & STIs	5,806	32,612	31,763	(3)%	0%	34,195	93 %
Maternal, Newborn, and Child Health	116	6,240	2,171	(65)%	0%	4,132	53 %
Non-communicable diseases	-	57	28	(51)%	0%	-	0 %
Safe Abortion	1,840	13,263	15,847	19%	0%	17,809	89 %
WASH	9	210	111	(47)%	0%	111	100 %
Rwanda	12,118	233,817	253,361	8 %	4%	272,046	93%
Modern Contraception	3,192	66,221	69,310	5%	1%	70,959	98 %
HIV & STIs	8,902	167,159	183,843	10%	3%	200,615	92 %
WASH	24	437	208	(52)%	0%	472	44 %
Swaziland	22,236	793,184	564,666	(29)%	8%	330,572	171%
Modern Contraception	1,417	51,387	35,519	(31)%	1%	18,016	197 %
HIV & STIs	20,819	741,797	529,147	(29)%	7%	312,556	169 %
Non-communicable diseases	-	-	-	0%	0%	-	0 %
Tuberculosis	-	-	-	0%	0%	-	0 %
Tanzania	16,199	1,061,037	470,523	(56)%	7%	506,709	93%
Modern Contraception	15,712	749,549	410,668	(45)%	6%	463,818	89 %
HIV & STIs	-	74,658	80	(100)%	0%	1,690	5 %
Malaria	-	226,626	52,086	(77)%	1%	32,909	158 %
Non-communicable diseases	-	-	-	0%	0%	-	0 %
Safe Abortion	487	9,787	7,302	(25)%	0%	7,808	94 %
WASH	1	418	387	(7)%	0%	484	80 %
Uganda	48,906	399,586	419,148	5 %	6%	285,612	147%
Modern Contraception	10,627	176,878	86,295	(51)%	1%	69,347	124 %
HIV & STIs	38,279	222,799	332,853	49%	5%	216,265	154 %
Malaria	-	-	-	0%	0%	-	0 %
Maternal, Newborn, and Child Health	-	178	-	(100)%	0%	-	0 %
Non-communicable diseases	-	28	-	(100)%	0%	-	0 %
Safe Abortion	-	(297)	-	(100)%	0%	-	0 %
WASH	-	-	-	(100)%	0%	-	0 %
Zambia	52,109	480,639	489,201	2 %	7%	510,034	96%
Modern Contraception	15,363	154,316	218,533	42%	3%	172,215	127 %
HIV & STIs	36,746	324,338	270,075	(17)%	4%	335,898	80 %
WASH	-	1,986	592	(70)%	0%	1,922	31 %

POPULATION SERVICES INTERNATIONAL
Monthly DALY Report by Country
Period: 12
Year: 2019

	DALY 12/2019	YTD DALY 2018	YTD DALY 2019	Percentage Change	Percentage of Category	Annual DALY Target	Percentage of Target Achieved
Zimbabwe	59,207	2,147,537	1,768,125	(18)%	25%	1,868,119	95%
Modern Contraception	6,918	76,512	93,687	22%	1%	87,065	108 %
HIV & STIs	52,282	2,070,343	1,673,010	(19)%	24%	1,780,790	94 %
Non-communicable diseases	7	220	1,428	548%	0%	264	541 %
Tuberculosis	-	48	-	(100)%	0%	-	0 %
WASH	-	414	-	(100)%	0%	-	0 %
Franco/Lusophone Africa Market Group	715,759	2,498,201	2,625,497	5%	100%	2,722,253	96%
Angola	6,184	698,314	296,140	(58)%	11%	276,666	107%
Modern Contraception	2,738	126,838	124,450	(2)%	5%	142,140	88 %
HIV & STIs	2,047	15,712	12,097	(23)%	0%	23,605	51 %
Malaria	261	549,478	147,306	(73)%	6%	106,722	138 %
Safe Abortion	977	4,992	10,834	117%	0%	2,557	424 %
WASH	162	1,294	1,454	12%	0%	1,641	89 %
Benin	37,285	303,564	286,737	(6)%	11%	306,792	93%
Modern Contraception	35,865	250,634	226,398	(10)%	9%	245,407	92 %
HIV & STIs	767	13,101	40,358	208%	2%	24,948	162 %
Malaria	3	686	8	(99)%	0%	-	0 %
Maternal, Newborn, and Child Health	177	36,620	14,653	(60)%	1%	33,329	44 %
Non-communicable diseases	-	6	2	(67)%	0%	-	0 %
Safe Abortion	60	492	970	97%	0%	-	0 %
WASH	412	2,024	4,349	115%	0%	3,108	140 %
Burundi	66,675	172,616	210,992	22 %	8%	151,589	139%
Modern Contraception	12,119	45,527	48,423	6%	2%	42,894	113 %
HIV & STIs	7,910	47,419	45,371	(4)%	2%	37,486	121 %
Malaria	46,620	79,470	116,894	47%	4%	70,791	165 %
Safe Abortion	25	200	305	52%	0%	418	73 %
Cameroon	232,586	529,278	691,231	31 %	26%	900,441	77%
Modern Contraception	17,186	348,630	348,511	0%	13%	272,311	128 %
HIV & STIs	11,945	140,955	128,782	(9)%	5%	152,624	84 %
Malaria	202,537	11,135	204,354	1,735%	8%	461,281	44 %
Maternal, Newborn, and Child Health	2	22,376	4,923	(78)%	0%	3,715	133 %
Nutrition	-	-	-	0%	0%	-	0 %
Safe Abortion	916	5,968	4,617	(23)%	0%	10,508	44 %
WASH	1	214	44	(80)%	0%	2	2,120 %
Cote d'Ivoire	7,173	23,105	139,081	502 %	5%	81,095	172%
Modern Contraception	5,964	18,920	133,056	603%	5%	78,028	171 %
HIV & STIs	1,147	3,805	4,815	27%	0%	2,387	202 %
WASH	62	380	1,211	219%	0%	679	178 %
Mozambique	69,969	513,571	506,589	(1)%	19%	588,280	86%
Modern Contraception	42,624	304,610	339,629	11%	13%	317,733	107 %
HIV & STIs	26,890	205,130	160,174	(22)%	6%	264,540	61 %
Malaria	-	95	-	(100)%	0%	-	0 %
WASH	455	3,736	6,786	82%	0%	6,006	113 %
Niger	279,793	132,613	402,999	204 %	15%	292,956	138%
Modern Contraception	10,714	58,092	126,545	118%	5%	65,342	194 %
HIV & STIs	-	239	5,596	2,246%	0%	1,328	421 %
Malaria	268,989	70,640	268,989	281%	10%	225,393	119 %

POPULATION SERVICES INTERNATIONAL
Monthly DALY Report by Country
Period: 12
Year: 2019

	DALY 12/2019	YTD DALY 2018	YTD DALY 2019	Percentage Change	Percentage of Category	Annual DALY Target	Percentage of Target Achieved
Safe Abortion	91	3,642	1,868	(49)%	0%	893	209 %
PSI Benin	1,283	45,270	38,235	(16)%	1%	50,634	76%
Modern Contraception	1,216	41,578	32,001	(23)%	1%	46,563	69 %
Safe Abortion	67	3,692	6,234	69%	0%	4,071	153 %
Senegal	14,811	79,870	53,493	(33)%	2%	73,800	72%
Modern Contraception	8,412	36,734	32,422	(12)%	1%	32,473	100 %
HIV & STIs	5,393	35,375	16,302	(54)%	1%	36,127	45 %
Malaria	947	7,552	4,338	(43)%	0%	4,608	94 %
Nutrition	-	-	-	0%	0%	-	0 %
WASH	60	209	431	106%	0%	593	73 %
Latin America & Asia Market Group	92,055	1,215,801	1,278,619	5%	100%	1,133,232	113%
Cambodia	10,361	232,921	213,730	(8)%	17%	250,805	85%
Modern Contraception	6,331	131,480	122,502	(7)%	10%	142,792	86 %
HIV & STIs	2,749	67,870	63,185	(7)%	5%	77,713	81 %
Malaria	-	395	8	(98)%	0%	160	5 %
Maternal, Newborn, and Child Health	176	5,849	6,902	18%	1%	1,752	394 %
Safe Abortion	1,105	27,327	21,133	(23)%	2%	28,390	74 %
Caribbean	-	-	-	- %	-%	-	-%
Non-communicable diseases	-	-	-	0%	0%	-	0 %
Costa Rica	271	2,369	2,194	(7)%	-%	2,522	87%
Modern Contraception	34	301	279	(7)%	0%	320	87 %
HIV & STIs	236	2,068	1,915	(7)%	0%	2,201	87 %
Dominican Republic	383	18,652	26,603	43 %	2%	15,540	171%
Modern Contraception	115	5,499	7,636	39%	1%	4,631	165 %
HIV & STIs	268	13,153	18,966	44%	1%	10,909	174 %
El Salvador	10	6,512	8,720	34 %	1%	7,134	122%
Modern Contraception	5	1,756	2,254	28%	0%	1,794	126 %
HIV & STIs	5	4,744	6,466	36%	1%	5,340	121 %
Maternal, Newborn, and Child Health	-	11	-	(100)%	0%	-	0 %
Non-communicable diseases	-	-	-	0%	0%	-	0 %
Safe Abortion	-	2	-	(100)%	0%	-	0 %
El Salvador SA	427	2,578	5,987	132 %	-%	1,910	314%
Modern Contraception	261	2,507	4,104	64%	0%	1,851	222 %
HIV & STIs	164	44	1,842	4,070%	0%	-	0 %
Safe Abortion	2	27	41	52%	0%	59	70 %
Guatemala	4	38,762	14,268	(63)%	1%	29,609	48%
Modern Contraception	3	23,967	6,359	(73)%	0%	13,146	48 %
HIV & STIs	1	14,686	7,909	(46)%	1%	16,463	48 %
Safe Abortion	-	109	-	(100)%	0%	-	0 %
Guatemala SA	983	64,123	66,414	4 %	5%	10,527	631%
Modern Contraception	(341)	63,646	59,902	(6)%	5%	10,203	587 %
HIV & STIs	1,308	124	6,027	4,771%	0%	-	0 %
Safe Abortion	16	353	485	37%	0%	324	150 %
Honduras	38	18,932	9,298	(51)%	1%	19,810	47%
Modern Contraception	37	3,000	1,911	(36)%	0%	2,693	71 %
HIV & STIs	2	15,932	7,387	(54)%	1%	17,117	43 %

POPULATION SERVICES INTERNATIONAL
Monthly DALY Report by Country
Period: 12
Year: 2019

	DALY 12/2019	YTD DALY 2018	YTD DALY 2019	Percentage Change	Percentage of Category	Annual DALY Target	Percentage of Target Achieved
Honduras SA	285	-	8,133	- %	1%	-	-%
Modern Contraception	38	-	1,097	0%	0%	-	0 %
HIV & STIs	247	-	7,036	0%	1%	-	0 %
Kazakhstan	91	965	1,068	11 %	-%	562	190%
Modern Contraception	1	10	17	75%	0%	4	408 %
HIV & STIs	90	955	1,051	10%	0%	558	188 %
Tuberculosis	-	-	-	0%	0%	-	0 %
Kyrgyzstan	59	602	729	21 %	-%	457	160%
Modern Contraception	-	13	12	(12)%	0%	22	52 %
HIV & STIs	59	589	717	22%	0%	435	165 %
Tuberculosis	-	-	-	0%	0%	-	0 %
Laos	714	29,900	22,541	(25)%	2%	27,508	82%
Modern Contraception	699	24,777	17,657	(29)%	1%	22,913	77 %
HIV & STIs	-	3,829	3,522	(8)%	0%	3,564	99 %
Malaria	14	250	174	(30)%	0%	156	112 %
Safe Abortion	-	982	1,159	18%	0%	837	138 %
Tuberculosis	-	64	29	(54)%	0%	38	77 %
Nepal	6,019	35,896	30,254	(16)%	2%	30,224	100%
Modern Contraception	3,967	20,428	16,464	(19)%	1%	17,110	96 %
HIV & STIs	-	5	-	(100)%	0%	-	0 %
Safe Abortion	2,052	15,463	13,791	(11)%	1%	13,114	105 %
Nicaragua	932	14,253	17,728	24 %	1%	-	3,693,519%
Modern Contraception	406	8,610	11,074	29%	1%	-	0 %
HIV & STIs	525	5,542	6,538	18%	1%	-	1,362,213 %
Safe Abortion	1	102	116	14%	0%	-	0 %
Nicaragua SA	-	-	-	- %	-%	16,895	-%
Modern Contraception	-	-	-	0%	0%	10,574	0 %
HIV & STIs	-	-	-	0%	0%	6,148	0 %
Safe Abortion	-	-	-	0%	0%	173	0 %
Pakistan	47,824	568,435	580,103	2 %	45%	383,003	151%
Modern Contraception	31,010	398,022	415,951	5%	33%	348,668	119 %
HIV & STIs	4,849	43,119	31,928	(26)%	2%	34,336	93 %
Nutrition	6	-	25	0%	0%	-	0 %
Safe Abortion	1,484	8,252	14,292	73%	1%	-	0 %
Tuberculosis	10,475	119,042	117,907	(1)%	9%	-	0 %
Panama	284	6,551	4,472	(32)%	-%	7,260	62%
Modern Contraception	67	1,538	1,038	(33)%	0%	1,719	60 %
HIV & STIs	217	5,013	3,434	(31)%	0%	5,542	62 %
Papua New Guinea	195	2,041	1,152	(44)%	-%	3,278	35%
Modern Contraception	102	169	584	246%	0%	1,889	31 %
HIV & STIs	93	154	537	249%	0%	1,309	41 %
Malaria	-	1,714	-	(100)%	0%	-	0 %
Maternal, Newborn, and Child Health	-	-	27	0%	0%	76	36 %
WASH	-	4	3	(19)%	0%	4	93 %
PSI Pakistan	23,022	118,333	248,606	110 %	19%	304,660	82%
Modern Contraception	22,685	117,247	237,845	103%	19%	292,577	81 %
HIV & STIs	337	1,086	10,760	891%	1%	12,083	89 %

POPULATION SERVICES INTERNATIONAL
Monthly DALY Report by Country
Period: 12
Year: 2019

	DALY 12/2019	YTD DALY 2018	YTD DALY 2019	Percentage Change	Percentage of Category	Annual DALY Target	Percentage of Target Achieved
Tajikistan	140	17,530	14,367	(18)%	1%	19,404	74%
Modern Contraception	5	415	65	(84)%	0%	80	81 %
HIV & STIs	135	17,115	14,302	(16)%	1%	19,324	74 %
Tuberculosis	-	-	-	0%	0%	-	0 %
Viet Nam	13	36,446	2,252	(94)%	-%	2,123	106%
Modern Contraception	7	184	240	30%	0%	76	314 %
HIV & STIs	-	36,079	1,912	(95)%	0%	1,912	100 %
Malaria	6	27	60	127%	0%	108	56 %
Non-communicable diseases	-	-	-	0%	0%	-	0 %
Tuberculosis	-	-	-	0%	0%	-	0 %
WASH	-	156	39	(75)%	0%	26	148 %
Foundation Market Group	2,386,388	7,586,885	6,338,408	(16)%	100%	7,584,880	84%
Haiti	9,720	169,008	126,628	(25)%	2%	87,193	145%
Modern Contraception	419	24,275	9,015	(63)%	0%	9,184	98 %
HIV & STIs	6,575	66,067	35,918	(46)%	1%	12,871	279 %
Malaria	759	1,995	36,309	1,720%	1%	23,585	154 %
Maternal, Newborn, and Child Health	1,967	-	7,366	0%	0%	7,462	99 %
Non-communicable diseases	-	1	-	(80)%	0%	-	0 %
Tuberculosis	-	76,671	38,021	(50)%	1%	34,091	112 %
Liberia	10	12,039	7,836	(35)%	-%	27,447	29%
Modern Contraception	-	5,528	3,547	(36)%	0%	12,602	28 %
HIV & STIs	10	6,378	4,198	(34)%	0%	14,733	28 %
WASH	-	133	91	(32)%	0%	112	81 %
Madagascar	106,245	2,112,645	1,093,857	(48)%	17%	1,094,187	100%
Modern Contraception	58,062	452,712	514,782	14%	8%	476,130	108 %
HIV & STIs	30,336	140,232	134,843	(4)%	2%	117,859	114 %
Malaria	12,375	1,443,630	378,404	(74)%	6%	459,706	82 %
Maternal, Newborn, and Child Health	4,835	65,741	58,077	(12)%	1%	36,677	158 %
Non-communicable diseases	1	23	9	(62)%	0%	-	0 %
Nutrition	-	119	-	(100)%	0%	-	0 %
Safe Abortion	634	4,684	6,217	33%	0%	3,618	172 %
WASH	2	5,504	1,525	(72)%	0%	197	773 %
Mali	1,285,020	3,372,072	3,231,077	(4)%	51%	3,114,047	104%
Modern Contraception	42,485	376,214	500,260	33%	8%	446,445	112 %
HIV & STIs	-	1	578	55,700%	0%	1,036	56 %
Malaria	,241,725	2,989,340	2,722,429	(9)%	43%	2,654,094	103 %
Non-communicable diseases	3	36	39	7%	0%	210	18 %
Safe Abortion	805	6,437	7,640	19%	0%	11,204	68 %
WASH	1	43	131	206%	0%	1,059	12 %
Somaliland	10,870	174,375	152,264	(13)%	2%	158,117	96%
Modern Contraception	634	4,596	5,524	20%	0%	4,893	113 %
HIV & STIs	35	119	193	62%	0%	131	147 %
Malaria	43	841	1,055	25%	0%	866	122 %
Maternal, Newborn, and Child Health	7,074	67,253	58,271	(13)%	1%	48,449	120 %
Non-communicable diseases	-	-	-	0%	0%	-	0 %
Nutrition	3,085	100,190	86,897	(13)%	1%	103,209	84 %
WASH	-	1,377	325	(76)%	0%	568	57 %

POPULATION SERVICES INTERNATIONAL
 Monthly DALY Report by Country
 Period: 12
 Year: 2019

	DALY 12/2019	YTD DALY 2018	YTD DALY 2019	Percentage Change	Percentage of Category	Annual DALY Target	Percentage of Target Achieved
South Sudan	974,523	1,746,746	1,726,746	(1)%	27%	3,103,888	56%
Malaria	974,523	1,202,671	1,726,746	44%	27%	3,103,888	56 %
Maternal, Newborn, and Child Health	-	540,043	-	(100)%	0%	-	0 %
Nutrition	-	4,031	-	(100)%	0%	-	0 %
Social Enterprise	124,424	1,433,239	1,011,719	(29)%	100%	1,661,860	61%
India LLC	34,339	649,269	372,241	(43)%	37%	805,943	46%
Modern Contraception	11,860	285,814	163,821	(43)%	16%	312,748	52 %
HIV & STIs	19,217	234,615	128,227	(45)%	13%	311,642	41 %
Maternal, Newborn, and Child Health	(76)	22,965	27,074	18%	3%	26,486	102 %
Safe Abortion	3,337	105,875	53,118	(50)%	5%	155,067	34 %
Other	-	-	-	0%	0%	-	0 %
Paraguay	3,048	25,359	24,842	(2)%	2%	24,784	100%
Modern Contraception	718	7,129	6,925	(3)%	1%	7,205	96 %
HIV & STIs	2,309	17,892	17,676	(1)%	2%	17,198	103 %
Nutrition	21	337	241	(29)%	0%	381	63 %
PSI South Africa	87,037	758,612	614,636	(19)%	61%	831,133	74%
Modern Contraception	5,270	47,409	37,977	(20)%	4%	56,569	67 %
HIV & STIs	81,767	711,203	576,659	(19)%	57%	774,565	74 %
Inactive	-	1,762	-	(100)%	-%	-	-%
Guinea	-	1,762	-	(100)%	-%	-	-%
Modern Contraception	-	1,520	-	(100)%	0%	-	0 %
HIV & STIs	-	242	-	(100)%	0%	-	0 %

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
Acute Malnutrition Screening_CU5	21	-	410	312	619,573	(100)%	619,573	621,360	410	-	-
Franco/Lusophone Africa Market Group	-	-	-	312	518	(100)%	518	1,895	-	-	-
Foundation Market Group	21	-	410	-	619,055	(100)%	619,055	619,465	410	-	-
Antiretroviral Treatment	-	-	-	-	-	-%	-	18,119	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	18,119	-	-	-
Antiretroviral Treatment (Currently Enrolled)	70,958	71,395	545,956	313,246	535,855	2%	535,855	1,554,153	45,496	-	98,464
Acceleration Market Group	15,532	15,167	174,024	170,176	152,003	14%	152,003	402,508	14,502	-	34,444
Anglophone Africa Market Group	14,751	14,210	163,277	105,390	148,026	10%	148,026	430,536	13,606	-	29,008
Franco/Lusophone Africa Market Group	6,113	6,367	62,079	7,723	19,016	226%	19,016	87,725	5,173	-	10,345
Latin America & Asia Market Group	-	827	7,541	-	233	3,136%	233	7,774	628	-	1,049
Foundation Market Group	34,562	34,824	139,035	29,957	216,577	(36)%	216,577	625,610	11,586	-	23,619
Antiretroviral Treatment (Newly Enrolled)	1,275	3,314	19,554	13,389	15,865	23%	15,865	62,517	19,554	-	-
Acceleration Market Group	263	309	3,744	3,981	3,434	9%	3,434	13,330	3,744	-	-
Anglophone Africa Market Group	607	685	7,255	4,695	6,634	9%	6,634	30,120	7,255	-	-
Franco/Lusophone Africa Market Group	139	159	1,404	1,396	1,807	(22)%	1,807	3,625	1,404	-	-
Latin America & Asia Market Group	-	47	449	-	92	388%	92	541	449	-	-
Foundation Market Group	266	2,114	6,702	3,317	3,898	72%	3,898	14,901	6,702	-	-
Antiretroviral Treatment (Tablet)	-	-	-	-	-	-%	-	97,980	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	97,980	-	-	-
ARV Prophylaxis 28 wks (Mother and Baby)	-	-	-	-	-	-%	-	382	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	382	-	-	-
ARV Prophylaxis 28 wks (Mother Only)	-	-	-	-	-	-%	-	359	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	359	-	-	-
Basic Care Package	-	-	-	-	1	(100)%	1	176,452,482	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	1,064,698	-	-	-
Anglophone Africa Market Group	-	-	-	-	1	(100)%	1	174,969,459	-	-	-
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	418,325	-	-	-

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
CD4 Tests Provided to HIV+ Clients	-	-	-	-	666	(100)%	666	16,834	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	4,995	-	-	-
Anglophone Africa Market Group	-	-	-	-	544	(100)%	544	9,416	-	-	-
Franco/Lusophone Africa Market Group	-	-	-	-	122	(100)%	122	1,919	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	504	-	-	-
Cervical Cancer-HPV DNA and Conization	3	2	10	-	-	-%	-	10	10	-	4
Anglophone Africa Market Group	3	2	10	-	-	-%	-	10	10	-	4
Cervical Cancer-HPV DNA and Cryotherapy	2	1	8	-	3	167%	3	11	8	-	3
Anglophone Africa Market Group	2	1	8	-	3	167%	3	11	8	-	3
Cervical Cancer-HPV DNA and Refer to any Treatment	1	-	2	-	-	-%	-	13	2	-	-
Anglophone Africa Market Group	1	-	2	-	-	-%	-	13	2	-	-
Cervical Cancer-HPV DNA and Refer to Conization	-	-	-	-	-	-%	-	9	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	9	-	-	-
Cervical Cancer-HPV DNA Screening	333	728	4,123	-	-	-%	-	4,123	4,123	-	-
Anglophone Africa Market Group	333	582	3,346	-	-	-%	-	3,346	3,346	-	-
Latin America & Asia Market Group	-	146	777	-	-	-%	-	777	777	-	-
Cervical Cancer-Pap and Conization	-	-	1,753	-	-	-%	-	1,753	1,753	-	778
Anglophone Africa Market Group	-	-	1,753	-	-	-%	-	1,753	1,753	-	778
Cervical Cancer-Pap and Cryotherapy	-	-	-	-	4	(100)%	4	39	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	25	-	-	-
Foundation Market Group	-	-	-	-	4	(100)%	4	4	-	-	-
Inactive	-	-	-	-	-	-%	-	10	-	-	-
Cervical Cancer-Pap and Refer to any Treatment	-	-	9	-	-	-%	-	11	9	-	2
Anglophone Africa Market Group	-	-	9	-	-	-%	-	11	9	-	2
Cervical Cancer-Pap and Refer to Conization	-	-	-	-	-	-%	-	9	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	9	-	-	-
Cervical Cancer-Pap Smear Screening	30	58	438	-	92	376%	92	7,795	438	-	-

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
Acceleration Market Group	-	-	-	-	-	-%	-	6,497	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	291	-	-	-
Latin America & Asia Market Group	30	58	438	-	92	376%	92	918	438	-	-
Inactive	-	-	-	-	-	-%	-	89	-	-	-
Cervical Cancer-VIA and Conization	11	18	245	290	126	94%	126	549	245	-	88
Anglophone Africa Market Group	11	18	245	290	126	94%	126	549	245	-	88
Cervical Cancer-VIA and Cryotherapy	25	59	2,077	1,247	1,162	79%	1,162	23,516	2,077	-	684
Acceleration Market Group	7	22	307	240	286	7%	286	11,553	307	-	73
Anglophone Africa Market Group	2	18	1,598	307	639	150%	639	10,047	1,598	-	561
Franco/Lusophone Africa Market Group	3	2	16	-	48	(67)%	48	390	16	-	2
Latin America & Asia Market Group	-	-	-	-	-	-%	-	8	-	-	-
Foundation Market Group	13	16	156	700	189	(17)%	189	1,498	156	-	48
Inactive	-	-	-	-	-	-%	-	20	-	-	-
Cervical Cancer-VIA and Refer to any Treatment	1	6	85	-	25	240%	25	523	85	-	15
Acceleration Market Group	-	-	-	-	-	-%	-	127	-	-	-
Anglophone Africa Market Group	1	6	85	-	25	240%	25	396	85	-	15
Cervical Cancer-VIA and Refer to Conization	1	3	23	290	102	(77)%	102	2,083	23	-	4
Acceleration Market Group	-	-	-	-	4	(100)%	4	4	-	-	-
Anglophone Africa Market Group	1	3	23	290	98	(77)%	98	2,079	23	-	4
Cervical Cancer-VIA and Refer to Cryotherapy	-	-	-	150	39	(100)%	39	2,084	-	-	-
Acceleration Market Group	-	-	-	150	29	(100)%	29	913	-	-	-
Anglophone Africa Market Group	-	-	-	-	10	(100)%	10	625	-	-	-
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	10	-	-	-
Foundation Market Group	-	-	-	-	-	-%	-	536	-	-	-
Cervical Cancer-VIA/VILI Screening	8,014	13,178	137,560	145,293	194,523	(29)%	194,523	1,178,264	137,560	-	-
Acceleration Market Group	288	1,514	37,955	21,500	34,714	9%	34,714	502,387	37,955	-	-
Anglophone Africa Market Group	1,325	4,178	45,450	88,793	95,922	(53)%	95,922	386,536	45,450	-	-

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
Franco/Lusophone Africa Market Group	3,329	3,156	28,676	-	50,592	(43)%	50,592	189,505	28,676	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	387	-	-	-
Foundation Market Group	3,072	4,329	25,479	35,000	13,295	92%	13,295	99,179	25,479	-	-
Inactive	-	-	-	-	-	-%	-	270	-	-	-
Chlorhexidine	563	5,793	38,321	25,755	130,742	(71)%	130,742	656,236	34,489	-	2,315
Acceleration Market Group	-	-	-	-	-	-%	-	148,406	-	-	-
Anglophone Africa Market Group	263	777	6,590	16,755	23,622	(72)%	23,622	43,255	5,931	-	458
Foundation Market Group	300	5,015	31,731	9,000	107,120	(70)%	107,120	464,575	28,558	-	1,857
Clean Delivery Kit	-	-	-	-	3,449	(100)%	3,449	1,708,471	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	346,994	-	-	-
Anglophone Africa Market Group	-	-	-	-	3,449	(100)%	3,449	470,003	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	710,114	-	-	-
Foundation Market Group	-	-	-	-	-	-%	-	180,586	-	-	-
Inactive	-	-	-	-	-	-%	-	774	-	-	-
Condom	44,472,930	37,377,252	417,858,083	553,397,069	504,429,167	(17)%	504,429,167	21,864,868,151	3,133,921	3,133,921	3,694,143
Acceleration Market Group	3,408,750	4,118,821	45,303,579	41,769,999	38,017,548	19%	38,017,548	9,799,101,930	339,777	339,777	1,000,040
Anglophone Africa Market Group	2,463,283	3,785,709	46,603,378	49,703,561	65,266,786	(29)%	65,266,786	3,193,512,061	349,525	349,525	932,948
Franco/Lusophone Africa Market Group	5,460,296	4,224,472	41,173,232	59,938,298	51,015,576	(19)%	51,015,576	1,670,441,894	308,799	308,799	522,101
Latin America & Asia Market Group	18,641,510	20,299,308	184,767,633	196,479,173	187,072,729	(1)%	187,072,729	4,038,875,034	1,385,757	1,385,757	394,062
Foundation Market Group	79,536	292,240	1,828,764	2,920,716	3,347,338	(45)%	3,347,338	954,325,997	13,716	13,716	16,365
Social Enterprise	14,419,555	4,656,703	98,181,497	202,585,322	159,709,190	(39)%	159,709,190	810,700,372	736,347	736,347	828,627
USA	-	-	-	-	-	-%	-	289,819	-	-	-
Inactive	-	-	-	-	-	-%	-	1,397,621,044	-	-	-
Condom Provided	-	-	-	-	-	-%	-	18,930,351	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	50,644	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	17,527,104	-	-	-
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	673,774	-	-	-

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
Latin America & Asia Market Group	-	-	-	-	-	-%	-	651,148	-	-	-
Foundation Market Group	-	-	-	-	-	-%	-	27,681	-	-	-
Counseling & Tx for Moderate Acute MalnutritionCU5	545	2,096	19,252	20,946	20,332	(5)%	20,332	194,739	19,252	-	60,218
Franco/Lusophone Africa Market Group	-	-	-	4	-	-%	-	8	-	-	-
Foundation Market Group	545	2,096	19,252	20,942	20,332	(5)%	20,332	194,731	19,252	-	60,218
Deworming Tablets	-	-	-	-	-	-%	-	1,095,308	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	1,095,308	-	-	-
Diarrhea Treatment Kit	12,890	22,424	432,701	780,367	666,448	(35)%	666,448	20,170,174	389,431	-	26,500
Acceleration Market Group	-	-	-	-	-	-%	-	6,854,139	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	24,379	-	-	-
Franco/Lusophone Africa Market Group	1,010	21,316	300,418	424,000	431,332	(30)%	431,332	4,433,547	270,376	-	17,600
Latin America & Asia Market Group	2,820	1,107	40,570	91,951	57,190	(29)%	57,190	989,246	36,513	-	798
Foundation Market Group	9,060	1	91,713	264,416	177,926	(48)%	177,926	5,121,917	82,542	-	8,103
Inactive	-	-	-	-	-	-%	-	2,746,946	-	-	-
Diarrhea Treatment Kit Provided	635	-	15,782	29,000	20,038	(21)%	20,038	84,713	15,782	-	572
Acceleration Market Group	-	-	15,147	29,000	18,226	(17)%	18,226	69,404	15,147	-	503
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	2,400	-	-	-
Foundation Market Group	635	-	635	-	1,812	(65)%	1,812	12,909	635	-	69
Early Infant Male Circumcision	-	-	-	-	-	-%	-	4,886	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	4,886	-	-	-
Emergency Contraception	323,667	350,839	3,186,854	2,499,767	3,049,904	4%	3,049,904	47,776,015	143,408	143,408	25,903
Acceleration Market Group	-	333	1,000	-	(121)	-%	(121)	16,367,341	45	45	4
Anglophone Africa Market Group	19,641	11,004	123,300	7,000	180,947	(32)%	180,947	1,771,057	5,549	5,549	2,145
Franco/Lusophone Africa Market Group	12,358	2,421	51,168	255,200	135,874	(62)%	135,874	727,474	2,303	2,303	1,389
Latin America & Asia Market Group	256,540	299,816	2,547,734	981,837	2,139,235	19%	2,139,235	23,609,520	114,648	114,648	19,909
Foundation Market Group	(4)	(6)	44,760	15,700	40,018	12%	40,018	165,291	2,014	2,014	547
Social Enterprise	35,132	37,270	418,892	1,240,030	553,951	(24)%	553,951	3,484,995	18,850	18,850	1,909

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
Inactive	-	-	-	-	-	-%	-	1,650,337	-	-	-
Emergency Contraception Provided	25,844	13,809	201,747	1,199,860	29,591	582%	29,591	266,696	10,087	10,087	3,283
Acceleration Market Group	20,252	9,473	75,323	19,800	4,173	1,705%	4,173	80,924	3,766	3,766	561
Anglophone Africa Market Group	1,578	1,144	91,980	30,493	6,887	1,236%	6,887	100,086	4,599	4,599	2,329
Franco/Lusophone Africa Market Group	307	295	4,060	3,000	2,877	41%	2,877	8,547	203	203	127
Latin America & Asia Market Group	3,703	2,891	30,261	1,146,567	15,372	97%	15,372	75,034	1,513	1,513	263
Foundation Market Group	4	6	123	-	282	(56)%	282	2,104	6	6	2
Inactive	-	-	-	-	-	-%	-	1	-	-	-
Expanded Clean Delivery Kit	-	-	-	-	13,160	(100)%	13,160	25,000	-	-	-
Anglophone Africa Market Group	-	-	-	-	13,160	(100)%	13,160	25,000	-	-	-
Expanded Clean Delivery Kit (+CHX)	669	973	11,709	20,285	14,531	(19)%	14,531	26,857	10,538	-	1,713
Anglophone Africa Market Group	669	973	11,709	20,285	14,531	(19)%	14,531	26,857	10,538	-	1,713
Family Planning Counseling	-	-	-	-	-	-%	-	42,190	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	15,882	-	-	-
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	21,833	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	3,787	-	-	-
Foundation Market Group	-	-	-	-	-	-%	-	688	-	-	-
Fecal Sludge Management (Households)	-	40	3,800	750	2,071	83%	2,071	7,453	18,942	-	-
Acceleration Market Group	-	6	489	400	697	(30)%	697	2,768	2,347	-	-
Franco/Lusophone Africa Market Group	-	34	3,311	350	1,374	141%	1,374	4,685	16,595	-	-
Fecal Sludge Management (Liters)	-	523,667	13,055,000	15,559,190	9,121,000	43%	9,121,000	29,322,200	-	-	1,443
Acceleration Market Group	-	30,000	1,914,000	2,000,000	4,011,000	(52)%	4,011,000	13,071,200	-	-	118
Franco/Lusophone Africa Market Group	-	493,667	11,141,000	13,559,190	5,110,000	118%	5,110,000	16,251,000	-	-	1,325
Female Condom	24,404	182,394	1,721,664	1,763,132	1,709,647	1%	1,709,647	87,884,528	12,912	12,912	21,698
Acceleration Market Group	-	-	85,553	70,000	79,641	7%	79,641	10,481,146	642	642	461
Anglophone Africa Market Group	1,124	13,751	174,851	533,000	469,229	(63)%	469,229	48,744,678	1,311	1,311	5,678
Franco/Lusophone Africa Market Group	23,280	168,643	1,461,260	1,160,132	1,160,677	26%	1,160,677	13,213,905	10,959	10,959	15,559

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
Latin America & Asia Market Group	-	-	-	-	100	(100)%	100	660,929	-	-	-
Foundation Market Group	-	-	-	-	-	-%	-	9,300,709	-	-	-
Social Enterprise	-	-	-	-	-	-%	-	985,104	-	-	-
Inactive	-	-	-	-	-	-%	-	4,498,057	-	-	-
Female Condom Provided	-	-	-	-	-	-%	-	112,394	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	87,306	-	-	-
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	22,060	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	1	-	-	-
Foundation Market Group	-	-	-	-	-	-%	-	3,027	-	-	-
Fever Cases Attended	178,135	101,571	1,051,956	286,938	916,338	15%	916,338	7,198,191	1,051,956	-	-
Acceleration Market Group	73,979	48,786	520,128	-	697,782	(25)%	697,782	2,978,275	520,128	-	-
Anglophone Africa Market Group	67,555	25,845	238,868	-	-	-%	-	238,868	238,868	-	-
Franco/Lusophone Africa Market Group	-	-	-	8,385	14,143	(100)%	14,143	26,907	-	-	-
Latin America & Asia Market Group	8,568	8,834	88,447	75,685	118,263	(25)%	118,263	368,372	88,447	-	-
Foundation Market Group	28,033	18,106	204,513	202,868	86,150	137%	86,150	3,585,769	204,513	-	-
Fever Cases Tested with Microscopy	4,030	5,064	44,156	30,340	56,797	(22)%	56,797	483,644	44,156	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	7,474	-	-	-
Latin America & Asia Market Group	-	2,246	6,737	-	-	-%	-	6,737	6,737	-	-
Foundation Market Group	4,030	2,818	37,419	30,340	56,797	(34)%	56,797	469,433	37,419	-	-
Fever Cases Tested with RDTs	182,893	111,364	1,162,076	276,374	1,120,815	4%	1,120,815	7,707,972	1,162,076	-	-
Acceleration Market Group	73,979	48,786	520,128	-	697,782	(25)%	697,782	2,970,447	520,128	-	-
Anglophone Africa Market Group	64,534	24,741	227,984	-	-	-%	-	227,984	227,984	-	-
Franco/Lusophone Africa Market Group	-	-	-	8,385	14,143	(100)%	14,143	42,041	-	-	-
Latin America & Asia Market Group	11,112	13,038	116,202	95,551	134,061	(13)%	134,061	411,889	116,202	-	-
Foundation Market Group	33,268	24,799	297,762	172,438	274,829	8%	274,829	4,055,611	297,762	-	-
Free Condom	11,706,959	9,588,115	105,689,754	109,721,482	180,808,636	(42)%	180,808,636	2,728,777,592	792,673	792,673	1,716,161
Acceleration Market Group	-	2,400	1,920,960	35,500,000	68,170,320	(97)%	68,170,320	1,487,878,858	14,407	14,407	56,881

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
Anglophone Africa Market Group	5,912,539	4,297,117	61,742,141	44,434,784	77,319,731	(20)%	77,319,731	791,688,792	463,066	463,066	1,352,880
Franco/Lusophone Africa Market Group	924,524	354,673	14,956,285	5,193,631	3,201,731	367%	3,201,731	84,946,478	112,172	112,172	98,975
Latin America & Asia Market Group	56,590	472,857	3,741,906	3,124,160	3,430,359	9%	3,430,359	61,743,271	28,064	28,064	8,033
Foundation Market Group	4,813,306	4,461,068	23,328,462	21,468,907	28,342,179	(18)%	28,342,179	183,879,714	174,963	174,963	199,393
Inactive	-	-	-	-	344,316	(100)%	344,316	118,640,479	-	-	-
Free Female Condom	62,429	385,890	1,563,995	333,000	1,803,686	(13)%	1,803,686	19,216,179	11,730	11,730	32,473
Acceleration Market Group	11,695	9,857	49,875	-	1,108,500	(96)%	1,108,500	6,617,636	374	374	269
Anglophone Africa Market Group	47,550	367,230	1,398,332	251,000	623,007	124%	623,007	7,487,195	10,487	10,487	31,104
Franco/Lusophone Africa Market Group	2,184	3,700	99,284	52,000	49,536	100%	49,536	1,153,978	745	745	1,021
Latin America & Asia Market Group	1,000	5,103	16,504	30,000	21,200	(22)%	21,200	370,278	124	124	80
Foundation Market Group	-	-	-	-	253	(100)%	253	3,329,424	-	-	-
Inactive	-	-	-	-	1,190	(100)%	1,190	257,668	-	-	-
HAART (Mother and Baby)	-	-	-	-	-	-%	-	256	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	256	-	-	-
HAART (Mother Only)	-	-	-	-	-	-%	-	239	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	239	-	-	-
HIV Self-Testing Kit	246,375	182,667	1,405,373	1,716,537	2,354,376	(40)%	2,354,376	4,129,296	1,264,836	-	-
Acceleration Market Group	5,390	155,147	647,230	1,066,643	1,357,422	(52)%	1,357,422	2,004,652	582,507	-	-
Anglophone Africa Market Group	240,457	27,198	756,647	641,306	996,954	(24)%	996,954	2,123,148	680,982	-	-
Franco/Lusophone Africa Market Group	-	-	-	1,388	-	-%	-	-	-	-	-
Latin America & Asia Market Group	528	323	1,496	7,200	-	-%	-	1,496	1,346	-	-
HIV Testing Services	122,645	158,837	1,375,018	1,174,518	2,232,177	(38)%	2,232,177	24,694,556	1,375,018	-	39,836
Acceleration Market Group	14,865	18,072	318,640	293,418	1,091,132	(71)%	1,091,132	7,344,676	318,640	-	12,203
Anglophone Africa Market Group	18,061	24,893	315,263	518,172	541,424	(42)%	541,424	10,763,361	315,263	-	23,436
Franco/Lusophone Africa Market Group	6,415	5,876	87,835	93,415	106,415	(17)%	106,415	3,088,407	87,835	-	663
Latin America & Asia Market Group	2,048	4,812	69,479	78,439	98,169	(29)%	98,169	441,260	69,479	-	154
Foundation Market Group	81,256	105,183	583,801	191,074	395,037	48%	395,037	2,282,402	583,801	-	3,380

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
Inactive	-	-	-	-	-	-%	-	774,450	-	-	-
Hypertension Diagnosis	21,912	3,203	80,787	34,572	100,760	(20)%	100,760	281,443	80,787	-	-
Acceleration Market Group	19,902	1,061	51,351	20,000	57,768	(11)%	57,768	162,354	51,351	-	-
Anglophone Africa Market Group	1,951	2,141	21,416	-	16,890	27%	16,890	58,632	21,416	-	-
Latin America & Asia Market Group	-	-	7,961	14,572	26,102	(70)%	26,102	60,398	7,961	-	-
Foundation Market Group	59	-	59	-	-	-%	-	59	59	-	-
Hypertension Screening	102,381	94,526	1,218,119	236,477	1,403,815	(13)%	1,403,815	3,884,487	1,218,119	-	-
Acceleration Market Group	27,633	1,934	108,524	50,000	176,640	(39)%	176,640	506,763	108,524	-	-
Anglophone Africa Market Group	74,748	92,591	917,675	36,477	813,698	13%	813,698	2,570,110	917,675	-	-
Latin America & Asia Market Group	-	-	191,920	150,000	413,477	(54)%	413,477	807,614	191,920	-	-
Hypertension_C Controlled Condition	16,782	833	51,877	13,009	74,033	(30)%	74,033	187,733	20,751	-	-
Acceleration Market Group	16,777	824	39,737	-	43,499	(9)%	43,499	124,883	15,895	-	-
Anglophone Africa Market Group	5	9	105	-	91	15%	91	262	42	-	-
Latin America & Asia Market Group	-	-	12,035	13,009	30,443	(60)%	30,443	62,588	4,814	-	-
Implant 3	23,954	18,098	110,512	87,804	35,182	214%	35,182	1,137,885	99,461	248,652	229,039
Acceleration Market Group	363	1,401	10,355	12,600	1,528	578%	1,528	828,901	9,320	23,299	15,549
Anglophone Africa Market Group	20,120	11,143	74,741	73,620	16,575	351%	16,575	226,811	67,267	168,167	171,357
Franco/Lusophone Africa Market Group	(582)	2,740	7,068	(4,896)	7,323	(3)%	7,323	30,592	6,361	15,903	11,843
Latin America & Asia Market Group	191	305	2,894	4,920	1,681	72%	1,681	26,738	2,605	6,512	886
Foundation Market Group	3,862	2,509	15,454	1,560	8,075	91%	8,075	27,108	13,909	34,772	29,405
Inactive	-	-	-	-	-	-%	-	(2,265)	-	-	-
Implant 3 Insertion	31,460	42,393	408,136	341,797	334,633	22%	334,633	1,351,860	408,136	1,020,340	893,288
Acceleration Market Group	8,449	10,592	51,603	38,123	8,884	481%	8,884	64,098	51,603	129,008	98,957
Anglophone Africa Market Group	12,604	19,783	217,237	201,554	240,316	(10)%	240,316	927,744	217,237	543,093	515,191
Franco/Lusophone Africa Market Group	4,819	5,839	69,284	27,532	24,546	182%	24,546	115,987	69,284	173,210	164,406
Latin America & Asia Market Group	745	900	12,010	12,195	12,809	(6)%	12,809	46,262	12,010	30,025	6,874
Foundation Market Group	4,843	5,278	58,002	62,393	48,078	21%	48,078	193,062	58,002	145,005	107,860

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
Inactive	-	-	-	-	-	-%	-	4,707	-	-	-
Implant 4	(437)	80	18,362	-	(3,897)	-%	(3,897)	39,389	16,526	52,883	47,402
Anglophone Africa Market Group	(436)	81	18,459	-	(3,883)	-%	(3,883)	26,452	16,613	53,162	47,669
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	6,200	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	(700)	-	-	-
Foundation Market Group	(1)	(1)	(97)	-	(14)	-%	(14)	7,437	(87)	(279)	(267)
Implant 4 Insertion	836	1,645	11,032	-	34,188	(68)%	34,188	55,405	11,032	35,302	31,682
Acceleration Market Group	-	-	-	-	288	(100)%	288	288	-	-	-
Anglophone Africa Market Group	835	1,644	10,829	-	33,884	(68)%	33,884	46,313	10,829	34,653	31,072
Franco/Lusophone Africa Market Group	-	-	21	-	2	950%	2	752	21	67	40
Latin America & Asia Market Group	-	-	-	-	-	-%	-	5,342	-	-	-
Foundation Market Group	1	1	182	-	14	1,200%	14	2,710	182	582	569
Implant 5	8,835	13,865	116,919	50,794	85,932	36%	85,932	877,382	105,227	399,863	353,093
Acceleration Market Group	(4,760)	(13)	(4,707)	(7,600)	2,423	(294)%	2,423	270,291	(4,236)	(16,098)	(11,752)
Anglophone Africa Market Group	4,956	5,823	54,899	26,000	29,617	85%	29,617	251,433	49,409	187,755	180,053
Franco/Lusophone Africa Market Group	6,194	4,497	31,813	29,052	27,720	15%	27,720	153,538	28,632	108,800	94,482
Latin America & Asia Market Group	2,446	1,958	14,480	3,342	20,838	(31)%	20,838	100,033	13,032	49,522	10,876
Foundation Market Group	(1)	1,600	20,434	-	5,334	283%	5,334	90,452	18,391	69,884	79,433
Inactive	-	-	-	-	-	-%	-	11,635	-	-	-
Implant 5 Insertion	34,099	40,627	449,186	372,974	373,214	20%	373,214	2,436,147	449,186	1,706,907	1,513,222
Acceleration Market Group	8,863	10,126	117,879	62,915	82,547	43%	82,547	552,515	117,879	447,940	394,964
Anglophone Africa Market Group	8,796	15,523	175,768	175,505	154,215	14%	154,215	948,502	175,768	667,918	601,310
Franco/Lusophone Africa Market Group	9,861	8,565	89,663	71,842	76,301	18%	76,301	391,935	89,663	340,719	304,059
Latin America & Asia Market Group	288	1,620	20,152	12,712	21,679	(7)%	21,679	107,932	20,152	76,578	15,843
Foundation Market Group	6,291	4,793	45,724	50,000	38,472	19%	38,472	371,665	45,724	173,751	197,046
Inactive	-	-	-	-	-	-%	-	63,598	-	-	-
Infant Fortified Food	-	-	-	-	-	-%	-	91,859	-	-	-

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
Latin America & Asia Market Group	-	-	-	-	-	-%	-	91,859	-	-	-
Injectable 1	15,091	18,068	203,675	150,016	130,168	56%	130,168	3,863,133	14,101	14,101	3,266
Acceleration Market Group	-	-	-	-	-	-%	-	1,546,164	-	-	-
Latin America & Asia Market Group	15,091	18,068	203,675	150,016	130,168	56%	130,168	2,316,960	14,101	14,101	3,266
Inactive	-	-	-	-	-	-%	-	9	-	-	-
Injectable 1 Provided	4,928	9,654	103,353	44,561	89,057	16%	89,057	330,980	7,950	7,950	1,621
Acceleration Market Group	6	5	44	-	37	19%	37	81	3	3	3
Anglophone Africa Market Group	-	2	42	36	537	(92)%	537	1,809	3	3	2
Latin America & Asia Market Group	4,922	9,648	102,997	44,525	88,483	16%	88,483	328,820	7,923	7,923	1,599
Foundation Market Group	-	-	270	-	-	-%	-	270	21	21	17
Injectable 2	(391)	1,854	146,097	39,747	188,630	(23)%	188,630	23,434,053	21,915	21,915	5,997
Acceleration Market Group	-	-	-	-	-	-%	-	15,907,000	-	-	-
Franco/Lusophone Africa Market Group	(391)	2,348	21,203	20,016	54,602	(61)%	54,602	315,547	3,180	3,180	1,697
Latin America & Asia Market Group	-	(494)	124,894	19,731	134,028	(7)%	134,028	7,211,502	18,734	18,734	4,300
Inactive	-	-	-	-	-	-%	-	4	-	-	-
Injectable 2 Provided	5,500	7,855	86,435	211,422	102,606	(16)%	102,606	313,335	14,406	14,406	6,494
Acceleration Market Group	1,175	1,296	13,459	-	5,875	129%	5,875	19,334	2,243	2,243	1,891
Anglophone Africa Market Group	2,923	2,009	21,725	29,000	22,699	(4)%	22,699	56,072	3,621	3,621	2,453
Franco/Lusophone Africa Market Group	1,399	941	12,209	50,000	15,848	(23)%	15,848	50,959	2,035	2,035	1,094
Latin America & Asia Market Group	3	3,609	39,042	132,422	58,184	(33)%	58,184	186,969	6,507	6,507	1,056
Inactive	-	-	-	-	-	-%	-	1	-	-	-
Injectable 3-IM	349,659	342,840	3,929,254	3,760,923	5,050,702	(22)%	5,050,702	95,873,439	884,082	884,082	367,013
Acceleration Market Group	58,149	43,750	514,301	480,600	493,679	4%	493,679	32,556,262	115,718	115,718	25,256
Anglophone Africa Market Group	16,948	35,134	721,284	605,251	1,797,775	(60)%	1,797,775	14,806,282	162,289	162,289	82,874
Franco/Lusophone Africa Market Group	10,421	21,826	180,120	105,000	272,940	(34)%	272,940	1,424,760	40,527	40,527	27,622
Latin America & Asia Market Group	13,221	15,108	323,866	560,836	687,092	(53)%	687,092	12,072,225	72,870	72,870	13,349
Foundation Market Group	241,325	228,903	2,150,139	1,988,500	1,669,487	29%	1,669,487	31,296,675	483,781	483,781	216,424

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
Social Enterprise	9,595	(1,882)	39,544	20,736	129,729	(70)%	129,729	238,354	8,897	8,897	1,489
Inactive	-	-	-	-	-	-%	-	3,478,881	-	-	-
Injectable 3-IM Provided	140,430	174,912	1,716,865	1,613,683	1,573,348	9%	1,573,348	4,855,256	429,216	429,216	214,181
Acceleration Market Group	47,032	59,148	385,457	204,422	175,770	119%	175,770	756,511	96,364	96,364	44,273
Anglophone Africa Market Group	21,679	32,953	416,171	357,197	342,639	21%	342,639	1,124,919	104,043	104,043	68,817
Franco/Lusophone Africa Market Group	28,879	27,482	317,069	255,395	272,082	17%	272,082	945,303	79,267	79,267	61,541
Latin America & Asia Market Group	32,026	47,770	517,607	761,629	705,711	(27)%	705,711	1,675,614	129,402	129,402	25,493
Foundation Market Group	10,814	7,559	80,561	35,040	77,146	4%	77,146	352,909	20,140	20,140	14,057
Injectable 3-SC	20,079	31,722	843,570	857,082	617,820	37%	617,820	2,514,134	189,803	189,803	102,517
Acceleration Market Group	3,278	2,602	31,405	32,150	-	-%	-	31,405	7,066	7,066	884
Anglophone Africa Market Group	1,959	12,052	91,046	53,892	55,900	63%	55,900	146,946	20,485	20,485	15,188
Franco/Lusophone Africa Market Group	14,448	10,433	211,263	151,480	26,328	702%	26,328	240,206	47,534	47,534	35,169
Latin America & Asia Market Group	-	(34)	(102)	1,400	-	-%	-	(102)	(23)	(23)	(1)
Foundation Market Group	394	6,669	509,958	618,160	535,592	(5)%	535,592	2,095,679	114,741	114,741	51,277
Injectable 3-SC Provided	18,471	13,222	108,959	44,763	5,904	1,746%	5,904	114,863	27,240	27,240	21,069
Acceleration Market Group	897	1,258	9,727	-	-	-%	-	9,727	2,432	2,432	2,050
Anglophone Africa Market Group	11,900	6,214	33,304	-	-	-%	-	33,304	8,326	8,326	6,144
Franco/Lusophone Africa Market Group	5,345	5,310	63,385	39,163	5,729	1,006%	5,729	69,114	15,846	15,846	12,592
Latin America & Asia Market Group	-	256	769	5,600	-	-%	-	769	192	192	5
Foundation Market Group	329	184	1,774	-	175	914%	175	1,949	444	444	277
IPTp2	2,066	881	12,028	291,388	85,804	(86)%	85,804	356,479	12,028	-	890
Acceleration Market Group	1,860	287	6,109	-	3,893	57%	3,893	20,406	6,109	-	228
Anglophone Africa Market Group	-	-	-	-	-	-%	-	44,748	-	-	-
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	54	-	-	-
Foundation Market Group	206	595	5,919	291,388	81,911	(93)%	81,911	291,271	5,919	-	662
Iron Folic Acid Tablet	-	-	-	19,843	-	-%	-	48,283,018	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	48,283,018	-	-	-

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
Foundation Market Group	-	-	-	19,843	-	-%	-	-	-	-	-
ITN	-	421,834	1,265,503	-	-	-%	-	20,663,108	2,050,115	-	45,033
Acceleration Market Group	-	-	-	-	-	-%	-	5,306,807	-	-	-
Anglophone Africa Market Group	-	421,834	1,265,503	-	-	-%	-	13,342,614	2,050,115	-	45,033
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	1,983,399	-	-	-
Inactive	-	-	-	-	-	-%	-	30,288	-	-	-
IUD 10	34,551	22,360	223,988	227,046	263,103	(15)%	263,103	3,174,241	201,589	927,310	665,817
Acceleration Market Group	(198)	3	(331)	(4,600)	684	(148)%	684	1,449,927	(298)	(1,370)	(1,500)
Anglophone Africa Market Group	26,966	17,835	118,862	93,709	94,747	25%	94,747	511,378	106,976	492,089	468,770
Franco/Lusophone Africa Market Group	3,322	1,641	15,548	28,463	29,804	(48)%	29,804	222,893	13,993	64,369	51,793
Latin America & Asia Market Group	3,085	833	77,261	102,474	64,790	19%	64,790	715,576	69,535	319,861	87,016
Foundation Market Group	1,381	2,055	12,638	7,000	7,568	67%	7,568	92,641	11,374	52,321	59,730
Social Enterprise	(5)	(7)	10	-	65,510	(100)%	65,510	65,520	9	41	9
Inactive	-	-	-	-	-	-%	-	116,306	-	-	-
IUD 10 Insertion	35,458	46,250	463,563	539,581	572,847	(19)%	572,847	3,670,801	463,563	2,132,390	1,503,202
Acceleration Market Group	8,223	10,578	101,968	103,790	90,084	13%	90,084	727,339	101,968	469,053	450,542
Anglophone Africa Market Group	4,852	10,992	107,088	188,592	220,262	(51)%	220,262	1,306,726	107,088	492,605	435,187
Franco/Lusophone Africa Market Group	4,422	5,729	75,712	76,812	73,738	3%	73,738	335,515	75,712	348,275	314,687
Latin America & Asia Market Group	15,164	15,522	141,791	123,733	148,352	(4)%	148,352	900,945	141,791	652,239	162,215
Foundation Market Group	2,797	3,430	37,004	46,654	40,411	(8)%	40,411	386,027	37,004	170,218	140,570
Inactive	-	-	-	-	-	-%	-	14,249	-	-	-
IUD 3	(125)	(20)	(57)	-	6,953	(101)%	6,953	6,896	(51)	(128)	(27)
Social Enterprise	(125)	(20)	(57)	-	6,953	(101)%	6,953	6,896	(51)	(128)	(27)
IUD 5	(5,436)	6,625	171,635	208,394	102,566	67%	102,566	4,557,494	154,472	509,756	124,188
Acceleration Market Group	48	24	362	2,500	472	(23)%	472	1,136,883	326	1,075	183
Anglophone Africa Market Group	-	(1)	(32)	-	(263)	-%	(263)	14,523	(29)	(95)	(96)
Latin America & Asia Market Group	(5,579)	6,348	40,646	94,294	22,736	79%	22,736	3,091,368	36,581	120,719	36,127

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
Social Enterprise	95	254	130,659	111,600	79,621	64%	79,621	310,994	117,593	388,057	87,975
Inactive	-	-	-	-	-	-%	-	3,726	-	-	-
IUD 5 Insertion	38,092	33,924	325,380	131,309	115,881	181%	115,881	1,481,666	325,380	1,073,754	289,835
Acceleration Market Group	27,103	20,992	162,738	65,000	51,661	215%	51,661	343,588	162,738	537,035	121,524
Anglophone Africa Market Group	-	1	162	-	345	(53)%	345	28,984	162	535	343
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	45	-	-	-
Latin America & Asia Market Group	10,962	12,906	162,215	65,998	63,576	155%	63,576	1,108,485	162,215	535,309	167,093
Foundation Market Group	27	24	265	311	299	(11)%	299	564	265	874	876
IUS 3	22	(95)	(328)	2,500	98	(435)%	98	(230)	(295)	(738)	(743)
Anglophone Africa Market Group	(65)	(82)	(379)	-	-	-%	-	(379)	(341)	(853)	(808)
Foundation Market Group	87	(12)	51	2,500	98	(48)%	98	149	46	115	65
IUS 3 Insertion	153	218	1,510	-	135	1,019%	135	1,645	1,510	3,775	2,510
Anglophone Africa Market Group	65	82	379	-	-	-%	-	379	379	948	898
Foundation Market Group	88	136	1,131	-	135	738%	135	1,266	1,131	2,828	1,611
IUS 5	(8)	(46)	803	5,128	126	537%	126	1,883	723	2,385	1,533
Anglophone Africa Market Group	(8)	(5)	395	(56)	126	213%	126	1,475	356	1,173	1,332
Foundation Market Group	-	10	(11)	-	-	-%	-	(11)	(10)	(33)	(81)
Social Enterprise	-	(51)	419	5,184	-	-%	-	419	377	1,244	282
IUS 5 Insertion	86	124	1,744	756	1,516	15%	1,516	4,253	1,744	5,755	5,993
Acceleration Market Group	75	103	1,102	-	775	42%	775	2,503	1,102	3,637	4,182
Anglophone Africa Market Group	8	21	550	756	739	(26)%	739	1,655	550	1,815	1,530
Latin America & Asia Market Group	3	1	10	-	2	400%	2	13	10	33	6
Foundation Market Group	-	-	82	-	-	-%	-	82	82	271	276
LifeStraw	-	-	-	-	-	-%	-	15,965	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	15,320	-	-	-
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	645	-	-	-
LLIN	1,547,796	1,186,194	9,265,240	18,656,324	31,104,885	(70)%	31,104,885	367,900,639	15,009,689	-	2,323,595

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
Acceleration Market Group	10,625	1,853	1,093,373	2,049,898	2,332,163	(53)%	2,332,163	65,044,809	1,771,264	-	41,770
Anglophone Africa Market Group	1	713	213,151	700,054	4,545,198	(95)%	4,545,198	56,897,553	345,305	-	11,557
Franco/Lusophone Africa Market Group	498,229	77,780	1,581,302	3,964,115	4,602,963	(66)%	4,602,963	54,057,803	2,561,709	-	156,725
Latin America & Asia Market Group	-	-	-	-	-	-%	-	5,197,868	-	-	-
Foundation Market Group	1,038,941	1,105,848	6,377,414	11,942,257	19,624,561	(68)%	19,624,561	182,641,487	10,331,411	-	2,113,544
Inactive	-	-	-	-	-	-%	-	4,061,119	-	-	-
LLIN (Hammock net)	-	-	781	1,350	1,259	(38)%	1,259	2,085	703	-	-
Latin America & Asia Market Group	-	-	781	1,350	1,259	(38)%	1,259	2,085	703	-	-
Lubricant	782,370	1,229,832	11,793,095	5,295,911	5,621,900	110%	5,621,900	89,574,969	-	-	-
Acceleration Market Group	271,000	286,000	2,318,836	70,000	51,861	4,371%	51,861	15,871,125	-	-	-
Anglophone Africa Market Group	245,469	324,724	2,926,726	1,900,761	2,574,286	14%	2,574,286	11,669,908	-	-	-
Franco/Lusophone Africa Market Group	2,184	2,667	11,039	-	45,024	(75)%	45,024	1,533,058	-	-	-
Latin America & Asia Market Group	43,136	350,729	2,810,451	731,208	1,423,274	97%	1,423,274	39,508,941	-	-	-
Foundation Market Group	197,340	265,160	3,676,834	2,500,000	1,223,813	200%	1,223,813	5,922,862	-	-	-
Social Enterprise	23,241	552	49,209	93,942	37,944	30%	37,944	635,465	-	-	-
Inactive	-	-	-	-	265,698	(100)%	265,698	14,433,610	-	-	-
Malaria PPT (ACT)	3,091,373	483,968	6,513,485	6,562,602	7,543,851	(14)%	7,543,851	141,646,077	5,862,137	-	1,926,050
Acceleration Market Group	1,089	391	174,362	182,270	256,333	(32)%	256,333	63,892,648	156,926	-	24,461
Anglophone Africa Market Group	-	-	-	-	-	-%	-	10,387,257	-	-	-
Franco/Lusophone Africa Market Group	828	10,131	409,310	326,390	297,014	38%	297,014	2,112,118	368,379	-	113,695
Latin America & Asia Market Group	-	(24)	(227)	-	147	(254)%	147	2,839,503	(204)	-	(25)
Foundation Market Group	3,089,456	473,470	5,930,040	6,053,942	6,990,357	(15)%	6,990,357	62,414,551	5,337,036	-	1,787,919
Malaria PPT (Non-ACT)	7,224	40,808	223,754	83,621	(2,041)	-%	(2,041)	14,118,042	201,379	-	24,351
Acceleration Market Group	224	174	2,954	3,621	(1,900)	-%	(1,900)	5,116,468	2,659	-	414
Latin America & Asia Market Group	-	-	-	-	(141)	-%	(141)	(141)	-	-	-
Foundation Market Group	7,000	40,633	220,800	80,000	-	-%	-	9,001,715	198,720	-	23,936
Malaria RDK	992,370	632,355	3,857,675	4,357,458	12,180,985	(68)%	12,180,985	63,305,638	3,471,908	-	-

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
Acceleration Market Group	-	-	-	432,337	743,410	(100)%	743,410	12,836,467	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	263,260	-	-	-
Franco/Lusophone Africa Market Group	-	35,092	147,125	250,000	177,919	(17)%	177,919	1,244,684	132,413	-	-
Latin America & Asia Market Group	6,920	3,497	35,300	25,000	305,189	(88)%	305,189	7,090,196	31,770	-	-
Foundation Market Group	985,450	593,767	3,675,250	3,650,121	10,954,467	(66)%	10,954,467	41,871,031	3,307,725	-	-
Male Circumcision (HIV-Positive)	-	-	-	-	-	-%	-	10,836	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	6,118	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	4,718	-	-	-
Male Vasodilator	80,000	5,467	1,766,180	3,029,400	-	-%	-	1,766,180	13,246	-	-
Social Enterprise	80,000	5,467	1,766,180	3,029,400	-	-%	-	1,766,180	13,246	-	-
Manual Vacuum Aspiration for PAC	7,637	10,745	120,829	20,937	70,499	71%	70,499	280,055	120,829	-	21,257
Acceleration Market Group	485	742	7,879	5,220	19,176	(59)%	19,176	32,351	7,879	-	6,309
Anglophone Africa Market Group	223	654	6,339	720	7,531	(16)%	7,531	16,860	6,339	-	943
Franco/Lusophone Africa Market Group	1,692	1,339	13,699	1,918	2,579	431%	2,579	18,082	13,699	-	6,214
Latin America & Asia Market Group	4,365	7,337	85,407	7,295	34,966	144%	34,966	191,371	85,407	-	4,157
Foundation Market Group	872	672	7,505	5,784	6,247	20%	6,247	21,391	7,505	-	3,633
Manual Vacuum Aspiration for SA	366	261	2,907	743	1,224	138%	1,224	4,131	2,907	-	965
Acceleration Market Group	-	-	-	-	-	-%	-	-	-	-	-
Anglophone Africa Market Group	35	67	805	-	411	96%	411	1,216	805	-	294
Franco/Lusophone Africa Market Group	310	138	1,406	507	562	150%	562	1,968	1,406	-	568
Latin America & Asia Market Group	21	56	696	236	251	177%	251	947	696	-	103
Foundation Market Group	-	-	-	-	-	-%	-	-	-	-	-
Medical Abortion	65,894	39,138	950,642	2,153,877	1,610,639	(41)%	1,610,639	6,378,182	855,578	-	92,659
Acceleration Market Group	-	652	2,000	9,000	-	-%	-	1,499,044	1,800	-	1,689
Anglophone Africa Market Group	711	1,449	10,999	9,331	13,999	(21)%	13,999	36,009	9,899	-	3,468
Franco/Lusophone Africa Market Group	132	200	2,359	19,550	172	1,272%	172	2,366	2,123	-	823
Latin America & Asia Market Group	29,143	20,692	363,772	459,996	457,334	(20)%	457,334	2,615,181	327,395	-	33,561

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
Social Enterprise	35,908	16,145	571,512	1,656,000	1,139,134	(50)%	1,139,134	2,225,582	514,361	-	53,118
Medical Abortion (Misoprostol) Provided	405	98	1,955	1,051	840	133%	840	2,795	1,955	-	660
Anglophone Africa Market Group	21	81	988	-	531	86%	531	1,519	988	-	309
Franco/Lusophone Africa Market Group	384	16	967	1,051	309	213%	309	1,276	967	-	351
Medical Abortion Provided	1,260	1,361	13,815	4,788	12,902	7%	12,902	35,498	13,815	-	1,589
Anglophone Africa Market Group	25	78	775	-	747	4%	747	2,143	775	-	271
Franco/Lusophone Africa Market Group	33	20	166	-	51	225%	51	407	166	-	62
Latin America & Asia Market Group	1,202	1,263	12,874	4,788	12,104	6%	12,104	32,948	12,874	-	1,255
Micronutrient Powder	11,539	33,427	326,950	35,000	8,746,552	(96)%	8,746,552	48,869,982	806	-	-
Acceleration Market Group	-	-	-	-	2,000,000	(100)%	2,000,000	9,499,690	-	-	-
Franco/Lusophone Africa Market Group	11,539	33,427	326,950	35,000	948,572	(66)%	948,572	8,297,562	806	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	9,502,912	-	-	-
Foundation Market Group	-	-	-	-	5,797,980	(100)%	5,797,980	20,562,598	-	-	-
Inactive	-	-	-	-	-	-%	-	1,007,220	-	-	-
Misoprostol for PAC Provided	12,898	12,652	125,102	26,807	86,914	44%	86,914	230,840	125,102	-	27,041
Acceleration Market Group	382	675	7,331	5,220	14,855	(51)%	14,855	22,186	7,331	-	6,952
Anglophone Africa Market Group	125	244	3,078	-	3,631	(15)%	3,631	7,914	3,078	-	623
Franco/Lusophone Africa Market Group	1,228	1,067	10,819	2,222	2,304	370%	2,304	14,199	10,819	-	5,930
Latin America & Asia Market Group	9,765	9,057	87,568	3,935	53,383	64%	53,383	144,675	87,568	-	5,209
Foundation Market Group	1,398	1,610	16,306	15,430	12,741	28%	12,741	41,866	16,306	-	8,327
Misoprostol for PPH	-	2,833	15,500	4,500	30,800	(50)%	30,800	6,332,438	4,650	-	101
Acceleration Market Group	-	-	-	-	-	-%	-	395,225	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	5,442,839	-	-	-
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	100,000	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	184,166	-	-	-
Foundation Market Group	-	2,833	15,500	4,500	30,800	(50)%	30,800	210,208	4,650	-	101
Misoprostol for Safe Abortion	396,982	453,480	5,680,307	5,447,828	6,085,267	(7)%	6,085,267	23,109,761	298,216	-	114,960

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
Acceleration Market Group	26,472	134,133	1,774,246	2,339,690	2,321,200	(24)%	2,321,200	6,080,296	93,148	-	78,213
Anglophone Africa Market Group	158,768	131,275	1,553,194	1,993,550	1,655,420	(6)%	1,655,420	10,593,170	81,543	-	17,241
Franco/Lusophone Africa Market Group	21,474	72,923	556,877	424,360	745,045	(25)%	745,045	2,527,771	29,236	-	10,879
Latin America & Asia Market Group	175,044	101,615	1,689,170	320,448	1,282,555	32%	1,282,555	3,737,897	88,681	-	6,731
Foundation Market Group	15,224	13,533	106,820	119,780	81,047	32%	81,047	170,627	5,608	-	1,897
Social Enterprise	-	-	-	250,000	-	-%	-	-	-	-	-
Multivitamin	126,780	123,987	1,436,450	2,256,202	2,424,220	(41)%	2,424,220	99,791,369	7,182	-	266
Acceleration Market Group	-	-	-	-	450,010	(100)%	450,010	3,531,010	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	12,270,645	-	-	-
Latin America & Asia Market Group	6,000	6,807	26,420	-	-	-%	-	11,510,725	132	-	25
Foundation Market Group	-	-	-	24,202	-	-%	-	-	-	-	-
Social Enterprise	120,780	117,180	1,410,030	2,232,000	1,974,210	(29)%	1,974,210	38,419,590	7,050	-	241
Inactive	-	-	-	-	-	-%	-	34,059,399	-	-	-
Naloxone	-	167	1,995	3,089	2,570	(22)%	2,570	70,246	1,796	-	2,722
Latin America & Asia Market Group	-	167	1,995	3,089	2,570	(22)%	2,570	34,452	1,796	-	2,722
Inactive	-	-	-	-	-	-%	-	35,794	-	-	-
Needle & Syringe	-	92,933	1,077,000	1,355,860	5,815,215	(81)%	5,815,215	33,442,758	3,757	-	11,984
Acceleration Market Group	-	-	10,100	-	-	-%	-	2,511,988	35	-	83
Latin America & Asia Market Group	-	92,933	1,066,900	1,355,860	5,815,215	(82)%	5,815,215	26,847,258	3,722	-	11,901
Inactive	-	-	-	-	-	-%	-	4,083,512	-	-	-
Neonates Receiving Essential Care	-	-	-	-	-	-%	-	174	-	-	-
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	174	-	-	-
NVP	-	-	-	-	-	-%	-	11,442	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	235	-	-	-
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	11,057	-	-	-
Foundation Market Group	-	-	-	-	-	-%	-	150	-	-	-
OCs	1,628,088	1,992,122	23,088,670	29,124,425	26,777,114	(14)%	26,777,114	658,745,207	1,385,320	1,385,320	418,287

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
Acceleration Market Group	750,138	996,206	9,114,680	10,222,400	9,492,397	(4)%	9,492,397	321,627,956	546,881	546,881	154,562
Anglophone Africa Market Group	15,301	208,582	1,545,840	2,258,175	2,600,283	(41)%	2,600,283	81,500,893	92,750	92,750	44,612
Franco/Lusophone Africa Market Group	198,011	89,289	1,647,001	851,499	1,347,096	22%	1,347,096	26,467,894	98,820	98,820	61,600
Latin America & Asia Market Group	290,792	509,620	7,120,821	6,917,751	6,484,744	10%	6,484,744	106,573,492	427,249	427,249	81,083
Foundation Market Group	167,144	142,346	2,317,388	1,777,420	2,094,239	11%	2,094,239	73,056,038	139,043	139,043	65,406
Social Enterprise	206,702	46,079	1,342,940	7,097,180	4,758,355	(72)%	4,758,355	17,426,340	80,576	80,576	11,023
Inactive	-	-	-	-	-	-%	-	32,092,594	-	-	-
OCs Provided	371,558	329,623	3,194,849	2,831,217	1,778,915	80%	1,778,915	7,564,163	212,990	212,990	85,645
Acceleration Market Group	144,657	101,057	756,782	181,469	151,894	398%	151,894	1,001,891	50,452	50,452	11,210
Anglophone Africa Market Group	29,805	42,815	535,112	357,372	321,499	66%	321,499	1,919,858	35,674	35,674	21,912
Franco/Lusophone Africa Market Group	43,694	62,377	530,857	683,520	367,827	44%	367,827	1,489,339	35,390	35,390	30,239
Latin America & Asia Market Group	151,667	122,220	1,359,110	1,601,361	921,067	48%	921,067	2,991,169	90,607	90,607	21,682
Foundation Market Group	1,735	1,155	12,988	7,495	16,628	(22)%	16,628	161,902	866	866	602
Inactive	-	-	-	-	-	-%	-	4	-	-	-
ORS	126,122	137,249	3,143,681	2,220,000	3,408,447	(8)%	3,408,447	443,579,240	1,414,656	-	62,922
Acceleration Market Group	38,020	124,149	847,044	600,000	514,198	65%	514,198	326,810,645	381,170	-	22,210
Anglophone Africa Market Group	-	-	-	-	-	-%	-	21,149,275	-	-	-
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	32,783,783	-	-	-
Latin America & Asia Market Group	12,797	28,283	648,134	-	500,000	30%	500,000	4,925,115	291,660	-	6,130
Foundation Market Group	79,104	1,080	299,226	300,000	1,249,743	(76)%	1,249,743	16,326,907	134,652	-	7,507
Social Enterprise	(3,799)	(16,263)	1,349,277	1,320,000	1,144,506	18%	1,144,506	2,820,211	607,175	-	27,074
Inactive	-	-	-	-	-	-%	-	38,763,304	-	-	-
ORS Provided	3,538	2,150	31,138	13,914	15,726	98%	15,726	112,100	31,138	-	1,549
Acceleration Market Group	-	-	2,043	-	2,217	(8)%	2,217	9,430	2,043	-	33
Foundation Market Group	3,538	2,150	29,095	13,914	13,509	115%	13,509	102,670	29,095	-	1,516
Pneumonia PPT	12,610	17,677	152,525	124,910	768,635	(80)%	768,635	7,277,183	137,273	-	55,974
Acceleration Market Group	-	-	-	28,910	-	-%	-	1,414,256	-	-	-

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
Anglophone Africa Market Group	-	-	-	-	-	-%	-	987,367	-	-	-
Franco/Lusophone Africa Market Group	-	-	-	-	30,316	(100)%	30,316	474,924	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	119,990	-	-	-
Foundation Market Group	12,610	17,677	152,525	96,000	738,319	(79)%	738,319	4,280,646	137,273	-	55,974
Pneumonia PPT Provided	7,458	1,982	38,483	-	31,754	21%	31,754	194,155	38,483	-	29,781
Acceleration Market Group	4,452	662	21,771	-	20,179	8%	20,179	79,844	21,771	-	10,472
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	2,500	-	-	-
Foundation Market Group	3,006	1,320	16,712	-	11,575	44%	11,575	111,811	16,712	-	19,309
Positive RDTs	48,406	20,466	190,515	11,333	52,281	264%	52,281	2,496,855	190,515	-	-
Acceleration Market Group	426	351	4,386	-	9,712	(55)%	9,712	43,623	4,386	-	-
Anglophone Africa Market Group	42,667	17,029	155,419	-	-	-%	-	155,419	155,419	-	-
Franco/Lusophone Africa Market Group	-	-	-	-	13,716	(100)%	13,716	40,358	-	-	-
Latin America & Asia Market Group	123	153	1,967	3,333	11,799	(83)%	11,799	40,540	1,967	-	-
Foundation Market Group	5,190	2,933	28,743	8,000	17,054	69%	17,054	2,216,915	28,743	-	-
Positive RDTs Given First Line Treatment	40,795	16,355	150,437	2,474	32,687	360%	32,687	2,295,492	150,437	-	-
Acceleration Market Group	417	348	4,242	-	8,937	(53)%	8,937	38,844	4,242	-	-
Anglophone Africa Market Group	40,275	15,902	144,641	-	-	-%	-	144,641	144,641	-	-
Franco/Lusophone Africa Market Group	-	-	-	-	13,647	(100)%	13,647	39,926	-	-	-
Latin America & Asia Market Group	103	105	1,554	2,474	10,103	(85)%	10,103	37,102	1,554	-	-
Foundation Market Group	-	-	-	-	-	-%	-	2,034,979	-	-	-
Pregnancy Test	21,082	21,401	313,592	1,188,000	575,675	(46)%	575,675	1,819,716	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	575,317	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	222,334	-	-	-
Social Enterprise	21,082	21,401	313,592	1,188,000	575,675	(46)%	575,675	889,267	-	-	-
Inactive	-	-	-	-	-	-%	-	132,798	-	-	-
PrEP	3,845	3,866	46,921	35,111	34,437	36%	34,437	84,474	3,910	-	1,493
Acceleration Market Group	69	75	547	-	-	-%	-	547	46	-	23

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
Anglophone Africa Market Group	3,776	3,791	46,374	35,111	34,437	35%	34,437	83,927	3,864	-	1,470
PUR	3,073,824	5,234,283	62,788,252	47,273,857	62,440,224	1%	62,440,224	694,317,579	516,068	-	1,518
Acceleration Market Group	2,779,200	2,809,843	32,575,220	19,000,000	28,508,349	14%	28,508,349	229,129,317	267,742	-	661
Anglophone Africa Market Group	294,624	2,424,440	30,213,032	28,273,857	33,931,875	(11)%	33,931,875	356,095,574	248,326	-	857
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	239,541	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	62,675,382	-	-	-
Foundation Market Group	-	-	-	-	-	-%	-	45,927,973	-	-	-
Inactive	-	-	-	-	-	-%	-	249,792	-	-	-
QAACTs Provided after Confirmatory Diagnosis	33,364	373	60,929	99,182	127,263	(52)%	127,263	2,267,422	60,929	-	10,169
Acceleration Market Group	33,218	108	58,000	95,000	101,767	(43)%	101,767	178,545	58,000	-	9,564
Franco/Lusophone Africa Market Group	-	-	-	-	13,647	(100)%	13,647	13,647	-	-	-
Latin America & Asia Market Group	59	95	1,181	2,254	9,977	(88)%	9,977	36,631	1,181	-	213
Foundation Market Group	87	170	1,748	1,928	1,872	(7)%	1,872	2,038,599	1,748	-	393
Referral to Advanced Cervical Cancer Treatment	-	2	62	136	17	265%	17	479	62	-	-
Anglophone Africa Market Group	-	2	62	136	17	265%	17	479	62	-	-
Referral to CD4/Clinical Staging	-	-	-	-	-	-%	-	34,138	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	3,364	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	30,613	-	-	-
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	18	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	143	-	-	-
Referral to Clinical Staging	-	-	-	-	-	-%	-	18,909	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	3,364	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	15,545	-	-	-
Referral to Diabetes Management (gestational)	-	-	-	-	67	(100)%	67	67	-	-	-
Anglophone Africa Market Group	-	-	-	-	67	(100)%	67	67	-	-	-
Referral to Diabetes Management (non-gestational)	-	-	-	-	-	-%	-	1	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	1	-	-	-

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
Referral to Early Infant Male Circumcision	-	-	-	-	-	-%	-	94	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	94	-	-	-
Referral to Emergency Contraception	-	1	2	1	32	(94)%	32	252	2	-	-
Anglophone Africa Market Group	-	-	-	1	1	(100)%	1	143	-	-	-
Latin America & Asia Market Group	-	1	2	-	31	(94)%	31	109	2	-	-
Referral to HIV Testing Services	666	977	55,716	91,736	24,729	125%	24,729	366,176	55,716	-	1,823
Acceleration Market Group	-	-	21,265	-	-	-%	-	47,140	21,265	-	754
Anglophone Africa Market Group	666	976	34,434	82,130	24,714	39%	24,714	232,695	34,434	-	1,070
Franco/Lusophone Africa Market Group	-	-	-	9,600	-	-%	-	17,256	-	-	-
Latin America & Asia Market Group	-	1	17	6	10	70%	10	35,719	17	-	-
Foundation Market Group	-	-	-	-	5	(100)%	5	33,366	-	-	-
Referral to Hypertension Management	13	28	336	-	567	(41)%	567	1,466	336	-	-
Anglophone Africa Market Group	13	28	336	-	567	(41)%	567	1,466	336	-	-
Referral to Implant 3 Insertion	119	216	2,357	1,915	1,457	62%	1,457	19,928	2,357	2,946	658
Acceleration Market Group	-	-	-	-	-	-%	-	996	-	-	-
Anglophone Africa Market Group	-	-	293	1,915	2	14,550%	2	8,248	293	366	309
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	1	-	-	-
Latin America & Asia Market Group	119	216	2,064	-	1,455	42%	1,455	5,831	2,064	2,580	349
Foundation Market Group	-	-	-	-	-	-%	-	1,674	-	-	-
Inactive	-	-	-	-	-	-%	-	3,178	-	-	-
Referral to Implant 5 Insertion	73	57	579	187	223	160%	223	20,308	579	1,100	259
Acceleration Market Group	-	-	-	-	-	-%	-	584	-	-	-
Anglophone Africa Market Group	-	-	11	187	2	450%	2	3,607	11	21	17
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	4,681	-	-	-
Latin America & Asia Market Group	73	57	568	-	221	157%	221	1,830	568	1,079	242
Foundation Market Group	-	-	-	-	-	-%	-	9,606	-	-	-
Referral to Implant Insertion (duration unknown)	-	4	20	-	-	-%	-	109	20	25	3

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
Anglophone Africa Market Group	-	-	-	-	-	-%	-	89	-	-	-
Latin America & Asia Market Group	-	4	20	-	-	-%	-	20	20	25	3
Referral to Injectable (duration unknown)	-	-	-	-	-	-%	-	773	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	110	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	663	-	-	-
Referral to Injectable 1	-	5	25	-	47	(47)%	47	436	25	1	-
Anglophone Africa Market Group	-	-	-	-	36	(100)%	36	400	-	-	-
Latin America & Asia Market Group	-	5	25	-	11	127%	11	36	25	1	-
Referral to Injectable 2	-	-	-	-	-	-%	-	56	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	56	-	-	-
Referral to Injectable 3	175	88	1,952	6,372	471	314%	471	25,425	1,952	244	92
Anglophone Africa Market Group	-	-	887	6,372	75	1,083%	75	7,834	887	111	69
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	8,596	-	-	-
Latin America & Asia Market Group	175	88	1,065	-	396	169%	396	8,995	1,065	133	23
Referral to IUD 10 Insertion	254	284	2,354	48	734	221%	734	135,617	2,354	5,414	973
Acceleration Market Group	-	-	-	-	-	-%	-	8,256	-	-	-
Anglophone Africa Market Group	-	-	4	48	5	(20)%	5	24,176	4	9	7
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	6,239	-	-	-
Latin America & Asia Market Group	254	284	2,350	-	729	222%	729	75,540	2,350	5,405	965
Foundation Market Group	-	-	-	-	-	-%	-	20,969	-	-	-
Inactive	-	-	-	-	-	-%	-	437	-	-	-
Referral to IUD 5 Insertion	-	-	-	-	-	-%	-	498	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	440	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	58	-	-	-
Referral to IUD Insertion (duration unknown)	-	2	19	-	-	-%	-	35	19	31	4
Anglophone Africa Market Group	-	-	-	-	-	-%	-	16	-	-	-
Latin America & Asia Market Group	-	2	19	-	-	-%	-	19	19	31	4

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
Referral to IUS 3 Insertion	-	-	-	-	-	-%	-	26	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	26	-	-	-
Referral to Linkage to HIV Care	10,251	13,749	121,913	45,296	26,986	352%	26,986	174,978	121,913	-	97,130
Acceleration Market Group	-	242	5,843	12,150	-	-%	-	5,843	5,843	-	2,767
Anglophone Africa Market Group	9,980	13,204	112,751	29,940	24,186	366%	24,186	159,395	112,751	-	91,588
Franco/Lusophone Africa Market Group	-	-	-	1,279	-	-%	-	281	-	-	-
Latin America & Asia Market Group	271	304	3,319	1,627	2,800	19%	2,800	9,451	3,319	-	2,776
Foundation Market Group	-	-	-	300	-	-%	-	-	-	-	-
Inactive	-	-	-	-	-	-%	-	8	-	-	-
Referral to Manual Vacuum Aspiration - PAC	-	-	-	-	-	-%	-	46	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	46	-	-	-
Referral to Medication Abortion	-	-	-	-	-	-%	-	24	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	24	-	-	-
Referral to OCs	132	78	1,119	665	484	131%	484	11,219	1,119	37	8
Anglophone Africa Market Group	-	-	84	665	93	(10)%	93	3,389	84	3	2
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	1,392	-	-	-
Latin America & Asia Market Group	132	78	1,035	-	391	165%	391	6,438	1,035	34	6
Referral to Opioid Treatment	8	5	84	37	135	(38)%	135	556	84	-	-
Latin America & Asia Market Group	8	5	84	37	135	(38)%	135	556	84	-	-
Referral to PAC Service (unknown)	-	-	-	-	-	-%	-	488	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	488	-	-	-
Referral to Pre-Exposure Prophylaxis (PrEP)	-	-	3	-	20	(85)%	20	253	3	-	-
Anglophone Africa Market Group	-	-	3	-	20	(85)%	20	253	3	-	-
Referral to STI Diagnosis (lab confirmed)	-	-	-	-	-	-%	-	332	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	332	-	-	-
Referral to STI Screening (syndromic)	-	-	-	112,000	7	(100)%	7	14,419	-	-	-
Anglophone Africa Market Group	-	-	-	112,000	7	(100)%	7	14,419	-	-	-

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
Referral to STI Treatment (unknown)	-	-	-	-	119	(100)%	119	9,012	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	1,690	-	-	-
Anglophone Africa Market Group	-	-	-	-	119	(100)%	119	4,864	-	-	-
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	128	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	2,330	-	-	-
Referral to TB Diagnosis	-	-	-	-	11	(100)%	11	30,963	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	3,898	-	-	-
Anglophone Africa Market Group	-	-	-	-	11	(100)%	11	16,052	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	11,013	-	-	-
Referral to TB DOTS (completion confirmed)	69	64	1,101	2,459	1,364	(19)%	1,364	4,627	1,101	-	3,191
Acceleration Market Group	69	55	1,020	2,349	1,214	(16)%	1,214	3,866	1,020	-	3,163
Anglophone Africa Market Group	-	-	-	-	2	(100)%	2	19	-	-	-
Latin America & Asia Market Group	-	9	81	110	148	(45)%	148	742	81	-	28
Referral to TB DOTS (completion unknown)	71	72	1,293	2,374	1,692	(24)%	1,692	10,981	1,293	-	3,599
Acceleration Market Group	71	72	1,289	2,374	1,575	(18)%	1,575	6,345	1,289	-	3,598
Anglophone Africa Market Group	-	-	-	-	74	(100)%	74	4,388	-	-	-
Latin America & Asia Market Group	-	-	4	-	43	(91)%	43	248	4	-	1
Referral to TB Screening	-	-	-	5,497	329	(100)%	329	115,621	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	85,548	-	-	-
Anglophone Africa Market Group	-	-	-	5,497	308	(100)%	308	29,857	-	-	-
Latin America & Asia Market Group	-	-	-	-	21	(100)%	21	216	-	-	-
Referral to Treatment for Cervicitis	-	-	-	-	47	(100)%	47	119	-	-	-
Anglophone Africa Market Group	-	-	-	-	47	(100)%	47	119	-	-	-
Referral to Treatment for Genital Herpes	-	-	-	-	3	(100)%	3	12	-	-	-
Anglophone Africa Market Group	-	-	-	-	3	(100)%	3	12	-	-	-
Referral to Treatment for Inguinal Bubo	-	-	-	112	2	(100)%	2	136	-	-	-
Anglophone Africa Market Group	-	-	-	112	2	(100)%	2	136	-	-	-

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
Referral to Treatment for Lower Abdominal Pain	-	-	-	112	1	(100)%	1	137	-	-	-
Anglophone Africa Market Group	-	-	-	112	1	(100)%	1	137	-	-	-
Referral to Treatment for Urethral Discharge (Men)	-	-	-	336	53	(100)%	53	2,659	-	-	-
Anglophone Africa Market Group	-	-	-	336	53	(100)%	53	2,659	-	-	-
Referral to Treatment for Vaginitis	-	-	1	-	-	-%	-	7,248	1	-	-
Anglophone Africa Market Group	-	-	1	-	-	-%	-	7,248	1	-	-
Referral to Tubal Ligation	-	-	-	-	2	(100)%	2	67	-	-	-
Anglophone Africa Market Group	-	-	-	-	2	(100)%	2	6	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	61	-	-	-
Referral to Tx for Nonherpetic Genital Ulcer	-	-	1	-	25	(96)%	25	1,100	1	-	-
Anglophone Africa Market Group	-	-	1	-	25	(96)%	25	1,100	1	-	-
Referral to Tx for Urethral Discharge (Women)	-	-	10	560	48	(79)%	48	2,480	10	-	1
Anglophone Africa Market Group	-	-	10	560	48	(79)%	48	2,480	10	-	1
Referral to Vasectomy	-	-	1	-	-	-%	-	3	1	5	1
Anglophone Africa Market Group	-	-	-	-	-	-%	-	2	-	-	-
Latin America & Asia Market Group	-	-	1	-	-	-%	-	1	1	5	1
Referral to Voluntary Medical Male Circumcision	-	-	3	-	139	(98)%	139	20,730	3	-	10
Acceleration Market Group	-	-	-	-	-	-%	-	3,382	-	-	-
Anglophone Africa Market Group	-	-	3	-	139	(98)%	139	17,348	3	-	10
Retreatment	-	-	-	-	-	-%	-	46,984,114	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	8,050,379	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	35,287,804	-	-	-
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	1,094,479	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	1,275,789	-	-	-
Foundation Market Group	-	-	-	-	-	-%	-	1,009,438	-	-	-
Inactive	-	-	-	-	-	-%	-	266,225	-	-	-
Retreatment IconMaxx	-	-	-	-	-	-%	-	4,873,846	-	-	-

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
Anglophone Africa Market Group	-	-	-	-	-	-%	-	2,297,300	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	2,576,546	-	-	-
Retreatment KO123	-	-	-	-	-	-%	-	9,124,110	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	1,106,836	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	8,013,192	-	-	-
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	4,082	-	-	-
Retreatment KO123 net	-	-	-	-	-	-%	-	10,259,477	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	2,151,532	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	8,107,945	-	-	-
Safe Injection Kit	-	-	-	-	-	-%	-	5	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	5	-	-	-
Safe Water Solution	232,025	247,281	4,422,513	4,507,380	5,579,483	(21)%	5,579,483	167,764,778	3,684,335	-	13,843
Acceleration Market Group	71,700	71,529	1,418,258	1,160,000	1,114,276	27%	1,114,276	34,407,902	1,165,692	-	2,876
Anglophone Africa Market Group	54,269	78,236	1,052,196	1,915,700	2,248,493	(53)%	2,248,493	83,404,668	789,591	-	2,730
Franco/Lusophone Africa Market Group	106,032	94,703	1,581,666	1,400,000	870,831	82%	870,831	14,310,787	1,299,999	-	6,786
Latin America & Asia Market Group	-	-	-	-	-	-%	-	2,276,004	-	-	-
Foundation Market Group	24	2,813	370,393	31,680	1,345,883	(72)%	1,345,883	28,782,744	429,053	-	1,452
Inactive	-	-	-	-	-	-%	-	4,582,673	-	-	-
SD NVP w/o Baby ARV Prophylaxis	-	-	-	-	-	-%	-	271	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	271	-	-	-
SD NVP with Baby ARV Prophylaxis	-	-	-	-	-	-%	-	235	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	235	-	-	-
SDM (Cycle Beads)	(14)	393	1,264	306	6,654	(81)%	6,654	628,869	1,138	1,706	1,340
Acceleration Market Group	-	-	-	-	-	-%	-	201,447	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	8,591	-	-	-
Franco/Lusophone Africa Market Group	(10)	408	1,449	306	1,533	(5)%	1,533	49,478	1,304	1,956	1,500
Latin America & Asia Market Group	-	-	-	-	-	-%	-	2,494	-	-	-

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
Foundation Market Group	(4)	(15)	(185)	-	5,121	(104)%	5,121	351,101	(167)	(250)	(160)
Inactive	-	-	-	-	-	-%	-	15,758	-	-	-
SDM (Cycle Beads) Provided	1,288	1,778	6,967	2,550	609	1,044%	609	19,632	6,967	10,451	8,155
Acceleration Market Group	1,252	1,755	6,606	-	3	220,100%	3	6,609	6,606	9,909	7,738
Anglophone Africa Market Group	-	-	-	-	-	-%	-	10	-	-	-
Franco/Lusophone Africa Market Group	10	3	110	2,550	96	15%	96	507	110	165	127
Latin America & Asia Market Group	-	-	4	-	7	(43)%	7	130	4	6	1
Foundation Market Group	26	20	247	-	503	(51)%	503	12,376	247	371	289
Seasonal Malaria Chemoprevention	-	-	-	-	2,009,973	(100)%	2,009,973	4,420,982	-	-	-
Franco/Lusophone Africa Market Group	-	-	-	-	344,748	(100)%	344,748	344,748	-	-	-
Foundation Market Group	-	-	-	-	1,665,225	(100)%	1,665,225	4,076,234	-	-	-
Seasonal Malaria Chemoprevention_children reached	4,772,814	-	4,772,814	2,761,537	-	-%	-	4,772,814	4,772,814	-	1,409,957
Franco/Lusophone Africa Market Group	2,780,737	-	2,780,737	990,000	-	-%	-	2,780,737	2,780,737	-	471,469
Foundation Market Group	1,992,077	-	1,992,077	1,771,537	-	-%	-	1,992,077	1,992,077	-	938,488
Skilled Birth Attendance	9,052	3,180	45,944	66,196	45,970	-%	45,970	201,710	45,944	-	50,135
Acceleration Market Group	6,891	1,327	25,405	40,000	20,115	26%	20,115	87,574	25,405	-	21,117
Anglophone Africa Market Group	-	-	-	-	-	-%	-	50,567	-	-	-
Franco/Lusophone Africa Market Group	91	89	1,560	9,000	9,160	(83)%	9,160	27,895	1,560	-	1,976
Foundation Market Group	2,070	1,764	18,979	17,196	16,695	14%	16,695	35,674	18,979	-	27,042
STI Kit	-	-	-	-	-	-%	-	691,263	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	240,890	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	438,695	-	-	-
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	329	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	9,882	-	-	-
Inactive	-	-	-	-	-	-%	-	1,467	-	-	-
STI Kit (Non-Ulcerative)	-	489	4,732	1,869	6,655	(29)%	6,655	4,022,900	4,259	-	304
Acceleration Market Group	-	-	-	-	-	-%	-	742,374	-	-	-

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
Anglophone Africa Market Group	-	489	4,732	1,869	6,655	(29)%	6,655	870,733	4,259	-	304
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	7,704	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	348,335	-	-	-
Foundation Market Group	-	-	-	-	-	-%	-	2,053,754	-	-	-
STI Kit (Ulcerative)	-	89	1,588	231	-	-%	-	1,855,742	1,429	-	305
Acceleration Market Group	-	-	-	-	-	-%	-	60,473	-	-	-
Anglophone Africa Market Group	-	89	1,588	231	-	-%	-	74,280	1,429	-	305
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	480	-	-	-
Foundation Market Group	-	-	-	-	-	-%	-	1,720,509	-	-	-
STI Screening	10,107	10,830	153,919	227,782	254,307	(39)%	254,307	1,440,307	153,919	-	-
Acceleration Market Group	842	1,085	16,593	-	27,221	(39)%	27,221	90,509	16,593	-	-
Anglophone Africa Market Group	7,745	8,329	118,274	144,457	75,388	57%	75,388	681,190	118,274	-	-
Franco/Lusophone Africa Market Group	626	628	9,457	-	8,747	8%	8,747	40,443	9,457	-	-
Latin America & Asia Market Group	23	48	265	-	99	168%	99	4,255	265	-	-
Foundation Market Group	871	740	9,330	83,325	142,852	(93)%	142,852	623,412	9,330	-	-
Inactive	-	-	-	-	-	-%	-	498	-	-	-
TB Diagnosis	3,829	3,890	52,626	28,643	62,691	(16)%	62,691	276,483	52,626	-	-
Acceleration Market Group	1,482	1,331	13,610	16,181	14,315	(5)%	14,315	101,005	13,610	-	-
Anglophone Africa Market Group	18	16	231	77	283	(18)%	283	1,708	231	-	-
Latin America & Asia Market Group	2,329	2,543	28,670	385	29,853	(4)%	29,853	114,306	28,670	-	-
Foundation Market Group	-	-	10,115	12,000	18,240	(45)%	18,240	49,245	10,115	-	-
Inactive	-	-	-	-	-	-%	-	10,219	-	-	-
TB DOTS	3,240	3,282	49,491	23,210	61,338	(19)%	61,338	434,057	49,491	-	234,269
Acceleration Market Group	948	1,179	12,584	13,173	12,891	(2)%	12,891	234,445	12,584	-	78,056
Anglophone Africa Market Group	3	3	35	77	35	-%	35	136	35	-	284
Latin America & Asia Market Group	2,289	2,100	25,764	-	26,012	(1)%	26,012	139,571	25,764	-	117,907
Foundation Market Group	-	-	11,108	9,960	22,400	(50)%	22,400	54,142	11,108	-	38,021

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
Inactive	-	-	-	-	-	-%	-	5,763	-	-	-
TB Screening	35,072	34,405	464,241	202,098	478,931	(3)%	478,931	2,644,521	464,241	-	-
Acceleration Market Group	8,077	9,721	118,645	149,616	103,950	14%	103,950	599,044	118,645	-	-
Anglophone Africa Market Group	17,982	19,005	241,495	34,396	225,880	7%	225,880	1,692,520	241,495	-	-
Latin America & Asia Market Group	9,013	5,679	65,241	4,086	72,433	(10)%	72,433	206,757	65,241	-	-
Foundation Market Group	-	-	38,860	14,000	76,668	(49)%	76,668	139,061	38,860	-	-
Inactive	-	-	-	-	-	-%	-	7,139	-	-	-
Toilets Constructed	-	-	-	-	-	-%	-	16,479	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	12,802	-	-	-
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	5	-	-	-
Foundation Market Group	-	-	-	-	-	-%	-	3,672	-	-	-
Toilets Sold	3,983	12,481	105,669	98,457	64,462	64%	64,462	374,180	514,069	-	14,812
Acceleration Market Group	-	7,881	68,647	60,000	50,363	36%	50,363	314,891	329,506	-	7,865
Anglophone Africa Market Group	2,028	2,929	20,460	25,600	5,651	262%	5,651	26,110	93,379	-	3,607
Franco/Lusophone Africa Market Group	1,948	1,493	15,356	8,107	4,017	282%	4,017	19,373	85,982	-	3,281
Latin America & Asia Market Group	-	175	1,113	750	4,405	(75)%	4,405	7,416	4,675	-	39
Foundation Market Group	6	3	93	4,000	27	239%	27	6,390	529	-	20
Toilets Sold - All	10,719	14,218	127,071	-	69,029	84%	69,029	196,100	612,561	-	-
Acceleration Market Group	6,161	7,881	74,808	-	50,363	49%	50,363	125,171	359,078	-	-
Anglophone Africa Market Group	2,028	3,968	27,092	-	7,266	273%	7,266	34,358	117,254	-	-
Franco/Lusophone Africa Market Group	2,403	2,113	22,150	-	5,726	287%	5,726	27,876	120,678	-	-
Latin America & Asia Market Group	-	175	1,113	-	4,159	(73)%	4,159	5,272	4,675	-	-
Foundation Market Group	127	81	1,908	-	1,515	26%	1,515	3,423	10,876	-	-
Treatment for Cervicitis	22	35	316	-	101	213%	101	735	316	-	15
Anglophone Africa Market Group	12	20	193	-	73	164%	73	556	193	-	15
Franco/Lusophone Africa Market Group	5	1	29	-	-	-%	-	42	29	-	-
Latin America & Asia Market Group	5	14	94	-	28	236%	28	137	94	-	-

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
Treatment for Genital Herpes	34	54	612	17	70	774%	70	783	612	-	11
Anglophone Africa Market Group	11	27	135	17	28	382%	28	234	135	-	4
Franco/Lusophone Africa Market Group	23	26	476	-	42	1,033%	42	540	476	-	7
Latin America & Asia Market Group	-	-	1	-	-	-%	-	9	1	-	-
Treatment for Inguinal Bubo	6	5	99	-	89	11%	89	319	99	-	-
Anglophone Africa Market Group	1	-	18	-	3	500%	3	35	18	-	-
Franco/Lusophone Africa Market Group	4	4	55	-	33	67%	33	122	55	-	-
Foundation Market Group	1	1	26	-	53	(51)%	53	162	26	-	-
Treatment for Lower Abdominal Pain	122	189	1,963	54	1,571	25%	1,571	5,340	1,963	-	-
Anglophone Africa Market Group	33	62	465	54	78	496%	78	678	465	-	-
Franco/Lusophone Africa Market Group	54	87	997	-	693	44%	693	2,064	997	-	-
Latin America & Asia Market Group	-	2	7	-	-	-%	-	7	7	-	-
Foundation Market Group	35	38	494	-	800	(38)%	800	2,591	494	-	-
Treatment for Nonherpetic Genital Ulcer	182	195	2,444	94	6,745	(64)%	6,745	18,971	2,444	-	425
Anglophone Africa Market Group	40	39	663	94	546	21%	546	1,809	663	-	205
Franco/Lusophone Africa Market Group	95	103	1,093	-	1,027	6%	1,027	2,882	1,093	-	143
Latin America & Asia Market Group	-	1	2	-	-	-%	-	4	2	-	-
Foundation Market Group	47	53	686	-	5,172	(87)%	5,172	14,276	686	-	77
Treatment for Pre-Eclampsia (with MgSO4)	108	40	453	413	392	16%	392	966	453	-	1,461
Acceleration Market Group	21	6	43	60	49	(12)%	49	213	43	-	38
Foundation Market Group	87	34	410	353	343	20%	343	753	410	-	1,423
Treatment for Severe Acute Malnutrition	362	746	6,999	9,896	12,893	(46)%	12,893	61,542	6,999	-	26,679
Franco/Lusophone Africa Market Group	-	-	-	8	-	-%	-	4	-	-	-
Foundation Market Group	362	746	6,999	9,888	12,893	(46)%	12,893	61,538	6,999	-	26,679
Treatment for Urethral Discharge (Men)	613	501	6,451	195	7,519	(14)%	7,519	23,526	12,643	-	124
Anglophone Africa Market Group	61	67	741	195	292	154%	292	1,643	1,363	-	80
Franco/Lusophone Africa Market Group	151	158	2,005	-	1,631	23%	1,631	4,961	4,010	-	23

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
Foundation Market Group	401	276	3,705	-	5,596	(34)%	5,596	16,922	7,270	-	21
Treatment for Urethral Discharge (Women)	669	341	4,783	2	2,577	86%	2,577	9,854	4,783	-	251
Anglophone Africa Market Group	104	107	1,141	2	507	125%	507	2,664	1,141	-	167
Franco/Lusophone Africa Market Group	283	234	3,359	-	2,054	64%	2,054	6,884	3,359	-	84
Latin America & Asia Market Group	-	-	1	-	1	-%	1	9	1	-	-
Foundation Market Group	282	-	282	-	15	1,780%	15	297	282	-	-
Treatment for Vaginitis	252	308	3,931	380	5,511	(29)%	5,511	18,211	3,931	-	90
Anglophone Africa Market Group	22	10	351	380	506	(31)%	506	2,563	351	-	62
Franco/Lusophone Africa Market Group	-	-	150	-	2	7,400%	2	157	150	-	-
Latin America & Asia Market Group	18	31	217	-	25	768%	25	245	217	-	-
Foundation Market Group	212	266	3,213	-	4,978	(35)%	4,978	15,246	3,213	-	28
Tubal Ligation	8,635	7,235	63,831	42,589	67,507	(5)%	67,507	435,387	63,831	769,998	261,292
Acceleration Market Group	7,964	4,709	44,513	25,000	38,957	14%	38,957	126,728	44,513	576,818	156,356
Anglophone Africa Market Group	667	1,525	10,713	17,589	16,391	(35)%	16,391	46,527	10,713	107,130	84,383
Franco/Lusophone Africa Market Group	-	-	-	-	204	(100)%	204	204	-	-	-
Latin America & Asia Market Group	3	996	8,574	-	11,913	(28)%	11,913	261,781	8,574	85,740	20,411
Foundation Market Group	1	4	31	-	42	(26)%	42	147	31	310	142
Type 2 Diabetes Diagnosis	26	-	27	-	4	575%	4	1,462	27	-	-
Anglophone Africa Market Group	-	-	-	-	3	(100)%	3	1,434	-	-	-
Latin America & Asia Market Group	-	-	1	-	1	-%	1	2	1	-	-
Foundation Market Group	26	-	26	-	-	-%	-	26	26	-	-
Type 2 Diabetes Screening	87	1,236	22,650	33,797	6,712	237%	6,712	39,243	22,650	-	-
Anglophone Africa Market Group	87	1,236	22,647	33,797	6,711	237%	6,711	39,237	22,647	-	-
Latin America & Asia Market Group	-	-	3	-	1	200%	1	6	3	-	-
Type 2 Diabetes Controlled Condition	-	-	2	-	6	(67)%	6	14	-	-	-
Anglophone Africa Market Group	-	-	-	-	6	(100)%	6	12	-	-	-
Latin America & Asia Market Group	-	-	2	-	-	-%	-	2	-	-	-

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
Vaginal Wash	(39)	45	18,625	71,280	-	-%	-	18,625	-	-	-
Social Enterprise	(39)	45	18,625	71,280	-	-%	-	18,625	-	-	-
Vasectomy	252	368	2,024	1,029	709	185%	709	7,025	2,024	25,373	6,898
Acceleration Market Group	252	338	1,717	1,000	287	498%	287	5,673	1,717	22,303	6,046
Anglophone Africa Market Group	-	4	17	29	-	-%	-	57	17	170	148
Franco/Lusophone Africa Market Group	-	-	-	-	104	(100)%	104	104	-	-	-
Latin America & Asia Market Group	-	25	290	-	318	(9)%	318	1,191	290	2,900	704
Vivax Treatment after Confirmatory Diagnosis	218	180	2,286	248	3,400	(33)%	3,400	11,657	2,286	-	421
Acceleration Market Group	171	134	1,993	-	3,244	(39)%	3,244	11,199	1,993	-	365
Latin America & Asia Market Group	47	47	293	248	156	88%	156	458	293	-	55
Voluntary Medical Male Circumcision	27,148	25,169	373,926	396,145	424,870	(12)%	424,870	2,866,695	373,926	-	2,482,667
Acceleration Market Group	16,334	3,934	103,723	90,000	78,885	31%	78,885	411,498	103,723	-	730,557
Anglophone Africa Market Group	10,814	21,235	270,203	306,145	345,985	(22)%	345,985	2,393,932	270,203	-	1,752,110
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	61,265	-	-	-
Water Treatment Tablets	2,224,020	2,777,283	33,092,882	35,643,920	38,726,042	(15)%	38,726,042	851,881,198	543,993	-	3,920
Acceleration Market Group	10,800	5,760	708,480	300,000	501,290	41%	501,290	6,648,847	11,646	-	29
Anglophone Africa Market Group	16,800	1,157,540	6,229,910	8,068,408	6,957,142	(10)%	6,957,142	364,414,420	102,409	-	405
Franco/Lusophone Africa Market Group	2,148,220	1,176,133	21,225,440	20,485,262	20,217,570	5%	20,217,570	185,471,340	348,911	-	2,882
Latin America & Asia Market Group	4,000	1,417	74,110	80,000	91,160	(19)%	91,160	10,827,093	1,218	-	3
Foundation Market Group	44,200	436,433	4,854,942	6,710,250	10,958,880	(56)%	10,958,880	284,519,498	79,807	-	600
Woman Condom	-	-	1,920	-	97,728	(98)%	97,728	141,480	14	14	40
Anglophone Africa Market Group	-	-	1,920	-	97,728	(98)%	97,728	141,480	14	14	40
Zika Prevention Kit	-	-	-	-	725	(100)%	725	114,581	-	-	-
Latin America & Asia Market Group	-	-	-	-	725	(100)%	725	114,581	-	-	-
Zinc	-	873	2,822	-	512,836	(99)%	512,836	7,212,221	2,540	-	62
Acceleration Market Group	-	-	-	-	-	-%	-	953,402	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	1,034,758	-	-	-

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	669,429	-	-	-
Latin America & Asia Market Group	-	23	132	-	-	-%	-	481,381	119	-	1
Foundation Market Group	-	850	2,690	-	512,836	(99)%	512,836	4,073,251	2,421	-	61
Zinc Provided	3,650	2,152	28,688	12,189	11,834	142%	11,834	73,597	28,688	-	752
Foundation Market Group	3,650	2,152	28,688	12,189	11,834	142%	11,834	73,597	28,688	-	752

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

Acceleration Market Group

POPULATION SERVICES INTERNATIONAL
CYPs, Cases, and Deaths by Country
1/2019 - 12/2019

	New HIV Infections	STI Deaths	PWID Deaths	TB Deaths	CYP*	Maternal Deaths	Unintended Pregnancies	Malaria Deaths	Diarrhea Deaths	Pneumonia Deaths	Cervical Cancer Death	Sum of All Deaths
Acceleration Market Group	41,942	-	-	3,129	3,382,778	4,670	1,501,143	1,085	564	123	3	26,663
India	-	-	-	-	1,199,348	350	628,605	-	257	-	-	3,805
Kenya	20,615	-	-	-	1,047,758	1,263	413,568	536	61	123	1	8,842
Myanmar	1,900	-	-	3,129	587,982	137	208,366	549	246	-	1	4,851
Nigeria	-	-	-	-	102,046	238	46,892	-	-	-	-	1,407
PSI Nigeria	-	-	-	-	445,644	2,681	203,712	-	-	-	-	7,759
South Africa	19,426	-	-	-	-	-	-	-	-	-	-	-

* Using USAID CYP conversion factors

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Market Group and Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE SALES	YTD USERS REACHED ^(a) 2019	YTD CYP 2019	YTD DALY 2019
Acceleration Market Group										3,382,778	3,642,740
Antiretroviral Treatment (Currently Enrolled)	15,532	15,167	174,024	170,176	152,003	14%	152,003	402,508	14,502	-	34,444
Antiretroviral Treatment (Newly Enrolled)	263	309	3,744	3,981	3,434	9%	3,434	13,330	3,744	-	-
Cervical Cancer-VIA and Cryotherapy	7	22	307	240	286	7%	286	4,580	307	-	73
Cervical Cancer-VIA and Refer to Conization	-	-	-	-	4	(100)%	4	4	-	-	-
Cervical Cancer-VIA and Refer to Cryotherapy	-	-	-	150	29	(100)%	29	48	-	-	-
Cervical Cancer-VIA/VILI Screening	288	1,514	37,955	21,500	34,714	9%	34,714	325,684	37,955	-	-
Condom	3,408,750	4,118,821	45,303,579	41,769,999	38,017,548	19%	38,017,548	1,020,807,627	339,777	339,777	1,000,040
Diarrhea Treatment Kit Provided	-	-	15,147	29,000	18,226	(17)%	18,226	69,404	15,147	-	503
Emergency Contraception	-	333	1,000	-	5	19,900%	5	178,869	45	45	4
Emergency Contraception Provided	20,252	9,473	75,323	19,800	4,173	1,705%	4,173	80,924	3,766	3,766	561
Fecal Sludge Management (Households)	-	6	489	400	697	(30)%	697	2,768	2,347	-	-
Fecal Sludge Management (Liters)	-	30,000	1,914,000	2,000,000	4,011,000	(52)%	4,011,000	13,071,200	-	-	118
Female Condom	-	-	85,553	70,000	79,641	7%	79,641	1,556,019	642	642	461
Fever Cases Attended	73,979	48,786	520,128	-	697,782	(25)%	697,782	2,951,296	520,128	-	-
Fever Cases Tested with RDTs	73,979	48,786	520,128	-	697,782	(25)%	697,782	2,951,296	520,128	-	-
Free Condom	-	2,400	1,920,960	35,500,000	68,170,320	(97)%	68,170,320	1,177,078,157	14,407	14,407	56,881
Free Female Condom	11,695	9,857	49,875	-	1,108,500	(96)%	1,108,500	5,080,475	374	374	269
HIV Self-Testing Kit	5,390	155,147	647,230	1,066,643	1,357,422	(52)%	1,357,422	2,004,652	582,507	-	-
HIV Testing Services	14,865	18,072	318,640	293,418	1,091,132	(71)%	1,091,132	6,376,603	318,640	-	12,203
Hypertension Diagnosis	19,902	1,061	51,351	20,000	57,768	(11)%	57,768	125,160	51,351	-	-
Hypertension Screening	27,633	1,934	108,524	50,000	176,640	(39)%	176,640	319,678	108,524	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Market Group and Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE SALES	YTD USERS REACHED ^(a) 2019	YTD CYP 2019	YTD DALY 2019
Hypertension_Controlled Condition	16,777	824	39,737	-	43,499	(9)%	43,499	95,546	15,895	-	-
Implant 3	363	1,401	10,355	12,600	1,528	578%	1,528	829,031	9,320	23,299	15,549
Implant 3 Insertion	8,449	10,592	51,603	38,123	8,884	481%	8,884	63,968	51,603	129,008	98,957
Implant 4 Insertion	-	-	-	-	288	(100)%	288	288	-	-	-
Implant 5	(4,760)	(13)	(4,707)	(7,600)	2,423	(294)%	2,423	49,283	(4,236)	(16,098)	(11,752)
Implant 5 Insertion	8,863	10,126	117,879	62,915	82,547	43%	82,547	532,580	117,879	447,940	394,964
Injectable 1 Provided	6	5	44	-	37	19%	37	81	3	3	3
Injectable 2 Provided	1,175	1,296	13,459	-	5,875	129%	5,875	19,334	2,243	2,243	1,891
Injectable 3-IM	58,149	43,750	514,301	480,600	644,429	(20)%	644,429	16,277,946	115,718	115,718	25,256
Injectable 3-IM Provided	47,032	59,148	385,457	204,422	175,770	119%	175,770	756,511	96,364	96,364	44,273
Injectable 3-SC	3,278	2,602	31,405	32,150	-	-%	-	31,405	7,066	7,066	884
Injectable 3-SC Provided	897	1,258	9,727	-	-	-%	-	9,727	2,432	2,432	2,050
IPTp2	1,860	287	6,109	-	3,893	57%	3,893	20,406	6,109	-	228
IUD 10	(198)	3	(331)	(4,600)	684	(148)%	684	13,015	(298)	(1,370)	(1,500)
IUD 10 Insertion	8,223	10,578	101,968	103,790	90,084	13%	90,084	631,496	101,968	469,053	450,542
IUD 5	48	24	362	2,500	472	(23)%	472	141,764	326	1,075	183
IUD 5 Insertion	27,103	20,992	162,738	65,000	51,661	215%	51,661	337,261	162,738	537,035	121,524
IUS 5 Insertion	75	103	1,102	-	775	42%	775	2,503	1,102	3,637	4,182
LLIN	10,625	1,853	1,093,373	2,049,898	2,332,163	(53)%	2,332,163	24,776,100	1,771,264	-	41,770
Lubricant	271,000	286,000	2,318,836	70,000	51,861	4,371%	51,861	7,551,522	-	-	-
Malaria PPT (ACT)	1,089	391	174,362	182,270	256,333	(32)%	256,333	3,363,258	156,926	-	24,461

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Market Group and Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE SALES	YTD USERS REACHED ^(a) 2019	YTD CYP 2019	YTD DALY 2019
Malaria PPT (Non-ACT)	224	174	2,954	3,621	(1,900)	-%	(1,900)	107,280	2,659	-	414
Malaria RDK	-	-	-	432,337	743,410	(100)%	743,410	4,731,974	-	-	-
Manual Vacuum Aspiration for PAC	485	742	7,879	5,220	19,176	(59)%	19,176	27,055	7,879	-	6,309
Medical Abortion	-	652	2,000	9,000	-	-%	-	2,000	1,800	-	1,689
Micronutrient Powder	-	-	-	-	2,000,000	(100)%	2,000,000	9,499,690	-	-	-
Misoprostol for PAC Provided	382	675	7,331	5,220	14,855	(51)%	14,855	22,186	7,331	-	6,952
Misoprostol for Safe Abortion	26,472	134,133	1,774,246	2,339,690	2,321,200	(24)%	2,321,200	4,095,446	93,148	-	78,213
Multivitamin	-	-	-	-	450,010	(100)%	450,010	883,520	-	-	-
Needle & Syringe	-	-	10,100	-	-	-%	-	1,956,069	35	-	83
OCs	750,138	996,206	9,114,680	10,222,400	9,535,861	(4)%	9,535,861	74,987,578	546,881	546,881	154,562
OCs Provided	144,657	101,057	756,782	181,469	151,894	398%	151,894	1,001,891	50,452	50,452	11,210
ORS	38,020	124,149	847,044	600,000	514,198	65%	514,198	2,077,898	381,170	-	22,210
ORS Provided	-	-	2,043	-	2,217	(8)%	2,217	9,430	2,043	-	33
Pneumonia PPT	-	-	-	28,910	-	-%	-	-	-	-	-
Pneumonia PPT Provided	4,452	662	21,771	-	20,179	8%	20,179	79,844	21,771	-	10,472
Positive RDTs	426	351	4,386	-	9,712	(55)%	9,712	39,857	4,386	-	-
Positive RDTs Given First Line Treatment	417	348	4,242	-	8,937	(53)%	8,937	35,245	4,242	-	-
PrEP	69	75	547	-	-	-%	-	547	46	-	23
PUR	2,779,200	2,809,843	32,575,220	19,000,000	28,508,349	14%	28,508,349	213,355,146	267,742	-	661
QAACts Provided after Confirmatory Diagnosis	33,218	108	58,000	95,000	101,767	(43)%	101,767	178,545	58,000	-	9,564
Referral to HIV Testing Services	-	-	21,265	-	-	-%	-	21,265	21,265	-	754

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Market Group and Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE SALES	YTD USERS REACHED ^(a) 2019	YTD CYP 2019	YTD DALY 2019
Referral to Linkage to HIV Care	-	242	5,843	12,150	-	-%	-	5,843	5,843	-	2,767
Referral to TB DOTS (completion confirmed)	69	55	1,020	2,349	1,214	(16)%	1,214	2,527	1,020	-	3,163
Referral to TB DOTS (completion unknown)	71	72	1,289	2,374	1,575	(18)%	1,575	2,864	1,289	-	3,598
Safe Water Solution	71,700	71,529	1,418,258	1,160,000	1,114,276	27%	1,114,276	22,892,158	1,165,692	-	2,876
SDM (Cycle Beads) Provided	1,252	1,755	6,606	-	3	220,100%	3	6,609	6,606	9,909	7,738
Skilled Birth Attendance	6,891	1,327	25,405	40,000	20,115	26%	20,115	87,574	25,405	-	21,117
STI Screening	842	1,085	16,593	-	27,221	(39)%	27,221	77,102	16,593	-	-
TB Diagnosis	1,482	1,331	13,610	16,181	14,315	(5)%	14,315	73,214	13,610	-	-
TB DOTS	948	1,179	12,584	13,173	12,891	(2)%	12,891	230,035	12,584	-	78,056
TB Screening	8,077	9,721	118,645	149,616	103,950	14%	103,950	490,852	118,645	-	-
Toilets Sold	-	7,881	68,647	60,000	50,363	36%	50,363	119,010	329,506	-	7,865
Toilets Sold - All	6,161	7,881	74,808	-	50,363	49%	50,363	125,171	359,078	-	-
Treatment for Pre-Eclampsia (with MgSO4)	21	6	43	60	49	(12)%	49	213	43	-	38
Tubal Ligation	7,964	4,709	44,513	25,000	38,957	14%	38,957	126,716	44,513	576,818	156,356
Vasectomy	252	338	1,717	1,000	287	498%	287	5,672	1,717	22,303	6,046
Vivax Treatment after Confirmatory Diagnosis	171	134	1,993	-	3,244	(39)%	3,244	11,199	1,993	-	365
Voluntary Medical Male Circumcision	16,334	3,934	103,723	90,000	78,885	31%	78,885	255,950	103,723	-	730,557
Water Treatment Tablets	10,800	5,760	708,480	300,000	501,290	41%	501,290	6,645,680	11,646	-	29

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Acceleration Market Group											3,382,778	3,642,740
India											1,199,348	299,908
Emergency Contraception Provided	19,269	8,490	69,642	18,000	2,574		2606%	2,574	72,216	3,482	3,482	444
Non-PSI Emergency Contraception Provided	19,269	8,490	69,642	18,000	2,574		2,606%	2,574	72,216	3,482	3,482	444
Fecal Sludge Management (Households)	-	6	489	400	697		(30)%	697	2,768	2,347	-	-
Fecal Sludge Management (Households)	-	6	489	400	697		(30)%	697	2,768	2,347	-	-
Fecal Sludge Management (Liters)	-	30,000	1,914,000	2,000,000	4,011,000		(52)%	4,011,000	13,071,200	-	-	118
Fecal Sludge Management (Liters)	-	30,000	1,914,000	2,000,000	4,011,000		(52)%	4,011,000	13,071,200	-	-	118
Hypertension Diagnosis	19,246	-	19,246	-	-		0%	-	19,246	19,246	-	-
Hypertension Diagnosis	19,246	-	19,246	-	-		-%	-	19,246	19,246	-	-
Hypertension Screening	26,346	-	26,346	-	-		0%	-	26,346	26,346	-	-
Hypertension Screening	26,346	-	26,346	-	-		-%	-	26,346	26,346	-	-
Hypertension_Controlled Condition	16,293	-	16,293	-	-		0%	-	16,293	6,517	-	-
Hypertension_Controlled Condition	16,293	-	16,293	-	-		-%	-	16,293	6,517	-	-
Injectable 3-IM Provided	13,107	11,380	98,086	35,000	16,479		495%	16,479	149,515	24,522	24,522	4,103
Non-PSI Injectable 3 IM Provided	13,107	11,380	98,086	35,000	16,479		495%	16,479	149,515	24,522	24,522	4,103
IUD 10 Insertion	-	-	-	-	41		(100)%	41	2,526	-	-	-
Non-PSI IUD 10 Inserted	-	-	-	-	41		(100)%	41	2,526	-	-	-
IUD 5 Insertion	26,999	20,903	161,532	65,000	49,622		226%	49,622	277,319	161,532	533,056	120,847
Non-PSI IUD 5 Inserted	26,999	20,903	161,532	65,000	49,622		226%	49,622	277,319	161,532	533,056	120,847
OCs Provided	135,882	89,453	680,972	150,000	100,521		577%	100,521	845,629	45,398	45,398	8,013
Non-PSI OCs Provided	135,882	89,453	680,972	150,000	100,521		577%	100,521	845,629	45,398	45,398	8,013
TB Diagnosis	-	-	-	400	-		0%	-	-	-	-	-
TB Diagnosis	-	-	-	400	-		-%	-	-	-	-	-
TB DOTS	-	-	-	500	-		0%	-	-	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
TB DOTS	-	-	-	500	-		-%	-	-	-	-	-
TB Screening	-	-	-	100,000	-		0%	-	-	-	-	-
TB Screening	-	-	-	100,000	-		-%	-	-	-	-	-
Toilets Sold	-	7,881	68,647	60,000	50,363		36%	50,363	119,010	329,506	-	7,865
Toilets Sold	-	7,881	68,647	60,000	50,363		36%	50,363	119,010	329,506	-	7,865
Toilets Sold - All	6,161	7,881	74,808	-	50,363		49%	50,363	125,171	359,078	-	-
Toilets Sold - All	6,161	7,881	74,808	-	50,363		49%	50,363	125,171	359,078	-	-
Tubal Ligation	7,902	4,524	43,896	25,000	38,957		13%	38,957	126,099	43,896	570,648	152,512
Tubal Ligation	7,902	4,524	43,896	25,000	38,957		13%	38,957	126,099	43,896	570,648	152,512
Vasectomy	249	337	1,711	1,000	287		496%	287	5,666	1,711	22,243	6,008
Vasectomy	249	337	1,711	1,000	287		496%	287	5,666	1,711	22,243	6,008
Kenya											1,047,758	1,610,141
Antiretroviral Treatment (Currently Enrolled)	8,244	8,032	94,314	92,100	85,622		10%	85,622	208,766	7,859	-	20,519
Antiretroviral Treatment (Currently Enrolled)	8,244	8,032	94,314	92,100	85,622		10%	85,622	208,766	7,859	-	20,519
Antiretroviral Treatment (Newly Enrolled)	124	124	1,427	1,754	1,227		16%	1,227	4,847	1,427	-	-
Antiretroviral Treatment (Newly Enrolled)	124	124	1,427	1,754	1,227		16%	1,227	4,847	1,427	-	-
Cervical Cancer-VIA and Cryotherapy	-	4	174	200	227		(23)%	227	3,490	174	-	40
Cervical Cancer-VIA and Cryotherapy	-	4	174	200	227	7/13	(23)%	227	3,490	174	-	40
Cervical Cancer-VIA and Refer to Conization	-	-	-	-	4		(100)%	4	4	-	-	-
Cervical Cancer-VIA and Refer to Conization	-	-	-	-	4		(100)%	4	4	-	-	-
Cervical Cancer-VIA and Refer to Cryotherapy	-	-	-	150	29		(100)%	29	48	-	-	-
Cervical Cancer-VIA and Refer to Cryotherapy	-	-	-	150	29	12/14	(100)%	29	48	-	-	-
Cervical Cancer-VIA/VILI Screening	-	1,168	34,361	18,000	31,803		8%	31,803	314,735	34,361	-	-
Cervical Cancer-VIA/VILI Screening	-	1,168	34,361	18,000	31,803		8%	31,803	314,735	34,361	-	-
Condom	2,536,128	2,650,825	31,033,515	26,249,999	25,124,074		24%	25,124,074	593,836,832	232,751	232,751	921,740

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Trust	2,190,312	2,225,784	25,288,945	20,922,493	19,627,309	10/93	29%	19,627,309	527,517,193	189,667	189,667	751,118
Trust Ribbed	44,280	43,872	706,873	591,117	701,493	5/14	1%	701,493	4,399,736	5,302	5,302	20,995
Trust Scented	-	-	216	-	60,552	5/14	(100)%	60,552	3,301,903	2	2	6
Trust Studded	301,536	381,168	5,037,481	4,736,389	4,734,720	1/08	6%	4,734,720	58,618,000	37,781	37,781	149,620
Diarrhea Treatment Kit Provided	-	-	15,147	29,000	18,226		(17)%	18,226	69,404	15,147	-	503
Non-PSI Diarrhea Treatment Kit Provided	-	-	15,147	29,000	18,226		(17)%	18,226	69,404	15,147	-	503
Emergency Contraception	-	-	-	-	(126)		0%	(126)	(1,554)	-	-	-
(b)PSI Emergency Contraception Distributed Provided	-	-	-	-	(126)		-%	(126)	(1,554)	-	-	-
Emergency Contraception Provided	977	972	5,618	1,800	1,539		265%	1,539	8,585	281	281	116
Non-PSI Emergency Contraception Provided	977	972	5,618	1,800	1,413		298%	1,413	7,031	281	281	116
PSI Emergency Contraception Provided	-	-	-	-	126		(100)%	126	1,554	-	-	-
Free Condom	-	-	1,913,760	35,000,000	28,851,120		(93)%	28,851,120	92,411,197	14,353	14,353	56,841
Free Male Condom - NASCOP	-	-	1,913,760	35,000,000	28,851,120	5/11	(93)%	28,851,120	92,411,197	14,353	14,353	56,841
HIV Self-Testing Kit	5,390	4,458	48,552	37,343	69,171		(30)%	69,171	117,723	43,697	-	-
INSTI HIVST (Blood based)	2,820	1,293	6,698	25,000	40,000		(83)%	40,000	46,698	6,028	-	-
INSTI-ORAQUICK HIVST BUNDLE	-	-	-	-	1,000		(100)%	1,000	1,000	-	-	-
ORAQUICK HIV Self-Testing Kit (Saliva based)	2,570	3,166	41,854	12,343	28,171		49%	28,171	70,025	37,669	-	-
HIV Testing Services	9,213	9,417	209,881	165,478	212,997		(1)%	212,997	1,397,443	209,881	-	8,767
VCT Individual (HIV-Negative)	9,039	9,245	206,369	161,373	209,785	9/11	(2)%	209,785	1,359,589	206,369	-	8,620
VCT Individual (HIV-Positive)	174	172	3,512	4,105	3,212	9/11	9%	3,212	37,854	3,512	-	147
Implant 3	-	1,333	9,150	6,000	1		914900%	1	816,143	8,235	20,588	15,088
Implanon	-	1,333	9,150	6,000	1	3/14	914,900%	1	816,143	8,235	20,588	15,088
Implant 3 Insertion	6,612	8,738	32,827	38,123	-		0%	-	32,827	32,827	82,068	60,144
Non-PSI Implant 3 Inserted	6,612	8,738	32,827	38,123	-		-%	-	32,827	32,827	82,068	60,144

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Implant 5	(4,760)	(13)	(4,800)	(7,600)	2,423		(298)%	2,423	49,083	(4,320)	(16,416)	(11,805)
Jadelle	-	2,470	18,820	2,400	23,710	1/09	(21)%	23,710	203,748	16,938	64,364	46,284
(b)PSI Implant 5 Distributed Inserted	(4,760)	(2,483)	(23,620)	(10,000)	(21,287)		-%	(21,287)	(154,665)	(21,258)	(80,780)	(58,089)
Implant 5 Insertion	5,160	5,501	71,230	35,000	50,514		41%	50,514	363,029	71,230	270,674	194,640
Non-PSI Implant 5 Inserted	400	3,018	47,610	25,000	29,227		63%	29,227	208,364	47,610	180,918	130,097
PSI Implant 5 Inserted	4,760	2,483	23,620	10,000	21,287		11%	21,287	154,665	23,620	89,756	64,543
Injectable 3-IM	2,160	11,150	115,590	79,400	117,204		(1)%	117,204	5,832,784	26,008	26,008	14,038
Femiplan Injectable	2,160	11,150	115,590	79,400	267,954	3/00	(57)%	267,954	6,143,868	26,008	26,008	14,038
(b)PSI Injectable 3 IM Distributed Provided	-	-	-	-	(150,750)		-%	(150,750)	(311,084)	-	-	-
Injectable 3-IM Provided	32,357	45,962	268,996	169,422	150,750		78%	150,750	580,080	67,249	67,249	36,298
Non-PSI Injectable 3 IM Provided	32,357	45,962	268,996	169,422	-		-%	-	268,996	67,249	67,249	36,298
PSI Injectable 3 IM Provided	-	-	-	-	150,750		(100)%	150,750	311,084	-	-	-
IPTp2	1,860	287	6,109	-	3,893		57%	3,893	20,406	6,109	-	228
IPTp2	1,860	287	6,109	-	3,893		57%	3,893	20,406	6,109	-	228
IUD 10	(228)	-	(588)	(4,600)	605		(197)%	605	9,439	(529)	(2,434)	(1,670)
CU 380A (Copper T)	-	47	190	2,400	10,551	3/09	(98)%	10,551	99,414	171	787	540
(b)PSI IUD 10 Distributed Inserted	(228)	(47)	(778)	(7,000)	(9,946)		-%	(9,946)	(89,975)	(700)	(3,221)	(2,210)
IUD 10 Insertion	3,810	4,454	31,353	27,350	17,347		81%	17,347	210,607	31,353	144,224	98,961
Non-PSI IUD 10 Inserted	3,582	4,407	30,575	20,350	7,401		313%	7,401	120,632	30,575	140,645	96,506
PSI IUD 10 Inserted	228	47	778	7,000	9,946		(92)%	9,946	89,975	778	3,579	2,456
LLIN	743	828	907,433	1,824,672	2,332,163		(61)%	2,332,163	24,552,080	1,470,041	-	29,927
ANC LLIN	-	-	-	1,800,000	-	7/08	-%	-	19,189,925	-	-	-
Supanet Conical	270	431	8,212	8,578	8,447	10/16	(3)%	8,447	23,840	13,303	-	271
Supanet Rectangular	473	397	7,390	16,094	13,913	10/16	(47)%	13,913	26,013	11,972	-	244

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Supanet XtraPower BL PNET USAID	-	-	891,831	-	2,309,803	3/14	(61)%	2,309,803	5,312,302	1,444,766	-	29,413
OCs	172,080	338,778	3,139,760	3,418,400	3,635,514		(14)%	3,635,514	41,786,533	188,386	188,386	107,270
Famipill	-	-	9,000	-	140,628	5/18	(94)%	140,628	149,628	540	540	307
Femi Girl Oral Pills	-	496	4,792	15,900	162,192	11/16	(97)%	162,192	176,728	288	288	164
Femiplan Pill	172,080	338,282	3,125,968	3,402,500	3,376,158	3/00	(7)%	3,376,158	41,532,720	187,558	187,558	106,798
(b)PSI OCs Distributed Provided	-	-	-	-	(43,464)		-%	(43,464)	(72,543)	-	-	-
OCs Provided	7,429	10,076	60,847	31,469	44,411		37%	44,411	134,337	4,056	4,056	2,310
Non-PSI OCs Provided	7,429	10,076	60,847	31,469	947		6,325%	947	61,794	4,056	4,056	2,310
PSI OCs Provided	-	-	-	-	43,464		(100)%	43,464	72,543	-	-	-
ORS Provided	-	-	2,043	-	2,217		(8)%	2,217	9,430	2,043	-	33
Non-PSI ORS Provided	-	-	2,043	-	2,217		(8)%	2,217	9,430	2,043	-	33
Pneumonia PPT	-	-	-	28,910	-		0%	-	-	-	-	-
5 & A Pneumonia Pack-Child	-	-	-	28,910	-		-%	-	-	-	-	-
Pneumonia PPT Provided	4,452	662	21,771	-	20,179		8%	20,179	79,844	21,771	-	10,472
Non-PSI Pneumonia PPT Provided	4,452	662	21,771	-	20,179		8%	20,179	79,844	21,771	-	10,472
PrEP	69	75	547	-	-		0%	-	547	46	-	23
PrEP	69	75	547	-	-		-%	-	547	46	-	23
PUR	2,779,200	2,809,843	32,575,220	19,000,000	27,875,040		17%	27,875,040	197,497,356	267,742	-	661
PuR	2,779,200	2,809,843	32,575,220	19,000,000	27,875,040	2/06	17%	27,875,040	197,497,356	267,742	-	661
QAACTs Provided after Confirmatory Diagnosis	33,091	-	56,824	95,000	96,981		(41)%	96,981	157,730	56,824	-	9,348
Non-PSI QAACTs Provided after Confirmed Diagnosis	33,091	-	56,824	95,000	96,981		(41)%	96,981	157,730	56,824	-	9,348
Safe Water Solution	71,700	71,529	1,418,258	1,160,000	1,114,276		27%	1,114,276	22,892,158	1,165,692	-	2,876
WaterGuard	71,700	71,529	1,418,258	1,160,000	1,114,276	5/03	27%	1,114,276	22,892,158	1,165,692	-	2,876
SDM (Cycle Beads) Provided	1,248	1,749	6,494	-	-		0%	-	6,494	6,494	9,741	7,534
Non-PSI SDM (Cycle Beads) Provided	1,248	1,749	6,494	-	-		-%	-	6,494	6,494	9,741	7,534

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Skilled Birth Attendance	6,891	1,327	25,405	40,000	20,115		26%	20,115	87,574	25,405	-	21,117
Skilled Birth Attendance	6,891	1,327	25,405	40,000	20,115		26%	20,115	87,574	25,405	-	21,117
TB Diagnosis	-	20	349	281	56		523%	56	1,020	349	-	-
TB Diagnosis	-	20	349	281	56		523%	56	1,020	349	-	-
TB Screening	-	2,337	40,435	7,816	6,339		538%	6,339	120,813	40,435	-	-
TB Screening	-	2,337	40,435	7,816	6,339		538%	6,339	120,813	40,435	-	-
Treatment for Pre-Eclampsia (with MgSO4)	21	6	43	60	49		(12)%	49	213	43	-	38
Treatment for Pre-Eclampsia (with MgSO4)	21	6	43	60	49		(12)%	49	213	43	-	38
Tubal Ligation	62	185	617	-	-		0%	-	617	617	6,170	3,845
Tubal Ligation	62	185	617	-	-		-%	-	617	617	6,170	3,845
Vasectomy	3	1	6	-	-		0%	-	6	6	60	38
Vasectomy	3	1	6	-	-		-%	-	6	6	60	38
Voluntary Medical Male Circumcision	-	-	31	-	-		0%	-	31	31	-	173
Voluntary Medical Male Circumcision	-	-	31	-	-		-%	-	31	31	-	173
Water Treatment Tablets	10,800	5,760	708,480	300,000	501,290		41%	501,290	6,645,680	11,646	-	29
Aquatab	10,800	5,760	708,480	300,000	501,290	3/09	41%	501,290	6,645,680	11,646	-	29
Myanmar											587,982	301,075
Antiretroviral Treatment (Currently Enrolled)	7,288	7,135	79,710	78,076	66,381		20%	66,381	193,742	6,642	-	13,925
Antiretroviral Treatment (Currently Enrolled)	7,288	7,135	79,710	78,076	66,381		20%	66,381	193,742	6,642	-	13,925
Antiretroviral Treatment (Newly Enrolled)	139	184	2,317	2,227	2,207		5%	2,207	8,483	2,317	-	-
Antiretroviral Treatment (Newly Enrolled)	139	184	2,317	2,227	2,207		5%	2,207	8,483	2,317	-	-
Cervical Cancer-VIA and Cryotherapy	7	19	133	40	59		125%	59	1,090	133	-	33
Cervical Cancer-VIA and Cryotherapy	7	19	133	40	59	11/12	125%	59	1,090	133	-	33
Cervical Cancer-VIA/VILI Screening	288	346	3,594	3,500	2,911		23%	2,911	10,949	3,594	-	-
Cervical Cancer-VIA/VILI Screening	288	346	3,594	3,500	2,911		23%	2,911	10,949	3,594	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Condom	872,622	1,467,996	14,270,064	15,520,000	12,893,474		11%	12,893,474	426,970,795	107,025	107,025	78,300
Aphaw	214,980	305,320	3,945,874	-	2,515,280	7/96	57%	2,515,280	195,211,553	29,594	29,594	21,651
Aphaw - Natural Touch	105,438	210,789	1,169,451	1,953,000	1,039,098	8/12	13%	1,039,098	15,947,124	8,771	8,771	6,417
Aphaw Deluxe GL (3x1)	-	-	-	3,515,400	-		-%	-	-	-	-	-
Aphaw Flavors	542,524	643,408	4,985,368	5,208,000	5,926,276	10/01	(16)%	5,926,276	181,806,059	37,390	37,390	27,355
Aphaw Studded	7,680	183,679	1,620,297	2,343,600	1,050,858	7/12	54%	1,050,858	20,068,842	12,152	12,152	8,891
Generic Male Condom	2,000	124,800	2,543,500	2,500,000	2,270,400	1/08	12%	2,270,400	8,702,429	19,076	19,076	13,956
OK Condom	-	-	5,574	-	91,562	5/03	(94)%	91,562	5,234,788	42	42	31
Emergency Contraception	-	333	1,000	-	5		19900%	5	178,869	45	45	4
Levonorgestrel 1.5 mg Tablet	-	333	1,000	-	-		-%	-	1,000	45	45	4
OK EC	-	-	-	-	5	8/07	(100)%	5	177,869	-	-	-
Female Condom	-	-	85,553	70,000	79,641		7%	79,641	1,556,019	642	642	461
Generic Female Condom	-	-	85,553	70,000	79,641	5/08	7%	79,641	1,556,019	642	642	461
Fever Cases Attended	73,979	48,786	520,128	-	697,782		(25)%	697,782	2,951,296	520,128	-	-
Fever Cases Attended	73,979	48,786	520,128	-	697,782		(25)%	697,782	2,951,296	520,128	-	-
Fever Cases Tested with RDTs	73,979	48,786	520,128	-	697,782		(25)%	697,782	2,951,296	520,128	-	-
Fever Cases Tested with RDTs	73,979	48,786	520,128	-	697,782		(25)%	697,782	2,951,296	520,128	-	-
Free Condom	-	2,400	7,200	-	-		0%	-	7,200	54	54	40
Free Male Condoms	-	2,400	7,200	-	-		-%	-	7,200	54	54	40
Free Female Condom	11,695	9,857	49,875	-	-		0%	-	49,875	374	374	269
FC2 Female Condom	11,695	9,857	49,875	-	-	11/16	-%	-	49,875	374	374	269
HIV Testing Services	5,652	5,510	61,315	64,440	48,784		26%	48,784	456,109	61,315	-	73
VCT Individual (HIV-Negative)	5,426	5,278	58,510	59,647	45,712	12/09	28%	45,712	425,467	58,510	-	70
VCT Individual (HIV-Positive)	226	232	2,805	4,793	3,072	12/09	(9)%	3,072	30,642	2,805	-	3

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Hypertension Diagnosis	656	1,061	32,105	20,000	57,768		(44)%	57,768	105,914	32,105	-	-
Hypertension Diagnosis	656	1,061	32,105	20,000	57,768		(44)%	57,768	105,914	32,105	-	-
Hypertension Screening	1,287	1,934	82,178	50,000	176,640		(53)%	176,640	293,332	82,178	-	-
Hypertension Screening	1,287	1,934	82,178	50,000	176,640		(53)%	176,640	293,332	82,178	-	-
Hypertension_Controlled Condition	484	824	23,444	-	43,499		(46)%	43,499	79,253	9,378	-	-
Hypertension_Controlled Condition	484	824	23,444	-	43,499		(46)%	43,499	79,253	9,378	-	-
Implant 3	363	68	1,205	6,600	1,527		(21)%	1,527	12,888	1,085	2,711	461
Implanon NXT	897	554	7,374	6,600	6,278	12/15	17%	6,278	27,289	6,637	16,592	2,821
(b)PSI Implant 3 Distributed Inserted	(534)	(486)	(6,169)	-	(4,751)		-%	(4,751)	(14,401)	(5,552)	(13,880)	(2,360)
Implant 3 Insertion	534	486	6,169	-	4,751		30%	4,751	14,401	6,169	15,423	2,622
PSI Implant 3 Inserted	534	486	6,169	-	4,751		30%	4,751	14,401	6,169	15,423	2,622
Implant 5	-	-	93	-	-		0%	-	200	84	318	53
Jadelle	-	-	93	-	-	5/16	-%	-	200	84	318	53
Injectable 3-IM	55,989	32,600	398,711	401,200	376,475		6%	376,475	10,134,078	89,710	89,710	11,218
OK-3 Injection	55,989	32,600	398,711	401,200	376,475	9/01	6%	376,475	10,134,078	89,710	89,710	11,218
Injectable 3-SC	3,278	2,602	31,405	32,150	-		0%	-	31,405	7,066	7,066	884
Sayana Press	3,278	2,602	31,405	32,150	-		-%	-	31,405	7,066	7,066	884
IUD 10	30	3	257	-	79		225%	79	3,576	231	1,064	170
OK IUD (Copper T Cu 380A)	30	3	257	-	79	10/14	225%	79	3,576	231	1,064	170
IUD 5	48	24	362	2,500	472		(23)%	472	141,764	326	1,075	183
OK IUD	-	-	-	2,500	1,206	5/03	(100)%	1,206	198,833	-	-	-
OK IUD (Inara Cu 375 Slek)	152	113	1,568	-	768		104%	768	2,336	1,411	4,657	792
(b)PSI IUD 5 Distributed Inserted	(104)	(89)	(1,206)	-	(1,502)		-%	(1,502)	(59,405)	(1,085)	(3,582)	(609)
IUD 5 Insertion	104	89	1,206	-	1,502		(20)%	1,502	59,405	1,206	3,980	677
PSI IUD 5 Inserted	104	89	1,206	-	1,502		(20)%	1,502	59,405	1,206	3,980	677

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
LLIN	9,882	1,025	185,940	225,226	-		0%	-	224,020	301,223	-	11,842
LLIN	9,882	1,025	185,940	225,226	-	11/16	-%	-	224,020	301,223	-	11,842
Lubricant	271,000	286,000	2,318,836	70,000	51,861		4371%	51,861	7,551,522	-	-	-
Aphaw Gel - Sachet	271,000	286,000	2,286,002	40,000	250	10/06	914,301%	250	6,714,310	-	-	-
Aphaw Gel - Tube 20 cc	-	-	12,378	30,000	51,611	10/06	(76)%	51,611	694,058	-	-	-
Aphaw Gel - Tube 20 cc - Flavors	-	-	20,456	-	-	10/14	-%	-	143,154	-	-	-
Malaria PPT (ACT)	1,089	391	174,362	182,270	256,333		(32)%	256,333	3,363,258	156,926	-	24,461
AL 1	248	80	2,847	126	3,413	7/12	(17)%	3,413	19,849	2,562	-	399
AL 2	250	70	2,906	126	3,390	7/12	(14)%	3,390	20,659	2,615	-	408
AL 3	260	88	3,251	379	3,470	1/11	(6)%	3,470	55,645	2,926	-	456
AL 4	188	214	5,324	5,689	13,664	1/11	(61)%	13,664	281,746	4,792	-	747
Arte+1	62	10	815	2,500	-	8/14	-%	-	23,094	734	-	114
Arte+2	66	10	818	2,500	-	8/14	-%	-	23,996	736	-	115
Arte+3	63	10	2,016	3,000	-	8/14	-%	-	28,558	1,814	-	283
Arte+4	79	17	74,629	79,975	114,680	8/14	(35)%	114,680	655,997	67,166	-	10,470
(b)PSI QAACTs Distributed Provided after Diagnosis	(127)	(108)	(1,176)	-	(4,786)		-%	(4,786)	(20,815)	(1,058)	-	(165)
Supa Arte 1	-	-	1,503	2,500	-	9/12	-%	-	122,214	1,353	-	211
Supa Arte 2	-	-	1,503	2,500	-	9/12	-%	-	118,055	1,353	-	211
Supa Arte 3	-	-	1,503	3,000	-	9/12	-%	-	197,962	1,353	-	211
Supa Arte 4	-	-	78,423	79,975	122,502	9/12	(36)%	122,502	1,836,298	70,581	-	11,002
Malaria PPT (Non-ACT)	224	174	2,954	3,621	(1,900)		0%	(1,900)	107,280	2,659	-	414
Chloroquine 10's	395	308	4,938	-	-		-%	-	4,938	4,444	-	693
(b)PSI Vivax Tx Distributed Provided after Diagnosis	(171)	(134)	(1,993)	-	(3,244)		-%	(3,244)	(11,199)	(1,794)	-	(280)
Vivax Treatment Kit	-	-	9	3,621	1,344	6/11	(99)%	1,344	113,541	8	-	1

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Malaria RDK	-	-	-	432,337	743,410		(100)%	743,410	4,731,974	-	-	-
Malaria RDT (Diagnosis)	-	-	-	432,337	743,410	3/11	(100)%	743,410	4,731,974	-	-	-
Micronutrient Powder	-	-	-	-	2,000,000		(100)%	2,000,000	9,499,690	-	-	-
Happy Kid (Micronutrient powder)	-	-	-	-	2,000,000	9/16	(100)%	2,000,000	9,499,690	-	-	-
Multivitamin	-	-	-	-	450,010		(100)%	450,010	883,520	-	-	-
May May Vita Plus	-	-	-	-	450,010	6/17	(100)%	450,010	883,520	-	-	-
Needle & Syringe	-	-	10,100	-	-		0%	-	1,956,069	35	-	83
Needle & Syringe (LDS)	-	-	10,100	-	-	10/15	-%	-	1,956,069	35	-	83
OCs	578,058	657,428	5,974,920	6,804,000	5,856,883		2%	5,856,883	33,128,502	358,495	358,495	47,293
OK Pills	578,016	656,643	5,961,595	6,804,000	5,831,882	9/01	2%	5,831,882	33,078,555	357,696	357,696	47,187
OK Pills (Zinnia F)	42	785	13,325	-	25,001	11/16	(47)%	25,001	49,947	800	800	105
ORS	38,020	124,149	847,044	600,000	514,198		65%	514,198	2,077,898	381,170	-	22,210
ORS	38,020	124,149	847,044	600,000	514,198	1/08	65%	514,198	2,077,898	381,170	-	22,210
Positive RDTs	426	351	4,386	-	9,712		(55)%	9,712	39,857	4,386	-	-
Positive RDTs	426	351	4,386	-	9,712		(55)%	9,712	39,857	4,386	-	-
Positive RDTs Given First Line Treatment	417	348	4,242	-	8,937		(53)%	8,937	35,245	4,242	-	-
Positive RDTs Given First Line Treatment	417	348	4,242	-	8,937		(53)%	8,937	35,245	4,242	-	-
PUR	-	-	-	-	633,309		(100)%	633,309	15,857,790	-	-	-
Purifier of Water	-	-	-	-	633,309	4/14	(100)%	633,309	15,857,790	-	-	-
QAACs Provided after Confirmatory Diagnosis	127	108	1,176	-	4,786		(75)%	4,786	20,815	1,176	-	216
PSI QAACs Provided after Confirmed Diagnosis	127	108	1,176	-	4,786		(75)%	4,786	20,815	1,176	-	216
Referral to TB DOTS (completion confirmed)	69	55	1,020	2,349	1,214		(16)%	1,214	2,527	1,020	-	3,163
Referral to TB DOTS (completion confirmed)	69	55	1,020	2,349	1,214		(16)%	1,214	2,527	1,020	-	3,163
Referral to TB DOTS (completion unknown)	71	72	1,289	2,374	1,575		(18)%	1,575	2,864	1,289	-	3,598
Referral to TB DOTS (completion unknown)	71	72	1,289	2,374	1,575		(18)%	1,575	2,864	1,289	-	3,598

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
STI Screening	842	1,085	16,593	-	27,221		(39)%	27,221	77,102	16,593	-	-
STI Screening	842	1,085	16,593	-	27,221		(39)%	27,221	77,102	16,593	-	-
TB Diagnosis	1,482	1,311	13,261	15,500	14,259		(7)%	14,259	72,194	13,261	-	-
TB Diagnosis	1,482	1,311	13,261	15,500	14,259		(7)%	14,259	72,194	13,261	-	-
TB DOTS	948	1,179	12,584	12,673	12,891		(2)%	12,891	230,035	12,584	-	78,056
TB DOTS	948	1,179	12,584	12,673	12,891	12/04	(2)%	12,891	230,035	12,584	-	78,056
TB Screening	8,077	7,385	78,210	41,800	97,611		(20)%	97,611	370,039	78,210	-	-
TB Screening	8,077	7,385	78,210	41,800	97,611		(20)%	97,611	370,039	78,210	-	-
Vivax Treatment after Confirmatory Diagnosis	171	134	1,993	-	3,244		(39)%	3,244	11,199	1,993	-	365
PSI Vivax Treatment after Confirmed Diagnosis	171	134	1,993	-	3,244		(39)%	3,244	11,199	1,993	-	365
Nigeria											102,046	112,654
Emergency Contraception Provided	-	-	10	-	60		(83)%	60	70	1	1	-
Non-PSI Emergency Contraception Provided	-	-	10	-	60		(83)%	60	70	1	1	-
HIV Testing Services	-	-	-	-	609,489		(100)%	609,489	2,485,606	-	-	-
VCT Individual (HIV-Negative)	-	-	-	-	604,543	12/09	(100)%	604,543	2,342,815	-	-	-
VCT Individual (HIV-Positive)	-	-	-	-	4,946	12/09	(100)%	4,946	142,791	-	-	-
Implant 3 Insertion	1,303	1,368	12,607	-	4,133		205%	4,133	16,740	12,607	31,518	36,190
Non-PSI Implant 3 Inserted	1,303	1,368	12,607	-	4,133		205%	4,133	16,740	12,607	31,518	36,190
Implant 4 Insertion	-	-	-	-	288		(100)%	288	288	-	-	-
Non-PSI Implant 4 Inserted	-	-	-	-	288		(100)%	288	288	-	-	-
Implant 5 Insertion	1,113	1,332	12,195	-	2,833		330%	2,833	105,897	12,195	46,341	52,369
Non-PSI Implant 5 Inserted	1,113	1,332	12,195	-	2,833	3/16	330%	2,833	105,897	12,195	46,341	52,369
Injectable 1 Provided	6	5	44	-	37		19%	37	81	3	3	3
Non-PSI Injectable 1 Provided	6	5	44	-	37		19%	37	81	3	3	3
Injectable 2 Provided	1,175	1,296	13,459	-	5,875		129%	5,875	19,334	2,243	2,243	1,891

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Non-PSI Injectable 2 Provided	1,175	1,296	13,459	-	5,875		129%	5,875	19,334	2,243	2,243	1,891
Injectable 3-IM Provided	1,558	1,802	18,189	-	6,118		197%	6,118	24,307	4,547	4,547	3,833
Non-PSI Injectable 3 IM Provided	1,558	1,802	18,189	-	6,118		197%	6,118	24,307	4,547	4,547	3,833
Injectable 3-SC Provided	897	1,258	9,727	-	-		0%	-	9,727	2,432	2,432	2,050
Non-PSI Injectable 3 SC Provided	897	1,258	9,727	-	-		-%	-	9,727	2,432	2,432	2,050
IUD 10 Insertion	155	163	2,325	-	-		0%	-	277,377	2,325	10,695	11,576
Non-PSI IUD 10 Inserted	155	163	2,325	-	-	3/16	-%	-	277,377	2,325	10,695	11,576
IUD 5 Insertion	-	-	-	-	479		(100)%	479	479	-	-	-
Non-PSI IUD 5 Inserted	-	-	-	-	479		(100)%	479	479	-	-	-
IUS 5 Insertion	75	103	1,102	-	716		54%	716	2,444	1,102	3,637	4,182
Non-PSI IUS 5 Inserted	75	103	1,102	-	716		54%	716	2,444	1,102	3,637	4,182
OCs Provided	892	1,008	9,451	-	5,586		69%	5,586	15,037	630	630	560
Non-PSI OCs Provided	892	1,008	9,451	-	5,586		69%	5,586	15,037	630	630	560
SDM (Cycle Beads) Provided	-	-	-	-	3		(100)%	3	3	-	-	-
Non-PSI SDM (Cycle Beads) Provided	-	-	-	-	3		(100)%	3	3	-	-	-
PSI Nigeria											445,644	581,695
Emergency Contraception Provided	6	11	53	-	-		0%	-	53	3	3	2
Non-PSI Emergency Contraception Provided	6	11	53	-	-		-%	-	53	3	3	2
Implant 5 Insertion	2,590	3,293	34,454	27,915	29,200		18%	29,200	63,654	34,454	130,925	147,955
Non-PSI Implant 5 Inserted	2,590	3,293	34,454	27,915	29,200		18%	29,200	63,654	34,454	130,925	147,955
Injectable 3-IM Provided	10	3	186	-	2,423		(92)%	2,423	2,609	47	47	39
Non-PSI Injectable 3 IM Provided	10	3	186	-	2,423		(92)%	2,423	2,609	47	47	39
IUD 10 Insertion	4,258	5,961	68,290	76,440	72,696		(6)%	72,696	140,986	68,290	314,134	340,005
Non-PSI IUD 10 Inserted	4,258	5,961	68,290	76,440	72,696		(6)%	72,696	140,986	68,290	314,134	340,005
IUD 5 Insertion	-	-	-	-	58		(100)%	58	58	-	-	-

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Non-PSI IUD 5 Inserted	-	-	-	-	58		(100)%	58	58	-	-	-
IUS 5 Insertion	-	-	-	-	59		(100)%	59	59	-	-	-
Non-PSI IUS 5 Inserted	-	-	-	-	59		(100)%	59	59	-	-	-
Manual Vacuum Aspiration for PAC	485	742	7,879	5,220	19,176		(59)%	19,176	27,055	7,879	-	6,309
MVA for PAC	485	742	7,879	5,220	19,176		(59)%	19,176	27,055	7,879	-	6,309
Medical Abortion	-	652	2,000	9,000	-		0%	-	2,000	1,800	-	1,689
Combipack	-	-	-	9,000	-		-%	-	-	-	-	-
Mariprist	-	652	2,000	-	-		-%	-	2,000	1,800	-	1,689
Misoprostol for PAC Provided	382	675	7,331	5,220	14,855		(51)%	14,855	22,186	7,331	-	6,952
PSI Misoprostol for PAC Provided	382	675	7,331	5,220	14,855		(51)%	14,855	22,186	7,331	-	6,952
Misoprostol for Safe Abortion	26,472	134,133	1,774,246	2,339,690	2,321,200		(24)%	2,321,200	4,095,446	93,148	-	78,213
Misoclear	28,000	136,833	1,803,570	2,360,570	2,380,620	3/18	(24)%	2,380,620	4,184,190	94,687	-	79,506
(b)PSI Misoprostol for Safe Abortion Dist Provided	(1,528)	(2,700)	(29,324)	(20,880)	(59,420)		-%	(59,420)	(88,744)	(1,540)	-	(1,293)
OCs Provided	454	520	5,512	-	1,376		301%	1,376	6,888	367	367	327
Non-PSI OCs Provided	454	520	5,512	-	1,376		301%	1,376	6,888	367	367	327
SDM (Cycle Beads) Provided	4	6	112	-	-		0%	-	112	112	168	204
Non-PSI SDM (Cycle Beads) Provided	4	6	112	-	-		-%	-	112	112	168	204
South Africa											-	737,267
Free Condom	-	-	-	500,000	39,319,200		(100)%	39,319,200	1,084,659,760	-	-	-
Public Distribution	-	-	-	500,000	39,319,200	1/04	(100)%	39,319,200	1,084,659,760	-	-	-
Free Female Condom	-	-	-	-	1,108,500		(100)%	1,108,500	5,030,600	-	-	-
Female Condom GOSA	-	-	-	-	1,108,500	10/13	(100)%	1,108,500	5,030,600	-	-	-
HIV Self-Testing Kit	-	150,688	598,678	1,029,300	1,288,251		(54)%	1,288,251	1,886,929	538,810	-	-
ORAQUICK HIV Self-Testing Kit (Pouch)	-	150,688	598,678	1,029,300	1,288,251		(54)%	1,288,251	1,886,929	538,810	-	-
HIV Testing Services	-	3,145	47,444	63,500	219,862		(78)%	219,862	2,037,445	47,444	-	3,362

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	^(a) YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
VCT Individual (HIV-Negative)	-	2,903	39,651	50,000	206,993	12/09	(81)%	206,993	1,869,831	39,651	-	2,810
VCT Individual (HIV-Positive)	-	242	7,793	13,500	12,869	12/09	(39)%	12,869	167,614	7,793	-	552
Referral to HIV Testing Services	-	-	21,265	-	-		0%	-	21,265	21,265	-	754
Referral to HIV Testing Services	-	-	21,265	-	-		-%	-	21,265	21,265	-	754
Referral to Linkage to HIV Care	-	242	5,843	12,150	-		0%	-	5,843	5,843	-	2,767
Referral to Linkage to HIV Care	-	242	5,843	12,150	-		-%	-	5,843	5,843	-	2,767
Voluntary Medical Male Circumcision	16,334	3,934	103,692	90,000	78,885		31%	78,885	255,919	103,692	-	730,384
Voluntary Medical Male Circumcision	16,334	3,934	103,692	90,000	78,885		31%	78,885	255,919	103,692	-	730,384

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

^(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

Anglophone Africa Market Group

POPULATION SERVICES INTERNATIONAL
CYPs, Cases, and Deaths by Country
1/2019 - 12/2019

	<u>New HIV Infections</u>	<u>STI Deaths</u>	<u>PWID Deaths</u>	<u>TB Deaths</u>	<u>CYP*</u>	<u>Maternal Deaths</u>	<u>Unintended Pregnancies</u>	<u>Malaria Deaths</u>	<u>Diarrhea Deaths</u>	<u>Pneumonia Deaths</u>	<u>Cervical Cancer Death</u>	<u>Sum of All Deaths</u>
Anglophone Africa Market Group	95,551	23	-	5	4,012,517	4,161	1,661,065	803	144	-	55	40,258
Ethiopia	2,675	13	-	-	106,827	46	30,146	-	119	-	-	781
Ghana	-	-	-	-	174,384	134	62,417	-	2	-	-	863
Lesotho	1,304	-	-	5	14,154	11	4,486	-	-	-	-	77
Malawi	16,037	-	-	-	701,509	1,216	274,013	64	3	-	-	6,616
Namibia	53	-	-	-	1,160	-	326	-	-	-	-	3
PSI Uganda	756	-	-	-	1,681,799	1,626	768,935	-	2	-	1	19,859
Rwanda	4,808	-	-	-	129,188	57	37,689	-	3	-	-	841
Swaziland	13,016	3	-	-	89,885	55	25,304	-	-	-	-	437
Tanzania	2	-	-	-	499,961	549	230,957	739	6	-	-	5,862
Uganda	7,501	-	-	-	144,136	80	40,576	-	-	-	-	1,041
Zambia	6,502	-	-	-	237,004	133	103,469	-	9	-	-	2,630
Zimbabwe	42,896	8	-	-	232,509	255	82,746	-	-	-	54	1,250

* Using USAID CYP conversion factors

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Market Group and Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE SALES	YTD USERS REACHED ^(a) 2019	YTD CYP 2019	YTD DALY 2019
Anglophone Africa Market Group										4,012,517	7,098,951
Antiretroviral Treatment (Currently Enrolled)	14,751	14,210	163,277	105,390	148,026	10%	148,026	430,536	13,606	-	29,008
Antiretroviral Treatment (Newly Enrolled)	607	685	7,255	4,695	6,634	9%	6,634	30,120	7,255	-	-
Basic Care Package	-	-	-	-	1	(100)%	1	1	-	-	-
CD4 Tests Provided to HIV+ Clients	-	-	-	-	544	(100)%	544	9,414	-	-	-
Cervical Cancer-HPV DNA and Conization	3	2	10	-	-	-%	-	10	10	-	4
Cervical Cancer-HPV DNA and Cryotherapy	2	1	8	-	3	167%	3	11	8	-	3
Cervical Cancer-HPV DNA and Refer to any Treat	1	-	2	-	-	-%	-	13	2	-	-
Cervical Cancer-HPV DNA Screening	333	582	3,346	-	-	-%	-	3,346	3,346	-	-
Cervical Cancer-Pap and Conization	-	-	1,753	-	-	-%	-	1,753	1,753	-	778
Cervical Cancer-Pap and Refer to any Treatment	-	-	9	-	-	-%	-	10	9	-	2
Cervical Cancer-VIA and Conization	11	18	245	290	126	94%	126	549	245	-	88
Cervical Cancer-VIA and Cryotherapy	2	18	1,598	307	639	150%	639	8,078	1,598	-	561
Cervical Cancer-VIA and Refer to any Treatment	1	6	85	-	25	240%	25	396	85	-	15
Cervical Cancer-VIA and Refer to Conization	1	3	23	290	98	(77)%	98	2,057	23	-	4
Cervical Cancer-VIA and Refer to Cryotherapy	-	-	-	-	10	(100)%	10	459	-	-	-
Cervical Cancer-VIA/VILI Screening	1,325	4,178	45,450	88,793	95,922	(53)%	95,922	386,536	45,450	-	-
Chlorhexidine	263	777	6,590	16,755	23,622	(72)%	23,622	43,255	5,931	-	458
Clean Delivery Kit	-	-	-	-	3,449	(100)%	3,449	181,765	-	-	-
Condom	2,463,283	3,785,709	46,603,378	49,703,561	65,266,786	(29)%	65,266,786	1,488,455,193	349,525	349,525	932,948
Emergency Contraception	19,641	11,004	123,300	7,000	180,947	(32)%	180,947	1,186,470	5,549	5,549	2,145
Emergency Contraception Provided	1,578	1,144	91,980	30,493	6,887	1,236%	6,887	100,032	4,599	4,599	2,329

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Market Group and Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE SALES	YTD USERS REACHED ^(a) 2019	YTD CYP 2019	YTD DALY 2019
Expanded Clean Delivery Kit	-	-	-	-	13,160	(100)%	13,160	13,160	-	-	-
Expanded Clean Delivery Kit (+CHX)	669	973	11,709	20,285	14,531	(19)%	14,531	26,857	10,538	-	1,713
Female Condom	1,124	13,751	174,851	533,000	469,229	(63)%	469,229	28,559,177	1,311	1,311	5,678
Fever Cases Attended	67,555	25,845	238,868	-	-	-%	-	238,868	238,868	-	-
Fever Cases Tested with RDTs	64,534	24,741	227,984	-	-	-%	-	227,984	227,984	-	-
Free Condom	5,912,539	4,297,117	61,742,141	44,434,784	77,319,731	(20)%	77,319,731	464,059,341	463,066	463,066	1,352,880
Free Female Condom	47,550	367,230	1,398,332	251,000	623,007	124%	623,007	6,280,158	10,487	10,487	31,104
HIV Self-Testing Kit	240,457	27,198	756,647	641,306	996,954	(24)%	996,954	2,123,148	680,982	-	-
HIV Testing Services	18,061	24,893	315,263	518,172	541,424	(42)%	541,424	6,136,279	315,263	-	23,436
Hypertension Diagnosis	1,951	2,141	21,416	-	16,890	27%	16,890	56,821	21,416	-	-
Hypertension Screening	74,748	92,591	917,675	36,477	813,698	13%	813,698	2,570,110	917,675	-	-
Hypertension_Controlled Condition	5	9	105	-	91	15%	91	262	42	-	-
Implant 3	20,120	11,143	74,741	73,620	23,285	221%	23,285	305,501	67,267	168,167	171,357
Implant 3 Insertion	12,604	19,783	217,237	201,554	240,316	(10)%	240,316	869,677	217,237	543,093	515,191
Implant 4	(436)	81	18,459	-	(3,883)	-%	(3,883)	14,576	16,613	53,162	47,669
Implant 4 Insertion	835	1,644	10,829	-	33,884	(68)%	33,884	44,829	10,829	34,653	31,072
Implant 5	4,956	5,823	54,899	26,000	34,917	57%	34,917	450,734	49,409	187,755	180,053
Implant 5 Insertion	8,796	15,523	175,768	175,505	154,215	14%	154,215	677,951	175,768	667,918	601,310
Injectable 1 Provided	-	2	42	36	537	(92)%	537	1,809	3	3	2
Injectable 2 Provided	2,923	2,009	21,725	29,000	22,699	(4)%	22,699	56,068	3,621	3,621	2,453
Injectable 3-IM	16,948	35,134	721,284	605,251	1,798,175	(60)%	1,798,175	8,898,393	162,289	162,289	82,874

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Market Group and Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE SALES	YTD USERS REACHED ^(a) 2019	YTD CYP 2019	YTD DALY 2019
Injectable 3-IM Provided	21,679	32,953	416,171	357,197	342,639	21%	342,639	1,108,394	104,043	104,043	68,817
Injectable 3-SC	1,959	12,052	91,046	53,892	55,900	63%	55,900	146,946	20,485	20,485	15,188
Injectable 3-SC Provided	11,900	6,214	33,304	-	-	-%	-	33,304	8,326	8,326	6,144
ITN	-	421,834	1,265,503	-	-	-%	-	1,265,503	2,050,115	-	45,033
IUD 10	26,966	17,835	118,862	93,709	111,944	6%	111,944	439,801	106,976	492,089	468,770
IUD 10 Insertion	4,852	10,992	107,088	188,592	220,262	(51)%	220,262	1,228,529	107,088	492,605	435,187
IUD 5	-	(1)	(32)	-	(134)	-%	(134)	(166)	(29)	(95)	(96)
IUD 5 Insertion	-	1	162	-	345	(53)%	345	28,727	162	535	343
IUS 3	(65)	(82)	(379)	-	-	-%	-	(379)	(341)	(853)	(808)
IUS 3 Insertion	65	82	379	-	-	-%	-	379	379	948	898
IUS 5	(8)	(5)	395	(56)	126	213%	126	1,475	356	1,173	1,332
IUS 5 Insertion	8	21	550	756	739	(26)%	739	1,655	550	1,815	1,530
LLIN	1	713	213,151	700,054	4,545,198	(95)%	4,545,198	12,902,398	345,305	-	11,557
Lubricant	245,469	324,724	2,926,726	1,900,761	2,574,286	14%	2,574,286	8,635,021	-	-	-
Manual Vacuum Aspiration for PAC	223	654	6,339	720	7,531	(16)%	7,531	16,860	6,339	-	943
Manual Vacuum Aspiration for SA	35	67	805	-	411	96%	411	2,414	805	-	294
Medical Abortion	711	1,449	10,999	9,331	16,535	(33)%	16,535	27,534	9,899	-	3,468
Medical Abortion (Misoprostol) Provided	21	81	988	-	531	86%	531	1,519	988	-	309
Medical Abortion Provided	25	78	775	-	747	4%	747	2,143	775	-	271
Misoprostol for PAC Provided	125	244	3,078	-	3,631	(15)%	3,631	7,914	3,078	-	623
Misoprostol for Safe Abortion	158,768	131,275	1,553,194	1,993,550	1,659,272	(6)%	1,659,272	8,167,266	81,543	-	17,241

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Market Group and Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE SALES	YTD USERS REACHED ^(a) 2019	YTD CYP 2019	YTD DALY 2019
OCs	15,301	208,582	1,545,840	2,258,175	2,600,349	(41)%	2,600,349	17,752,358	92,750	92,750	44,612
OCs Provided	29,805	42,815	535,112	357,372	321,499	66%	321,499	1,879,346	35,674	35,674	21,912
Positive RDTs	42,667	17,029	155,419	-	-	-%	-	155,419	155,419	-	-
Positive RDTs Given First Line Treatment	40,275	15,902	144,641	-	-	-%	-	144,641	144,641	-	-
PrEP	3,776	3,791	46,374	35,111	34,437	35%	34,437	83,927	3,864	-	1,470
PUR	294,624	2,424,440	30,213,032	28,273,857	33,931,875	(11)%	33,931,875	234,872,031	248,326	-	857
Referral to Advanced Cervical Cancer Treatment	-	2	62	136	17	265%	17	479	62	-	-
Referral to Diabetes Management (gestational)	-	-	-	-	67	(100)%	67	67	-	-	-
Referral to Emergency Contraception	-	-	-	1	1	(100)%	1	134	-	-	-
Referral to HIV Testing Services	666	976	34,434	82,130	24,714	39%	24,714	204,242	34,434	-	1,070
Referral to Hypertension Management	13	28	336	-	567	(41)%	567	1,466	336	-	-
Referral to Implant 3 Insertion	-	-	293	1,915	2	14,550%	2	1,441	293	366	309
Referral to Implant 5 Insertion	-	-	11	187	2	450%	2	1,307	11	21	17
Referral to Injectable 1	-	-	-	-	36	(100)%	36	384	-	-	-
Referral to Injectable 3	-	-	887	6,372	75	1,083%	75	4,717	887	111	69
Referral to IUD 10 Insertion	-	-	4	48	5	(20)%	5	352	4	9	7
Referral to Linkage to HIV Care	9,980	13,204	112,751	29,940	24,186	366%	24,186	159,395	112,751	-	91,588
Referral to OCs	-	-	84	665	93	(10)%	93	2,389	84	3	2
Referral to Pre-Exposure Prophylaxis (PrEP)	-	-	3	-	20	(85)%	20	253	3	-	-
Referral to STI Screening (syndromic)	-	-	-	112,000	7	(100)%	7	14,416	-	-	-
Referral to STI Treatment (unknown)	-	-	-	-	119	(100)%	119	2,584	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Market Group and Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE SALES	YTD USERS REACHED ^(a) 2019	YTD CYP 2019	YTD DALY 2019
Referral to TB Diagnosis	-	-	-	-	11	(100)%	11	255	-	-	-
Referral to TB DOTS (completion confirmed)	-	-	-	-	2	(100)%	2	19	-	-	-
Referral to TB DOTS (completion unknown)	-	-	-	-	74	(100)%	74	2,704	-	-	-
Referral to TB Screening	-	-	-	5,497	308	(100)%	308	29,857	-	-	-
Referral to Treatment for Cervicitis	-	-	-	-	47	(100)%	47	116	-	-	-
Referral to Treatment for Genital Herpes	-	-	-	-	3	(100)%	3	6	-	-	-
Referral to Treatment for Inguinal Bubo	-	-	-	112	2	(100)%	2	2	-	-	-
Referral to Treatment for Lower Abdominal Pain	-	-	-	112	1	(100)%	1	28	-	-	-
Referral to Treatment for Urethral Discharge (Mer	-	-	-	336	53	(100)%	53	113	-	-	-
Referral to Treatment for Vaginitis	-	-	1	-	-	-%	-	9	1	-	-
Referral to Tubal Ligation	-	-	-	-	2	(100)%	2	3	-	-	-
Referral to Tx for Nonherpetic Genital Ulcer	-	-	1	-	25	(96)%	25	73	1	-	-
Referral to Tx for Urethral Discharge (Women)	-	-	10	560	48	(79)%	48	557	10	-	1
Referral to Voluntary Medical Male Circumcision	-	-	3	-	139	(98)%	139	15,555	3	-	10
Safe Water Solution	54,269	78,236	1,052,196	1,915,700	2,248,493	(53)%	2,248,493	74,763,319	789,591	-	2,730
STI Kit (Non-Ulcerative)	-	489	4,732	1,869	6,655	(29)%	6,655	836,263	4,259	-	304
STI Kit (Ulcerative)	-	89	1,588	231	-	-%	-	73,816	1,429	-	305
STI Screening	7,745	8,329	118,274	144,457	75,388	57%	75,388	681,190	118,274	-	-
TB Diagnosis	18	16	231	77	283	(18)%	283	1,708	231	-	-
TB DOTS	3	3	35	77	35	-%	35	136	35	-	284
TB Screening	17,982	19,005	241,495	34,396	225,880	7%	225,880	1,692,520	241,495	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Market Group and Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE SALES	YTD USERS REACHED ^(a) 2019	YTD CYP 2019	YTD DALY 2019
Toilets Sold	2,028	2,929	20,460	25,600	5,651	262%	5,651	26,110	93,379	-	3,607
Toilets Sold - All	2,028	3,968	27,092	-	7,266	273%	7,266	34,358	117,254	-	-
Treatment for Cervicitis	12	20	193	-	73	164%	73	556	193	-	15
Treatment for Genital Herpes	11	27	135	17	28	382%	28	215	135	-	4
Treatment for Inguinal Bubo	1	-	18	-	3	500%	3	35	18	-	-
Treatment for Lower Abdominal Pain	33	62	465	54	78	496%	78	678	465	-	-
Treatment for Nonherpetic Genital Ulcer	40	39	663	94	546	21%	546	1,809	663	-	205
Treatment for Urethral Discharge (Men)	61	67	741	195	292	154%	292	1,643	1,363	-	80
Treatment for Urethral Discharge (Women)	104	107	1,141	2	507	125%	507	2,664	1,141	-	167
Treatment for Vaginitis	22	10	351	380	506	(31)%	506	2,563	351	-	62
Tubal Ligation	667	1,525	10,713	17,589	16,391	(35)%	16,391	46,527	10,713	107,130	84,383
Type 2 Diabetes Diagnosis	-	-	-	-	3	(100)%	3	8	-	-	-
Type 2 Diabetes Screening	87	1,236	22,647	33,797	6,711	237%	6,711	39,237	22,647	-	-
Type 2 Diabetes_Controlled Condition	-	-	-	-	6	(100)%	6	12	-	-	-
Vasectomy	-	4	17	29	-	-%	-	17	17	170	148
Voluntary Medical Male Circumcision	10,814	21,235	270,203	306,145	345,985	(22)%	345,985	984,225	270,203	-	1,752,110
Water Treatment Tablets	16,800	1,157,540	6,229,910	8,068,408	6,957,142	(10)%	6,957,142	126,574,261	102,409	-	405
Woman Condom	-	-	1,920	-	97,728	(98)%	97,728	141,480	14	14	40

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Anglophone Africa Market Group											4,012,517	7,098,951
Ethiopia											106,827	165,192
Antiretroviral Treatment (Currently Enrolled)	838	1,037	13,267	18,804	16,938		(22)%	16,938	40,517	1,106	-	2,123
Antiretroviral Treatment (Newly Enrolled)	45	41	521	1,155	1,115		(53)%	1,115	3,091	521	-	-
Free Condom	2,346,080	629,133	14,086,380	11,820,960	23,871,707		(41)%	23,871,707	178,649,825	105,648	105,648	153,969
No Logo Condom	2,346,080	629,133	12,807,680	11,820,960	5,869,000	8/09	118%	5,869,000	22,792,680	96,058	96,058	139,993
Protector Plus	-	-	1,278,700	-	18,002,707	12/12	(93)%	18,002,707	155,857,145	9,590	9,590	13,977
Free Female Condom	500	5,000	89,231	138,000	138,000		(35)%	138,000	988,320	669	669	932
Free Female Condoms	500	5,000	89,231	138,000	138,000	10/13	(35)%	138,000	988,320	669	669	932
HIV Self-Testing Kit	-	293	958	3,000	14,958		(94)%	14,958	15,916	862	-	-
ORAQUICK HIV Self-Testing Kit (Pouch)	-	293	958	3,000	14,958		(94)%	14,958	15,916	862	-	-
HIV Testing Services	3,412	2,763	38,841	31,606	219,864		(82)%	219,864	1,228,055	38,841	-	207
VCT Individual (HIV-Negative)	3,164	2,586	36,820	30,390	213,839	3/13	(83)%	213,839	1,197,906	36,820	-	196
VCT Individual (HIV-Positive)	248	178	2,021	1,216	6,025	3/13	(66)%	6,025	30,149	2,021	-	11
Hypertension Diagnosis	1,931	2,114	21,145	-	16,612		27%	16,612	55,992	21,145	-	-
Hypertension Screening	69,252	83,113	783,040	-	665,905		18%	665,905	1,937,022	783,040	-	-
LLIN	-	-	14	-	-		0%	-	305,347	23	-	1
PermaNet NGO Bag	-	-	14	-	-	9/04	-%	-	305,347	23	-	1
Lubricant	5,100	4,828	20,309	761	62,647		(68)%	62,647	82,956	-	-	-
Lubricant gel 4.5 g	5,100	4,828	20,309	761	62,647		(68)%	62,647	82,956	-	-	-
PrEP	264	273	2,464	-	-		0%	-	2,464	205	-	-

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
PrEP	264	273	2,464	-	-		-%	-	2,464	205	-	-
PUR	6,600	1,960,187	18,892,846	19,333,057	20,446,684		(8)%	20,446,684	103,605,251	155,284	-	557
P&G Purifier of Water	6,600	1,960,187	18,892,846	19,333,057	20,446,684	11/15	(8)%	20,446,684	103,605,251	155,284	-	557
Referral to Emergency Contraception	-	-	-	1	1		(100)%	1	134	-	-	-
Referral to Emergency Contraception	-	-	-	1	1	2/15	(100)%	1	134	-	-	-
Referral to HIV Testing Services	-	-	-	30,390	9		(100)%	9	119,940	-	-	-
Referral to HIV Testing Services	-	-	-	30,390	9	12/13	(100)%	9	119,940	-	-	-
Referral to Implant 3 Insertion	-	-	293	1,915	-		0%	-	1,430	293	366	309
Referral to Implant 3 Insertion	-	-	293	1,915	-	12/14	-%	-	1,430	293	366	309
Referral to Implant 5 Insertion	-	-	11	187	-		0%	-	315	11	21	17
Referral to Implant 5 Insertion	-	-	11	187	-	12/14	-%	-	315	11	21	17
Referral to Injectable 3	-	-	887	6,372	-		0%	-	3,301	887	111	69
Referral to Injectable 3	-	-	887	6,372	-	1/15	-%	-	3,301	887	111	69
Referral to IUD 10 Insertion	-	-	4	48	-		0%	-	143	4	9	7
Referral to IUD 10 Insertion	-	-	4	48	-	12/14	-%	-	143	4	9	7
Referral to Linkage to HIV Care	213	161	1,780	1,216	33		5294%	33	4,613	1,780	-	905
Referral to Linkage to HIV Care	213	161	1,780	1,216	33		5,294%	33	4,613	1,780	-	905
Referral to OCs	-	-	84	665	-		0%	-	974	84	3	2
Referral to OCs	-	-	84	665	-	1/15	-%	-	974	84	3	2
Referral to STI Screening (syndromic)	-	-	-	112,000	4		(100)%	4	14,311	-	-	-
Referrals to STI Screening (syndromic)	-	-	-	112,000	4		(100)%	4	14,311	-	-	-
Referral to TB Screening	-	-	-	319	4		(100)%	4	13,488	-	-	-
Referrals to TB Screening	-	-	-	319	4		(100)%	4	13,488	-	-	-
Referral to Treatment for Inguinal Bubo	-	-	-	112	-		0%	-	-	-	-	-
Referral to Treatment for Inguinal Bubo	-	-	-	112	-	12/14	-%	-	-	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Referral to Treatment for Lower Abdominal Pain	-	-	-	112	-		0%	-	-	-	-	-
Referral to Treatment for Lower Abdominal Pain	-	-	-	112	-	12/14	-%	-	-	-	-	-
Referral to Treatment for Urethral Discharge (Men)	-	-	-	336	-		0%	-	-	-	-	-
Referral to Treatment for Urethral Discharge (Men)	-	-	-	336	-	12/14	-%	-	-	-	-	-
Referral to Tx for Urethral Discharge (Women)	-	-	-	560	-		0%	-	-	-	-	-
Referral to Tx for Urethral Discharge (Women)	-	-	-	560	-	12/14	-%	-	-	-	-	-
Safe Water Solution	39,855	77,608	659,686	740,700	791,708		(17)%	791,708	25,233,577	542,208	-	1,946
Wuha Agar	39,855	77,608	659,686	740,700	791,708	2/06	(17)%	791,708	25,233,577	542,208	-	1,946
STI Kit (Non-Ulcerative)	-	489	4,732	1,869	6,655		(29)%	6,655	836,263	4,259	-	304
STI kit for Urethral Discharge	-	280	2,542	882	2,397	11/10	6%	2,397	452,641	2,288	-	140
STI Kit for Vaginal Discharge	-	209	2,190	987	4,258	11/10	(49)%	4,258	383,622	1,971	-	165
STI Kit (Ulcerative)	-	89	1,588	231	-		0%	-	73,816	1,429	-	305
STI Kit for Genital Ulcer	-	89	1,588	231	-	11/10	-%	-	73,816	1,429	-	305
STI Screening	3,787	2,289	29,237	112,000	33,336		(12)%	33,336	469,287	29,237	-	-
STI Screening	3,787	2,289	29,237	112,000	33,336		(12)%	33,336	469,287	29,237	-	-
TB Screening	3,885	2,552	33,046	31,910	31,664		4%	31,664	451,788	33,046	-	-
TB Screening	3,885	2,552	33,046	31,910	31,664		4%	31,664	451,788	33,046	-	-
Toilets Sold	2,028	2,813	19,723	25,000	5,471		261%	5,471	25,194	90,726	-	3,536
Toilets Sold	2,028	2,813	19,723	25,000	5,471		261%	5,471	25,194	90,726	-	3,536
Toilets Sold - All	2,028	2,813	19,723	-	5,471		261%	5,471	25,194	90,726	-	-
Toilets Sold - All	2,028	2,813	19,723	-	5,471		261%	5,471	25,194	90,726	-	-
Treatment for Inguinal Bubo	-	-	1	-	-		0%	-	1	1	-	-
Treatment for Inguinal Bubo	-	-	1	-	-		-%	-	1	1	-	-
Treatment for Lower Abdominal Pain	-	1	3	-	4		(25)%	4	70	3	-	-
Treatment for Lower Abdominal Pain	-	1	3	-	4		(25)%	4	70	3	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Treatment for Nonherpetic Genital Ulcer	-	-	8	-	16		(50)%	16	79	8	-	1
Treatment for Nonherpetic Genital Ulcer	-	-	8	-	16		(50)%	16	79	8	-	1
Treatment for Urethral Discharge (Men)	3	2	21	-	5		320%	5	166	42	-	-
Treatment for Urethral Discharge (Men)	3	2	21	-	5		320%	5	166	42	-	-
Treatment for Urethral Discharge (Women)	-	-	-	-	12		(100)%	12	76	-	-	-
Treatment for Urethral Discharge (Women)	-	-	-	-	12		(100)%	12	76	-	-	-
Treatment for Vaginitis	12	9	117	-	116		1%	116	1,352	117	-	2
Treatment for Vaginitis	12	9	117	-	116		1%	116	1,352	117	-	2
Ghana											174,384	69,948
Condom	-	-	-	412,211	14,700		(100)%	14,700	799,268	-	-	-
Protector	-	-	-	412,211	14,700		(100)%	14,700	799,268	-	-	-
Injectable 3-IM	-	7,400	455,554	495,534	1,376,081		(67)%	1,376,081	3,596,197	102,500	102,500	40,152
Famplan	-	7,400	455,554	495,534	1,376,481		(67)%	1,376,481	3,596,597	102,500	102,500	40,152
(b)PSI Injectable 3 IM Distributed Provided	-	-	-	-	(400)		-%	(400)	(400)	-	-	-
Injectable 3-IM Provided	-	-	-	-	400		(100)%	400	400	-	-	-
PSI Injectable 3 IM Provided	-	-	-	-	400		(100)%	400	400	-	-	-
OCs	-	154,980	1,198,080	2,068,038	1,969,134		(39)%	1,969,134	5,590,439	71,885	71,885	29,706
(b)PSI OCs Distributed Provided	-	-	-	-	(66)		-%	(66)	(66)	-	-	-
Secure	-	154,980	1,198,080	2,068,038	1,969,200		(39)%	1,969,200	5,590,505	71,885	71,885	29,706
OCs Provided	-	-	-	-	66		(100)%	66	66	-	-	-
PSI OCs Provided	-	-	-	-	66		(100)%	66	66	-	-	-
Toilets Sold	-	115	737	600	180		311%	180	916	2,653	-	72
Toilets Sold	-	115	737	600	180		311%	180	916	2,653	-	72
Toilets Sold - All	-	1,154	7,369	-	1,795		311%	1,795	9,164	26,528	-	-
Toilets Sold - All	-	1,154	7,369	-	1,795		311%	1,795	9,164	26,528	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Water Treatment Tablets	-	19,067	461,800	1,066,668	844,900		(45)%	844,900	1,400,100	7,591	-	18
Aquatabs 67 mg (20 L)	-	19,067	461,800	1,066,668	844,900	7/17	(45)%	844,900	1,400,100	7,591	-	18
Lesotho											14,154	59,567
Antiretroviral Treatment (Currently Enrolled)	1,369	1,361	16,092	1,443	18,922		(15)%	18,922	54,571	1,341	-	3,046
Antiretroviral Treatment (Currently Enrolled)	1,369	1,361	16,092	1,443	18,922		(15)%	18,922	54,571	1,341	-	3,046
Antiretroviral Treatment (Newly Enrolled)	5	9	97	169	110		(12)%	110	325	97	-	-
Antiretroviral Treatment (Newly Enrolled)	5	9	97	169	110		(12)%	110	325	97	-	-
Emergency Contraception Provided	15	25	178	25	20		790%	20	349	9	9	3
Non-PSI Emergency Contraception Provided	15	25	178	25	20		790%	20	349	9	9	3
Female Condom	120	206	1,606	3,000	96,546		(98)%	96,546	2,512,688	12	12	46
Generic	120	206	1,606	3,000	96,546	1/08	(98)%	96,546	2,512,688	12	12	46
Free Condom	36,136	118,959	976,636	193,872	13,845,256		(93)%	13,845,256	33,185,018	7,325	7,325	28,420
Camouflage Free	-	-	56,900	13,872	747,700	1/16	(92)%	747,700	3,015,000	427	427	1,656
Vibe Condom	36,136	118,959	919,736	180,000	13,097,556	9/14	(93)%	13,097,556	30,170,018	6,898	6,898	26,764
HIV Self-Testing Kit	16,878	17,762	119,625	111,335	56,275		113%	56,275	175,900	107,663	-	-
ORAQUICK HIV Self-Testing Kit (Pouch)	16,878	17,762	119,625	111,335	56,275		113%	56,275	175,900	107,663	-	-
HIV Testing Services	6,672	7,672	114,646	137,092	158,712		(28)%	158,712	1,217,407	114,646	-	12,011
VCT Individual (HIV-Negative)	6,170	7,157	108,695	129,331	153,406	12/09	(29)%	153,406	1,145,877	108,695	-	11,387
VCT Individual (HIV-Positive)	502	515	5,951	7,761	5,306	12/09	12%	5,306	71,530	5,951	-	623
Hypertension Screening	6	49	743	4,020	2,494		(70)%	2,494	14,439	743	-	-
Hypertension Screening	6	49	743	4,020	2,494		(70)%	2,494	14,439	743	-	-
Implant 3 Insertion	-	-	10	10	6		67%	6	850	10	25	15
Non-PSI Implant 3 Inserted	-	-	10	10	6		67%	6	850	10	25	15
Implant 5 Insertion	-	-	8	20	12		(33)%	12	135	8	30	18
Non-PSI Implant 5 Inserted	-	-	8	20	12		(33)%	12	135	8	30	18

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Injectable 1 Provided	-	-	1	-	-		0%	-	9	-	-	-
Non-PSI Injectable 1 Provided	-	-	1	-	-		-%	-	9	-	-	-
Injectable 2 Provided	1,324	719	4,767	1,000	2,864		66%	2,864	9,689	795	795	359
Non-PSI Injectable 2 Provided	1,324	719	4,767	1,000	2,864		66%	2,864	9,689	795	795	359
Injectable 3-IM Provided	554	1,667	17,973	19,508	12,574		43%	12,574	42,682	4,493	4,493	2,030
Non-PSI Injectable 3 IM Provided	554	1,667	17,973	19,508	12,574		43%	12,574	42,682	4,493	4,493	2,030
OCs Provided	764	1,111	21,974	20,147	17,197		28%	17,197	66,229	1,465	1,465	698
Non-PSI OCs Provided	764	1,111	21,974	20,147	17,197		28%	17,197	66,229	1,465	1,465	698
PrEP	71	68	688	84	14		4814%	14	702	57	-	57
PrEP	71	68	688	84	14		4,814%	14	702	57	-	57
Referral to HIV Testing Services	-	-	-	1,740	1,299		(100)%	1,299	26,462	-	-	-
Referral to HIV Testing Services	-	-	-	1,740	1,299	3/16	(100)%	1,299	26,462	-	-	-
Referral to Linkage to HIV Care	297	365	4,257	6,985	3,328		28%	3,328	15,005	4,257	-	2,559
Referral to Linkage to HIV Care	297	365	4,257	6,985	3,328		28%	3,328	15,005	4,257	-	2,559
TB Diagnosis	4	1	33	77	41		(20)%	41	119	33	-	-
TB Diagnosis	4	1	33	77	41		(20)%	41	119	33	-	-
TB DOTS	3	3	35	77	31		13%	31	82	35	-	284
TB DOTS	3	3	35	77	31		13%	31	82	35	-	284
TB Screening	1,394	1,409	19,017	1,443	21,329		(11)%	21,329	47,045	19,017	-	-
TB Screening	1,394	1,409	19,017	1,443	21,329		(11)%	21,329	47,045	19,017	-	-
Type 2 Diabetes Screening	-	1	30	1,340	395		(92)%	395	3,969	30	-	-
Type 2 Diabetes Screening	-	1	30	1,340	395		(92)%	395	3,969	30	-	-
Voluntary Medical Male Circumcision	107	175	767	500	2,962		(74)%	2,962	4,398	767	-	10,020
Voluntary Medical Male Circumcision	107	175	767	500	2,962		(74)%	2,962	4,398	767	-	10,020
Malawi											701,509	1,161,833

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Cervical Cancer-VIA/VILI Screening	1,060	1,798	14,788	10,000	19,630		(25)%	19,630	34,418	14,788	-	-
Cervical Cancer-VIA/VILI Screening	1,060	1,798	14,788	10,000	19,630		(25)%	19,630	34,418	14,788	-	-
Condom	498,528	1,043,016	13,907,980	12,000,000	17,252,824		(19)%	17,252,824	239,372,906	104,310	104,310	285,883
Chishango	498,528	1,043,016	13,907,980	12,000,000	17,252,824	10/94	(19)%	17,252,824	239,372,906	104,310	104,310	285,883
Emergency Contraception	4,318	5,990	51,274	7,000	11,120		361%	11,120	159,614	2,307	2,307	1,171
Levonorgestrel Tablet 0.75 mg x 2's	5,840	7,030	141,636	-	1,545		9,067%	1,545	143,181	6,374	6,374	3,233
NORLEVO (Norlevo 1.5mg)	-	-	-	35,000	13,994	2/14	(100)%	13,994	111,455	-	-	-
(b)PSI Emergency Contraception Distributed Provided	(1,522)	(1,040)	(90,362)	(28,000)	(4,419)		-%	(4,419)	(95,022)	(4,066)	(4,066)	(2,063)
Emergency Contraception Provided	1,523	1,067	90,453	28,000	4,419		1947%	4,419	95,113	4,523	4,523	2,294
Non-PSI Emergency Contraception Provided	1	27	91	-	-		-%	-	91	5	5	2
PSI Emergency Contraception Provided	1,522	1,040	90,362	28,000	4,419		1,945%	4,419	95,022	4,518	4,518	2,292
Female Condom	4	878	78,045	90,000	86,203		(9)%	86,203	870,528	585	585	1,563
Care	4	878	78,045	90,000	86,203	1/08	(9)%	86,203	870,528	585	585	1,563
Free Condom	710,128	1,315,220	15,496,066	11,069,952	10,466,262		48%	10,466,262	45,075,945	116,220	116,220	318,526
Blue Gold Condoms	-	-	-	-	590,724	8/17	(100)%	590,724	1,856,634	-	-	-
Free Male Condoms	-	41,564	1,000,080	-	-	2/14	-%	-	2,659,852	7,501	7,501	20,557
Generic Male Condom	-	-	-	395,000	-		-%	-	-	-	-	-
Key Population Male Condom	710,128	1,273,656	14,495,986	10,000,000	9,131,741	7/16	59%	9,131,741	34,764,859	108,720	108,720	297,969
One Community Male Condom	-	-	-	-	743,797	7/16	(100)%	743,797	5,247,751	-	-	-
VMMC Male Condom	-	-	-	674,952	-	1/15	-%	-	546,849	-	-	-
Free Female Condom	2,800	6,224	51,483	-	151,992		(66)%	151,992	459,324	386	386	1,031
Free Female Condoms	2,800	6,224	51,483	-	68,719	2/14	(25)%	68,719	359,389	386	386	1,031
Key Population Female Condom	-	-	-	-	83,273	12/17	(100)%	83,273	99,935	-	-	-
HIV Self-Testing Kit	750	2,063	178,804	173,086	258,868		(31)%	258,868	526,669	160,924	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
INSTI HIVST (Blood based)	750	2,062	9,376	-	-		-%	-	9,376	8,438	-	-
ORAQUICK HIV Self-Testing Kit (Pouch)	-	1	169,078	173,086	258,868	8/17	(35)%	258,868	516,943	152,170	-	-
Sure Check HIV Self-Test	-	-	350	-	-		-%	-	350	315	-	-
HIV Testing Services	4,164	7,556	76,528	35,408	76,101		1%	76,101	318,477	76,528	-	3,255
VCT Individual (HIV-Negative)	4,023	7,328	74,351	34,571	72,736	12/14	2%	72,736	309,891	74,351	-	3,163
VCT Individual (HIV-Positive)	141	227	2,177	837	3,365	12/14	(35)%	3,365	8,586	2,177	-	93
Implant 3	(1,093)	(462)	(2,609)	1,000	(11,432)		0%	(11,432)	4,073	(2,348)	(5,870)	(5,333)
Implanon	-	-	-	1,000	18,883	10/12	(100)%	18,883	84,144	-	-	-
Implanon NXT	121	1,617	23,465	-	2,901		709%	2,901	26,366	21,119	52,796	47,962
(b)PSI Implant 3 Distributed Inserted	(1,214)	(2,079)	(26,074)	-	(33,216)		-%	(33,216)	(106,437)	(23,467)	(58,667)	(53,295)
Implant 3 Insertion	2,252	3,346	33,105	49,000	33,272		(1)%	33,272	113,524	33,105	82,763	75,185
Non-PSI Implant 3 Inserted	1,038	1,267	7,031	49,000	56		12,455%	56	7,087	7,031	17,578	15,968
PSI Implant 3 Inserted	1,214	2,079	26,074	-	33,216		(22)%	33,216	106,437	26,074	65,185	59,217
Implant 4	(436)	81	18,459	-	(3,883)		0%	(3,883)	14,576	16,613	53,162	47,669
Levonplant	250	513	25,503	-	30,000		(15)%	30,000	55,503	22,953	73,449	65,859
(b)PSI Implant 4 Distributed Inserted	(686)	(432)	(7,044)	-	(33,883)		-%	(33,883)	(40,927)	(6,340)	(20,287)	(18,191)
Implant 4 Insertion	835	1,644	10,829	-	33,883		(68)%	33,883	44,712	10,829	34,653	31,072
Non-PSI Implant 4 Inserted	149	1,212	3,785	-	-		-%	-	3,785	3,785	12,112	10,861
PSI Implant 4 Inserted	686	432	7,044	-	33,883		(79)%	33,883	40,927	7,044	22,541	20,212
Implant 5	(1,211)	(154)	1,106	1,000	(9,003)		0%	(9,003)	11,677	995	3,783	3,387
Jadelle	180	2,203	25,456	1,000	27,995	10/12	(9)%	27,995	146,846	22,910	87,060	77,949
(b)PSI Implant 5 Distributed Inserted	(1,391)	(2,357)	(24,350)	-	(36,998)	3/16	-%	(36,998)	(135,169)	(21,915)	(83,277)	(74,563)
Implant 5 Insertion	1,971	3,377	29,893	55,000	37,102		(19)%	37,102	140,816	29,893	113,593	101,707
Non-PSI Implant 5 Inserted	580	1,020	5,543	55,000	104		5,230%	104	5,647	5,543	21,063	18,859

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
PSI Implant 5 Inserted	1,391	2,357	24,350	-	36,998	3/16	(34)%	36,998	135,169	24,350	92,530	82,847
Injectable 3-IM	(2,698)	5,215	79,713	35,000	60,576		32%	60,576	1,908,550	17,935	17,935	11,942
Depo-Provera	4,934	12,487	165,251	-	9,721		1,600%	9,721	174,972	37,181	37,181	24,758
(b)PSI Injectable 3 IM Distributed Provided	(7,632)	(7,272)	(85,538)	-	(66,440)		-%	(66,440)	(159,318)	(19,246)	(19,246)	(12,815)
SafePlan Inj3	-	-	-	35,000	117,295	1/08	(100)%	117,295	1,892,896	-	-	-
Injectable 3-IM Provided	8,973	10,172	96,789	84,000	67,465		43%	67,465	171,594	24,197	24,197	16,112
Non-PSI Injectable 3 IM Provided	1,341	2,900	11,251	84,000	1,025		998%	1,025	12,276	2,813	2,813	1,873
PSI Injectable 3 IM Provided	7,632	7,272	85,538	-	66,440		29%	66,440	159,318	21,385	21,385	14,239
Injectable 3-SC	(141)	648	3,446	-	-		0%	-	3,446	775	775	516
(b)PSI Injectable 3 SC Distributed Provided	(509)	(85)	(775)	-	-		-%	-	(775)	(174)	(174)	(116)
Sayana Press	368	733	4,221	-	-		-%	-	4,221	950	950	632
Injectable 3-SC Provided	934	106	1,263	-	-		0%	-	1,263	316	316	210
Non-PSI Injectable 3 SC Provided	425	21	488	-	-		-%	-	488	122	122	81
PSI Injectable 3 SC Provided	509	85	775	-	-		-%	-	775	194	194	129
ITN	-	1,603	4,808	-	-		0%	-	4,808	7,789	-	212
PBO Net	-	1,603	4,808	-	-		-%	-	4,808	7,789	-	212
IUD 10	77	60	1,587	500	(818)		0%	(818)	6,839	1,428	6,570	5,644
IUD Copper T 380A	250	266	5,025	500	5,154	10/12	(3)%	5,154	22,174	4,523	20,803	17,872
(b)PSI IUD 10 Distributed Inserted	(173)	(206)	(3,438)	-	(5,972)	3/16	-%	(5,972)	(15,335)	(3,094)	(14,233)	(12,228)
IUD 10 Insertion	308	459	4,375	5,136	5,972		(27)%	5,972	16,272	4,375	20,125	17,290
Non-PSI IUD 10 Inserted	135	253	937	5,136	-		-%	-	937	937	4,310	3,703
PSI IUD 10 Inserted	173	206	3,438	-	5,972	3/16	(42)%	5,972	15,335	3,438	15,815	13,587
LLIN	1	713	68,507	45,000	34,209		100%	34,209	500,550	110,981	-	4,290
Super Chitetezo Net	1	713	68,507	45,000	34,209	2/11	100%	34,209	500,550	110,981	-	4,290

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Lubricant	154,369	159,910	1,549,435	1,300,000	1,071,889		45%	1,071,889	4,627,783	-	-	-
Personal Lubricant Water 4.5 g	154,369	159,910	1,549,435	1,300,000	1,071,889	12/12	45%	1,071,889	4,627,783	-	-	-
OCs	(104)	14,143	125,327	65,000	164,930		(24)%	164,930	942,285	7,520	7,520	5,282
Microgynon	-	2,607	36,996	-	150,604	11/11	(75)%	150,604	842,736	2,220	2,220	1,559
Microgynon combination 3	2,633	15,419	210,866	65,000	13,640		1,446%	13,640	224,506	12,652	12,652	8,887
Microlut	-	-	-	-	47,803	8/17	(100)%	47,803	58,879	-	-	-
(b)PSI OCs Distributed Provided	(2,737)	(3,883)	(122,535)	-	(47,117)		-%	(47,117)	(183,836)	(7,352)	(7,352)	(5,164)
OCs Provided	3,850	6,716	137,790	35,000	58,051		137%	58,051	210,025	9,186	9,186	6,453
Non-PSI OCs Provided	1,113	2,832	15,255	35,000	10,934		40%	10,934	26,189	1,017	1,017	714
PSI OCs Provided	2,737	3,883	122,535	-	47,117		160%	47,117	183,836	8,169	8,169	5,738
PUR	-	-	6,811,200	4,540,800	5,781,185		18%	5,781,185	66,919,640	55,982	-	170
PuR WaterGuard Waufa	-	-	6,811,200	4,540,800	5,781,185	3/06	18%	5,781,185	66,919,640	55,982	-	170
Safe Water Solution	-	-	716	-	143,085		(99)%	143,085	8,496,271	588	-	2
WaterGuard	-	-	716	-	143,085	12/02	(99)%	143,085	8,496,271	588	-	2
STI Screening	245	413	3,162	-	2,620		21%	2,620	5,782	3,162	-	-
STI Screening	245	413	3,162	-	2,620		21%	2,620	5,782	3,162	-	-
Treatment for Cervicitis	2	9	34	-	-		0%	-	34	34	-	-
Treatment for Cervicitis	2	9	34	-	-		-%	-	34	34	-	-
Treatment for Genital Herpes	1	1	7	-	-		0%	-	7	7	-	-
Treatment for Genital Herpes	1	1	7	-	-		-%	-	7	7	-	-
Treatment for Lower Abdominal Pain	32	58	368	-	-		0%	-	368	368	-	-
Treatment for Lower Abdominal Pain	32	58	368	-	-		-%	-	368	368	-	-
Treatment for Nonherpetic Genital Ulcer	3	7	91	-	-		0%	-	91	91	-	-
Treatment for Nonherpetic Genital Ulcer	3	7	91	-	-		-%	-	91	91	-	-
Treatment for Urethral Discharge (Men)	14	16	119	-	-		0%	-	119	119	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Treatment for Urethral Discharge (Men)	14	16	119	-	-		-%	-	119	119	-	-
Treatment for Urethral Discharge (Women)	26	32	235	-	-		0%	-	235	235	-	-
Treatment for Urethral Discharge (Women)	26	32	235	-	-		-%	-	235	235	-	-
Treatment for Vaginitis	10	-	10	-	-		0%	-	10	10	-	-
Treatment for Vaginitis	10	-	10	-	-		-%	-	10	10	-	-
Tubal Ligation	666	1,486	10,447	17,281	16,027		(35)%	16,027	45,613	10,447	104,470	82,084
Tubal Ligation	666	1,486	10,447	17,281	16,027	1/15	(35)%	16,027	45,613	10,447	104,470	82,084
Voluntary Medical Male Circumcision	926	3,457	40,008	56,645	53,033		(25)%	53,033	133,468	40,008	-	144,214
Voluntary Medical Male Circumcision	926	3,457	40,008	56,645	53,033		(25)%	53,033	133,468	40,008	-	144,214
Namibia											1,160	2,252
Free Condom	-	18,937	151,681	-	-		0%	-	16,697,726	1,138	1,138	2,209
Smile	-	18,937	151,681	-	-	1/08	-%	-	16,697,726	1,138	1,138	2,209
Free Female Condom	-	299	3,005	-	-		0%	-	513,071	23	23	43
Femidom Free	-	299	3,005	-	-	2/07	-%	-	513,071	23	23	43
HIV Self-Testing Kit	-	753	17,384	-	-		0%	-	17,384	15,646	-	-
ORAQUICK HIV Self-Testing Kit (Pouch)	-	753	17,384	-	-	1/18	-%	-	17,384	15,646	-	-
Lubricant	-	21,686	140,982	-	-		0%	-	140,982	-	-	-
Personal Lubricant 4.5 g	-	21,686	140,982	-	-	1/18	-%	-	140,982	-	-	-
PSI Uganda											1,681,799	1,675,134
Basic Care Package	-	-	-	-	1		(100)%	1	1	-	-	-
PLP Kit - NFB (with WaterGuard Tab)	-	-	-	-	1		(100)%	1	1	-	-	-
Cervical Cancer-VIA and Cryotherapy	-	6	74	-	150		(51)%	150	224	74	-	28
Cervical Cancer-VIA and Cryotherapy	-	6	74	-	150		(51)%	150	224	74	-	28
Cervical Cancer-VIA/VILI Screening	-	1,517	15,275	60,000	38,866		(61)%	38,866	54,141	15,275	-	-
Cervical Cancer-VIA/VILI Screening	-	1,517	15,275	60,000	38,866		(61)%	38,866	54,141	15,275	-	-

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Chlorhexidine	263	777	6,590	16,755	23,211		(72)%	23,211	29,801	5,931	-	458
Chlorhexidine Gel, 5 g tube	263	777	6,590	16,755	23,211		(72)%	23,211	29,801	5,931	-	458
Clean Delivery Kit	-	-	-	-	2,840		(100)%	2,840	2,840	-	-	-
Maama Kit	-	-	-	-	572		(100)%	572	572	-	-	-
Maama Kit Extra Clean Delivery	-	-	-	-	2,268		(100)%	2,268	2,268	-	-	-
Condom	447,192	155,856	2,446,488	2,633,850	1,604,736		52%	1,604,736	4,051,224	18,349	18,349	42,753
Trust	115,776	39,168	737,424	675,000	630,504		17%	630,504	1,367,928	5,531	5,531	12,887
Trust Ribbed	117,288	42,144	592,632	665,550	87,408		578%	87,408	680,040	4,445	4,445	10,356
Trust Scented	100,008	36,240	566,496	652,050	349,272		62%	349,272	915,768	4,249	4,249	9,900
Trust Studded	114,120	38,304	549,936	641,250	537,552		2%	537,552	1,087,488	4,125	4,125	9,610
Emergency Contraception	-	(6)	(60)	-	(107)		0%	(107)	(167)	(3)	(3)	(2)
(b)PSI Emergency Contraception Distributed Provided	-	(6)	(60)	-	(107)		-%	(107)	(167)	(3)	(3)	(2)
Emergency Contraception Provided	-	13	102	-	109		(6)%	109	211	5	5	3
Non-PSI Emergency Contraception Provided	-	7	42	-	2		2,000%	2	44	2	2	1
PSI Emergency Contraception Provided	-	6	60	-	107		(44)%	107	167	3	3	2
Expanded Clean Delivery Kit	-	-	-	-	13,160		(100)%	13,160	13,160	-	-	-
Mama Kit Expanded(Chlorhexidine 400gm&Misoprostol)	-	-	-	-	13,160		(100)%	13,160	13,160	-	-	-
Expanded Clean Delivery Kit (+CHX)	669	973	11,709	20,285	13,837		(15)%	13,837	25,546	10,538	-	1,713
Mama Kit with Chlorhexidine	669	973	11,709	20,285	13,837		(15)%	13,837	25,546	10,538	-	1,713
Free Condom	-	-	-	-	576,000		(100)%	576,000	576,000	-	-	-
Generic Male Condom	-	-	-	-	576,000		(100)%	576,000	576,000	-	-	-
Implant 3	21,213	11,606	77,791	72,620	34,268		127%	34,268	112,059	70,012	175,030	177,226
Implanon	8,446	7,355	63,640	92,900	55,110		15%	55,110	118,750	57,276	143,190	144,987
Levonplant	12,957	6,483	34,207	-	-		-%	-	34,207	30,786	76,966	77,931

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
(b)PSI Implant 3 Distributed Inserted	(190)	(2,232)	(20,056)	(20,280)	(20,842)		-%	(20,842)	(40,898)	(18,050)	(45,126)	(45,692)
Implant 3 Insertion	8,414	10,312	114,111	100,280	99,913		14%	99,913	214,024	114,111	285,278	288,857
Non-PSI Implant 3 Inserted	8,224	8,080	94,055	80,000	79,071		19%	79,071	173,126	94,055	235,138	238,088
PSI Implant 3 Inserted	190	2,232	20,056	20,280	20,842		(4)%	20,842	40,898	20,056	50,140	50,769
Implant 5	4,509	4,523	49,558	25,000	41,363		20%	41,363	90,921	44,602	169,488	168,680
Jadelle	4,580	5,600	59,210	40,000	53,160		11%	53,160	112,370	53,289	202,498	201,532
(b)PSI Implant 5 Distributed Inserted	(71)	(1,077)	(9,652)	(15,000)	(11,797)		-%	(11,797)	(21,449)	(8,687)	(33,010)	(32,852)
Implant 5 Insertion	3,095	4,311	57,179	45,160	33,335		72%	33,335	90,514	57,179	217,280	216,244
Non-PSI Implant 5 Inserted	3,024	3,234	47,527	30,160	21,538		121%	21,538	69,065	47,527	180,603	179,741
PSI Implant 5 Inserted	71	1,077	9,652	15,000	11,797		(18)%	11,797	21,449	9,652	36,678	36,503
Injectable 3-IM	19,196	22,557	162,766	48,097	59,649		173%	59,649	222,415	36,622	36,622	27,261
Depo-Provera	19,450	25,192	187,350	68,097	82,175		128%	82,175	269,525	42,154	42,154	31,378
(b)PSI Injectable 3 IM Distributed Provided	(254)	(2,634)	(24,584)	(20,000)	(22,526)		-%	(22,526)	(47,110)	(5,531)	(5,531)	(4,117)
Injectable 3-IM Provided	263	2,683	25,418	21,700	24,298		5%	24,298	49,716	6,355	6,355	4,730
Non-PSI Injectable 3 IM Provided	9	49	834	1,700	1,772		(53)%	1,772	2,606	209	209	155
PSI Injectable 3 IM Provided	254	2,634	24,584	20,000	22,526		9%	22,526	47,110	6,146	6,146	4,575
Injectable 3-SC	2,100	11,404	87,600	53,892	55,900		57%	55,900	143,500	19,710	19,710	14,672
Sayana Press	2,100	11,404	87,600	53,892	55,900		57%	55,900	143,500	19,710	19,710	14,672
IUD 10	25,588	17,399	117,001	90,759	112,806		4%	112,806	229,807	105,301	484,384	460,982
Copper T 380	24,000	13,685	107,755	87,000	110,545		(3)%	110,545	218,300	96,980	446,106	424,553
IUD PACK CU T380A	1,933	6,524	30,334	60,000	43,587		(30)%	43,587	73,921	27,301	125,583	119,515
PPIUD Cu T380A	-	78	2,025	1,359	2,675		(24)%	2,675	4,700	1,823	8,383	7,978
(b)PSI IUD 10 Distributed Inserted	(345)	(2,888)	(23,113)	(57,600)	(44,001)		-%	(44,001)	(67,114)	(20,802)	(95,688)	(91,065)
IUD 10 Insertion	2,838	6,409	57,538	112,680	89,907		(36)%	89,907	147,445	57,538	264,675	251,887

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Non-PSI IUD 10 Inserted	2,493	3,520	34,425	55,080	45,906		(25)%	45,906	80,331	34,425	158,355	150,704
PSI IUD 10 Inserted	345	2,888	23,113	57,600	44,001		(47)%	44,001	67,114	23,113	106,320	101,183
IUD 5	-	(1)	(32)	-	(134)		0%	(134)	(166)	(29)	(95)	(96)
(b)PSI IUD 5 Distributed Inserted	-	(1)	(32)	-	(134)		-%	(134)	(166)	(29)	(95)	(96)
IUD 5 Insertion	-	1	34	-	135		(75)%	135	169	34	112	114
Non-PSI IUD 5 Inserted	-	-	2	-	1		100%	1	3	2	7	7
PSI IUD 5 Inserted	-	1	32	-	134		(76)%	134	166	32	106	107
Manual Vacuum Aspiration for PAC	9	66	861	720	469		84%	469	1,330	861	-	253
MVA for PAC	9	66	861	720	469		84%	469	1,330	861	-	253
Manual Vacuum Aspiration for SA	35	67	805	-	261		208%	261	1,066	805	-	294
Manual Vacuum Aspiration for SA	35	67	805	-	261		208%	261	1,066	805	-	294
Medical Abortion	711	1,449	10,999	9,331	16,535		(33)%	16,535	27,534	9,899	-	3,468
Divabo - Combipack (1+4's)	736	1,528	11,774	9,331	16,804		(30)%	16,804	28,578	10,597	-	3,712
(b)PSI Medical Abortion Distributed Provided	(25)	(78)	(775)	-	(269)		-%	(269)	(1,044)	(698)	-	(244)
Medical Abortion (Misoprostol) Provided	21	81	988	-	344		187%	344	1,332	988	-	309
PSI Medical Abortion (Misoprostol) Provided	21	81	988	-	344		187%	344	1,332	988	-	309
Medical Abortion Provided	25	78	775	-	269		188%	269	1,044	775	-	271
PSI Medical Abortion Provided	25	78	775	-	269		188%	269	1,044	775	-	271
Misoprostol for PAC Provided	5	48	858	-	586		46%	586	1,444	858	-	294
PSI Misoprostol for PAC Provided	5	48	858	-	586		46%	586	1,444	858	-	294
Misoprostol for Safe Abortion	96,528	66,831	668,042	893,550	452,048		48%	452,048	1,120,090	35,072	-	10,957
Misoprostol 200 mcg Tablet	96,800	68,000	521,230	-	-		-%	-	521,230	27,365	-	8,549
Misoprostol for Safe Abortion	-	-	162,100	893,550	458,520		(65)%	458,520	620,620	8,510	-	2,659
(b)PSI Misoprostol for Safe Abortion Dist Provided	(272)	(1,169)	(15,288)	-	(6,472)		-%	(6,472)	(21,760)	(803)	-	(251)
OCs	8,205	5,400	63,013	45,277	43,581		45%	43,581	106,594	3,781	3,781	2,969

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Combination 3	-	167	3,100	-	7,900		(61)%	7,900	11,000	186	186	146
Family Planning Pills	-	-	-	26,280	28,590		(100)%	28,590	28,590	-	-	-
Microlut - Oral Contraceptive	1,332	1,614	8,096	2,000	699		1,058%	699	8,795	486	486	381
(b)PSI OCs Distributed Provided	(16)	(321)	(2,682)	(3,003)	(2,890)		-%	(2,890)	(5,572)	(161)	(161)	(126)
Zinnia	6,889	3,940	54,499	20,000	9,282		487%	9,282	63,781	3,270	3,270	2,568
OCs Provided	16	331	2,821	3,103	3,066		(8)%	3,066	5,887	188	188	148
Non-PSI OCs Provided	-	10	139	100	176		(21)%	176	315	9	9	7
PSI OCs Provided	16	321	2,682	3,003	2,890		(7)%	2,890	5,572	179	179	140
PUR	288,000	304,080	3,387,421	3,400,000	6,413,745		(47)%	6,413,745	9,801,166	27,842	-	111
PuR	288,000	304,080	3,387,421	3,400,000	6,413,745		(47)%	6,413,745	9,801,166	27,842	-	111
Referral to HIV Testing Services	-	-	-	-	11,703		(100)%	11,703	11,703	-	-	-
Referral to HIV Testing Services	-	-	-	-	11,703		(100)%	11,703	11,703	-	-	-
Referral to Linkage to HIV Care	-	-	-	-	4,614		(100)%	4,614	4,614	-	-	-
Referral to Linkage to HIV Care	-	-	-	-	4,614		(100)%	4,614	4,614	-	-	-
Tubal Ligation	-	2	47	-	46		2%	46	93	47	470	404
Tubal Ligation	-	2	47	-	46		2%	46	93	47	470	404
Vasectomy	-	4	17	-	-		0%	-	17	17	170	148
Vasectomy	-	4	17	-	-		-%	-	17	17	170	148
Rwanda											129,188	253,361
Condom	729,268	1,504,655	15,062,917	16,437,500	13,673,659		10%	13,673,659	215,967,803	112,972	112,972	242,349
Plaisir	239,049	280,660	3,300,189	2,000,000	1,688,521	2/13	95%	1,688,521	19,880,209	24,751	24,751	53,097
Prudence Plus	490,219	1,223,995	11,762,728	14,437,500	11,985,138	2/13	(2)%	11,985,138	196,087,594	88,220	88,220	189,252
Free Condom	131	40	386	-	22,662		(98)%	22,662	2,390,794	3	3	6
Military Condom	131	40	386	-	22,662	4/14	(98)%	22,662	2,390,794	3	3	6

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Injectable 3-IM	450	-	26,582	26,620	42,020		(37)%	42,020	108,194	5,981	5,981	3,850
Confiance Depo-Provera	450	-	26,582	26,620	42,020	2/13	(37)%	42,020	108,194	5,981	5,981	3,850
OCs	7,200	34,170	170,539	79,860	170,171		0%	170,171	537,342	10,232	10,232	6,948
Microgynon	7,200	34,170	170,539	79,860	170,171	6/15	-%	170,171	537,342	10,232	10,232	6,948
PUR	24	160,173	1,121,565	1,000,000	1,286,421		(13)%	1,286,421	13,982,194	9,218	-	19
PuR	24	160,173	1,121,565	1,000,000	1,286,421	2/13	(13)%	1,286,421	13,982,194	9,218	-	19
Safe Water Solution	14,414	596	114,438	275,000	250,823		(54)%	250,823	4,180,021	94,059	-	190
Sur Eau	14,414	596	114,438	275,000	250,823	2/13	(54)%	250,823	4,180,021	94,059	-	190
Swaziland											89,885	564,666
Antiretroviral Treatment (Currently Enrolled)	1,715	1,561	15,930	19,040	9,037		76%	9,037	26,840	1,327	-	3,277
Antiretroviral Treatment (Currently Enrolled)	1,715	1,561	15,930	19,040	9,037		76%	9,037	26,840	1,327	-	3,277
Antiretroviral Treatment (Newly Enrolled)	27	55	728	359	593		23%	593	1,890	728	-	-
Antiretroviral Treatment (Newly Enrolled)	27	55	728	359	593		23%	593	1,890	728	-	-
CD4 Tests Provided to HIV+ Clients	-	-	-	-	101		(100)%	101	1,499	-	-	-
CD4 Tests Provided to HIV+ Clients	-	-	-	-	101		(100)%	101	1,499	-	-	-
Cervical Cancer-VIA/VILI Screening	8	26	85	-	-		0%	-	86	85	-	-
Cervical Cancer-VIA/VILI Screening	8	26	85	-	-		-%	-	86	85	-	-
Condom	-	-	-	-	5,072,763		(100)%	5,072,763	24,040,979	-	-	-
Lovers Plus	-	-	-	-	288	2/01	(100)%	288	1,271,986	-	-	-
Lovers Plus C&F	-	-	-	-	253	1/05	(100)%	253	188,237	-	-	-
Lovers Plus R&S	-	-	-	-	80	5/10	(100)%	80	111,824	-	-	-
Trust Regular BGF	-	-	-	-	234	7/08	(100)%	234	74,421	-	-	-
Trust Studded	-	-	-	-	1,908	1/05	(100)%	1,908	5,550,730	-	-	-
Trust Workplace	-	-	-	-	5,070,000	2/06	(100)%	5,070,000	16,843,781	-	-	-
Emergency Contraception Provided	-	-	3	-	2		50%	2	10	-	-	-

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Non-PSI Emergency Contraception Provided	-	-	3	-	2		50%	2	10	-	-	-
Female Condom	1,000	12,667	94,000	60,000	116,500		(19)%	116,500	1,126,727	705	705	4,040
Female Condom	1,000	12,667	94,000	60,000	116,500	7/06	(19)%	116,500	1,126,727	705	705	4,040
Free Condom	477,000	1,159,000	11,877,000	6,000,000	11,994,690		(1)%	11,994,690	85,118,108	89,077	89,077	515,030
Generic	279,000	920,000	8,589,000	3,750,000	11,283,000	4/05	(24)%	11,283,000	70,727,544	64,417	64,417	372,450
Vanilla & Strawberry	198,000	239,000	3,288,000	2,250,000	711,000		362%	711,000	3,999,000	24,660	24,660	142,580
Workplace	-	-	-	-	690	10/01	(100)%	690	10,391,564	-	-	-
HIV Self-Testing Kit	3,086	5,311	27,687	27,000	36,575		(24)%	36,575	64,262	24,918	-	-
ORAQUICK HIV Self-Testing Kit (Pouch)	3,086	5,311	27,687	27,000	36,575		(24)%	36,575	64,262	24,918	-	-
HIV Testing Services	1,178	1,546	33,375	32,457	37,788		(12)%	37,788	653,346	33,375	-	4,538
VCT Individual (HIV-Negative)	1,027	1,192	28,812	27,006	32,716	12/09	(12)%	32,716	596,609	28,812	-	3,917
VCT Individual (HIV-Positive)	151	354	4,563	5,451	5,072	12/09	(10)%	5,072	56,737	4,563	-	620
Hypertension Screening	123	779	6,115	32,457	3,270		87%	3,270	14,619	6,115	-	-
Hypertension Screening	123	779	6,115	32,457	3,270		87%	3,270	14,619	6,115	-	-
Implant 3 Insertion	-	-	25	33	170		(85)%	170	197	25	63	42
Non-PSI Implant 3 Inserted	-	-	25	33	170		(85)%	170	197	25	63	42
Injectable 1 Provided	-	1	41	36	537		(92)%	537	1,800	3	3	2
Non-PSI Injectable 1 Provided	-	1	41	36	537		(92)%	537	1,800	3	3	2
Injectable 3-IM Provided	-	1	121	102	1,194		(90)%	1,194	2,954	30	30	15
Non-PSI Injectable 3 IM Provided	-	1	121	102	1,194		(90)%	1,194	2,954	30	30	15
Lubricant	53,000	101,333	795,000	600,000	1,342,000		(41)%	1,342,000	2,810,000	-	-	-
Lifestyles Liquid Personal Lubricant (4.5 g)	53,000	101,333	795,000	600,000	1,342,000	8/11	(41)%	1,342,000	2,810,000	-	-	-
OCs Provided	-	1	97	70	692		(86)%	692	2,308	6	6	3
Non-PSI OCs Provided	-	1	97	70	692		(86)%	692	2,308	6	6	3
PrEP	13	13	177	-	78		127%	78	255	15	-	10

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
PrEP	13	13	177	-	78		127%	78	255	15	-	10
Referral to Hypertension Management	-	-	1	-	3		(67)%	3	46	1	-	-
Referral to Hypertension Management	-	-	1	-	3		(67)%	3	46	1	-	-
Referral to Injectable 1	-	-	-	-	36		(100)%	36	384	-	-	-
Referral to Injectable 1	-	-	-	-	36		(100)%	36	384	-	-	-
Referral to Injectable 3	-	-	-	-	55		(100)%	55	646	-	-	-
Referral to Injectable 3	-	-	-	-	55		(100)%	55	646	-	-	-
Referral to Linkage to HIV Care	68	178	2,374	5,178	2,541		(7)%	2,541	8,977	2,374	-	1,551
Referral to Linkage to HIV Care	68	178	2,374	5,178	2,541		(7)%	2,541	8,977	2,374	-	1,551
Referral to OCs	-	-	-	-	76		(100)%	76	547	-	-	-
Referral to OCs	-	-	-	-	76		(100)%	76	547	-	-	-
Referral to STI Treatment (unknown)	-	-	-	-	26		(100)%	26	247	-	-	-
Referral to STI Treatment (unknown)	-	-	-	-	26	12/14	(100)%	26	247	-	-	-
Referral to TB Screening	-	-	-	5,178	303		(100)%	303	4,032	-	-	-
Referrals to TB Screening	-	-	-	5,178	303		(100)%	303	4,032	-	-	-
Referral to Voluntary Medical Male Circumcision	-	-	-	-	19		(100)%	19	4,737	-	-	-
Referral to Voluntary Medical Male Circumcision	-	-	-	-	19	12/14	(100)%	19	4,737	-	-	-
STI Screening	1,188	1,586	33,799	32,457	37,972		(11)%	37,972	143,247	33,799	-	-
STI Screening	1,188	1,586	33,799	32,457	37,972		(11)%	37,972	143,247	33,799	-	-
TB Screening	1,357	1,683	33,964	1,043	37,910		(10)%	37,910	134,261	33,964	-	-
TB Screening	1,357	1,683	33,964	1,043	37,910		(10)%	37,910	134,261	33,964	-	-
Treatment for Genital Herpes	1	4	24	17	17		41%	17	68	24	-	2
Treatment for Genital Herpes	1	4	24	17	17		41%	17	68	24	-	2
Treatment for Inguinal Bubo	-	-	-	-	1		(100)%	1	5	-	-	-
Treatment for Inguinal Bubo	-	-	-	-	1		(100)%	1	5	-	-	-

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Treatment for Lower Abdominal Pain	-	-	64	54	54		19%	54	173	64	-	-
Treatment for Lower Abdominal Pain	-	-	64	54	54		19%	54	173	64	-	-
Treatment for Nonherpetic Genital Ulcer	-	3	80	94	94		(15)%	94	319	80	-	31
Treatment for Nonherpetic Genital Ulcer	-	3	80	94	94		(15)%	94	319	80	-	31
Treatment for Urethral Discharge (Men)	6	13	270	195	195		38%	195	684	540	-	38
Treatment for Urethral Discharge (Men)	6	13	270	195	195		38%	195	684	540	-	38
Treatment for Urethral Discharge (Women)	-	-	3	2	2		50%	2	7	3	-	1
Treatment for Urethral Discharge (Women)	-	-	3	2	2		50%	2	7	3	-	1
Treatment for Vaginitis	-	1	216	380	380		(43)%	380	1,182	216	-	57
Treatment for Vaginitis	-	1	216	380	380		(43)%	380	1,182	216	-	57
Type 2 Diabetes Screening	54	1,200	22,275	32,457	658		3285%	658	23,192	22,275	-	-
Type 2 Diabetes Screening	54	1,200	22,275	32,457	658		3,285%	658	23,192	22,275	-	-
Voluntary Medical Male Circumcision	68	115	2,580	4,000	2,766		(7)%	2,766	9,447	2,580	-	36,031
Voluntary Medical Male Circumcision	68	115	2,580	4,000	2,766		(7)%	2,766	9,447	2,580	-	36,031
Tanzania											499,961	470,523
Cervical Cancer-VIA/VILI Screening	-	-	-	-	39		(100)%	39	19,810	-	-	-
Cervical Cancer-VIA/VILI Screening	-	-	-	-	39		(100)%	39	19,810	-	-	-
Condom	-	1,440	10,368	220,000	9,719,136		(100)%	9,719,136	614,748,380	78	78	119
Salama Hali	-	432	1,296	-	4,191,696	2/11	(100)%	4,191,696	345,729,800	10	10	15
Salama Scented	-	-	-	220,000	4,398,624	8/06	(100)%	4,398,624	136,918,956	-	-	-
Salama Studded	-	1,008	9,072	-	1,128,816	6/04	(99)%	1,128,816	132,099,624	68	68	104
Emergency Contraception	-	-	(484)	-	(779)		0%	(779)	(1,312)	(22)	(22)	(10)
(b)PSI Emergency Contraception Distributed Provided	-	-	(484)	-	(779)		-%	(779)	(1,312)	(22)	(22)	(10)
Emergency Contraception Provided	25	29	1,135	2,468	2,258		(50)%	2,258	3,533	57	57	27
Non-PSI Emergency Contraception Provided	25	29	651	2,468	1,479		(56)%	1,479	2,221	33	33	16

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
PSI Emergency Contraception Provided	-	-	484	-	779		(38)%	779	1,312	24	24	12
Implant 3 Insertion	698	4,808	55,755	49,779	73,748		(24)%	73,748	219,156	55,755	139,388	118,923
Non-PSI Implant 3 Inserted	698	4,808	55,755	49,779	73,748		(24)%	73,748	219,156	55,755	139,388	118,923
Implant 5	260	-	260	-	-		0%	-	84,260	234	889	744
Jadelle	260	-	260	-	-	11/09	-%	-	84,260	234	889	744
Implant 5 Insertion	1,298	4,398	43,609	32,829	45,509		(4)%	45,509	148,671	43,609	165,714	138,730
Non-PSI Implant 5 Inserted	1,298	4,398	43,609	32,829	45,509		(4)%	45,509	148,671	43,609	165,714	138,730
Injectable 3-IM	-	-	(650)	-	241,911		(100)%	241,911	1,900,188	(146)	(146)	(92)
Familia Injectable 3 Kit	-	-	-	-	246,600	1/10	(100)%	246,600	1,913,951	-	-	-
(b)PSI Injectable 3 IM Distributed Provided	-	-	(650)	-	(4,689)		-%	(4,689)	(13,763)	(146)	(146)	(92)
Injectable 3-IM Provided	1,489	4,082	43,198	7,419	37,606		15%	37,606	149,635	10,800	10,800	6,786
Non-PSI Injectable 3 IM Provided	1,489	4,082	42,548	7,419	32,917		29%	32,917	135,872	10,637	10,637	6,684
PSI Injectable 3 IM Provided	-	-	650	-	4,689		(86)%	4,689	13,763	163	163	102
ITN	-	420,232	1,260,695	-	-		0%	-	1,260,695	2,042,326	-	44,820
PBO Net	-	420,232	1,260,695	-	-		-%	-	1,260,695	2,042,326	-	44,820
IUD 10	1,313	413	1,313	2,450	-		0%	-	(35,659)	1,182	5,436	4,342
Familia IUD Kit	-	413	2,340	2,450	12,820	11/09	(82)%	12,820	255,969	2,106	9,688	7,739
Pregna IUD (no safe load)	1,313	-	1,313	-	-	3/17	-%	-	18,650	1,182	5,436	4,342
(b)PSI IUD 10 Distributed Inserted	-	-	(2,340)	-	(12,820)		-%	(12,820)	(310,278)	(2,106)	(9,688)	(7,739)
IUD 10 Insertion	1,279	3,329	37,319	66,000	96,804		(61)%	96,804	616,923	37,319	171,667	137,134
Non-PSI IUD 10 Inserted	1,279	3,329	34,979	66,000	83,984		(58)%	83,984	306,645	34,979	160,903	128,535
PSI IUD 10 Inserted	-	-	2,340	-	12,820		(82)%	12,820	310,278	2,340	10,764	8,599
LLIN	-	-	144,630	655,054	4,510,989		(97)%	4,510,989	12,096,501	234,301	-	7,266
"New Brand" (School Net Program)	-	-	-	-	97,352		(100)%	97,352	1,255,210	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Olyset Nets Health Facility	-	-	59,760	-	486,680		(88)%	486,680	546,440	96,811	-	3,002
Permanet (180x160x180 CM) SI	-	-	-	-	978,840	2/16	(100)%	978,840	7,261,864	-	-	-
Permanet Health Facility	-	-	84,496	655,054	91,648		(8)%	91,648	176,144	136,884	-	4,245
Permanet Nets School	-	-	374	-	2,856,469		(100)%	2,856,469	2,856,843	606	-	19
Manual Vacuum Aspiration for PAC	214	588	5,478	-	6,674		(18)%	6,674	13,226	5,478	-	690
MVA for PAC	214	588	5,478	-	6,674		(18)%	6,674	13,226	5,478	-	690
Misoprostol for PAC Provided	120	196	2,220	-	2,547		(13)%	2,547	4,818	2,220	-	329
PSI Misoprostol for PAC Provided	120	196	2,220	-	2,547		(13)%	2,547	4,818	2,220	-	329
Misoprostol for Safe Abortion	62,240	64,444	885,152	1,100,000	1,207,224		(27)%	1,207,224	7,047,176	46,470	-	6,283
Misoprostol Cipla 200 mcg	62,720	65,227	894,032	1,100,000	776,776		15%	776,776	1,670,808	46,937	-	6,346
Misoprostol for Safe Abortion	-	-	-	-	440,636	3/18	(100)%	440,636	5,395,640	-	-	-
(b)PSI Misoprostol for Safe Abortion Dist Provided	(480)	(783)	(8,880)	-	(10,188)		-%	(10,188)	(19,272)	(466)	-	(63)
OCs	-	-	(969)	-	287,100		(100)%	287,100	10,206,220	(58)	(58)	(39)
Familia [OC]	-	-	-	-	295,056	2/08	(100)%	295,056	10,228,009	-	-	-
(b)PSI OCs Distributed Provided	-	-	(969)	-	(7,956)		-%	(7,956)	(21,789)	(58)	(58)	(39)
OCs Provided	1,638	10,823	92,392	11,708	75,344		23%	75,344	212,657	6,159	6,159	4,083
Non-PSI OCs Provided	1,638	10,823	91,423	11,708	67,388		36%	67,388	190,868	6,095	6,095	4,040
PSI OCs Provided	-	-	969	-	7,956		(88)%	7,956	21,789	65	65	43
Water Treatment Tablets	16,800	1,138,473	5,768,110	7,001,740	6,112,242		(6)%	6,112,242	125,174,161	94,818	-	387
Aquatab Tubs 8.68g	-	-	-	1,740	960	3/16	(100)%	960	446,520	-	-	-
WaterGuard Tablet ENF	-	-	1,166,640	7,000,000	6,111,282	7/12	(81)%	6,111,282	52,372,322	19,178	-	78
WaterGuard Tablets	16,800	1,138,473	4,601,470	-	-	11/05	-%	-	72,355,319	75,641	-	308
Uganda											144,136	419,148
Cervical Cancer-VIA and Cryotherapy	-	-	-	-	74		(100)%	74	2,360	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Cervical Cancer-VIA and Cryotherapy	-	-	-	-	74	11/13	(100)%	74	2,360	-	-	-
Cervical Cancer-VIA/VILI Screening	-	-	-	-	18,884		(100)%	18,884	176,960	-	-	-
Cervical Cancer-VIA/VILI Screening	-	-	-	-	18,884		(100)%	18,884	176,960	-	-	-
Chlorhexidine	-	-	-	-	411		(100)%	411	13,454	-	-	-
Chlorhexidine Gel, 5 g tube	-	-	-	-	411	11/16	(100)%	411	13,454	-	-	-
Clean Delivery Kit	-	-	-	-	609		(100)%	609	178,925	-	-	-
Maama Kit Extra Clean Delivery	-	-	-	-	609	8/10	(100)%	609	178,925	-	-	-
Condom	-	-	-	-	180,648		(100)%	180,648	46,911,638	-	-	-
Trust	-	-	-	-	49,392	6/06	(100)%	49,392	44,987,870	-	-	-
Trust Ribbed	-	-	-	-	39,528	11/15	(100)%	39,528	610,632	-	-	-
Trust Scented	-	-	-	-	42,408	11/15	(100)%	42,408	649,224	-	-	-
Trust Studded	-	-	-	-	49,320	11/15	(100)%	49,320	663,912	-	-	-
Expanded Clean Delivery Kit (+CHX)	-	-	-	-	694		(100)%	694	1,311	-	-	-
Mama Kit with Chlorhexidine	-	-	-	-	694	11/17	(100)%	694	1,311	-	-	-
Fever Cases Attended	67,555	25,845	238,868	-	-		0%	-	238,868	238,868	-	-
Fever Cases Attended	67,555	25,845	238,868	-	-		-%	-	238,868	238,868	-	-
Fever Cases Tested with RDTs	64,534	24,741	227,984	-	-		0%	-	227,984	227,984	-	-
Fever Cases Tested with RDTs	64,534	24,741	227,984	-	-		-%	-	227,984	227,984	-	-
Free Condom	2,343,064	1,055,827	19,153,992	15,350,000	16,543,154		16%	16,543,154	102,365,925	143,655	143,655	334,720
Generic	2,112,664	911,827	13,251,432	10,350,000	13,304,596	1/99	-%	13,304,596	93,224,807	99,386	99,386	231,571
Ulinzi Condoms	230,400	144,000	5,902,560	5,000,000	3,238,558		82%	3,238,558	9,141,118	44,269	44,269	103,148
Free Female Condom	26,000	4,273	64,080	100,000	105,995		(40)%	105,995	2,374,710	481	481	1,082
Female Condom Free	26,000	4,273	64,080	100,000	105,995	11/09	(40)%	105,995	2,374,710	481	481	1,082
HIV Testing Services	-	1,010	3,031	-	-		0%	-	130,754	3,031	-	188
VCT Individual (HIV-Negative)	-	996	2,987	-	-	8/13	-%	-	126,391	2,987	-	186

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
VCT Individual (HIV-Positive)	-	15	44	-	-	8/13	-%	-	4,363	44	-	3
Implant 3	-	-	-	-	(5,778)		0%	(5,778)	105,174	-	-	-
Implanon	-	-	-	-	932	12/08	(100)%	932	192,634	-	-	-
(b)PSI Implant 3 Distributed Inserted	-	-	-	-	(6,710)		-%	(6,710)	(87,460)	-	-	-
Implant 3 Insertion	-	-	-	-	27,489		(100)%	27,489	292,024	-	-	-
Non-PSI Implant 3 Inserted	-	-	-	-	20,779		(100)%	20,779	204,564	-	-	-
PSI Implant 3 Inserted	-	-	-	-	6,710		(100)%	6,710	87,460	-	-	-
Implant 5	-	-	-	-	(4,540)		0%	(4,540)	95,981	-	-	-
Jadelle	-	-	-	-	760	12/08	(100)%	760	181,319	-	-	-
(b)PSI Implant 5 Distributed Inserted	-	-	-	-	(5,300)		-%	(5,300)	(85,338)	-	-	-
Implant 5 Insertion	-	-	-	-	5,464		(100)%	5,464	114,325	-	-	-
Non-PSI Implant 5 Inserted	-	-	-	-	164		(100)%	164	28,987	-	-	-
PSI Implant 5 Inserted	-	-	-	-	5,300		(100)%	5,300	85,338	-	-	-
Injectable 3-IM	-	-	-	-	3,950		(100)%	3,950	263,573	-	-	-
Depo-Provera	-	-	-	-	3,950	11/11	(100)%	3,950	263,573	-	-	-
IUD 10	-	-	-	-	(16,307)		0%	(16,307)	1,791	-	-	-
IUD PACK CU T380A	-	-	-	-	890	4/11	(100)%	890	238,341	-	-	-
(b)PSI IUD 10 Distributed Inserted	-	-	-	-	(17,197)		-%	(17,197)	(236,550)	-	-	-
IUD 10 Insertion	-	-	-	-	23,549		(100)%	23,549	426,314	-	-	-
Non-PSI IUD 10 Inserted	-	-	-	-	6,352		(100)%	6,352	189,765	-	-	-
PSI IUD 10 Inserted	-	-	-	-	17,197		(100)%	17,197	236,550	-	-	-
IUD 5	-	-	-	-	(129)		0%	(129)	(17,342)	-	-	-
(b)PSI IUD 5 Distributed Inserted	-	-	-	-	(129)		-%	(129)	(17,342)	-	-	-
IUD 5 Insertion	-	-	-	-	130		(100)%	130	28,350	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Non-PSI IUD 5 Inserted	-	-	-	-	1		(100)%	1	11,007	-	-	-
PSI IUD 5 Inserted	-	-	-	-	129		(100)%	129	17,342	-	-	-
Manual Vacuum Aspiration for PAC	-	-	-	-	388		(100)%	388	2,304	-	-	-
MVA for PAC	-	-	-	-	388	3/16	(100)%	388	2,304	-	-	-
Manual Vacuum Aspiration for SA	-	-	-	-	150		(100)%	150	1,348	-	-	-
Manual Vacuum Aspiration for SA	-	-	-	-	150		(100)%	150	1,348	-	-	-
Medical Abortion	-	-	-	-	(2,536)		0%	(2,536)	8,475	-	-	-
Divabo - Combipack (1+4's)	-	-	-	-	(2,058)	5/17	-%	(2,058)	9,574	-	-	-
(b)PSI Medical Abortion Distributed Provided	-	-	-	-	(478)		-%	(478)	(1,099)	-	-	-
Medical Abortion (Misoprostol) Provided	-	-	-	-	187		(100)%	187	187	-	-	-
Non-PSI Medical Abortion (Misoprostol) Provided	-	-	-	-	26		(100)%	26	26	-	-	-
PSI Medical Abortion (Misoprostol) Provided	-	-	-	-	161		(100)%	161	161	-	-	-
Medical Abortion Provided	-	-	-	-	478		(100)%	478	1,099	-	-	-
PSI Medical Abortion Provided	-	-	-	-	478		(100)%	478	1,099	-	-	-
Misoprostol for PAC Provided	-	-	-	-	498		(100)%	498	1,652	-	-	-
Non-PSI Misoprostol for PAC Provided	-	-	-	-	18		(100)%	18	36	-	-	-
PSI Misoprostol for PAC Provided	-	-	-	-	480		(100)%	480	1,616	-	-	-
Misoprostol for Safe Abortion	-	-	-	-	(3,852)		0%	(3,852)	(8,396)	-	-	-
(b)PSI Misoprostol for Safe Abortion Dist Provided	-	-	-	-	(3,852)		-%	(3,852)	(8,396)	-	-	-
OCs	-	-	-	-	1,425		(100)%	1,425	394,086	-	-	-
Family Planning Pills	-	-	-	-	1,425	11/11	(100)%	1,425	394,086	-	-	-
Positive RDTs	42,667	17,029	155,419	-	-		0%	-	155,419	155,419	-	-
Positive RDTs	42,667	17,029	155,419	-	-		-%	-	155,419	155,419	-	-
Positive RDTs Given First Line Treatment	40,275	15,902	144,641	-	-		0%	-	144,641	144,641	-	-
Positive RDTs Given First Line Treatment	40,275	15,902	144,641	-	-		-%	-	144,641	144,641	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
PUR	-	-	-	-	3,840		(100)%	3,840	40,563,780	-	-	-
PuR	-	-	-	-	3,840	10/04	(100)%	3,840	40,563,780	-	-	-
Referral to HIV Testing Services	666	976	34,434	50,000	11,703		194%	11,703	46,137	34,434	-	1,070
Referral to HIV Testing Services	666	976	34,434	50,000	11,703		194%	11,703	46,137	34,434	-	1,070
Referral to Linkage to HIV Care	8,794	11,736	96,237	16,561	4,614		1986%	4,614	100,851	96,237	-	82,089
Referral to Linkage to HIV Care	8,794	11,736	96,237	16,561	4,614		1,986%	4,614	100,851	96,237	-	82,089
Tubal Ligation	-	-	-	-	10		(100)%	10	123	-	-	-
Tubal Ligation	-	-	-	-	10		(100)%	10	123	-	-	-
Zambia											237,004	489,201
Emergency Contraception Provided	10	-	11	-	1		1000%	1	12	1	1	-
Non-PSI Emergency Contraception Provided	10	-	11	-	1		1,000%	1	12	1	1	-
Free Female Condom	-	-	-	13,000	3,020		(100)%	3,020	192,200	-	-	-
Free Female Condoms	-	-	-	13,000	3,020	1/12	(100)%	3,020	192,200	-	-	-
HIV Self-Testing Kit	500	1,017	136,450	326,885	394,250		(65)%	394,250	811,250	122,805	-	-
HIV Self Testing Kits-Blood based	500	667	5,000	-	-		-%	-	5,000	4,500	-	-
ORAQUICK HIV Self-Testing Kit (Pouch)	-	350	131,450	326,885	394,250	5/16	(67)%	394,250	806,250	118,305	-	-
Implant 3 Insertion	1,194	1,193	11,040	-	4,567		142%	4,567	16,504	11,040	27,600	27,856
Non-PSI Implant 3 Inserted	1,194	1,193	11,040	-	4,567		142%	4,567	16,504	11,040	27,600	27,856
Implant 4 Insertion	-	-	-	-	1		(100)%	1	117	-	-	-
Non-PSI Implant 4 Inserted	-	-	-	-	1		(100)%	1	117	-	-	-
Implant 5 Insertion	1,728	2,230	30,475	30,000	24,703		23%	24,703	78,318	30,475	115,805	115,046
Non-PSI Implant 5 Inserted	1,728	2,230	30,475	30,000	24,703		23%	24,703	78,318	30,475	115,805	115,046
Injectable 2 Provided	1,599	1,291	16,958	28,000	19,835		(15)%	19,835	46,379	2,826	2,826	2,094
Non-PSI Injectable 2 Provided	1,599	1,291	16,958	28,000	19,835		(15)%	19,835	46,379	2,826	2,826	2,094
Injectable 3-IM Provided	7,869	11,425	186,823	172,000	157,477		19%	157,477	427,734	46,706	46,706	34,601

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Non-PSI Injectable 3 IM Provided	7,869	11,425	186,823	172,000	157,477		19%	157,477	427,734	46,706	46,706	34,601
Injectable 3-SC Provided	10,966	6,108	32,041	-	-		0%	-	32,041	8,010	8,010	5,934
Non-PSI Injectable 3 SC Provided	10,966	6,108	32,041	-	-		-%	-	32,041	8,010	8,010	5,934
IUD 10 Insertion	347	611	5,135	3,000	2,175		136%	2,175	9,253	5,135	23,621	22,479
Non-PSI IUD 10 Inserted	347	611	5,135	3,000	2,175		136%	2,175	9,253	5,135	23,621	22,479
IUS 3	(65)	(82)	(379)	-	-		0%	-	(379)	(341)	(853)	(808)
(b)PSI IUS 3 Distributed Inserted	(65)	(82)	(379)	-	-		-%	-	(379)	(341)	(853)	(808)
IUS 3 Insertion	65	82	379	-	-		0%	-	379	379	948	898
PSI IUS 3 Inserted	65	82	379	-	-		-%	-	379	379	948	898
IUS 5	-	-	500	-	-		0%	-	1,300	450	1,485	1,501
LNG-IUS	-	-	500	-	-		-%	-	1,300	450	1,485	1,501
IUS 5 Insertion	-	-	353	700	595		(41)%	595	1,126	353	1,165	1,178
Non-PSI IUS 5 Inserted	-	-	353	700	595		(41)%	595	1,126	353	1,165	1,178
OCs Provided	11,475	10,628	112,295	100,000	64,379		74%	64,379	210,088	7,486	7,486	5,851
Non-PSI OCs Provided	11,475	10,628	112,295	100,000	64,379		74%	64,379	210,088	7,486	7,486	5,851
Safe Water Solution	-	32	277,356	900,000	930,072		(70)%	930,072	36,072,791	152,736	-	592
Clorin	-	32	277,356	900,000	930,072	11/98	(70)%	930,072	36,072,791	152,736	-	592
Tubal Ligation	1	37	219	308	308		(29)%	308	698	219	2,190	1,896
Tubal Ligation	1	37	219	308	308		(29)%	308	698	219	2,190	1,896
Vasectomy	-	-	-	29	-		0%	-	-	-	-	-
Vasectomy	-	-	-	29	-		-%	-	-	-	-	-
Voluntary Medical Male Circumcision	4,926	1,641	36,201	45,000	43,253		(16)%	43,253	183,600	36,201	-	270,043
Voluntary Medical Male Circumcision	4,926	1,641	36,201	45,000	43,253		(16)%	43,253	183,600	36,201	-	270,043
Woman Condom	-	-	1,920	-	97,728		(98)%	97,728	141,480	14	14	40
MAXIMUM DIVA	-	-	1,920	-	97,728	4/16	(98)%	97,728	141,480	14	14	40

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Zimbabwe											232,509	1,768,125
Antiretroviral Treatment (Currently Enrolled)	10,829	10,251	117,988	66,103	103,129		14%	103,129	308,608	9,832	-	20,562
Antiretroviral Treatment (Currently Enrolled)	10,829	10,251	117,988	66,103	103,129		14%	103,129	308,608	9,832	-	20,562
Antiretroviral Treatment (Newly Enrolled)	530	580	5,909	3,012	4,816		23%	4,816	24,814	5,909	-	-
Antiretroviral Treatment (Newly Enrolled)	530	580	5,909	3,012	4,816		23%	4,816	24,814	5,909	-	-
CD4 Tests Provided to HIV+ Clients	-	-	-	-	443		(100)%	443	7,915	-	-	-
CD4 Tests Provided to HIV+ Clients	-	-	-	-	443		(100)%	443	7,915	-	-	-
Cervical Cancer-HPV DNA and Conization	3	2	10	-	-		0%	-	10	10	-	4
Cervical Cancer-HPV DNA and Conization	3	2	10	-	-		-%	-	10	10	-	4
Cervical Cancer-HPV DNA and Cryotherapy	2	1	8	-	3		167%	3	11	8	-	3
Cervical Cancer-HPV DNA and Cryotherapy	2	1	8	-	3		167%	3	11	8	-	3
Cervical Cancer-HPV DNA and Refer to any Treatm	1	-	2	-	-		0%	-	13	2	-	-
Cervical Cancer-HPV DNA and Refer to any Treatment	1	-	2	-	-		-%	-	13	2	-	-
Cervical Cancer-HPV DNA Screening	333	582	3,346	-	-		0%	-	3,346	3,346	-	-
Cervical Cancer-HPV DNA Screening	333	582	3,346	-	-		-%	-	3,346	3,346	-	-
Cervical Cancer-Pap and Conization	-	-	1,753	-	-		0%	-	1,753	1,753	-	778
Cervical Cancer-Pap and Conization	-	-	1,753	-	-		-%	-	1,753	1,753	-	778
Cervical Cancer-Pap and Refer to any Treatment	-	-	9	-	-		0%	-	10	9	-	2
Cervical Cancer-Pap and Refer to any Treatment	-	-	9	-	-		-%	-	10	9	-	2
Cervical Cancer-VIA and Conization	11	18	245	290	126		94%	126	549	245	-	88
Cervical Cancer-VIA and Conization	11	18	245	290	126		94%	126	549	245	-	88
Cervical Cancer-VIA and Cryotherapy	2	12	1,524	307	415		267%	415	5,494	1,524	-	533
Cervical Cancer-VIA and Cryotherapy	2	12	1,524	307	415	11/13	267%	415	5,494	1,524	-	533
Cervical Cancer-VIA and Refer to any Treatment	1	6	85	-	25		240%	25	396	85	-	15
Cervical Cancer-VIA and Refer to any Treatment	1	6	85	-	25	1/15	240%	25	396	85	-	15

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Cervical Cancer-VIA and Refer to Conization	1	3	23	290	98		(77)%	98	2,057	23	-	4
Cervical Cancer-VIA and Refer to Conization	1	3	23	290	98	12/14	(77)%	98	2,057	23	-	4
Cervical Cancer-VIA and Refer to Cryotherapy	-	-	-	-	10		(100)%	10	459	-	-	-
Cervical Cancer-VIA and Refer to Cryotherapy	-	-	-	-	10	12/14	(100)%	10	459	-	-	-
Cervical Cancer-VIA/VILI Screening	257	838	15,302	18,793	18,503		(17)%	18,503	101,121	15,302	-	-
Cervical Cancer-VIA/VILI Screening	257	838	15,302	18,793	18,503		(17)%	18,503	101,121	15,302	-	-
Condom	788,295	1,080,742	15,175,625	18,000,000	17,748,320		(14)%	17,748,320	342,562,995	113,817	113,817	361,844
Protector Plus	180,600	212,117	2,928,600	3,600,000	3,626,960	1/08	(19)%	3,626,960	279,624,450	21,964	21,964	69,829
Protector Plus Flavors	607,695	868,625	12,247,025	14,400,000	14,121,360	3/14	(13)%	14,121,360	62,938,545	91,853	91,853	292,015
Emergency Contraception	15,323	5,020	72,570	-	170,713		(57)%	170,713	1,028,335	3,266	3,266	986
Pregnon	-	-	37,805	-	160,767	9/10	(76)%	160,767	900,767	1,701	1,701	514
(b)PSI Emergency Contraception Distributed Provided	(5)	(9)	(92)	-	(54)		-%	(54)	(589)	(4)	(4)	(1)
Revoke-72	15,328	5,030	34,857	-	10,000	12/15	249%	10,000	128,157	1,569	1,569	474
Emergency Contraception Provided	5	9	98	-	78		26%	78	804	5	5	1
Non-PSI Emergency Contraception Provided	-	-	6	-	24		(75)%	24	215	-	-	-
PSI Emergency Contraception Provided	5	9	92	-	54		70%	54	589	5	5	1
Female Condom	-	-	1,200	380,000	169,980		(99)%	169,980	24,049,234	9	9	28
Care	-	-	1,200	380,000	169,980	6/97	(99)%	169,980	24,049,234	9	9	28
Free Female Condom	18,250	351,433	1,190,533	-	224,000		431%	224,000	1,752,533	8,929	8,929	28,015
Care (Free Distribution)	18,250	351,433	1,190,533	-	224,000	12/11	431%	224,000	1,752,533	8,929	8,929	28,015
HIV Self-Testing Kit	219,243	-	275,739	-	236,028		17%	236,028	511,767	248,165	-	-
ORAQUICK HIV Self-Testing Kit (Pouch)	219,243	-	275,739	-	236,028		17%	236,028	511,767	248,165	-	-
HIV Testing Services	2,635	4,346	48,842	281,609	48,959		0%	48,959	2,588,240	48,842	-	3,238
VCT Individual (HIV-Negative)	1,801	2,995	34,401	264,340	31,915	12/09	8%	31,915	2,281,571	34,401	-	2,280
VCT Individual (HIV-Positive)	834	1,351	14,441	17,269	17,044	12/09	(15)%	17,044	306,669	14,441	-	957

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Hypertension Diagnosis	20	27	271	-	278		(3)%	278	829	271	-	-
Hypertension Diagnosis	20	27	271	-	278		(3)%	278	829	271	-	-
Hypertension Screening	5,367	8,651	127,777	-	142,029		(10)%	142,029	604,030	127,777	-	-
Hypertension Screening	5,367	8,651	127,777	-	142,029		(10)%	142,029	604,030	127,777	-	-
Hypertension_Controlled Condition	5	9	105	-	91		15%	91	262	42	-	-
Hypertension_Controlled Condition	5	9	105	-	91		15%	91	262	42	-	-
Implant 3	-	(1)	(441)	-	(483)		0%	(483)	(3,265)	(397)	(992)	(536)
(b)PSI Implant 3 Distributed Inserted	-	(1)	(441)	-	(483)		-%	(483)	(3,265)	(397)	(992)	(536)
Implant 3 Insertion	46	124	3,191	2,452	1,151		177%	1,151	13,398	3,191	7,978	4,313
Non-PSI Implant 3 Inserted	46	123	2,750	2,452	668	3/16	312%	668	10,133	2,750	6,875	3,717
PSI Implant 3 Inserted	-	1	441	-	483		(9)%	483	3,265	441	1,103	596
Implant 5	1,398	1,454	3,975	-	1,797		121%	1,797	82,557	3,578	13,594	7,243
Jadelle	1,400	1,500	7,400	-	6,500	9/09	14%	6,500	120,108	6,660	25,308	13,483
(b)PSI Implant 5 Distributed Inserted	(2)	(46)	(3,425)	-	(4,703)		-%	(4,703)	(37,551)	(3,083)	(11,713)	(6,241)
Implant 5 Insertion	704	1,208	14,604	12,496	8,090		81%	8,090	105,172	14,604	55,495	29,566
Non-PSI Implant 5 Inserted	702	1,162	11,179	12,496	3,387	1/14	230%	3,387	67,621	11,179	42,480	22,632
PSI Implant 5 Inserted	2	46	3,425	-	4,703		(27)%	4,703	37,551	3,425	13,015	6,934
Injectable 3-IM	-	(38)	(2,681)	-	13,588		(120)%	13,588	898,876	(603)	(603)	(239)
Depo-Provera	-	-	-	-	26,562	9/00	(100)%	26,562	724,283	-	-	-
Petogen	-	-	-	-	700	9/09	(100)%	700	230,835	-	-	-
(b)PSI Injectable 3 IM Distributed Provided	-	(38)	(2,681)	-	(13,674)		-%	(13,674)	(56,242)	(603)	(603)	(239)
Injectable 3-IM Provided	2,531	2,923	45,849	52,468	41,625		10%	41,625	263,679	11,462	11,462	4,543
Non-PSI Injectable 3 IM Provided	2,531	2,885	43,168	52,468	27,951		54%	27,951	207,437	10,792	10,792	4,277
PSI Injectable 3 IM Provided	-	38	2,681	-	13,674		(80)%	13,674	56,242	670	670	266
IUD 10	(12)	(37)	(1,039)	-	(934)		0%	(934)	473	(935)	(4,301)	(2,198)

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
(b)PSI IUD 10 Distributed Inserted	(12)	(37)	(1,039)	-	(1,684)	3/16	-%	(1,684)	(10,268)	(935)	(4,301)	(2,198)
TCU 380A IUCD Copper T	-	-	-	-	750	4/12	(100)%	750	10,741	-	-	-
IUD 10 Insertion	80	184	2,721	1,776	1,855		47%	1,855	12,322	2,721	12,517	6,397
Non-PSI IUD 10 Inserted	68	147	1,682	1,776	171		884%	171	2,054	1,682	7,737	3,954
PSI IUD 10 Inserted	12	37	1,039	-	1,684	3/16	(38)%	1,684	10,268	1,039	4,779	2,443
IUD 5 Insertion	-	-	128	-	80		60%	80	208	128	422	229
Non-PSI IUD 5 Inserted	-	-	128	-	80		60%	80	208	128	422	229
IUS 5	(8)	(5)	(105)	(56)	126		(183)%	126	175	(95)	(312)	(169)
LNG-IUS	-	10	60	-	270		(78)%	270	655	54	178	97
(b)PSI IUS 5 Distributed Inserted	(8)	(15)	(165)	(56)	(144)		-%	(144)	(480)	(149)	(490)	(266)
IUS 5 Insertion	8	21	197	56	144		37%	144	529	197	650	352
Non-PSI IUS 5 Inserted	-	6	32	-	-		-%	-	49	32	106	57
PSI IUS 5 Inserted	8	15	165	56	144		15%	144	480	165	544	295
Lubricant	33,000	36,967	421,000	-	97,750		331%	97,750	973,300	-	-	-
Personal lubricants water based 4.5 g	33,000	36,967	421,000	-	97,750	2/17	331%	97,750	973,300	-	-	-
OCs	-	(110)	(10,150)	-	(36,058)		0%	(36,058)	(24,674)	(609)	(609)	(255)
(b)PSI OCs Distributed Provided	-	(110)	(10,150)	-	(43,258)		-%	(43,258)	(285,823)	(609)	(609)	(255)
Secure POP	-	-	-	-	7,200	4/12	(100)%	7,200	261,149	-	-	-
OCs Provided	12,062	13,206	167,743	187,344	102,704		63%	102,704	1,172,086	11,183	11,183	4,676
Non-PSI OCs Provided	12,062	13,096	157,593	187,344	59,446		165%	59,446	886,263	10,506	10,506	4,393
PSI OCs Provided	-	110	10,150	-	43,258		(77)%	43,258	285,823	677	677	283
PrEP	3,428	3,437	43,045	35,027	34,345		25%	34,345	80,506	3,587	-	1,403
PrEP	3,428	3,437	43,045	35,027	34,345		25%	34,345	80,506	3,587	-	1,403
Referral to Advanced Cervical Cancer Treatment	-	2	62	136	17		265%	17	479	62	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	^(a) YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Referral to Advanced Cervical Cancer Treatment	-	2	62	136	17	12/14	265%	17	479	62	-	-
Referral to Diabetes Management (gestational)	-	-	-	-	67		(100)%	67	67	-	-	-
Referral to Diabetes Management (gestational)	-	-	-	-	67		(100)%	67	67	-	-	-
Referral to Hypertension Management	13	28	335	-	564		(41)%	564	1,420	335	-	-
Referral to Hypertension Management	13	28	335	-	564		(41)%	564	1,420	335	-	-
Referral to Implant 3 Insertion	-	-	-	-	2		(100)%	2	11	-	-	-
Referral to Implant 3 Insertion	-	-	-	-	2		(100)%	2	11	-	-	-
Referral to Implant 5 Insertion	-	-	-	-	2		(100)%	2	992	-	-	-
Referral to Implant 5 Insertion	-	-	-	-	2	12/13	(100)%	2	992	-	-	-
Referral to Injectable 3	-	-	-	-	20		(100)%	20	770	-	-	-
Referral to Injectable 3	-	-	-	-	20		(100)%	20	770	-	-	-
Referral to IUD 10 Insertion	-	-	-	-	5		(100)%	5	209	-	-	-
Referral to IUD 10 Insertion	-	-	-	-	5	12/13	(100)%	5	209	-	-	-
Referral to Linkage to HIV Care	608	764	8,103	-	9,056		(11)%	9,056	25,335	8,103	-	4,485
Referral to Linkage to HIV Care	608	764	8,103	-	9,056		(11)%	9,056	25,335	8,103	-	4,485
Referral to OCs	-	-	-	-	17		(100)%	17	868	-	-	-
Referral to OCs	-	-	-	-	17	1/15	(100)%	17	868	-	-	-
Referral to Pre-Exposure Prophylaxis (PrEP)	-	-	3	-	20		(85)%	20	253	3	-	-
Referral to Pre-Exposure Prophylaxis (PrEP)	-	-	3	-	20		(85)%	20	253	3	-	-
Referral to STI Screening (syndromic)	-	-	-	-	3		(100)%	3	105	-	-	-
Referrals to STI Screening (syndromic)	-	-	-	-	3		(100)%	3	105	-	-	-
Referral to STI Treatment (unknown)	-	-	-	-	93		(100)%	93	2,337	-	-	-
Referral to STI Treatment (unknown)	-	-	-	-	93	1/15	(100)%	93	2,337	-	-	-
Referral to TB Diagnosis	-	-	-	-	11		(100)%	11	255	-	-	-
Referral to TB Diagnosis	-	-	-	-	11		(100)%	11	255	-	-	-

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Referral to TB DOTS (completion confirmed)	-	-	-	-	2		(100)%	2	19	-	-	-
Referral to TB DOTS (completion confirmed)	-	-	-	-	2		(100)%	2	19	-	-	-
Referral to TB DOTS (completion unknown)	-	-	-	-	74		(100)%	74	2,704	-	-	-
Referral to TB DOTS (completion unknown)	-	-	-	-	74	12/13	(100)%	74	2,704	-	-	-
Referral to TB Screening	-	-	-	-	1		(100)%	1	12,337	-	-	-
Referrals to TB Screening	-	-	-	-	1		(100)%	1	12,337	-	-	-
Referral to Treatment for Cervicitis	-	-	-	-	47		(100)%	47	116	-	-	-
Referral to Treatment for Cervicitis	-	-	-	-	47	1/15	(100)%	47	116	-	-	-
Referral to Treatment for Genital Herpes	-	-	-	-	3		(100)%	3	6	-	-	-
Referral to Treatment for Genital Herpes	-	-	-	-	3		(100)%	3	6	-	-	-
Referral to Treatment for Inguinal Bubo	-	-	-	-	2		(100)%	2	2	-	-	-
Referral to Treatment for Inguinal Bubo	-	-	-	-	2		(100)%	2	2	-	-	-
Referral to Treatment for Lower Abdominal Pain	-	-	-	-	1		(100)%	1	28	-	-	-
Referral to Treatment for Lower Abdominal Pain	-	-	-	-	1		(100)%	1	28	-	-	-
Referral to Treatment for Urethral Discharge (Men)	-	-	-	-	53		(100)%	53	113	-	-	-
Referral to Treatment for Urethral Discharge (Men)	-	-	-	-	53		(100)%	53	113	-	-	-
Referral to Treatment for Vaginitis	-	-	1	-	-		0%	-	9	1	-	-
Referral to Treatment for Vaginitis	-	-	1	-	-	1/15	-%	-	9	1	-	-
Referral to Tubal Ligation	-	-	-	-	2		(100)%	2	3	-	-	-
Referral to Tubal Ligation	-	-	-	-	2		(100)%	2	3	-	-	-
Referral to Tx for Nonherpetic Genital Ulcer	-	-	1	-	25		(96)%	25	73	1	-	-
Referral to Tx for Nonherpetic Genital Ulcer	-	-	1	-	25		(96)%	25	73	1	-	-
Referral to Tx for Urethral Discharge (Women)	-	-	10	-	48		(79)%	48	557	10	-	1
Referral to Tx for Urethral Discharge (Women)	-	-	10	-	48		(79)%	48	557	10	-	1
Referral to Voluntary Medical Male Circumcision	-	-	3	-	120		(98)%	120	10,818	3	-	10

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Referral to Voluntary Medical Male Circumcision	-	-	3	-	120	12/14	(98)%	120	10,818	3	-	10
Safe Water Solution	-	-	-	-	132,805		(100)%	132,805	780,659	-	-	-
WaterGuard Solution 150mL SI	-	-	-	-	132,805	4/14	(100)%	132,805	780,659	-	-	-
STI Screening	2,525	4,041	52,076	-	1,460		3467%	1,460	62,874	52,076	-	-
STI Screening	2,525	4,041	52,076	-	1,460		3,467%	1,460	62,874	52,076	-	-
TB Diagnosis	14	15	198	-	242		(18)%	242	1,589	198	-	-
TB Diagnosis	14	15	198	-	242		(18)%	242	1,589	198	-	-
TB DOTS	-	-	-	-	4		(100)%	4	54	-	-	-
TB DOTS	-	-	-	-	4	7/14	(100)%	4	54	-	-	-
TB Screening	11,346	13,360	155,468	-	134,977		15%	134,977	1,059,426	155,468	-	-
TB Screening	11,346	13,360	155,468	-	134,977		15%	134,977	1,059,426	155,468	-	-
Treatment for Cervicitis	10	11	159	-	73		118%	73	522	159	-	15
Treatment for Cervicitis	10	11	159	-	73		118%	73	522	159	-	15
Treatment for Genital Herpes	9	23	104	-	11		845%	11	140	104	-	3
Treatment for Genital Herpes	9	23	104	-	11		845%	11	140	104	-	3
Treatment for Inguinal Bubo	1	-	17	-	2		750%	2	29	17	-	-
Treatment for Inguinal Bubo	1	-	17	-	2		750%	2	29	17	-	-
Treatment for Lower Abdominal Pain	1	3	30	-	20		50%	20	67	30	-	-
Treatment for Lower Abdominal Pain	1	3	30	-	20		50%	20	67	30	-	-
Treatment for Nonherpetic Genital Ulcer	37	28	484	-	436		11%	436	1,320	484	-	173
Treatment for Nonherpetic Genital Ulcer	37	28	484	-	436		11%	436	1,320	484	-	173
Treatment for Urethral Discharge (Men)	38	36	331	-	92		260%	92	674	662	-	41
Treatment for Urethral Discharge (Men)	38	36	331	-	92		260%	92	674	662	-	41
Treatment for Urethral Discharge (Women)	78	75	903	-	493		83%	493	2,346	903	-	166
Treatment for Urethral Discharge (Women)	78	75	903	-	493		83%	493	2,346	903	-	166

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	^(a) YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Treatment for Vaginitis	-	-	8	-	10		(20)%	10	19	8	-	2
Treatment for Vaginitis	-	-	8	-	10		(20)%	10	19	8	-	2
Type 2 Diabetes Diagnosis	-	-	-	-	3		(100)%	3	8	-	-	-
Type 2 Diabetes Diagnosis	-	-	-	-	3		(100)%	3	8	-	-	-
Type 2 Diabetes Screening	33	35	342	-	5,658		(94)%	5,658	12,076	342	-	-
Type 2 Diabetes Screening	33	35	342	-	5,658		(94)%	5,658	12,076	342	-	-
Type 2 Diabetes_Controlled Condition	-	-	-	-	6		(100)%	6	12	-	-	-
Type 2 Diabetes_Controlled Condition	-	-	-	-	6		(100)%	6	12	-	-	-
Voluntary Medical Male Circumcision	4,787	15,847	190,647	200,000	243,971		(22)%	243,971	653,312	190,647	-	1,291,803
Voluntary Medical Male Circumcision	4,787	15,847	190,647	200,000	243,971		(22)%	243,971	653,312	190,647	-	1,291,803

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

^(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

Franco/Lusophone Africa Market Group

POPULATION SERVICES INTERNATIONAL
CYPs, Cases, and Deaths by Country
1/2019 - 12/2019

	New HIV Infections	STI Deaths	PWID Deaths	TB Deaths	CYP*	Maternal Deaths	Unintended Pregnancies	Malaria Deaths	Diarrhea Deaths	Pneumonia Deaths	Cervical Cancer Death	Sum of All Deaths
Franco/Lusophone Africa Market Gro	10,209	4	-	-	1,811,247	2,577	726,890	8,990	456	-	-	27,282
Angola	335	-	-	-	136,513	332	53,860	1,791	22	-	-	3,521
Benin	994	-	-	-	374,757	385	148,969	-	235	-	-	3,070
Burundi	1,119	4	-	-	62,463	94	20,609	1,659	-	-	-	2,269
Cameroon	3,043	-	-	-	459,385	697	178,766	2,365	58	-	-	6,822
Cote d'Ivoire	83	-	-	-	177,825	315	82,002	-	28	-	-	1,707
Mozambique	4,072	-	-	-	353,562	350	142,371	-	105	-	-	4,222
Niger	129	-	-	-	126,202	196	53,660	3,115	-	-	-	4,699
PSI Benin	-	-	-	-	46,501	161	21,114	-	-	-	-	505
Senegal	435	-	-	-	74,038	46	25,539	59	9	-	-	468

* Using USAID CYP conversion factors

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Market Group and Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE SALES	YTD USERS REACHED ^(a) 2019	YTD CYP 2019	YTD DALY 2019
Franco/Lusophone Africa Market Group										1,811,247	2,625,497
Acute Malnutrition Screening_CU5	-	-	-	312	518	(100)%	518	1,895	-	-	-
Antiretroviral Treatment (Currently Enrolled)	6,113	6,367	62,079	7,723	19,016	226%	19,016	87,725	5,173	-	10,345
Antiretroviral Treatment (Newly Enrolled)	139	159	1,404	1,396	1,807	(22)%	1,807	3,625	1,404	-	-
CD4 Tests Provided to HIV+ Clients	-	-	-	-	122	(100)%	122	1,327	-	-	-
Cervical Cancer-VIA and Cryotherapy	3	2	16	-	48	(67)%	48	390	16	-	2
Cervical Cancer-VIA/VILI Screening	3,329	3,156	28,676	-	50,592	(43)%	50,592	180,151	28,676	-	-
Condom	5,460,296	4,224,472	41,173,232	59,938,298	51,015,576	(19)%	51,015,576	368,049,363	308,799	308,799	522,101
Counseling & Tx for Moderate Acute Malnutrition	-	-	-	4	-	-%	-	-	-	-	-
Diarrhea Treatment Kit	1,010	21,316	300,418	424,000	431,332	(30)%	431,332	4,435,947	270,376	-	17,600
Emergency Contraception	12,358	2,421	51,168	255,200	135,874	(62)%	135,874	222,111	2,303	2,303	1,389
Emergency Contraception Provided	307	295	4,060	3,000	2,877	41%	2,877	7,463	203	203	127
Fecal Sludge Management (Households)	-	34	3,311	350	1,374	141%	1,374	4,685	16,595	-	-
Fecal Sludge Management (Liters)	-	493,667	11,141,000	13,559,190	5,110,000	118%	5,110,000	16,251,000	-	-	1,325
Female Condom	23,280	168,643	1,461,260	1,160,132	1,160,677	26%	1,160,677	11,058,752	10,959	10,959	15,559
Fever Cases Attended	-	-	-	8,385	14,143	(100)%	14,143	26,907	-	-	-
Fever Cases Tested with RDTs	-	-	-	8,385	14,143	(100)%	14,143	42,041	-	-	-
Free Condom	924,524	354,673	14,956,285	5,193,631	3,201,731	367%	3,201,731	37,282,166	112,172	112,172	98,975
Free Female Condom	2,184	3,700	99,284	52,000	49,536	100%	49,536	359,613	745	745	1,021
HIV Self-Testing Kit	-	-	-	1,388	-	-%	-	-	-	-	-
HIV Testing Services	6,415	5,876	87,835	93,415	106,415	(17)%	106,415	1,068,964	87,835	-	663
Implant 3	(582)	2,740	7,068	(4,896)	7,414	(5)%	7,414	33,512	6,361	15,903	11,843

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Market Group and Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE SALES	YTD USERS REACHED ^(a) 2019	YTD CYP 2019	YTD DALY 2019
Implant 3 Insertion	4,819	5,839	69,284	27,532	24,546	182%	24,546	113,158	69,284	173,210	164,406
Implant 4 Insertion	-	-	21	-	2	950%	2	41	21	67	40
Implant 5	6,194	4,497	31,813	29,052	27,721	15%	27,721	26,116	28,632	108,800	94,482
Implant 5 Insertion	9,861	8,565	89,663	71,842	76,301	18%	76,301	391,880	89,663	340,719	304,059
Injectable 2	(391)	2,348	21,203	20,016	54,602	(61)%	54,602	315,547	3,180	3,180	1,697
Injectable 2 Provided	1,399	941	12,209	50,000	15,848	(23)%	15,848	50,959	2,035	2,035	1,094
Injectable 3-IM	10,421	21,826	180,120	105,000	272,940	(34)%	272,940	611,510	40,527	40,527	27,622
Injectable 3-IM Provided	28,879	27,482	317,069	255,395	272,082	17%	272,082	936,039	79,267	79,267	61,541
Injectable 3-SC	14,448	10,433	211,263	151,480	26,328	702%	26,328	240,206	47,534	47,534	35,169
Injectable 3-SC Provided	5,345	5,310	63,385	39,163	5,729	1,006%	5,729	69,114	15,846	15,846	12,592
IUD 10	3,322	1,641	15,548	28,463	29,864	(48)%	29,864	227,955	13,993	64,369	51,793
IUD 10 Insertion	4,422	5,729	75,712	76,812	73,738	3%	73,738	330,354	75,712	348,275	314,687
LLIN	498,229	77,780	1,581,302	3,964,115	4,602,963	(66)%	4,602,963	32,441,422	2,561,709	-	156,725
Lubricant	2,184	2,667	11,039	-	45,024	(75)%	45,024	624,396	-	-	-
Malaria PPT (ACT)	828	10,131	409,310	326,390	297,174	38%	297,174	894,251	368,379	-	113,695
Malaria RDK	-	35,092	147,125	250,000	177,919	(17)%	177,919	1,239,746	132,413	-	-
Manual Vacuum Aspiration for PAC	1,692	1,339	13,699	1,918	2,579	431%	2,579	18,082	13,699	-	6,214
Manual Vacuum Aspiration for SA	310	138	1,406	507	562	150%	562	2,589	1,406	-	568
Medical Abortion	132	200	2,359	19,550	215	997%	215	2,469	2,123	-	823
Medical Abortion (Misoprostol) Provided	384	16	967	1,051	309	213%	309	1,276	967	-	351
Medical Abortion Provided	33	20	166	-	51	225%	51	407	166	-	62

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Market Group and Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE SALES	YTD USERS REACHED ^(a) 2019	YTD CYP 2019	YTD DALY 2019
Micronutrient Powder	11,539	33,427	326,950	35,000	948,572	(66)%	948,572	2,663,542	806	-	-
Misoprostol for PAC Provided	1,228	1,067	10,819	2,222	2,304	370%	2,304	14,197	10,819	-	5,930
Misoprostol for Safe Abortion	21,474	72,923	556,877	424,360	745,045	(25)%	745,045	2,101,171	29,236	-	10,879
OCs	198,011	89,289	1,647,001	851,499	1,347,096	22%	1,347,096	7,317,710	98,820	98,820	61,600
OCs Provided	43,694	62,377	530,857	683,520	367,827	44%	367,827	1,477,878	35,390	35,390	30,239
Pneumonia PPT	-	-	-	-	30,316	(100)%	30,316	477,424	-	-	-
Positive RDTs	-	-	-	-	13,716	(100)%	13,716	40,358	-	-	-
Positive RDTs Given First Line Treatment	-	-	-	-	13,647	(100)%	13,647	39,926	-	-	-
QAACs Provided after Confirmatory Diagnosis	-	-	-	-	13,647	(100)%	13,647	13,647	-	-	-
Referral to HIV Testing Services	-	-	-	9,600	-	-%	-	-	-	-	-
Referral to Linkage to HIV Care	-	-	-	1,279	-	-%	-	-	-	-	-
Safe Water Solution	106,032	94,703	1,581,666	1,400,000	870,831	82%	870,831	7,687,396	1,299,999	-	6,786
SDM (Cycle Beads)	(10)	408	1,449	306	1,533	(5)%	1,533	49,478	1,304	1,956	1,500
SDM (Cycle Beads) Provided	10	3	110	2,550	96	15%	96	373	110	165	127
Seasonal Malaria Chemoprevention	-	-	-	-	344,748	(100)%	344,748	344,748	-	-	-
Seasonal Malaria Chemoprevention_children reached	2,780,737	-	2,780,737	990,000	-	-%	-	2,780,737	2,780,737	-	471,469
Skilled Birth Attendance	91	89	1,560	9,000	9,160	(83)%	9,160	27,895	1,560	-	1,976
STI Screening	626	628	9,457	-	8,747	8%	8,747	40,443	9,457	-	-
Toilets Sold	1,948	1,493	15,356	8,107	4,017	282%	4,017	19,373	85,982	-	3,281
Toilets Sold - All	2,403	2,113	22,150	-	5,726	287%	5,726	27,876	120,678	-	-
Treatment for Cervicitis	5	1	29	-	-	-%	-	29	29	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Market Group and Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE SALES	YTD USERS REACHED ^(a) 2019	YTD CYP 2019	YTD DALY 2019
Treatment for Genital Herpes	23	26	476	-	42	1,033%	42	540	476	-	7
Treatment for Inguinal Bubo	4	4	55	-	33	67%	33	122	55	-	-
Treatment for Lower Abdominal Pain	54	87	997	-	693	44%	693	2,064	997	-	-
Treatment for Nonherpetic Genital Ulcer	95	103	1,093	-	1,027	6%	1,027	2,882	1,093	-	143
Treatment for Severe Acute Malnutrition	-	-	-	8	-	-%	-	-	-	-	-
Treatment for Urethral Discharge (Men)	151	158	2,005	-	1,631	23%	1,631	4,961	4,010	-	23
Treatment for Urethral Discharge (Women)	283	234	3,359	-	2,054	64%	2,054	6,884	3,359	-	84
Treatment for Vaginitis	-	-	150	-	2	7,400%	2	157	150	-	-
Tubal Ligation	-	-	-	-	204	(100)%	204	204	-	-	-
Vasectomy	-	-	-	-	104	(100)%	104	104	-	-	-
Water Treatment Tablets	2,148,220	1,176,133	21,225,440	20,485,262	20,217,570	5%	20,217,570	175,082,520	348,911	-	2,882

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Franco/Lusophone Africa Market Group											1,811,247	2,625,497
Angola											136,513	296,140
Condom	494,244	230,328	2,921,076	5,700,000	3,793,904		(23)%	3,793,904	21,535,230	21,908	21,908	26,426
Sensual Champagne	108,756	528	138,312	700,000	314,100		(56)%	314,100	823,032	1,037	1,037	1,251
Sensual Chocolate	111,276	312	531,792	1,250,000	804,168	12/12	(34)%	804,168	4,206,876	3,988	3,988	4,811
Sensual Maracuja	37,296	50,556	505,044	1,250,000	631,476		(20)%	631,476	1,774,764	3,788	3,788	4,569
Sensual Menta	88,056	75,060	517,176	1,250,000	1,138,688	12/12	(55)%	1,138,688	5,336,244	3,879	3,879	4,679
Sensual Morango	80,820	60,012	883,728	1,250,000	905,472	12/12	(2)%	905,472	5,455,647	6,628	6,628	7,995
Sensual Saliências	68,040	43,860	345,024	-	-	11/13	-%	-	3,938,667	2,588	2,588	3,121
Emergency Contraception	8,541	2,398	41,177	250,000	45,514		(10)%	45,514	86,691	1,853	1,853	1,148
Pronta	8,541	2,398	41,177	250,000	45,514		(10)%	45,514	86,691	1,853	1,853	1,148
Implant 5	2	8	79	1,000	1,334		(94)%	1,334	1,913	71	270	294
Jadelle	2	8	79	1,000	1,334	12/17	(94)%	1,334	1,913	71	270	294
Injectable 3-SC	-	-	123,600	120,000	-		0%	-	123,600	27,810	27,810	22,604
Sayana Press	-	-	123,600	120,000	-		-%	-	123,600	27,810	27,810	22,604
IUD 10	1	(808)	(8,045)	-	981		(920)%	981	225	(7,240)	(33,306)	(34,645)
Copper T 380 A – ENOVA	1	939	15,224	15,000	20,092		(24)%	20,092	45,001	13,702	63,027	65,560
(b)PSI IUD 10 Distributed Inserted	-	(1,747)	(23,269)	(15,000)	(19,111)		-%	(19,111)	(44,776)	(20,942)	(96,334)	(100,205)
IUD 10 Insertion	-	1,747	23,269	15,000	19,111		22%	19,111	44,776	23,269	107,037	111,339
PSI IUD 10 Inserted	-	1,747	23,269	15,000	19,111		22%	19,111	44,776	23,269	107,037	111,339
LLIN	231	442	251,144	120,000	3,520,905		(93)%	3,520,905	13,278,738	406,853	-	33,611
Generic LLINs	-	-	143,875	-	3,409,889	4/11	(96)%	3,409,889	12,303,308	233,078	-	19,255
Joia	231	442	107,269	20,000	11,016	11/04	874%	11,016	453,228	173,776	-	14,356
PermaNet	-	-	-	100,000	100,000	10/12	(100)%	100,000	522,202	-	-	-
Malaria PPT (ACT)	828	10,131	409,310	326,390	281,787		45%	281,787	791,243	368,379	-	113,695

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
ALU 20mg/120mg, 12's, 3-8Yrs (15-24Kg)	190	3,094	99,134	96,000	59,156	6/17	68%	59,156	187,717	89,221	-	27,537
ALU 20mg/120mg, 18's, 9-14Yrs (25-34Kg)	514	4,003	85,569	64,000	89,660	6/17	(5)%	89,660	190,074	77,012	-	23,769
ALU 20mg/120mg, 24's, >14Yrs (>34Kg)	123	967	87,744	64,000	85,439	6/17	3%	85,439	200,429	78,970	-	24,373
ALU 20mg/120mg, 6's, >3Yrs (5-14Kg)	1	2,068	136,863	96,000	47,532	6/17	188%	47,532	213,023	123,177	-	38,017
AZAQ 100 mg AS/270 mg AQ, 3 tablets	-	-	-	639	-		-%	-	-	-	-	-
AZAQ 100 mg AS/270 mg AQ, 6 tablets	-	-	-	639	-		-%	-	-	-	-	-
AZAQ 25 mg AS/67.5 mg AQ, 3 tablets	-	-	-	2,556	-		-%	-	-	-	-	-
AZAQ 50 mg AS/135 mg AQ, 3 tablets	-	-	-	2,556	-		-%	-	-	-	-	-
Malaria RDK	-	35,092	147,125	250,000	161,350		(9)%	161,350	1,022,900	132,413	-	-
Bioline (RDT)	-	-	41,825	250,000	161,350	2/14	(74)%	161,350	917,600	37,643	-	-
mRDT Allere	-	35,092	105,300	-	-		-%	-	105,300	94,770	-	-
Manual Vacuum Aspiration for PAC	888	1,142	10,495	-	-		0%	-	10,718	10,495	-	4,926
MVA for PAC	888	1,142	10,495	-	-	11/16	-%	-	10,718	10,495	-	4,926
Misoprostol for PAC Provided	597	931	8,086	-	-		0%	-	8,086	8,086	-	4,455
PSI Misoprostol for PAC Provided	597	931	8,086	-	-		-%	-	8,086	8,086	-	4,455
Misoprostol for Safe Abortion	9,056	20,231	56,832	100,000	195,208		(71)%	195,208	498,968	2,984	-	1,453
ACE Miso (Misoprostol 200mcg tablet)	11,444	23,956	89,176	100,000	195,208	3/18	(54)%	195,208	531,312	4,682	-	2,280
(b)PSI Misoprostol for Safe Abortion Dist Provided	(2,388)	(3,725)	(32,344)	-	-		-%	-	(32,344)	(1,698)	-	(827)
OCs	1,235	1,935	182,343	190,000	123,041		48%	123,041	327,035	10,941	10,941	9,381
MEURI	1,235	1,935	182,343	190,000	123,041		48%	123,041	327,035	10,941	10,941	9,381
Water Treatment Tablets	984,100	528,133	8,858,700	10,000,000	7,883,400		12%	7,883,400	76,973,162	145,622	-	1,454
Certeza Water Tabs	984,100	528,133	8,858,700	10,000,000	7,883,400	4/11	12%	7,883,400	76,973,162	145,622	-	1,454
Benin											374,757	286,737
Cervical Cancer-VIA and Cryotherapy	3	2	16	-	48		(67)%	48	390	16	-	2

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Cervical Cancer-VIA and Cryotherapy	3	2	16	-	48	2/13	(67)%	48	390	16	-	2
Cervical Cancer-VIA/VILI Screening	3,329	3,156	28,676	-	50,592		(43)%	50,592	180,151	28,676	-	-
Cervical Cancer-VIA/VILI Screening	3,329	3,156	28,676	-	50,592		(43)%	50,592	180,151	28,676	-	-
Condom	304,662	419,855	4,851,772	7,300,000	4,658,955		4%	4,658,955	81,575,709	36,388	36,388	27,266
Kool	38,370	35,388	144,566	-	176,099	2/10	(18)%	176,099	16,947,868	1,084	1,084	812
Kool Banane	38,820	50,307	517,794	600,000	360,744	4/18	44%	360,744	878,538	3,883	3,883	2,910
Kool Fraise	34,620	49,306	510,681	750,000	352,122	4/18	45%	352,122	862,803	3,830	3,830	2,870
Kool Menthe	-	20,320	433,113	950,000	407,334	4/18	6%	407,334	840,447	3,248	3,248	2,434
Prudence Plus	192,852	264,534	3,245,618	5,000,000	3,362,656	1/08	(3)%	3,362,656	62,046,053	24,342	24,342	18,240
Diarrhea Treatment Kit	980	17,246	202,350	350,000	399,297		(49)%	399,297	3,557,825	182,115	-	12,677
Orasel Zinc DTK	980	17,246	202,350	350,000	399,297	4/08	(49)%	399,297	3,557,825	182,115	-	12,677
Fecal Sludge Management (Households)	-	-	2,909	-	1,059		175%	1,059	3,968	14,545	-	-
Fecal Sludge Management (Households)	-	-	2,909	-	1,059		175%	1,059	3,968	14,545	-	-
Fecal Sludge Management (Liters)	-	-	5,212,000	7,868,190	1,743,000		199%	1,743,000	6,955,000	-	-	747
Fecal Sludge Management (Liters)	-	-	5,212,000	7,868,190	1,743,000		199%	1,743,000	6,955,000	-	-	747
Female Condom	1,920	1,310	6,894	5,202	9,985		(31)%	9,985	40,540	52	52	36
Cupid	1,920	1,310	6,894	5,202	9,985	3/14	(31)%	9,985	40,540	52	52	36
Free Condom	6,156	10,599	11,852,217	3,000,000	683,616		1634%	683,616	14,789,312	88,892	88,892	66,608
No Logo	6,156	10,599	11,852,217	3,000,000	683,616	1/12	1,634%	683,616	14,789,312	88,892	88,892	66,608
HIV Testing Services	2,909	2,850	43,454	40,171	47,885		(9)%	47,885	668,205	43,454	-	230
VCT Individual (HIV-Negative)	2,909	2,841	43,335	40,171	47,316	1/10	(8)%	47,316	660,974	43,335	-	229
VCT Individual (HIV-Positive)	-	9	119	-	569	1/10	(79)%	569	7,231	119	-	1
Implant 3	1,100	768	4,406	-	-		0%	-	4,406	3,965	9,914	7,201
Implanon	1,100	768	4,406	-	-	4/17	-%	-	4,406	3,965	9,914	7,201
Implant 5	3,286	842	13,887	27,440	28,303		(51)%	28,303	10,677	12,498	47,494	33,942

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Implant 5 (insertion)	3,850	1,537	21,750	35,000	37,266	12/09	(42)%	37,266	151,387	19,575	74,385	53,161
(b)PSI Implant 5 Distributed Inserted	(564)	(694)	(7,863)	(7,560)	(8,963)		-%	(8,963)	(140,710)	(7,077)	(26,891)	(19,219)
Implant 5 Insertion	5,591	2,698	28,182	22,060	38,442		(27)%	38,442	220,802	28,182	107,092	76,535
Non-PSI Implant 5 Inserted	5,027	2,003	20,319	14,410	29,479		(31)%	29,479	80,092	20,319	77,212	55,181
PSI Implant 5 Inserted	564	694	7,863	7,650	8,963		(12)%	8,963	140,710	7,863	29,879	21,354
Injectable 2	(391)	2,348	21,203	20,016	54,602		(61)%	54,602	315,547	3,180	3,180	1,697
Noristerat	-	2,817	27,958	65,016	62,728	1/12	(55)%	62,728	346,739	4,194	4,194	2,237
(b)PSI Injectable 2 Distributed Provided	(391)	(468)	(6,755)	(45,000)	(8,126)		-%	(8,126)	(31,192)	(1,013)	(1,013)	(541)
Injectable 2 Provided	1,154	817	10,890	50,000	14,475		(25)%	14,475	48,267	1,815	1,815	968
Non-PSI Injectable 2 Provided	763	348	4,135	5,000	6,349		(35)%	6,349	17,075	689	689	368
PSI Injectable 2 Provided	391	468	6,755	45,000	8,126		(17)%	8,126	31,192	1,126	1,126	601
Injectable 3-IM	-	(87)	(261)	-	-		0%	-	(7,229)	(59)	(59)	(31)
(b)PSI Injectable 3 IM Distributed Provided	-	(87)	(261)	-	-		-%	-	(7,229)	(59)	(59)	(31)
Injectable 3-IM Provided	-	96	289	-	-		0%	-	7,257	72	72	39
Non-PSI Injectable 3 IM Provided	-	9	28	-	-		-%	-	28	7	7	4
PSI Injectable 3 IM Provided	-	87	261	-	-		-%	-	7,229	65	65	35
Injectable 3-SC	(96)	67	9,618	10,000	-		0%	-	9,618	2,164	2,164	1,154
(b)PSI Injectable 3 SC Distributed Provided	(96)	(100)	(2,382)	-	-		-%	-	(2,382)	(536)	(536)	(286)
Sayana Press	-	167	12,000	10,000	-		-%	-	12,000	2,700	2,700	1,440
Injectable 3-SC Provided	151	127	2,730	-	-		0%	-	2,730	683	683	364
Non-PSI Injectable 3 SC Provided	55	28	348	-	-		-%	-	348	87	87	46
PSI Injectable 3 SC Provided	96	100	2,382	-	-		-%	-	2,382	596	596	318
IUD 10	447	(910)	(6,379)	10,487	(6,402)		0%	(6,402)	38,947	(5,741)	(26,409)	(18,069)
IUD (insertion)	-	-	-	-	1,109	12/09	(100)%	1,109	13,420	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
IUD Copper-T TCU 380A	1,300	150	5,785	14,000	7,435	9/09	(22)%	7,435	144,793	5,207	23,950	16,387
(b)PSI IUD 10 Distributed Inserted	(853)	(1,060)	(12,164)	(3,513)	(14,946)		-%	(14,946)	(119,266)	(10,948)	(50,359)	(34,456)
IUD 10 Insertion	2,482	1,445	18,134	10,513	20,070		(10)%	20,070	136,469	18,134	83,416	57,075
Non-PSI IUD 10 Inserted	1,629	386	5,970	7,000	5,124		17%	5,124	17,203	5,970	27,462	18,790
PSI IUD 10 Inserted	853	1,060	12,164	3,513	14,946		(19)%	14,946	119,266	12,164	55,954	38,285
LLIN	20	3	55	-	5,018		(99)%	5,018	734,506	89	-	8
Super Moustiquaire Longue Durée	-	-	-	-	4,808	5/06	(100)%	4,808	730,601	-	-	-
SuperMoustiquaire (blanche 1 place)	20	3	55	-	210	9/15	(74)%	210	3,905	89	-	8
Lubricant	-	-	-	-	9,920		(100)%	9,920	485,348	-	-	-
Gel Lubricant 5 mL	-	-	-	-	9,920	12/16	(100)%	9,920	485,348	-	-	-
Manual Vacuum Aspiration for PAC	62	108	1,200	-	803		49%	803	3,170	1,200	-	383
MVA for PAC	62	108	1,200	-	803	10/16	49%	803	3,170	1,200	-	383
Manual Vacuum Aspiration for SA	82	138	980	-	211		364%	211	1,812	980	-	384
Manual Vacuum Aspiration for SA	82	138	980	-	211		364%	211	1,812	980	-	384
Medical Abortion	(33)	(20)	(166)	-	-		0%	-	(271)	(149)	-	(56)
(b)PSI Medical Abortion Distributed Provided	(33)	(20)	(166)	-	-		-%	-	(271)	(149)	-	(56)
Medical Abortion (Misoprostol) Provided	18	16	194	-	93		109%	93	287	194	-	65
PSI Medical Abortion (Misoprostol) Provided	18	16	194	-	93		109%	93	287	194	-	65
Medical Abortion Provided	33	20	166	-	-		0%	-	271	166	-	62
PSI Medical Abortion Provided	33	20	166	-	-		-%	-	271	166	-	62
Misoprostol for PAC Provided	16	39	559	-	459		22%	459	1,295	559	-	212
PSI Misoprostol for PAC Provided	16	39	559	-	459		22%	459	1,295	559	-	212
Misoprostol for Safe Abortion	(280)	(352)	(4,564)	-	(2,952)		0%	(2,952)	(8,624)	(240)	-	(81)
(b)PSI Misoprostol for Safe Abortion Dist Provided	(280)	(352)	(4,564)	-	(2,952)		-%	(2,952)	(8,624)	(240)	-	(81)
OCs	19,179	13,947	291,863	70,934	215,192		36%	215,192	1,588,988	17,512	17,512	9,855

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Laafia Pilule	19,679	14,502	296,348	300,434	218,541	6/12	36%	218,541	1,621,942	17,781	17,781	10,007
(b)PSI OCs Distributed Provided	(500)	(556)	(4,485)	(229,500)	(3,349)		-%	(3,349)	(32,954)	(269)	(269)	(151)
OCs Provided	1,040	801	6,471	255,000	5,041		28%	5,041	38,047	431	431	243
Non-PSI OCs Provided	540	245	1,986	25,500	1,692		17%	1,692	5,093	132	132	75
PSI OCs Provided	500	556	4,485	229,500	3,349		34%	3,349	32,954	299	299	168
SDM (Cycle Beads)	(10)	408	1,449	306	1,520		(5)%	1,520	38,771	1,304	1,956	1,500
CycleBeads	-	410	1,550	2,601	1,612	12/04	(4)%	1,612	39,120	1,395	2,093	1,604
(b)PSI SDM (Cycle Beads) Distributed Provided	(10)	(2)	(101)	(2,295)	(92)		-%	(92)	(349)	(91)	(136)	(105)
SDM (Cycle Beads) Provided	10	3	110	2,550	96		15%	96	373	110	165	127
Non-PSI SDM (Cycle Beads) Provided	-	1	9	255	4		125%	4	24	9	14	10
PSI SDM (Cycle Beads) Provided	10	2	101	2,295	92		10%	92	349	101	152	116
Skilled Birth Attendance	91	89	1,560	9,000	9,160		(83)%	9,160	27,895	1,560	-	1,976
Skilled Birth Attendance	91	89	1,560	9,000	9,160		(83)%	9,160	27,895	1,560	-	1,976
STI Screening	136	162	2,404	-	3,265		(26)%	3,265	21,186	2,404	-	-
STI Screening	136	162	2,404	-	3,265		(26)%	3,265	21,186	2,404	-	-
Toilets Sold	1,324	1,104	9,213	3,428	2,776		232%	2,776	11,989	46,063	-	2,304
Toilets Sold	1,324	1,104	9,213	3,428	2,776		232%	2,776	11,989	46,063	-	2,304
Toilets Sold - All	1,522	1,522	13,043	-	3,296		296%	3,296	16,339	65,215	-	-
Toilets Sold - All	1,522	1,522	13,043	-	3,296		296%	3,296	16,339	65,215	-	-
Treatment for Cervicitis	5	1	29	-	-		0%	-	29	29	-	-
Treatment for Cervicitis	5	1	29	-	-		-%	-	29	29	-	-
Treatment for Genital Herpes	16	13	187	-	-		0%	-	187	187	-	-
Treatment for Genital Herpes	16	13	187	-	-		-%	-	187	187	-	-
Treatment for Inguinal Bubo	-	-	14	-	-		0%	-	14	14	-	-
Treatment for Inguinal Bubo	-	-	14	-	-		-%	-	14	14	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Treatment for Lower Abdominal Pain	10	15	174	-	-		0%	-	174	174	-	-
Treatment for Lower Abdominal Pain	10	15	174	-	-		-%	-	174	174	-	-
Treatment for Nonherpetic Genital Ulcer	-	8	136	-	-		0%	-	136	136	-	-
Treatment for Nonherpetic Genital Ulcer	-	8	136	-	-		-%	-	136	136	-	-
Treatment for Urethral Discharge (Men)	11	25	349	-	-		0%	-	465	698	-	3
Treatment for Urethral Discharge (Men)	11	25	349	-	-		-%	-	465	698	-	3
Treatment for Urethral Discharge (Women)	83	85	1,145	-	-		0%	-	1,283	1,145	-	13
Treatment for Urethral Discharge (Women)	83	85	1,145	-	-		-%	-	1,283	1,145	-	13
Treatment for Vaginitis	-	-	148	-	-		0%	-	148	148	-	-
Treatment for Vaginitis	-	-	148	-	-		-%	-	148	148	-	-
Water Treatment Tablets	621,600	476,433	9,947,200	8,605,083	8,283,060		20%	8,283,060	83,998,730	163,516	-	1,297
Aquatab	621,600	476,433	9,947,200	8,605,083	8,283,060	1/08	20%	8,283,060	83,998,730	163,516	-	1,297
Burundi											62,463	210,992
Antiretroviral Treatment (Currently Enrolled)	2,684	2,604	29,611	2,500	10,802		174%	10,802	47,043	2,468	-	5,562
Antiretroviral Treatment (Currently Enrolled)	2,684	2,604	29,611	2,500	10,802		174%	10,802	47,043	2,468	-	5,562
Antiretroviral Treatment (Newly Enrolled)	47	54	622	443	1,346		(54)%	1,346	2,382	622	-	-
Antiretroviral Treatment (Newly Enrolled)	47	54	622	443	1,346		(54)%	1,346	2,382	622	-	-
CD4 Tests Provided to HIV+ Clients	-	-	-	-	56		(100)%	56	539	-	-	-
CD4 Tests Provided to HIV+ Clients	-	-	-	-	56		(100)%	56	539	-	-	-
Condom	360,180	672,030	3,742,920	3,500,000	5,134,060		(27)%	5,134,060	32,905,633	28,072	28,072	46,000
Prudence Class	360,180	672,030	3,742,920	3,500,000	5,134,060	12/09	(27)%	5,134,060	32,905,633	28,072	28,072	46,000
Emergency Contraception	8	38	1,427	1,000	3,720		(62)%	3,720	5,447	64	64	40
Nowill	280	318	4,880	4,000	5,699	9/17	(14)%	5,699	11,038	220	220	138
(b)PSI Emergency Contraception Distributed Provided	(272)	(279)	(3,453)	(3,000)	(1,979)		-%	(1,979)	(5,591)	(155)	(155)	(98)
Emergency Contraception Provided	272	279	3,453	3,000	1,979		74%	1,979	5,591	173	173	108

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
PSI Emergency Contraception Provided	272	279	3,453	3,000	1,979		74%	1,979	5,591	173	173	108
Free Condom	648,000	-	1,648,800	1,500,000	1,000,800		65%	1,000,800	11,920,016	12,366	12,366	20,264
Free Male Condoms	648,000	-	1,648,800	1,500,000	1,000,800	5/11	65%	1,000,800	11,920,016	12,366	12,366	20,264
Free Female Condom	-	-	-	40,000	16,000		(100)%	16,000	160,930	-	-	-
Free Female Condoms	-	-	-	40,000	16,000	5/11	(100)%	16,000	160,930	-	-	-
HIV Testing Services	1,418	1,382	19,655	22,923	24,249		(19)%	24,249	150,688	19,655	-	130
VCT Individual (HIV-Negative)	1,361	1,324	18,945	22,449	23,617	12/09	(20)%	23,617	147,993	18,945	-	125
VCT Individual (HIV-Positive)	57	58	710	474	632	12/09	12%	632	2,695	710	-	5
Implant 5	(22)	25	(62)	500	88		(170)%	88	1,021	(56)	(212)	(234)
Jadelle	88	125	1,285	2,000	1,413	2/14	(9)%	1,413	7,043	1,157	4,395	4,843
(b)PSI Implant 5 Distributed Inserted	(110)	(100)	(1,347)	(1,500)	(1,325)		-%	(1,325)	(6,022)	(1,212)	(4,607)	(5,077)
Implant 5 Insertion	110	100	1,347	1,500	1,325		2%	1,325	6,022	1,347	5,119	5,641
PSI Implant 5 Inserted	110	100	1,347	1,500	1,325		2%	1,325	6,022	1,347	5,119	5,641
Injectable 3-IM	(83)	(24)	(16)	3,000	2,296		(101)%	2,296	11,650	(4)	(4)	(3)
DMPA 3-month Injectable	2,380	2,323	26,468	20,000	23,387	2/14	13%	23,387	92,357	5,955	5,955	4,910
(b)PSI Injectable 3 IM Distributed Provided	(2,463)	(2,347)	(26,484)	(17,000)	(21,091)		-%	(21,091)	(80,707)	(5,959)	(5,959)	(4,913)
Injectable 3-IM Provided	2,463	2,347	26,484	17,000	21,091		26%	21,091	80,707	6,621	6,621	5,459
PSI Injectable 3 IM Provided	2,463	2,347	26,484	17,000	21,091		26%	21,091	80,707	6,621	6,621	5,459
IUD 10	1,358	(4)	1,660	400	126		1217%	126	2,940	1,494	6,872	7,242
Copper-T 380-A IUD	1,403	29	2,124	1,000	670	2/14	217%	670	5,078	1,912	8,793	9,266
(b)PSI IUD 10 Distributed Inserted	(45)	(33)	(464)	(600)	(544)		-%	(544)	(2,138)	(418)	(1,921)	(2,024)
IUD 10 Insertion	45	33	464	600	544		(15)%	544	2,138	464	2,134	2,249
PSI IUD 10 Inserted	45	33	464	600	544		(15)%	544	2,138	464	2,134	2,249
LLIN	463,700	65,233	1,162,677	704,115	790,442		47%	790,442	9,059,864	1,883,537	-	116,894
MII Peranet Free	-	-	-	704,115	-	4/10	-%	-	6,624,958	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
MILDA - DAWA PLUS 2.0	463,700	65,233	1,162,677	-	790,442	5/17	47%	790,442	2,434,906	1,883,537	-	116,894
Manual Vacuum Aspiration for PAC	10	14	128	80	66		94%	66	281	128	-	79
MVA for PAC	10	14	128	80	66	6/16	94%	66	281	128	-	79
Misoprostol for PAC Provided	17	22	325	500	179		82%	179	667	325	-	239
PSI Misoprostol for PAC Provided	17	22	325	500	179		82%	179	667	325	-	239
Misoprostol for Safe Abortion	186	(79)	(397)	-	779		(151)%	779	1,470	(21)	-	(14)
Misoprostol for Safe Abortion	254	8	903	2,000	1,495	3/18	(40)%	1,495	4,138	47	-	32
(b)PSI Misoprostol for Safe Abortion Dist Provided	(68)	(87)	(1,300)	(2,000)	(716)		-%	(716)	(2,668)	(68)	-	(46)
OCs	171	296	6,837	5,000	4,428		54%	4,428	25,828	410	410	357
Confiance OC	1,428	1,511	19,548	15,000	16,422	2/14	19%	16,422	71,133	1,173	1,173	1,020
(b)PSI OCs Distributed Provided	(1,257)	(1,215)	(12,711)	(10,000)	(11,994)		-%	(11,994)	(45,305)	(763)	(763)	(663)
OCs Provided	1,257	1,215	12,711	10,000	11,994		6%	11,994	45,305	847	847	737
PSI OCs Provided	1,257	1,215	12,711	10,000	11,994		6%	11,994	45,305	847	847	737
STI Screening	490	466	7,053	-	5,482		29%	5,482	19,257	7,053	-	-
STI Screening	490	466	7,053	-	5,482		29%	5,482	19,257	7,053	-	-
Treatment for Genital Herpes	7	13	289	-	42		588%	42	353	289	-	7
Treatment for Genital Herpes	7	13	289	-	42		588%	42	353	289	-	7
Treatment for Inguinal Bubo	4	3	41	-	33		24%	33	108	41	-	-
Treatment for Inguinal Bubo	4	3	41	-	33		24%	33	108	41	-	-
Treatment for Lower Abdominal Pain	44	72	823	-	693		19%	693	1,890	823	-	-
Treatment for Lower Abdominal Pain	44	72	823	-	693		19%	693	1,890	823	-	-
Treatment for Nonherpetic Genital Ulcer	95	95	957	-	1,027		(7)%	1,027	2,746	957	-	143
Treatment for Nonherpetic Genital Ulcer	95	95	957	-	1,027		(7)%	1,027	2,746	957	-	143
Treatment for Urethral Discharge (Men)	140	133	1,656	-	1,631		2%	1,631	4,496	3,312	-	20
Treatment for Urethral Discharge (Men)	140	133	1,656	-	1,631		2%	1,631	4,496	3,312	-	20

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Treatment for Urethral Discharge (Women)	200	149	2,214	-	2,054		8%	2,054	5,601	2,214	-	71
Treatment for Urethral Discharge (Women)	200	149	2,214	-	2,054		8%	2,054	5,601	2,214	-	71
Treatment for Vaginitis	-	-	2	-	2		0%	2	9	2	-	-
Treatment for Vaginitis	-	-	2	-	2		-%	2	9	2	-	-
Cameroon											459,385	691,231
Condom	1,666,514	1,805,491	16,623,328	20,364,000	18,305,203		(9)%	18,305,203	88,056,035	124,675	124,675	186,397
Lovers Plus	-	-	(2,010)	-	(15,109)	1/15	-%	(15,109)	3,213,161	(15)	(15)	(23)
Préservatif Masculin Aromatisé UNFPA	8,254	5,424	24,526	41,000	7,200	12/15	241%	7,200	33,800	184	184	275
Préservatif Masculin UNFPA	1,440	42,903	1,595,770	323,000	932,290	12/15	71%	932,290	2,648,900	11,968	11,968	17,893
Prudence Plus Nouveau	1,656,820	1,757,164	15,005,042	20,000,000	17,380,822	1/15	(14)%	17,380,822	82,160,174	112,538	112,538	168,251
Diarrhea Treatment Kit	30	4,070	98,068	74,000	32,035		206%	32,035	878,122	88,261	-	4,923
Orasel Zinc	30	4,070	98,068	74,000	32,035	10/09	206%	32,035	878,122	88,261	-	4,923
Emergency Contraception	3,809	(15)	8,564	4,200	86,640		(90)%	86,640	129,973	385	385	201
Norlevo	3,840	-	8,785	4,200	86,934	11/15	(90)%	86,934	130,698	395	395	206
(b)PSI Emergency Contraception Distributed Provided	(31)	(15)	(221)	-	(294)		-%	(294)	(725)	(10)	(10)	(5)
Emergency Contraception Provided	35	15	227	-	307		(26)%	307	749	11	11	6
Non-PSI Emergency Contraception Provided	4	-	6	-	13		(54)%	13	24	-	-	-
PSI Emergency Contraception Provided	31	15	221	-	294		(25)%	294	725	11	11	6
Female Condom	21,360	167,333	1,454,366	1,154,930	1,150,692		26%	1,150,692	11,018,212	10,908	10,908	15,523
Préservatif Féminin CUPID	-	-	-	-	160,327	7/14	(100)%	160,327	1,125,022	-	-	-
Préservatif Féminins UNFPA	21,360	83,133	316,082	608,930	26,300	3/15	1,102%	26,300	1,146,501	2,371	2,371	3,374
Protectiv	-	-	-	546,000	-	11/02	-%	-	4,184,561	-	-	-
Protectiv Plus	-	84,200	675,800	-	-	4/14	-%	-	1,633,957	5,068	5,068	7,213
Securite Plus Female Condom	-	-	462,484	-	964,065	11/13	(52)%	964,065	2,928,171	3,469	3,469	4,936

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Fever Cases Attended	-	-	-	8,385	14,143		(100)%	14,143	26,907	-	-	-
Fever Cases Attended	-	-	-	8,385	14,143		(100)%	14,143	26,907	-	-	-
Fever Cases Tested with RDTs	-	-	-	8,385	14,143		(100)%	14,143	42,041	-	-	-
Fever Cases Tested with RDTs	-	-	-	8,385	14,143		(100)%	14,143	42,041	-	-	-
Free Condom	-	-	3,300	-	419,155		(99)%	419,155	1,350,160	25	25	37
Generic MC	-	-	3,300	-	419,155	11/16	(99)%	419,155	1,350,160	25	25	37
Free Female Condom	-	2,000	92,000	-	23,300		295%	23,300	118,400	690	690	982
Generic FC	-	2,000	92,000	-	23,300	1/08	295%	23,300	118,400	690	690	982
HIV Testing Services	-	-	7,402	9,600	5,827		27%	5,827	74,445	7,402	-	173
VCT Individual (HIV-Negative)	-	-	7,247	9,380	5,742	1/10	26%	5,742	70,507	7,247	-	169
VCT Individual (HIV-Positive)	-	-	155	220	85	1/10	82%	85	3,938	155	-	4
Implant 3	(1,682)	1,078	(22)	(4,896)	7,414		(100)%	7,414	26,422	(20)	(50)	(46)
Implanon NXT	140	3,146	29,545	11,000	22,089	12/15	34%	22,089	83,821	26,591	66,476	61,975
(b)PSI Implant 3 Distributed Inserted	(1,822)	(2,069)	(29,567)	(15,896)	(14,675)	3/16	-%	(14,675)	(57,399)	(26,610)	(66,526)	(62,021)
Implant 3 Insertion	1,826	2,072	29,638	15,896	14,684		102%	14,684	57,482	29,638	74,095	69,078
Non-PSI Implant 3 Inserted	4	4	71	-	9		689%	9	83	71	178	165
PSI Implant 3 Inserted	1,822	2,069	29,567	15,896	14,675	3/16	101%	14,675	57,399	29,567	73,918	68,912
Implant 5	168	865	3,880	-	(1,373)		0%	(1,373)	6,865	3,492	13,270	12,160
Jadelle UNFPA	230	980	5,080	-	550	3/15	824%	550	39,496	4,572	17,374	15,921
(b)PSI Implant 5 Distributed Inserted	(62)	(115)	(1,200)	-	(1,923)		-%	(1,923)	(32,631)	(1,080)	(4,104)	(3,761)
Implant 5 Insertion	70	125	1,502	-	3,201		(53)%	3,201	35,372	1,502	5,708	5,230
Non-PSI Implant 5 Inserted	8	10	302	-	1,278		(76)%	1,278	2,741	302	1,148	1,052
PSI Implant 5 Inserted	62	115	1,200	-	1,923		(38)%	1,923	32,631	1,200	4,560	4,179
Injectable 3-IM	7,604	19,737	180,906	102,000	130,960		38%	130,960	490,210	40,704	40,704	27,896
Depo-Provera UNFPA	10,000	-	10,000	-	-	3/15	-%	-	162,093	2,250	2,250	1,542

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Equilibre	2,825	25,625	249,166	132,000	170,812	5/16	46%	170,812	473,580	56,062	56,062	38,422
(b)PSI Injectable 3 IM Distributed Provided	(5,221)	(5,888)	(78,260)	(30,000)	(39,852)		-%	(39,852)	(145,463)	(17,609)	(17,609)	(12,068)
Injectable 3-IM Provided	5,235	5,916	78,683	30,000	40,845		93%	40,845	147,354	19,671	19,671	13,481
Non-PSI Injectable 3 IM Provided	14	28	423	-	993		(57)%	993	1,891	106	106	72
PSI Injectable 3 IM Provided	5,221	5,888	78,260	30,000	39,852		96%	39,852	145,463	19,565	19,565	13,409
Injectable 3-SC	-	540	5,524	2,400	3,476		59%	3,476	9,000	1,243	1,243	852
Sayana Press	-	540	5,524	2,400	3,476	3/18	59%	3,476	9,000	1,243	1,243	852
IUD 10	816	1,634	14,335	16,220	20,481		(30)%	20,481	135,450	12,902	59,347	52,007
DIU UNFPA	-	-	-	11,000	2,077	3/15	(100)%	2,077	24,810	-	-	-
IUD	1,700	2,067	24,451	-	25,200	9/09	(3)%	25,200	177,673	22,006	101,227	88,707
IUD Copper T 380A	-	757	10,085	23,220	12,066	2/16	(16)%	12,066	40,061	9,077	41,752	36,588
(b)PSI IUD 10 Distributed Inserted	(884)	(1,189)	(20,201)	(18,000)	(18,862)		-%	(18,862)	(107,094)	(18,181)	(83,632)	(73,288)
IUD 10 Insertion	888	1,221	20,878	18,000	21,794		(4)%	21,794	111,932	20,878	96,039	84,160
Non-PSI IUD 10 Inserted	4	32	677	-	2,932		(77)%	2,932	4,838	677	3,114	2,729
PSI IUD 10 Inserted	884	1,189	20,201	18,000	18,862		7%	18,862	107,094	20,201	92,925	81,431
LLIN	368	652	12,087	2,975,000	15,521		(22)%	15,521	8,028,014	19,581	-	1,874
Super Moustiquaire	348	568	11,816	2,975,000	9,665	1/09	22%	9,665	8,021,843	19,142	-	1,832
Super Moustiquaire Interceptor	20	84	271	-	5,856	10/15	(95)%	5,856	6,171	439	-	42
Lubricant	-	-	855	-	16,186		(95)%	16,186	37,415	-	-	-
Lubricant 60 mL bottle	-	-	855	-	6,061	12/15	(86)%	6,061	16,415	-	-	-
Water-based Lubricant, 4 mL sachet	-	-	-	-	10,125	12/16	(100)%	10,125	21,000	-	-	-
Malaria PPT (ACT)	-	-	-	-	15,227		(100)%	15,227	109,448	-	-	-
ACT 1 (ASAQ 25 / 67.5 mg, 3 tablets)_2 -11 months	-	-	-	-	(160)	2/15	-%	(160)	6,440	-	-	-
ACT 2 (ASAQ 50 / 135.5 mg, 3 tablets)_1 - 5 years	-	-	-	-	11,449	2/15	(100)%	11,449	67,905	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
ACT 3 (ASAQ 100 / 270 mg, 3 tablets)_6 - 13 years	-	-	-	-	1,685	2/15	(100)%	1,685	17,250	-	-	-
ACT 4 (ASAQ 100 / 270 mg, 6 tablets)_14 years & up	-	-	-	-	2,253	2/15	(100)%	2,253	17,853	-	-	-
Malaria RDK	-	-	-	-	16,569		(100)%	16,569	216,846	-	-	-
Malaria Ag Pf/Pan_PA	-	-	-	-	16,569	12/12	(100)%	16,569	216,846	-	-	-
Manual Vacuum Aspiration for PAC	654	-	1,105	578	1,309		(16)%	1,309	2,741	1,105	-	389
MVA for PAC	654	-	1,105	578	1,309		(16)%	1,309	2,741	1,105	-	389
Manual Vacuum Aspiration for SA	228	-	426	426	351		21%	351	777	426	-	184
Manual Vacuum Aspiration for SA	228	-	426	426	351		21%	351	777	426	-	184
Medical Abortion	-	-	785	19,550	172		356%	172	897	707	-	292
Mifepack	-	-	785	19,550	215		265%	215	1,000	707	-	292
(b)PSI Medical Abortion Distributed Provided	-	-	-	-	(43)		-%	(43)	(103)	-	-	-
Medical Abortion (Misoprostol) Provided	366	-	773	868	216		258%	216	989	773	-	286
Non-PSI Medical Abortion (Misoprostol) Provided	65	-	101	-	24		321%	24	125	101	-	37
PSI Medical Abortion (Misoprostol) Provided	301	-	672	868	192		250%	192	864	672	-	249
Medical Abortion Provided	-	-	-	-	51		(100)%	51	136	-	-	-
Non-PSI Medical Abortion Provided	-	-	-	-	8		(100)%	8	33	-	-	-
PSI Medical Abortion Provided	-	-	-	-	43		(100)%	43	103	-	-	-
Micronutrient Powder	11,539	33,427	326,950	35,000	948,572		(66)%	948,572	2,663,542	806	-	-
Super Bebe	11,539	33,427	326,950	35,000	948,572	9/16	(66)%	948,572	2,663,542	806	-	-
Misoprostol for PAC Provided	551	-	799	594	1,105		(28)%	1,105	2,538	799	-	335
Non-PSI Misoprostol for PAC Provided	92	-	104	-	183		(43)%	183	287	104	-	44
PSI Misoprostol for PAC Provided	459	-	695	594	922		(25)%	922	2,251	695	-	291
Misoprostol for Safe Abortion	11,352	10,747	161,064	117,208	243,174		(34)%	243,174	903,599	8,456	-	3,131
Avertiso	16,800	-	16,800	-	-		-%	-	16,800	882	-	327

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Misoprostol for Safe Abortion	-	10,747	155,108	130,000	249,166	3/18	(38)%	249,166	906,171	8,143	-	3,015
(b)PSI Misoprostol for Safe Abortion Dist Provided	(5,448)	-	(10,844)	(12,792)	(5,992)		-%	(5,992)	(19,372)	(569)	-	(211)
OCs	(3,330)	824	157,872	85,000	341,853		(54)%	341,853	1,167,792	9,472	9,472	6,848
Microgynon Ed Fe	48	4,675	105,483	-	19,981	7/14	428%	19,981	583,656	6,329	6,329	4,576
Microlut	-	-	-	-	5,001	12/17	(100)%	5,001	5,001	-	-	-
Novelle Duo	-	313	100,000	100,000	340,259	1/08	(71)%	340,259	670,368	6,000	6,000	4,338
(b)PSI OCs Distributed Provided	(3,378)	(4,164)	(47,611)	(15,000)	(23,388)		-%	(23,388)	(91,233)	(2,857)	(2,857)	(2,065)
OCs Provided	3,381	4,167	47,887	15,000	23,718		102%	23,718	92,034	3,192	3,192	2,308
Non-PSI OCs Provided	3	3	276	-	330		(16)%	330	801	18	18	13
PSI OCs Provided	3,378	4,164	47,611	15,000	23,388		104%	23,388	91,233	3,174	3,174	2,295
Pneumonia PPT	-	-	-	-	30,316		(100)%	30,316	477,424	-	-	-
Amoxicillin 500mg x 15's -- Children 1-5 years	-	-	-	-	28,750	1/13	(100)%	28,750	326,142	-	-	-
Amoxicillin 500mg x 7's - Children 2-11 months	-	-	-	-	1,566	1/13	(100)%	1,566	151,282	-	-	-
Positive RDTs	-	-	-	-	13,716		(100)%	13,716	40,358	-	-	-
Positive RDTs	-	-	-	-	13,716		(100)%	13,716	40,358	-	-	-
Positive RDTs Given First Line Treatment	-	-	-	-	13,647		(100)%	13,647	39,926	-	-	-
Positive RDTs Given First Line Treatment	-	-	-	-	13,647		(100)%	13,647	39,926	-	-	-
QAACTs Provided after Confirmatory Diagnosis	-	-	-	-	13,647		(100)%	13,647	13,647	-	-	-
Non-PSI QAACTs Provided after Confirmed Diagnosis	-	-	-	-	13,647		(100)%	13,647	13,647	-	-	-
Referral to HIV Testing Services	-	-	-	9,600	-		0%	-	-	-	-	-
Referral to HIV Testing Services	-	-	-	9,600	-	12/13	-%	-	-	-	-	-
Seasonal Malaria Chemoprevention_children reache	1,599,252	-	1,599,252	-	-		0%	-	1,599,252	1,599,252	-	202,480
SMC for Children ages 12-59 months	1,348,534	-	1,348,534	-	-		-%	-	1,348,534	1,348,534	-	170,737
SMC for Infants ages 3-11 months	250,718	-	250,718	-	-		-%	-	250,718	250,718	-	31,743

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Tubal Ligation	-	-	-	-	204		(100)%	204	204	-	-	-
Tubal Ligation	-	-	-	-	204		(100)%	204	204	-	-	-
Vasectomy	-	-	-	-	104		(100)%	104	104	-	-	-
Vasectomy	-	-	-	-	104		(100)%	104	104	-	-	-
Water Treatment Tablets	6,900	8,293	424,100	20,000	2,071,710		(80)%	2,071,710	2,649,522	6,972	-	44
Aquatabs 67 mg (20 L)	6,900	8,293	424,100	20,000	2,071,710	12/15	(80)%	2,071,710	2,649,522	6,972	-	44
Cote d'Ivoire											177,825	139,081
Antiretroviral Treatment (Currently Enrolled)	3,429	3,324	26,722	5,223	7,589		252%	7,589	34,311	2,227	-	3,686
Antiretroviral Treatment (Currently Enrolled)	3,429	3,324	26,722	5,223	7,589		252%	7,589	34,311	2,227	-	3,686
Antiretroviral Treatment (Newly Enrolled)	92	103	751	953	460		63%	460	1,211	751	-	-
Antiretroviral Treatment (Newly Enrolled)	92	103	751	953	460		63%	460	1,211	751	-	-
CD4 Tests Provided to HIV+ Clients	-	-	-	-	66		(100)%	66	788	-	-	-
CD4 Tests Provided to HIV+ Clients	-	-	-	-	66		(100)%	66	788	-	-	-
Emergency Contraception Provided	-	-	-	-	16		(100)%	16	16	-	-	-
Non-PSI Emergency Contraception Provided	-	-	-	-	16		(100)%	16	16	-	-	-
Fecal Sludge Management (Households)	-	34	402	350	315		28%	315	717	2,050	-	-
Fecal Sludge Management (Households)	-	34	402	350	315		28%	315	717	2,050	-	-
Fecal Sludge Management (Liters)	-	493,667	5,929,000	5,691,000	3,367,000		76%	3,367,000	9,296,000	-	-	578
Fecal Sludge Management (Liters)	-	493,667	5,929,000	5,691,000	3,367,000		76%	3,367,000	9,296,000	-	-	578
Free Condom	270,368	3,753	431,008	393,631	1,091,536		(61)%	1,091,536	6,749,821	3,233	3,233	2,526
Free Distribution	270,368	3,753	431,008	393,631	1,091,536	1/08	(61)%	1,091,536	6,749,821	3,233	3,233	2,526
Free Female Condom	2,184	1,700	7,284	12,000	10,236		(29)%	10,236	80,283	55	55	39
Female Condom Free	2,184	1,700	7,284	12,000	10,236	8/12	(29)%	10,236	80,283	55	55	39
HIV Self-Testing Kit	-	-	-	1,388	-		0%	-	-	-	-	-
HIV Self-Testing Kit (Oral Fluid)	-	-	-	1,388	-		-%	-	-	-	-	-

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
HIV Testing Services	2,088	1,062	9,706	17,622	13,282		(27)%	13,282	136,191	9,706	-	70
VCT Individual (HIV-Negative)	1,893	939	8,821	16,343	12,419	1/10	(29)%	12,419	129,034	8,821	-	63
VCT Individual (HIV-Positive)	195	124	885	1,279	863	1/10	3%	863	7,157	885	-	6
Implant 3	-	895	2,684	-	-		0%	-	2,684	2,416	6,039	4,688
Implanon NXT	-	895	2,684	-	-		-%	-	2,684	2,416	6,039	4,688
Implant 3 Insertion	942	2,055	18,416	3,308	2,070		790%	2,070	20,486	18,416	46,040	35,742
Non-PSI Implant 3 Inserted	942	2,055	18,416	3,308	2,070		790%	2,070	20,486	18,416	46,040	35,742
Implant 5	-	813	2,439	-	-		0%	-	2,439	2,195	8,341	6,364
Jadelle	-	813	2,439	-	-		-%	-	2,439	2,195	8,341	6,364
Implant 5 Insertion	881	2,360	23,764	17,956	2,823		742%	2,823	26,587	23,764	90,303	68,897
Non-PSI Implant 5 Inserted	881	2,360	23,764	17,956	2,823		742%	2,823	26,587	23,764	90,303	68,897
Injectable 2 Provided	245	124	1,319	-	1,373		(4)%	1,373	2,692	220	220	125
Non-PSI Injectable 2 Provided	245	124	1,319	-	1,373		(4)%	1,373	2,692	220	220	125
Injectable 3-IM	-	983	2,950	-	-		0%	-	2,950	664	664	379
Depo-Provera	-	983	2,950	-	-	5/10	-%	-	2,950	664	664	379
Injectable 3-IM Provided	2,502	2,107	23,223	7,144	7,836		196%	7,836	31,059	5,806	5,806	3,314
Non-PSI Injectable 3 IM Provided	2,502	2,107	23,223	7,144	7,836		196%	7,836	31,059	5,806	5,806	3,314
Injectable 3-SC	-	439	1,318	-	-		0%	-	1,318	297	297	169
Sayana Press	-	439	1,318	-	-		-%	-	1,318	297	297	169
Injectable 3-SC Provided	528	946	7,252	9,808	1,258		476%	1,258	8,510	1,813	1,813	1,035
Non-PSI Injectable 3 SC Provided	528	946	7,252	9,808	1,258		476%	1,258	8,510	1,813	1,813	1,035
IUD 10	-	248	745	-	-		0%	-	745	671	3,084	2,250
Eve's TCU380A	-	248	745	-	-		-%	-	745	671	3,084	2,250
IUD 10 Insertion	46	304	2,394	4,576	390		514%	390	2,784	2,394	11,012	8,033
Non-PSI IUD 10 Inserted	46	304	2,394	4,576	390		514%	390	2,784	2,394	11,012	8,033

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Lubricant	2,184	2,667	10,184	-	18,918		(46)%	18,918	101,633	-	-	-
Gel Lubricant 4.5 g	2,184	2,667	10,184	-	18,918	9/12	(46)%	18,918	101,633	-	-	-
OCs	-	510	1,530	-	-		0%	-	1,530	92	92	55
Microgynon	-	163	490	-	-		-%	-	490	29	29	18
Microlut	-	347	1,040	-	-		-%	-	1,040	62	62	38
OCs Provided	836	932	12,397	9,584	4,743		161%	4,743	17,140	826	826	498
Non-PSI OCs Provided	836	932	12,397	9,584	4,743		161%	4,743	17,140	826	826	498
Referral to Linkage to HIV Care	-	-	-	1,279	-		0%	-	-	-	-	-
Referral to Linkage to HIV Care	-	-	-	1,279	-		-%	-	-	-	-	-
Toilets Sold	340	253	3,461	679	282		1125%	282	3,743	17,650	-	633
Toilets Sold	340	253	3,461	679	282		1,125%	282	3,743	17,650	-	633
Toilets Sold - All	597	410	6,289	-	1,472		327%	1,472	7,761	32,074	-	-
Toilets Sold - All	597	410	6,289	-	1,472		327%	1,472	7,761	32,074	-	-
Mozambique											353,562	506,589
Condom	1,728,000	882,600	10,293,192	17,000,000	13,175,544		(22)%	13,175,544	110,291,652	77,199	77,199	212,359
J0.1	-	-	853,920	1,700,000	144	10/17	592,900%	144	2,582,064	6,404	6,404	17,617
J1	1,728,000	166,416	5,073,120	5,100,000	4,752,480	10/12	7%	4,752,480	52,830,432	38,048	38,048	104,663
J14	-	-	-	1,700,000	-	4/14	-%	-	141,840	-	-	-
J18	-	-	-	1,700,000	1,728,000	4/18	(100)%	1,728,000	1,728,000	-	-	-
J2	-	24	1,353,672	1,700,000	1,469,880	10/12	(8)%	1,469,880	18,753,192	10,153	10,153	27,928
J24	-	-	-	-	1,728,000	10/17	(100)%	1,728,000	3,456,000	-	-	-
J3	-	716,160	3,012,480	5,100,000	3,449,088	10/12	(13)%	3,449,088	25,961,040	22,594	22,594	62,150
Jeito 4	-	-	-	-	44,568	11/13	(100)%	44,568	3,487,464	-	-	-
Jeito 5	-	-	-	-	3,384	1/14	(100)%	3,384	1,351,620	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Emergency Contraception Provided	-	-	380	-	575		(34)%	575	1,107	19	19	12
Non-PSI Emergency Contraception Provided	-	-	380	-	575		(34)%	575	1,107	19	19	12
Free Condom	-	-	-	-	6,624		(100)%	6,624	697,377	-	-	-
No Logo Condom Lubricant Combo	-	-	-	-	6,624	5/15	(100)%	6,624	697,377	-	-	-
Implant 3 Insertion	136	134	886	-	40		2115%	40	926	886	2,215	2,528
Non-PSI Implant 3 Inserted	136	134	886	-	40		2,115%	40	926	886	2,215	2,528
Implant 5	2,610	1,687	9,820	-	(631)		0%	(631)	1,431	8,838	33,584	37,630
Jadelle	2,610	1,687	10,571	-	3,427	12/15	208%	3,427	21,705	9,514	36,153	40,507
(b)PSI Implant 5 Distributed Inserted	-	-	(751)	-	(4,058)		-%	(4,058)	(20,274)	(676)	(2,568)	(2,878)
Implant 5 Insertion	2,759	2,838	29,810	24,990	28,867		3%	28,867	94,680	29,810	113,278	126,922
Non-PSI Implant 5 Inserted	2,759	2,838	29,059	24,990	24,809		17%	24,809	74,406	29,059	110,424	123,725
PSI Implant 5 Inserted	-	-	751	-	4,058		(81)%	4,058	20,274	751	2,854	3,198
Injectable 3-IM	2,900	1,217	9,587	-	139,684		(93)%	139,684	126,975	2,157	2,157	1,812
Enaf Injectable	2,900	1,217	11,039	-	162,512	6/13	(93)%	162,512	249,232	2,484	2,484	2,087
(b)PSI Injectable 3 IM Distributed Provided	-	-	(1,452)	-	(22,828)		-%	(22,828)	(122,257)	(327)	(327)	(274)
Injectable 3-IM Provided	9,847	8,149	87,939	156,870	161,823		(46)%	161,823	507,849	21,985	21,985	18,469
Non-PSI Injectable 3 IM Provided	9,847	8,149	86,487	156,870	138,995		(38)%	138,995	385,592	21,622	21,622	18,164
PSI Injectable 3 IM Provided	-	-	1,452	-	22,828		(94)%	22,828	122,257	363	363	305
Injectable 3-SC	4,200	4,642	38,149	-	8,364		356%	8,364	46,513	8,584	8,584	7,211
(b)PSI Injectable 3 SC Distributed Provided	-	-	(3,829)	-	(1,038)		-%	(1,038)	(4,867)	(862)	(862)	(724)
Sayana Press	4,200	4,642	41,978	-	9,402		346%	9,402	51,380	9,445	9,445	7,935
Injectable 3-SC Provided	4,168	3,644	45,921	29,355	4,471		927%	4,471	50,392	11,480	11,480	9,644
Non-PSI Injectable 3 SC Provided	4,168	3,644	42,092	29,355	3,433		1,126%	3,433	45,525	10,523	10,523	8,840
PSI Injectable 3 SC Provided	-	-	3,829	-	1,038		269%	1,038	4,867	957	957	804
IUD 10	400	780	3,462	-	-		0%	-	25,200	3,116	14,333	15,334

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
DIU Copper T 380A	400	780	3,462	-	-	1/15	-%	-	25,200	3,116	14,333	15,334
IUD 10 Insertion	873	786	8,255	14,055	8,354		(1)%	8,354	24,849	8,255	37,973	40,626
Non-PSI IUD 10 Inserted	873	786	8,255	14,055	8,354	3/16	(1)%	8,354	24,849	8,255	37,973	40,626
LLIN	-	-	-	-	695		(100)%	695	199,832	-	-	-
Serena	-	-	-	-	695	4/14	(100)%	695	199,832	-	-	-
OCs	4,929	7,984	293,170	-	(1,935)		0%	(1,935)	290,883	17,590	17,590	15,589
Microginon Mobiz	-	-	-	-	1,682	5/15	(100)%	1,682	7,430	-	-	-
Microlenyn 30 Combined OC	1,089	6,517	245,214	-	38,163	6/13	543%	38,163	447,480	14,713	14,713	13,039
Progestyn OC	3,840	1,467	59,492	-	10,218	6/13	482%	10,218	149,198	3,570	3,570	3,163
(b)PSI OCs Distributed Provided	-	-	(11,536)	-	(51,998)		-%	(51,998)	(313,225)	(692)	(692)	(613)
OCs Provided	18,812	18,196	197,476	285,460	223,704		(12)%	223,704	861,176	13,165	13,165	11,667
Non-PSI OCs Provided	18,812	18,196	185,940	285,460	171,706		8%	171,706	547,951	12,396	12,396	10,986
PSI OCs Provided	-	-	11,536	-	51,998		(78)%	51,998	313,225	769	769	682
Safe Water Solution	106,032	94,703	1,581,666	1,400,000	870,831		82%	870,831	7,687,396	1,299,999	-	6,786
Certeza Commercial ISM	46,032	41,555	447,483	700,000	323,748	9/12	38%	323,748	3,435,498	367,794	-	1,920
Certeza Free ISM	60,000	53,148	1,134,183	700,000	547,083	9/12	107%	547,083	4,251,898	932,205	-	4,866
SDM (Cycle Beads)	-	-	-	-	13		(100)%	13	10,707	-	-	-
Missangas Ciclo	-	-	-	-	13	2/11	(100)%	13	10,707	-	-	-
Niger											126,202	402,999
Antiretroviral Treatment (Currently Enrolled)	-	439	5,746	-	625		819%	625	6,371	479	-	1,097
Antiretroviral Treatment (Currently Enrolled)	-	439	5,746	-	625		819%	625	6,371	479	-	1,097
Antiretroviral Treatment (Newly Enrolled)	-	2	31	-	1		3000%	1	32	31	-	-
Antiretroviral Treatment (Newly Enrolled)	-	2	31	-	1		3,000%	1	32	31	-	-
Free Condom	-	340,320	1,020,960	300,000	-		0%	-	1,775,480	7,657	7,657	9,540

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Generic Condom	-	340,320	1,020,960	300,000	-	6/16	-%	-	1,775,480	7,657	7,657	9,540
HIV Testing Services	-	582	7,618	3,008	14,858		(49)%	14,858	38,532	7,618	-	61
VCT Individual (HIV-Negative)	-	580	7,567	3,000	14,820		(49)%	14,820	37,833	7,567	-	61
VCT Individual (HIV-Positive)	-	2	51	8	38		34%	38	699	51	-	-
Implant 3	-	-	-	-	(91)		0%	(91)	(91)	-	-	-
(b)PSI Implant 3 Distributed Inserted	-	-	-	-	(91)		-%	(91)	(91)	-	-	-
Implant 3 Insertion	1,915	1,574	20,175	8,287	7,625		165%	7,625	33,901	20,175	50,438	56,803
Non-PSI Implant 3 Inserted	1,915	1,574	20,175	8,287	7,534		168%	7,534	33,810	20,175	50,438	56,803
PSI Implant 3 Inserted	-	-	-	-	91		(100)%	91	91	-	-	-
Implant 5	-	-	-	-	(1)		0%	(1)	(1)	-	-	-
(b)PSI Implant 5 Distributed Inserted	-	-	-	-	(1)		-%	(1)	(1)	-	-	-
Implant 5 Insertion	450	441	4,832	1,634	1,486		225%	1,486	7,955	4,832	18,362	20,323
Non-PSI Implant 5 Inserted	450	441	4,832	1,634	1,485		225%	1,485	7,954	4,832	18,362	20,323
PSI Implant 5 Inserted	-	-	-	-	1		(100)%	1	1	-	-	-
Injectable 3-IM	-	-	(13,046)	-	-		0%	-	(13,046)	(2,935)	(2,935)	(2,431)
(b)PSI Injectable 3 IM Distributed Provided	-	-	(13,046)	-	-		-%	-	(13,046)	(2,935)	(2,935)	(2,431)
Injectable 3-IM Provided	8,832	8,864	100,304	44,336	40,305		149%	40,305	161,383	25,076	25,076	20,764
Non-PSI Injectable 3 IM Provided	8,832	8,864	87,258	44,336	40,305		116%	40,305	148,337	21,815	21,815	18,063
PSI Injectable 3 IM Provided	-	-	13,046	-	-		-%	-	13,046	3,262	3,262	2,701
Injectable 3-SC	-	-	(1,463)	-	-		0%	-	(1,463)	(329)	(329)	(273)
(b)PSI Injectable 3 SC Distributed Provided	-	-	(1,463)	-	-		-%	-	(1,463)	(329)	(329)	(273)
Injectable 3-SC Provided	498	593	7,482	-	-		0%	-	7,482	1,871	1,871	1,549
Non-PSI Injectable 3 SC Provided	498	593	6,019	-	-		-%	-	6,019	1,505	1,505	1,246
PSI Injectable 3 SC Provided	-	-	1,463	-	-		-%	-	1,463	366	366	303
IUD 10	-	-	-	-	(60)		0%	(60)	(60)	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
(b)PSI IUD 10 Distributed Inserted	-	-	-	-	(60)		-%	(60)	(60)	-	-	-
IUD 10 Insertion	88	191	2,283	3,727	3,448		(34)%	3,448	7,325	2,283	10,502	11,114
Non-PSI IUD 10 Inserted	88	191	2,283	3,727	3,388		(33)%	3,388	7,265	2,283	10,502	11,114
PSI IUD 10 Inserted	-	-	-	-	60		(100)%	60	60	-	-	-
Manual Vacuum Aspiration for PAC	78	76	771	450	401		92%	401	1,172	771	-	436
MVA for PAC	78	76	771	450	401	1/16	92%	401	1,172	771	-	436
Misoprostol for PAC Provided	47	75	1,050	600	561		87%	561	1,611	1,050	-	689
Non-PSI Misoprostol for PAC Provided	47	75	1,050	600	561		87%	561	1,611	1,050	-	689
Misoprostol for Safe Abortion	520	4,949	24,338	8,000	99,856		(76)%	99,856	177,174	1,278	-	743
Misoprostol for Safe Abortion	520	4,949	24,338	8,000	99,856	3/18	(76)%	99,856	177,174	1,278	-	743
OCs	-	-	(22,753)	-	-		0%	-	(22,753)	(1,365)	(1,365)	(1,193)
(b)PSI OCs Distributed Provided	-	-	(22,753)	-	-		-%	-	(22,753)	(1,365)	(1,365)	(1,193)
OCs Provided	18,368	37,066	253,911	108,471	98,610		157%	98,610	424,149	16,927	16,927	14,786
Non-PSI OCs Provided	18,368	37,066	231,158	108,471	98,610		134%	98,610	401,396	15,411	15,411	13,461
PSI OCs Provided	-	-	22,753	-	-		-%	-	22,753	1,517	1,517	1,325
Seasonal Malaria Chemoprevention	-	-	-	-	344,748		(100)%	344,748	344,748	-	-	-
SMC for Children ages 12-59 months	-	-	-	-	291,064		(100)%	291,064	291,064	-	-	-
SMC for Infants ages 3-11 months	-	-	-	-	53,684		(100)%	53,684	53,684	-	-	-
Seasonal Malaria Chemoprevention_children reache	1,181,485	-	1,181,485	990,000	-		0%	-	1,181,485	1,181,485	-	268,989
SMC for Children ages 12-59 months	999,635	-	999,635	825,000	-		-%	-	999,635	999,635	-	227,587
SMC for Infants ages 3-11 months	181,850	-	181,850	165,000	-		-%	-	181,850	181,850	-	41,402
PSI Benin											46,501	38,235
Implant 5	150	257	1,770	112	-		0%	-	1,770	1,593	6,053	4,326
Jadelle	150	257	1,770	3,766	-	1/18	-%	-	1,770	1,593	6,053	4,326

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
(b)PSI Implant 5 Distributed Inserted	-	-	-	(3,654)	-		-%	-	-	-	-	-
Implant 5 Insertion	-	-	-	3,654	-		0%	-	-	-	-	-
PSI Implant 5 Inserted	-	-	-	3,654	-		-%	-	-	-	-	-
IUD 10	300	700	9,770	1,356	14,678		(33)%	14,678	24,448	8,793	40,448	27,675
IUD Copper T 380A	300	700	9,770	11,690	14,678	1/18	(33)%	14,678	24,448	8,793	40,448	27,675
(b)PSI IUD 10 Distributed Inserted	-	-	-	(10,334)	-		-%	-	-	-	-	-
IUD 10 Insertion	-	-	-	10,334	-		0%	-	-	-	-	-
PSI IUD 10 Inserted	-	-	-	10,334	-		-%	-	-	-	-	-
Manual Vacuum Aspiration for PAC	-	-	-	810	-		0%	-	-	-	-	-
MVA for PAC	-	-	-	810	-		-%	-	-	-	-	-
Manual Vacuum Aspiration for SA	-	-	-	81	-		0%	-	-	-	-	-
Manual Vacuum Aspiration for SA	-	-	-	81	-		-%	-	-	-	-	-
Medical Abortion	165	220	1,740	-	-		0%	-	1,740	1,566	-	587
Mifeso	165	220	1,740	-	-		-%	-	1,740	1,566	-	587
Medical Abortion (Misoprostol) Provided	-	-	-	183	-		0%	-	-	-	-	-
PSI Medical Abortion (Misoprostol) Provided	-	-	-	183	-		-%	-	-	-	-	-
Misoprostol for PAC Provided	-	-	-	528	-		0%	-	-	-	-	-
PSI Misoprostol for PAC Provided	-	-	-	528	-		-%	-	-	-	-	-
Misoprostol for Safe Abortion	640	37,428	319,604	199,152	208,980		53%	208,980	528,584	16,779	-	5,647
Misoprostol for Safe Abortion	640	37,428	319,604	203,460	208,980	3/18	53%	208,980	528,584	16,779	-	5,647
(b)PSI Misoprostol for Safe Abortion Dist Provided	-	-	-	(4,308)	-		-%	-	-	-	-	-
Senegal											74,038	53,493
Acute Malnutrition Screening_CU5	-	-	-	312	518		(100)%	518	1,895	-	-	-
Acute Malnutrition Screening_CU5	-	-	-	312	518		(100)%	518	1,895	-	-	-
Condom	906,696	214,168	2,740,944	6,074,298	5,947,910		(54)%	5,947,910	33,685,104	20,557	20,557	23,653

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Fagaru	127,768	57,309	593,936	2,100,223	2,751,835	11/12	(78)%	2,751,835	12,413,121	4,455	4,455	5,125
Protec Fraise	147,040	36,005	443,360	710,207	822,288	1/13	(46)%	822,288	4,598,964	3,325	3,325	3,826
Protec Naturel	631,888	120,853	1,703,648	3,263,868	2,373,787	1/13	(28)%	2,373,787	16,673,019	12,777	12,777	14,701
Counseling & Tx for Moderate Acute MalnutritionCU1	-	-	-	4	-		0%	-	-	-	-	-
Counseling & Tx for Moderate Acute MalnutritionCU5	-	-	-	4	-		-%	-	-	-	-	-
HIV Testing Services	-	-	-	91	314		(100)%	314	903	-	-	-
VCT Individual (HIV-Negative)	-	-	-	90	313		(100)%	313	888	-	-	-
VCT Individual (HIV-Positive)	-	-	-	1	1		(100)%	1	15	-	-	-
Implant 3 Insertion	-	4	169	41	127		33%	127	363	169	423	255
Non-PSI Implant 3 Inserted	-	4	169	41	127		33%	127	363	169	423	255
Implant 4 Insertion	-	-	21	-	2		950%	2	41	21	67	40
Non-PSI Implant 4 Inserted	-	-	21	-	2		950%	2	41	21	67	40
Implant 5 Insertion	-	2	226	48	157		44%	157	462	226	859	510
Non-PSI Implant 5 Inserted	-	2	226	48	157		44%	157	462	226	859	510
Injectable 3-IM Provided	-	3	147	45	182		(19)%	182	430	37	37	16
Non-PSI Injectable 3 IM Provided	-	3	147	45	182		(19)%	182	430	37	37	16
Injectable 3-SC	10,344	4,744	34,517	19,080	14,488		138%	14,488	51,620	7,766	7,766	3,451
Securil Press	10,344	4,744	34,517	19,080	14,488		138%	14,488	51,620	7,766	7,766	3,451
IUD 10 Insertion	-	2	35	7	27		30%	27	81	35	161	91
Non-PSI IUD 10 Inserted	-	2	35	7	27		30%	27	81	35	161	91
LLIN	33,910	11,450	155,339	165,000	270,382		(43)%	270,382	1,140,468	251,649	-	4,338
MILDA	33,910	11,450	155,339	165,000	270,382	8/13	(43)%	270,382	1,140,468	251,649	-	4,338
OCs	175,827	63,793	736,139	500,565	664,517		11%	664,517	3,938,407	44,168	44,168	20,707
Securil	175,827	63,793	736,139	500,565	664,517	11/12	11%	664,517	3,938,407	44,168	44,168	20,707
OCs Provided	-	-	4	5	17		(76)%	17	27	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	^(a) YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Non-PSI OCs Provided	-	-	4	5	17		(76)%	17	27	-	-	-
Toilets Sold	284	136	2,683	4,000	958		180%	958	3,641	22,269	-	343
Toilets Sold	284	136	2,683	4,000	958		180%	958	3,641	22,269	-	343
Toilets Sold - All	284	181	2,818	-	958		194%	958	3,776	23,389	-	-
Toilets Sold - All	284	181	2,818	-	958		194%	958	3,776	23,389	-	-
Treatment for Severe Acute Malnutrition	-	-	-	8	-		0%	-	-	-	-	-
Treatment for Severe Acute Malnutrition	-	-	-	8	-		-%	-	-	-	-	-
Water Treatment Tablets	535,620	163,273	1,995,440	1,860,179	1,979,400		1%	1,979,400	11,461,106	32,802	-	88
Aquatabs 67 mg (20 L)	535,620	163,273	1,995,440	1,860,179	1,979,400	11/12	1%	1,979,400	11,461,106	32,802	-	88

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

^(b)DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

Latin America & Asia Market Group

POPULATION SERVICES INTERNATIONAL
CYPs, Cases, and Deaths by Country
1/2019 - 12/2019

	New HIV Infections	STI Deaths	PWID Deaths	TB Deaths	CYP*	Maternal Deaths	Unintended Pregnancies	Malaria Deaths	Diarrhea Deaths	Pneumonia Deaths	Cervical Cancer Death	Sum of All Deaths
Latin America & Asia Market Group	4,244	-	48	2,195	4,186,405	1,947	1,591,750	3	78	-	-	14,232
Cambodia	1,586	-	-	-	654,532	504	247,565	-	77	-	-	1,944
Caribbean	-	-	-	-	-	-	-	-	-	-	-	-
Costa Rica	53	-	-	-	13,457	-	3,790	-	-	-	-	3
Dominican Republic	482	-	-	-	101,758	12	28,670	-	-	-	-	93
El Salvador	179	-	-	-	38,149	3	11,291	-	-	-	-	27
El Salvador SA	51	-	-	-	48,719	6	20,630	-	-	-	-	50
Guatemala	190	-	-	-	49,723	5	14,423	-	-	-	-	77
Guatemala SA	145	-	-	-	309,512	50	137,199	-	-	-	-	727
Honduras	175	-	-	-	20,127	4	6,743	-	-	-	-	24
Honduras SA	167	-	-	-	13,682	2	3,853	-	-	-	-	14
Kazakhstan	19	-	-	-	703	-	198	-	-	-	-	-
Kyrgyzstan	14	-	-	-	273	-	77	-	-	-	-	-
Laos	93	-	-	14	84,321	34	33,700	2	-	-	-	249
Nepal	-	-	-	-	93,104	270	42,111	-	-	-	-	443
Nicaragua	147	-	-	-	81,121	24	31,623	-	-	-	-	138
Pakistan	610	-	-	2,181	1,705,140	747	636,775	-	-	-	-	7,480
Panama	86	-	-	-	16,747	2	4,717	-	-	-	-	13
Papua New Guinea	14	-	-	-	1,634	1	456	-	-	-	-	7
PSI Pakistan	206	-	-	-	945,604	282	364,555	-	-	-	-	2,888
Tajikistan	27	-	48	-	1,330	-	375	-	-	-	-	49
Viet Nam	-	-	-	-	6,768	1	3,000	1	1	-	-	5

* Using USAID CYP conversion factors

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Market Group and Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE SALES	YTD USERS REACHED ^(a) 2019	YTD CYP 2019	YTD DALY 2019
Latin America & Asia Market Group										4,186,405	1,278,619
Antiretroviral Treatment (Currently Enrolled)	-	827	7,541	-	233	3,136%	233	7,774	628	-	1,049
Antiretroviral Treatment (Newly Enrolled)	-	47	449	-	92	388%	92	541	449	-	-
Cervical Cancer-HPV DNA Screening	-	146	777	-	-	-%	-	777	777	-	-
Cervical Cancer-Pap Smear Screening	30	58	438	-	92	376%	92	766	438	-	-
Condom	18,641,510	20,299,308	184,767,633	196,479,173	187,077,716	(1)%	187,077,716	3,668,710,609	1,385,757	1,385,757	394,062
Diarrhea Treatment Kit	2,820	1,107	40,570	91,951	57,190	(29)%	57,190	989,246	36,513	-	798
Emergency Contraception	256,540	299,816	2,547,734	981,837	2,139,292	19%	2,139,292	11,755,753	114,648	114,648	19,909
Emergency Contraception Provided	3,703	2,891	30,261	1,146,567	15,372	97%	15,372	74,111	1,513	1,513	263
Female Condom	-	-	-	-	100	(100)%	100	338,539	-	-	-
Fever Cases Attended	8,568	8,834	88,447	75,685	118,263	(25)%	118,263	368,372	88,447	-	-
Fever Cases Tested with Microscopy	-	2,246	6,737	-	-	-%	-	6,737	6,737	-	-
Fever Cases Tested with RDTs	11,112	13,038	116,202	95,551	134,061	(13)%	134,061	411,889	116,202	-	-
Free Condom	56,590	472,857	3,741,906	3,124,160	3,430,359	9%	3,430,359	14,336,639	28,064	28,064	8,033
Free Female Condom	1,000	5,103	16,504	30,000	21,200	(22)%	21,200	62,274	124	124	80
HIV Self-Testing Kit	528	323	1,496	7,200	-	-%	-	1,496	1,346	-	-
HIV Testing Services	2,048	4,812	69,479	78,439	98,169	(29)%	98,169	423,279	69,479	-	154
Hypertension Diagnosis	-	-	7,961	14,572	26,102	(70)%	26,102	60,396	7,961	-	-
Hypertension Screening	-	-	191,920	150,000	413,477	(54)%	413,477	807,614	191,920	-	-
Hypertension_Controlled Condition	-	-	12,035	13,009	30,443	(60)%	30,443	62,586	4,814	-	-
Implant 3	191	305	2,894	4,920	1,681	72%	1,681	5,437	2,605	6,512	886
Implant 3 Insertion	745	900	12,010	12,195	12,809	(6)%	12,809	38,770	12,010	30,025	6,874

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Market Group and Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE SALES	YTD USERS REACHED ^(a) 2019	YTD CYP 2019	YTD DALY 2019
Implant 5	2,446	1,958	14,480	3,342	21,705	(33)%	21,705	90,073	13,032	49,522	10,876
Implant 5 Insertion	288	1,620	20,152	12,712	21,679	(7)%	21,679	107,884	20,152	76,578	15,843
Injectable 1	15,091	18,068	203,675	150,016	131,181	55%	131,181	2,172,189	14,101	14,101	3,266
Injectable 1 Provided	4,922	9,648	102,997	44,525	88,483	16%	88,483	327,953	7,923	7,923	1,599
Injectable 2	-	(494)	124,894	19,731	134,028	(7)%	134,028	7,208,977	18,734	18,734	4,300
Injectable 2 Provided	3	3,609	39,042	132,422	58,184	(33)%	58,184	185,618	6,507	6,507	1,056
Injectable 3-IM	13,221	15,108	323,866	560,836	688,678	(53)%	688,678	8,823,089	72,870	72,870	13,349
Injectable 3-IM Provided	32,026	47,770	517,607	761,629	705,711	(27)%	705,711	1,673,157	129,402	129,402	25,493
Injectable 3-SC	-	(34)	(102)	1,400	-	-%	-	(102)	(23)	(23)	(1)
Injectable 3-SC Provided	-	256	769	5,600	-	-%	-	769	192	192	5
IUD 10	3,085	833	77,261	102,474	67,041	15%	67,041	206,178	69,535	319,861	87,016
IUD 10 Insertion	15,164	15,522	141,791	123,733	148,352	(4)%	148,352	900,259	141,791	652,239	162,215
IUD 5	(5,579)	6,348	40,646	94,294	22,736	79%	22,736	3,059,819	36,581	120,719	36,127
IUD 5 Insertion	10,962	12,906	162,215	65,998	63,576	155%	63,576	1,101,500	162,215	535,309	167,093
IUS 5 Insertion	3	1	10	-	2	400%	2	13	10	33	6
LLIN (Hammock net)	-	-	781	1,350	1,259	(38)%	1,259	2,085	703	-	-
Lubricant	43,136	350,729	2,810,451	731,208	1,423,274	97%	1,423,274	19,342,251	-	-	-
Malaria PPT (ACT)	-	(24)	(227)	-	357	(164)%	357	860,468	(204)	-	(25)
Malaria RDK	6,920	3,497	35,300	25,000	305,189	(88)%	305,189	3,317,776	31,770	-	-
Manual Vacuum Aspiration for PAC	4,365	7,337	85,407	7,295	34,966	144%	34,966	191,371	85,407	-	4,157
Manual Vacuum Aspiration for SA	21	56	696	236	251	177%	251	947	696	-	103

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Market Group and Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE SALES	YTD USERS REACHED ^(a) 2019	YTD CYP 2019	YTD DALY 2019
Medical Abortion	29,143	20,692	363,772	459,996	457,337	(20)%	457,337	2,474,932	327,395	-	33,561
Medical Abortion Provided	1,202	1,263	12,874	4,788	12,104	6%	12,104	32,948	12,874	-	1,255
Misoprostol for PAC Provided	9,765	9,057	87,568	3,935	53,383	64%	53,383	144,601	87,568	-	5,209
Misoprostol for Safe Abortion	175,044	101,615	1,689,170	320,448	1,285,943	31%	1,285,943	3,675,307	88,681	-	6,731
Multivitamin	6,000	6,807	26,420	-	-	-%	-	26,420	132	-	25
Naloxone	-	167	1,995	3,089	2,570	(22)%	2,570	18,708	1,796	-	2,722
Needle & Syringe	-	92,933	1,066,900	1,355,860	5,815,215	(82)%	5,815,215	26,575,968	3,722	-	11,901
OCs	290,792	509,620	7,120,821	6,917,751	6,487,754	10%	6,487,754	71,779,939	427,249	427,249	81,083
OCs Provided	151,667	122,220	1,359,110	1,601,361	921,067	48%	921,067	2,982,464	90,607	90,607	21,682
ORS	12,797	28,283	648,134	-	500,000	30%	500,000	1,177,368	291,660	-	6,130
Positive RDTs	123	153	1,967	3,333	11,799	(83)%	11,799	40,540	1,967	-	-
Positive RDTs Given First Line Treatment	103	105	1,554	2,474	10,103	(85)%	10,103	37,102	1,554	-	-
QAACTs Provided after Confirmatory Diagnosis	59	95	1,181	2,254	9,977	(88)%	9,977	36,631	1,181	-	213
Referral to Emergency Contraception	-	1	2	-	31	(94)%	31	109	2	-	-
Referral to HIV Testing Services	-	1	17	6	10	70%	10	20,745	17	-	-
Referral to Implant 3 Insertion	119	216	2,064	-	1,455	42%	1,455	3,519	2,064	2,580	349
Referral to Implant 5 Insertion	73	57	568	-	221	157%	221	1,595	568	1,079	242
Referral to Implant Insertion (duration unknown)	-	4	20	-	-	-%	-	20	20	25	3
Referral to Injectable 1	-	5	25	-	11	127%	11	36	25	1	-
Referral to Injectable 3	175	88	1,065	-	396	169%	396	2,700	1,065	133	23
Referral to IUD 10 Insertion	254	284	2,350	-	729	222%	729	60,594	2,350	5,405	965

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
 Monthly Distribution by Market Group and Product
 Period: 12
 Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE SALES	YTD USERS REACHED ^(a) 2019	YTD CYP 2019	YTD DALY 2019
Referral to IUD Insertion (duration unknown)	-	2	19	-	-	-%	-	19	19	31	4
Referral to Linkage to HIV Care	271	304	3,319	1,627	2,800	19%	2,800	9,451	3,319	-	2,776
Referral to OCs	132	78	1,035	-	391	165%	391	1,977	1,035	34	6
Referral to Opioid Treatment	8	5	84	37	135	(38)%	135	556	84	-	-
Referral to TB DOTS (completion confirmed)	-	9	81	110	148	(45)%	148	472	81	-	28
Referral to TB DOTS (completion unknown)	-	-	4	-	43	(91)%	43	248	4	-	1
Referral to TB Screening	-	-	-	-	21	(100)%	21	50	-	-	-
Referral to Vasectomy	-	-	1	-	-	-%	-	1	1	5	1
SDM (Cycle Beads) Provided	-	-	4	-	7	(43)%	7	126	4	6	1
STI Screening	23	48	265	-	99	168%	99	4,158	265	-	-
TB Diagnosis	2,329	2,543	28,670	385	29,853	(4)%	29,853	114,306	28,670	-	-
TB DOTS	2,289	2,100	25,764	-	26,012	(1)%	26,012	139,239	25,764	-	117,907
TB Screening	9,013	5,679	65,241	4,086	72,433	(10)%	72,433	206,757	65,241	-	-
Toilets Sold	-	175	1,113	750	4,405	(75)%	4,405	7,416	4,675	-	39
Toilets Sold - All	-	175	1,113	-	4,159	(73)%	4,159	5,272	4,675	-	-
Treatment for Cervicitis	5	14	94	-	28	236%	28	137	94	-	-
Treatment for Genital Herpes	-	-	1	-	-	-%	-	9	1	-	-
Treatment for Lower Abdominal Pain	-	2	7	-	-	-%	-	7	7	-	-
Treatment for Nonherpetic Genital Ulcer	-	1	2	-	-	-%	-	4	2	-	-
Treatment for Urethral Discharge (Women)	-	-	1	-	1	-%	1	9	1	-	-
Treatment for Vaginitis	18	31	217	-	25	768%	25	245	217	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Market Group and Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE SALES	YTD USERS REACHED ^(a) 2019	YTD CYP 2019	YTD DALY 2019
Tubal Ligation	3	996	8,574	-	11,913	(28)%	11,913	35,995	8,574	85,740	20,411
Type 2 Diabetes Diagnosis	-	-	1	-	1	-%	1	2	1	-	-
Type 2 Diabetes Screening	-	-	3	-	1	200%	1	6	3	-	-
Type 2 Diabetes_Controlled Condition	-	-	2	-	-	-%	-	2	-	-	-
Vasectomy	-	25	290	-	318	(9)%	318	1,191	290	2,900	704
Vivax Treatment after Confirmatory Diagnosis	47	47	293	248	156	88%	156	458	293	-	55
Water Treatment Tablets	4,000	1,417	74,110	80,000	91,160	(19)%	91,160	1,052,893	1,218	-	3
Zika Prevention Kit	-	-	-	-	725	(100)%	725	2,621	-	-	-
Zinc	-	23	132	-	-	-%	-	32,976	119	-	1

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Latin America & Asia Market Group											4,186,405	1,278,619
Cambodia											654,532	213,730
Condom	432,069	678,088	9,931,395	12,214,854	10,667,766		(7)%	10,667,766	395,995,946	74,485	74,485	73,597
Number One	242,136	111,648	2,869,632	4,448,814	4,440,816	12/94	(35)%	4,440,816	272,141,701	21,522	21,522	21,265
OK Condom	189,933	566,440	7,061,763	7,766,040	6,226,950	2/04	13%	6,226,950	123,854,245	52,963	52,963	52,331
Diarrhea Treatment Kit	2,820	1,107	40,570	89,037	57,190		(29)%	57,190	971,010	36,513	-	798
Orasel Kit	2,820	1,107	40,570	89,037	57,190	3/09	(29)%	57,190	971,010	36,513	-	798
Emergency Contraception	5,496	3,508	65,413	94,412	73,948		(12)%	73,948	367,948	2,944	2,944	390
NEXT 72 EC	5,500	3,510	65,460	90,602	73,979	8/13	(12)%	73,979	368,059	2,946	2,946	390
Pronta1	-	-	-	3,810	-		-%	-	-	-	-	-
(b)PSI Emergency Contraception Distributed Provided	(4)	(2)	(47)	-	(31)		-%	(31)	(111)	(2)	(2)	-
Emergency Contraception Provided	4	2	47	-	31		52%	31	111	2	2	-
PSI Emergency Contraception Provided	4	2	47	-	31		52%	31	111	2	2	-
Fever Cases Attended	2,122	1,695	15,323	15,685	75,172		(80)%	75,172	241,096	15,323	-	-
Fever Cases Attended	2,122	1,695	15,323	15,685	75,172		(80)%	75,172	241,096	15,323	-	-
Fever Cases Tested with RDTs	2,122	1,695	14,958	15,551	75,088		(80)%	75,088	240,625	14,958	-	-
Fever Cases Tested with RDTs	2,122	1,695	14,958	15,551	75,088		(80)%	75,088	240,625	14,958	-	-
Implant 3 Insertion	20	23	287	-	112		156%	112	399	287	718	169
Non-PSI Implant 3 Inserted	20	23	287	-	112		156%	112	399	287	718	169
Implant 5	153	135	6,252	8,643	8,131		(23)%	8,131	28,280	5,627	21,382	4,960
Implant 5	307	315	8,381	11,184	10,570	5/09	(21)%	10,570	61,707	7,543	28,663	6,649
(b)PSI Implant 5 Distributed Inserted	(154)	(180)	(2,129)	(2,541)	(2,439)		-%	(2,439)	(33,427)	(1,916)	(7,281)	(1,689)
Implant 5 Insertion	154	180	2,129	2,541	2,439		(13)%	2,439	33,427	2,129	8,090	1,877
PSI Implant 5 Inserted	154	180	2,129	2,541	2,439		(13)%	2,439	33,427	2,129	8,090	1,877
Injectable 3-IM	13,935	15,356	255,335	334,044	290,704		(12)%	290,704	5,809,564	57,450	57,450	9,980

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
OK Injection-3	14,175	15,717	259,600	334,044	294,200	2/02	(12)%	294,200	5,828,159	58,410	58,410	10,147
(b)PSI Injectable 3 IM Distributed Provided	(240)	(360)	(4,265)	-	(3,496)		-%	(3,496)	(18,595)	(960)	(960)	(167)
Injectable 3-IM Provided	240	360	4,265	-	3,496		22%	3,496	18,595	1,066	1,066	185
PSI Injectable 3 IM Provided	240	360	4,265	-	3,496		22%	3,496	18,595	1,066	1,066	185
IUD 10	311	319	12,455	25,008	20,787		(40)%	20,787	104,989	11,210	51,564	11,429
IUD Copper T	1,280	1,545	28,830	40,488	40,515	1/10	(29)%	40,515	265,155	25,947	119,356	26,456
(b)PSI IUD 10 Distributed Inserted	(969)	(1,226)	(16,375)	(15,480)	(19,728)		-%	(19,728)	(160,166)	(14,738)	(67,792)	(15,026)
IUD 10 Insertion	969	1,226	16,375	15,480	19,728		(17)%	19,728	160,166	16,375	75,325	16,696
PSI IUD 10 Inserted	969	1,226	16,375	15,480	19,728		(17)%	19,728	160,166	16,375	75,325	16,696
Lubricant	15,420	38,380	611,460	-	521,340		17%	521,340	9,789,560	-	-	-
OK Plus Lubricant	15,420	38,380	611,460	-	521,340	6/09	17%	521,340	9,789,560	-	-	-
Malaria PPT (ACT)	-	(24)	(227)	-	(7,425)		0%	(7,425)	14,991	(204)	-	(25)
ASMQ for Adult	-	-	-	-	776	5/16	(100)%	776	46,378	-	-	-
ASMQ for Children	-	-	-	-	175	10/16	(100)%	175	2,033	-	-	-
(b)PSI QAACTs Distributed Provided after Diagnosis	-	(24)	(227)	-	(8,376)		-%	(8,376)	(33,420)	(204)	-	(25)
Malaria RDK	-	-	-	-	276,500		(100)%	276,500	1,896,300	-	-	-
Malaria RDT (Diagnosis)	-	-	-	-	276,500	6/15	(100)%	276,500	1,896,300	-	-	-
Medical Abortion	13,024	9,899	256,683	360,280	334,762		(23)%	334,762	2,002,800	231,015	-	20,226
Medabon	9,447	10,812	180,127	185,650	240,656	11/09	(25)%	240,656	1,840,108	162,114	-	14,194
Mifeso	4,473	46	86,911	174,630	104,939		(17)%	104,939	191,850	78,220	-	6,849
(b)PSI Medical Abortion Distributed Provided	(896)	(959)	(10,355)	-	(10,833)		-%	(10,833)	(29,158)	(9,320)	-	(816)
Medical Abortion Provided	897	959	10,356	-	10,833		(4)%	10,833	29,159	10,356	-	907
Non-PSI Medical Abortion Provided	1	-	1	-	-		-%	-	1	1	-	-
PSI Medical Abortion Provided	896	959	10,355	-	10,833		(4)%	10,833	29,158	10,355	-	907

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
OCs	327,400	409,327	5,954,034	6,233,333	5,456,565		9%	5,456,565	66,144,867	357,242	357,242	65,468
Marvelon	84,120	85,140	1,169,255	1,006,355	908,657	12/12	29%	908,657	3,533,467	70,155	70,155	12,857
OK Pills	243,612	324,708	4,789,224	5,226,978	4,551,732	9/97	5%	4,551,732	62,628,404	287,353	287,353	52,660
(b)PSI OCs Distributed Provided	(332)	(522)	(4,445)	-	(3,824)		-%	(3,824)	(17,004)	(267)	(267)	(49)
OCs Provided	332	522	4,445	-	3,825		16%	3,825	17,006	296	296	54
Non-PSI OCs Provided	-	-	-	-	1		(100)%	1	2	-	-	-
PSI OCs Provided	332	522	4,445	-	3,824		16%	3,824	17,004	296	296	54
ORS	12,797	28,283	646,022	-	500,000		29%	500,000	1,146,022	290,710	-	6,104
Orasel ORS Sachet	12,797	28,283	646,022	-	500,000		29%	500,000	1,146,022	290,710	-	6,104
Positive RDTs	35	28	390	1,143	9,841		(96)%	9,841	36,264	390	-	-
Positive RDTs	35	28	390	1,143	9,841		(96)%	9,841	36,264	390	-	-
Positive RDTs Given First Line Treatment	35	24	262	1,099	8,376		(97)%	8,376	33,455	262	-	-
Positive RDTs Given First Line Treatment	35	24	262	1,099	8,376		(97)%	8,376	33,455	262	-	-
QAACTs Provided after Confirmatory Diagnosis	-	24	228	1,099	8,400		(97)%	8,400	33,476	228	-	33
Non-PSI QAACTs Provided after Confirmed Diagnosis	-	-	1	1,099	24		(96)%	24	56	1	-	-
PSI QAACTs Provided after Confirmed Diagnosis	-	24	227	-	8,376		(97)%	8,376	33,420	227	-	33
Referral to Emergency Contraception	-	1	2	-	31		(94)%	31	109	2	-	-
Referral to Emergency Contraception	-	1	2	-	31		(94)%	31	109	2	-	-
Referral to Implant 5 Insertion	67	52	493	-	190		159%	190	1,464	493	937	217
Referral to Implant 5 Insertion	67	52	493	-	190		159%	190	1,464	493	937	217
Referral to Injectable 3	175	88	1,047	-	396		164%	396	2,682	1,047	131	23
Referral to Injectable 3	175	88	1,047	-	396		164%	396	2,682	1,047	131	23
Referral to IUD 10 Insertion	215	142	1,246	-	677		84%	677	10,725	1,246	2,866	635
Referral to IUD 10 Insertion	215	142	1,246	-	677	12/11	84%	677	10,725	1,246	2,866	635
Referral to OCs	132	78	1,030	-	389		165%	389	1,970	1,030	34	6

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Referral to OCs	132	78	1,030	-	389		165%	389	1,970	1,030	34	6
Caribbean												
Cervical Cancer-HPV DNA Screening	-	146	777	-	-		0%	-	777	777	-	-
Cervical Cancer-HPV DNA Screening	-	146	777	-	-		-%	-	777	777	-	-
Costa Rica											13,457	2,194
Condom	221,334	137,218	1,794,252	2,062,125	1,937,134		(7)%	1,937,134	20,540,315	13,457	13,457	2,194
Combo-Pack Lub Fresa	-	264	16,308	27,338	29,308	10/10	(44)%	29,308	102,139	122	122	20
Vive	118,896	83,315	1,049,394	243,763	504,093	12/97	108%	504,093	6,212,902	7,870	7,870	1,283
Vive Amor	-	208	624	999,666	602,928	6/04	(100)%	602,928	8,043,545	5	5	1
Vive Colors/Mas Colors	71,142	24,050	405,312	487,706	489,846	5/03	(17)%	489,846	4,081,029	3,040	3,040	496
Vive Mas Fuerte /Retardante	10,392	14,028	151,374	127,286	133,953	6/04	13%	133,953	928,962	1,135	1,135	185
Vive Mas Natural /Sensitivo	20,904	15,353	171,240	176,366	177,006	6/04	(3)%	177,006	1,171,738	1,284	1,284	209
Lubricant	2,035	3,017	31,938	-	22,294		43%	22,294	193,739	-	-	-
Vive Lub Natural (sachet)	100	483	7,250	-	5,532	5/11	31%	5,532	61,764	-	-	-
Vive Lub Natural (tube)	700	535	7,211	-	5,433	5/11	33%	5,433	30,566	-	-	-
Vive Lub Sachet Fresa 5 mL	500	1,133	8,200	-	3,809	5/12	115%	3,809	66,388	-	-	-
Vive Lub Tubo Fresa 120 mL	735	865	9,277	-	7,520	1/12	23%	7,520	35,021	-	-	-
Dominican Republic											101,758	26,603
Antiretroviral Treatment (Currently Enrolled)	-	827	7,541	-	233		3136%	233	7,774	628	-	1,049
Antiretroviral Treatment (Currently Enrolled)	-	827	7,541	-	233		3,136%	233	7,774	628	-	1,049
Antiretroviral Treatment (Newly Enrolled)	-	47	449	-	92		388%	92	541	449	-	-
Antiretroviral Treatment (Newly Enrolled)	-	47	449	-	92		388%	92	541	449	-	-
Condom	203,600	1,871,798	10,326,835	5,720,648	7,560,134		37%	7,560,134	52,893,413	77,451	77,451	19,419
Pante	179,600	1,861,422	10,210,699	5,433,008	7,554,566	6/14	35%	7,554,566	52,771,709	76,580	76,580	19,201

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Vive Colors/Mas Colors	12,000	4,912	56,688	244,800	2,784		1,936%	2,784	59,472	425	425	107
VIVE Mas/Sensitivo	6,000	1,864	27,720	24,480	1,392		1,891%	1,392	29,112	208	208	52
Vive Mas/Texturizado	6,000	3,600	31,728	18,360	1,392		2,179%	1,392	33,120	238	238	60
Free Condom	-	383,667	3,233,000	2,511,000	2,214,000		46%	2,214,000	11,090,423	24,247	24,247	6,080
No Logo	-	383,667	3,233,000	2,511,000	2,214,000	6/14	46%	2,214,000	11,090,423	24,247	24,247	6,080
HIV Testing Services	-	1,990	19,440	25,152	31,033		(37)%	31,033	127,305	19,440	-	47
VCT Individual (HIV-Negative)	-	1,912	18,725	24,237	30,230	9/13	(38)%	30,230	123,939	18,725	-	45
VCT Individual (HIV-Positive)	-	78	715	915	803	9/13	(11)%	803	3,366	715	-	2
Lubricant	-	255,667	1,037,000	236,000	278,000		273%	278,000	2,825,992	-	-	-
No Logo Lubricant (4.5 gram sachet)	-	255,667	1,037,000	236,000	278,000	6/14	273%	278,000	2,825,992	-	-	-
Referral to Implant Insertion (duration unknown)	-	4	20	-	-		0%	-	20	20	25	3
Referral to Implant Insertion (duration unknown)	-	4	20	-	-		-%	-	20	20	25	3
Referral to Injectable 1	-	4	12	-	-		0%	-	12	12	-	-
Referral to Injectable 1	-	4	12	-	-		-%	-	12	12	-	-
Referral to Injectable 3	-	-	16	-	-		0%	-	16	16	2	-
Referral to Injectable 3	-	-	16	-	-		-%	-	16	16	2	-
Referral to IUD Insertion (duration unknown)	-	2	19	-	-		0%	-	19	19	31	4
Referral to IUD Insertion (duration unknown)	-	2	19	-	-		-%	-	19	19	31	4
Referral to Linkage to HIV Care	-	-	-	-	371		(100)%	371	412	-	-	-
Referral to Linkage to HIV Care	-	-	-	-	371		(100)%	371	412	-	-	-
Referral to OCs	-	-	3	-	-		0%	-	3	3	-	-
Referral to OCs	-	-	3	-	-		-%	-	3	3	-	-
El Salvador											38,149	8,720
Cervical Cancer-Pap Smear Screening	30	58	438	-	92		376%	92	766	438	-	-
Cervical Cancer-Pap Smear Screening	30	58	438	-	92		376%	92	766	438	-	-

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Condom	9	4	4,346,863	3,630,855	3,210,525		35%	3,210,525	44,548,599	32,601	32,601	8,223
Combo-Mix Lub Natural	-	-	-	-	48	10/10	(100)%	48	19,432	-	-	-
Combo-Pack Lub Fresa	-	1	28,514	4,682	4,896	5/12	482%	4,896	38,738	214	214	54
Vive	-	-	1,110,432	960,267	739,008	4/98	50%	739,008	16,315,276	8,328	8,328	2,101
Vive Amor	-	-	1,631,520	1,617,436	1,534,176	7/04	6%	1,534,176	16,089,937	12,236	12,236	3,086
Vive Colors/Mas Colors	6	2	1,163,052	695,657	597,348	10/03	95%	597,348	8,466,666	8,723	8,723	2,200
Vive Mas Fuerte /Retardante	3	1	280,425	263,210	206,016	7/04	36%	206,016	1,834,853	2,103	2,103	530
Vive Mas Natural /Sensitivo	-	-	132,920	89,603	87,849	7/04	51%	87,849	933,625	997	997	251
Vive Mas/Texturizado	-	-	-	-	41,184	7/04	(100)%	41,184	850,072	-	-	-
HIV Testing Services	290	401	4,668	2,340	2,945		59%	2,945	49,472	4,668	-	7
VCT Individual (HIV-Negative)	276	383	4,474	2,206	2,823	12/09	58%	2,823	48,626	4,474	-	6
VCT Individual (HIV-Positive)	14	18	194	134	122	12/09	59%	122	846	194	-	-
Hypertension Screening	-	-	4	-	2		100%	2	9	4	-	-
Hypertension Screening	-	-	4	-	2		100%	2	9	4	-	-
Implant 5	-	(8)	(12)	(7,072)	(25)		0%	(25)	4,351	(11)	(41)	(4)
Jadelle	12	16	122	-	336	12/08	(64)%	336	5,738	110	417	39
(b)PSI Implant 5 Distributed Inserted	(12)	(24)	(134)	(7,072)	(361)		-%	(361)	(1,387)	(121)	(458)	(43)
Implant 5 Insertion	12	24	134	7,072	361		(63)%	361	1,387	134	509	48
PSI Implant 5 Inserted	12	24	134	7,072	361		(63)%	361	1,387	134	509	48
Injectable 1	-	-	(6)	-	(2)		0%	(2)	(18)	-	-	-
(b)PSI Injectable 1 Distributed Provided	-	-	(6)	-	(2)		-%	(2)	(18)	-	-	-
Injectable 1 Provided	-	-	9	-	19		(53)%	19	89	1	1	-
Non-PSI Injectable 1 Provided	-	-	3	-	17		(82)%	17	71	-	-	-
PSI Injectable 1 Provided	-	-	6	-	2		200%	2	18	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
IUD 10	(13)	(26)	(153)	(255)	(761)		0%	(761)	(25,334)	(138)	(633)	(57)
(b)PSI IUD 10 Distributed Inserted	(13)	(26)	(153)	(255)	(761)		-%	(761)	(25,334)	(138)	(633)	(57)
IUD 10 Insertion	13	26	153	255	1,118		(86)%	1,118	36,569	153	704	63
Non-PSI IUD 10 Inserted	-	-	-	-	357	11/13	(100)%	357	11,235	-	-	-
PSI IUD 10 Inserted	13	26	153	255	761		(80)%	761	25,334	153	704	63
Lubricant	2	2	524,124	236,034	175,111		199%	175,111	1,951,703	-	-	-
Vive Lub (sachet)	-	-	236,000	116,513	94,900	12/06	149%	94,900	1,038,390	-	-	-
Vive Lub (tube)	1	1	36,790	-	8,084	12/06	355%	8,084	99,849	-	-	-
Vive Lub (tube) 5ml	-	-	-	2,464	-		-%	-	-	-	-	-
Vive Lub Natural (sachet)	-	-	240,550	117,057	65,700	1/10	266%	65,700	773,402	-	-	-
Vive Lub Natural (tube)	1	1	10,784	-	6,427	1/10	68%	6,427	40,062	-	-	-
Manual Vacuum Aspiration for PAC	-	-	-	-	109		(100)%	109	2,666	-	-	-
MVA for PAC	-	-	-	-	109	8/16	(100)%	109	2,666	-	-	-
OCs	9	12	82,004	-	22,861		259%	22,861	253,945	4,920	4,920	363
(b)PSI OCs Distributed Provided	-	(1)	(11)	-	(17)		-%	(17)	(37)	(1)	(1)	-
Segura Plus	9	13	82,015	-	22,878	2/12	258%	22,878	253,982	4,921	4,921	363
OCs Provided	-	1	11	-	51		(78)%	51	77	1	1	-
Non-PSI OCs Provided	-	-	-	-	34		(100)%	34	40	-	-	-
PSI OCs Provided	-	1	11	-	17		(35)%	17	37	1	1	-
Referral to HIV Testing Services	-	1	3	-	2		50%	2	472	3	-	-
Referral to HIV Testing Services	-	1	3	-	2	12/13	50%	2	472	3	-	-
Referral to Implant 5 Insertion	-	2	24	-	4		500%	4	30	24	46	4
Referral to Implant 5 Insertion	-	2	24	-	4	12/11	500%	4	30	24	46	4
Referral to Injectable 1	-	-	7	-	6		17%	6	13	7	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Referral to Injectable 1	-	-	7	-	6		17%	6	13	7	-	-
Referral to IUD 10 Insertion	-	1	18	-	4		350%	4	18,956	18	41	4
Referral to IUD 10 Insertion	-	1	18	-	4	12/11	350%	4	18,956	18	41	4
Referral to Linkage to HIV Care	10	13	141	-	41		244%	41	331	141	-	69
Referral to Linkage to HIV Care	10	13	141	-	41		244%	41	331	141	-	69
Referral to OCs	-	-	2	-	-		0%	-	2	2	-	-
Referral to OCs	-	-	2	-	-		-%	-	2	2	-	-
STI Screening	23	48	265	-	60		342%	60	2,960	265	-	-
STI Screening	23	48	265	-	60		342%	60	2,960	265	-	-
Treatment for Cervicitis	5	14	94	-	28		236%	28	137	94	-	-
Treatment for Cervicitis	5	14	94	-	28		236%	28	137	94	-	-
Treatment for Genital Herpes	-	-	1	-	-		0%	-	9	1	-	-
Treatment for Genital Herpes	-	-	1	-	-		-%	-	9	1	-	-
Treatment for Lower Abdominal Pain	-	2	7	-	-		0%	-	7	7	-	-
Treatment for Lower Abdominal Pain	-	2	7	-	-		-%	-	7	7	-	-
Treatment for Nonherpetic Genital Ulcer	-	1	2	-	-		0%	-	4	2	-	-
Treatment for Nonherpetic Genital Ulcer	-	1	2	-	-		-%	-	4	2	-	-
Treatment for Urethral Discharge (Women)	-	-	1	-	1		0%	1	9	1	-	-
Treatment for Urethral Discharge (Women)	-	-	1	-	1		-%	1	9	1	-	-
Treatment for Vaginitis	18	31	217	-	25		768%	25	245	217	-	-
Treatment for Vaginitis	18	31	217	-	25		768%	25	245	217	-	-
Type 2 Diabetes Diagnosis	-	-	1	-	1		0%	1	2	1	-	-
Type 2 Diabetes Diagnosis	-	-	1	-	1		-%	1	2	1	-	-
Type 2 Diabetes Screening	-	-	3	-	1		200%	1	6	3	-	-
Type 2 Diabetes Screening	-	-	3	-	1		200%	1	6	3	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Type 2 Diabetes_Controlled Condition	-	-	2	-	-		0%	-	2	-	-	-
Type 2 Diabetes_Controlled Condition	-	-	2	-	-		-%	-	2	-	-	-
Zika Prevention Kit	-	-	-	-	725		(100)%	725	2,621	-	-	-
Zika Prevention Kit	-	-	-	-	725	7/16	(100)%	725	2,621	-	-	-
El Salvador SA											48,719	5,987
Condom	111,512	304,349	1,252,992	-	30,048		4070%	30,048	1,283,040	9,397	9,397	2,370
Combo-Pack Lub Fresa	32	5	48	-	-		-%	-	48	-	-	-
Vive	18,336	76,480	323,280	-	-		-%	-	323,280	2,425	2,425	612
Vive Amor	51,024	153,440	595,008	-	30,048	10/17	1,880%	30,048	625,056	4,463	4,463	1,126
Vive Colors/Mas Colors	26,448	49,848	221,712	-	-		-%	-	221,712	1,663	1,663	419
Vive Mas Fuerte /Retardante	10,104	14,632	75,144	-	-		-%	-	75,144	564	564	142
Vive Mas Natural /Sensitivo	5,568	9,944	37,800	-	-		-%	-	37,800	283	283	72
Implant 3 Insertion	25	51	512	-	-		0%	-	512	512	1,280	122
Non-PSI Implant 3 Inserted	25	51	512	-	-		-%	-	512	512	1,280	122
Implant 5	33	290	3,559	574	911		291%	911	4,470	3,203	12,172	1,140
Jadelle	41	299	3,650	1,032	976	10/17	274%	976	4,626	3,285	12,483	1,169
(b)PSI Implant 5 Distributed Inserted	(8)	(10)	(91)	(458)	(65)		-%	(65)	(156)	(82)	(311)	(29)
Implant 5 Insertion	8	10	91	458	69		32%	69	160	91	346	32
Non-PSI Implant 5 Inserted	-	-	-	-	4		(100)%	4	4	-	-	-
PSI Implant 5 Inserted	8	10	91	458	65		40%	65	156	91	346	32
Injectable 1 Provided	1	2	49	-	4		1125%	4	53	4	4	-
Non-PSI Injectable 1 Provided	1	2	49	-	4		1,125%	4	53	4	4	-
IUD 10	320	181	2,328	150	2,576		(10)%	2,576	4,904	2,095	9,638	865
Copper T 380	379	307	3,985	3,660	4,021	10/17	(1)%	4,021	8,006	3,587	16,498	1,480

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
(b)PSI IUD 10 Distributed Inserted	(59)	(126)	(1,657)	(3,510)	(1,445)		-%	(1,445)	(3,102)	(1,491)	(6,860)	(615)
IUD 10 Insertion	183	284	3,326	3,510	2,956		13%	2,956	6,282	3,326	15,300	1,372
Non-PSI IUD 10 Inserted	124	158	1,669	-	1,511		10%	1,511	3,180	1,669	7,677	689
PSI IUD 10 Inserted	59	126	1,657	3,510	1,445		15%	1,445	3,102	1,657	7,622	684
Lubricant	3,516	10,734	42,312	-	12		352500%	12	42,324	-	-	-
Vive Lub (sachet)	2,950	7,417	28,600	-	-		-%	-	28,600	-	-	-
Vive Lub (tube)	481	2,752	11,488	-	-		-%	-	11,488	-	-	-
Vive Lub Natural (tube)	85	565	2,224	-	12	10/17	18,433%	12	2,236	-	-	-
Manual Vacuum Aspiration for PAC	26	26	498	1,800	965		(48)%	965	1,463	498	-	9
MVA for PAC	26	26	498	1,800	965		(48)%	965	1,463	498	-	9
Medical Abortion	-	-	-	-	(3)		0%	(3)	(3)	-	-	-
(b)PSI Medical Abortion Distributed Provided	-	-	-	-	(3)		-%	(3)	(3)	-	-	-
Medical Abortion Provided	-	-	-	-	8		(100)%	8	8	-	-	-
Non-PSI Medical Abortion Provided	-	-	-	-	5		(100)%	5	5	-	-	-
PSI Medical Abortion Provided	-	-	-	-	3		(100)%	3	3	-	-	-
Misoprostol for PAC Provided	7	2	278	360	291		(4)%	291	569	278	-	5
Non-PSI Misoprostol for PAC Provided	6	-	241	-	250		(4)%	250	491	241	-	4
PSI Misoprostol for PAC Provided	1	2	37	360	41		(10)%	41	78	37	-	1
Misoprostol for Safe Abortion	1,956	2,180	30,612	23,552	5,928		416%	5,928	36,540	1,607	-	28
Misoprostol for Safe Abortion	1,960	2,188	30,760	24,992	6,092	3/18	405%	6,092	36,852	1,615	-	28
(b)PSI Misoprostol for Safe Abortion Dist Provided	(4)	(8)	(148)	(1,440)	(164)		-%	(164)	(312)	(8)	-	-
OCs	8	2,445	9,514	-	100		9414%	100	9,614	571	571	42
Segura Plus	8	2,445	9,514	-	100	10/17	9,414%	100	9,614	571	571	42
OCs Provided	-	3	29	-	-		0%	-	29	2	2	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Non-PSI OCs Provided	-	3	29	-	-		-%	-	29	2	2	-
Tubal Ligation	-	-	1	-	1		0%	1	2	1	10	1
Tubal Ligation	-	-	1	-	1		-%	1	2	1	10	1
Guatemala											49,723	14,268
Condom	-	496	6,050,778	12,678,434	11,280,624		(46)%	11,280,624	150,841,319	45,381	45,381	13,488
Combo Pack	-	496	15,024	33,486	28,752	4/05	(48)%	28,752	462,280	113	113	33
Vive	-	-	2,082,912	4,031,144	3,743,136	4/98	(44)%	3,743,136	59,787,789	15,622	15,622	4,643
Vive Amor	-	-	3,237,840	7,075,590	6,293,856	7/04	(49)%	6,293,856	70,365,759	24,284	24,284	7,218
Vive Colors/Mas Colors	-	-	409,146	938,160	725,880	4/02	(44)%	725,880	14,714,920	3,069	3,069	912
Vive Mas Fuerte /Retardante	-	-	226,608	495,025	393,648	7/04	(42)%	393,648	3,388,784	1,700	1,700	505
Vive Mas Natural /Sensitivo	-	-	67,224	105,029	86,712	7/04	(22)%	86,712	1,150,093	504	504	150
Vive Mas/Texturizado	-	-	12,024	-	8,640	7/04	39%	8,640	971,694	90	90	27
Emergency Contraception	-	-	-	-	(1)		0%	(1)	(1)	-	-	-
(b)PSI Emergency Contraception Distributed Provided	-	-	-	-	(1)		-%	(1)	(1)	-	-	-
Emergency Contraception Provided	-	-	-	-	1		(100)%	1	1	-	-	-
PSI Emergency Contraception Provided	-	-	-	-	1		(100)%	1	1	-	-	-
HIV Testing Services	92	172	2,714	2,912	2,755		(1)%	2,755	54,612	2,714	-	7
VCT Individual (HIV-Negative)	88	166	2,622	2,749	2,647	12/09	(1)%	2,647	53,733	2,622	-	7
VCT Individual (HIV-Positive)	4	6	92	163	108	12/09	(15)%	108	879	92	-	-
Implant 5	-	-	-	-	(867)		0%	(867)	(14,210)	-	-	-
(b)PSI Implant 5 Distributed Inserted	-	-	-	-	(867)		-%	(867)	(14,210)	-	-	-
Implant 5 Insertion	-	-	-	-	2,308		(100)%	2,308	34,014	-	-	-
Non-PSI Implant 5 Inserted	-	-	-	-	1,441		(100)%	1,441	19,804	-	-	-
PSI Implant 5 Inserted	-	-	-	-	867		(100)%	867	14,210	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Injectable 1	-	-	23,566	40,420	29,950		(21)%	29,950	281,246	1,631	1,631	273
Cyclofem	-	-	23,566	40,420	30,961	5/11	(24)%	30,961	288,460	1,631	1,631	273
(b)PSI Injectable 1 Distributed Provided	-	-	-	-	(1,011)		-%	(1,011)	(7,214)	-	-	-
Injectable 1 Provided	-	-	-	-	14,790		(100)%	14,790	62,320	-	-	-
Non-PSI Injectable 1 Provided	-	-	-	-	13,779		(100)%	13,779	55,106	-	-	-
PSI Injectable 1 Provided	-	-	-	-	1,011		(100)%	1,011	7,214	-	-	-
Injectable 2 Provided	-	-	-	-	13,271		(100)%	13,271	34,974	-	-	-
Non-PSI Injectable 2 Provided	-	-	-	-	13,271		(100)%	13,271	34,974	-	-	-
Injectable 3-IM Provided	-	-	-	-	130,743		(100)%	130,743	266,096	-	-	-
Non-PSI Injectable 3 IM Provided	-	-	-	-	130,743		(100)%	130,743	266,096	-	-	-
IUD 10	-	-	-	-	(2,251)		0%	(2,251)	(88,649)	-	-	-
(b)PSI IUD 10 Distributed Inserted	-	-	-	-	(2,251)		-%	(2,251)	(88,649)	-	-	-
IUD 10 Insertion	-	-	-	-	2,939		(100)%	2,939	111,458	-	-	-
Non-PSI IUD 10 Inserted	-	-	-	-	688		(100)%	688	22,809	-	-	-
PSI IUD 10 Inserted	-	-	-	-	2,251		(100)%	2,251	88,649	-	-	-
Lubricant	-	-	107,862	-	115,766		(7)%	115,766	1,658,856	-	-	-
Vive Lub (sachet)	-	-	52,210	-	54,903	4/05	(5)%	54,903	1,051,851	-	-	-
Vive Lub (tube)	-	-	15,309	-	14,996	4/05	2%	14,996	163,075	-	-	-
Vive Lub Natural (sachet)	-	-	23,900	-	29,200	1/10	(18)%	29,200	325,677	-	-	-
Vive Lub Natural (tube)	-	-	16,443	-	16,667	1/10	(1)%	16,667	118,253	-	-	-
Manual Vacuum Aspiration for PAC	-	-	-	-	1,431		(100)%	1,431	9,176	-	-	-
MVA for PAC	-	-	-	-	1,431	5/16	(100)%	1,431	9,176	-	-	-
Misoprostol for PAC Provided	-	-	-	-	2,281		(100)%	2,281	5,883	-	-	-
Non-PSI Misoprostol for PAC Provided	-	-	-	-	1,452		(100)%	1,452	3,049	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
PSI Misoprostol for PAC Provided	-	-	-	-	829		(100)%	829	2,834	-	-	-
Misoprostol for Safe Abortion	-	-	-	-	(3,316)		0%	(3,316)	(11,336)	-	-	-
(b)PSI Misoprostol for Safe Abortion Dist Provided	-	-	-	-	(3,316)		-%	(3,316)	(11,336)	-	-	-
OCs	-	-	40,983	89,184	63,764		(36)%	63,764	230,644	2,459	2,459	400
(b)PSI OCs Distributed Provided	-	-	-	-	(699)		-%	(699)	(4,667)	-	-	-
Segura Plus	-	-	40,983	89,184	64,463	5/14	(36)%	64,463	235,311	2,459	2,459	400
OCs Provided	-	-	-	-	31,295		(100)%	31,295	85,031	-	-	-
Non-PSI OCs Provided	-	-	-	-	30,596		(100)%	30,596	80,364	-	-	-
PSI OCs Provided	-	-	-	-	699		(100)%	699	4,667	-	-	-
Referral to Implant 5 Insertion	6	3	51	-	27		89%	27	101	51	97	20
Referral to Implant 5 Insertion	6	3	51	-	27	12/11	89%	27	101	51	97	20
Referral to Injectable 1	-	-	6	-	5		20%	5	11	6	-	-
Referral to Injectable 1	-	-	6	-	5		20%	5	11	6	-	-
Referral to IUD 10 Insertion	2	7	65	-	48		35%	48	29,892	65	149	30
Referral to IUD 10 Insertion	2	7	65	-	48	12/11	35%	48	29,892	65	149	30
Referral to Linkage to HIV Care	1	6	70	-	55		27%	55	291	70	-	49
Referral to Linkage to HIV Care	1	6	70	-	55		27%	55	291	70	-	49
Referral to OCs	-	-	-	-	2		(100)%	2	2	-	-	-
Referral to OCs	-	-	-	-	2		(100)%	2	2	-	-	-
Referral to Vasectomy	-	-	1	-	-		0%	-	1	1	5	1
Referral to Vasectomy	-	-	1	-	-		-%	-	1	1	5	1
SDM (Cycle Beads) Provided	-	-	-	-	1		(100)%	1	116	-	-	-
Non-PSI SDM (Cycle Beads) Provided	-	-	-	-	1		(100)%	1	116	-	-	-
Tubal Ligation	-	-	-	-	1,807		(100)%	1,807	17,292	-	-	-
Tubal Ligation	-	-	-	-	1,807	7/12	(100)%	1,807	17,292	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Vasectomy	-	-	-	-	77		(100)%	77	660	-	-	-
Vasectomy	-	-	-	-	77	7/12	(100)%	77	660	-	-	-
Guatemala SA											309,512	66,414
Condom	1,007,560	850,429	4,643,512	-	95,328		4771%	95,328	4,738,840	34,826	34,826	10,351
Combo Pack	160	2,613	11,200	-	-		-%	-	11,200	84	84	25
Vive	278,448	317,792	1,551,024	-	50,832	7/17	2,951%	50,832	1,601,856	11,633	11,633	3,458
Vive Amor	637,872	412,032	2,480,400	-	44,496	7/17	5,474%	44,496	2,524,896	18,603	18,603	5,529
Vive Colors/Mas Colors	61,200	76,944	372,936	-	-		-%	-	372,936	2,797	2,797	831
Vive Mas Fuerte /Retardante	28,080	34,960	162,240	-	-		-%	-	162,240	1,217	1,217	362
Vive Mas Natural /Sensitivo	1,800	6,088	65,712	-	-		-%	-	65,712	493	493	146
Emergency Contraception	-	-	-	-	(4)		0%	(4)	(4)	-	-	-
(b)PSI Emergency Contraception Distributed Provided	-	-	-	-	(4)		-%	(4)	(4)	-	-	-
Emergency Contraception Provided	-	1	22	-	6		267%	6	28	1	1	-
Non-PSI Emergency Contraception Provided	-	1	22	-	2		1,000%	2	24	1	1	-
PSI Emergency Contraception Provided	-	-	-	-	4		(100)%	4	4	-	-	-
Implant 5	(40)	73	(2,619)	1,152	1,602		(263)%	1,602	(1,017)	(2,357)	(8,957)	(1,848)
Jadelle	14	189	590	3,365	3,672	7/17	(84)%	3,672	4,262	531	2,018	416
(b)PSI Implant 5 Distributed Inserted	(54)	(116)	(3,209)	(2,213)	(2,070)		-%	(2,070)	(5,279)	(2,888)	(10,975)	(2,265)
Implant 5 Insertion	57	1,324	17,001	2,213	15,706		8%	15,706	32,707	17,001	64,604	13,331
Non-PSI Implant 5 Inserted	3	1,208	13,792	-	13,636		1%	13,636	27,428	13,792	52,410	10,815
PSI Implant 5 Inserted	54	116	3,209	2,213	2,070		55%	2,070	5,279	3,209	12,194	2,516
Injectable 1	1,607	3,201	19,027	-	417		4463%	417	19,444	1,317	1,317	220
Cyclofem	1,638	3,287	21,521	-	2,127	7/17	912%	2,127	23,648	1,490	1,490	249
(b)PSI Injectable 1 Distributed Provided	(31)	(86)	(2,494)	-	(1,710)		-%	(1,710)	(4,204)	(173)	(173)	(29)

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Injectable 1 Provided	42	5,702	58,151	-	50,852		14%	50,852	109,003	4,473	4,473	748
Non-PSI Injectable 1 Provided	11	5,616	55,657	-	49,142		13%	49,142	104,799	4,281	4,281	716
PSI Injectable 1 Provided	31	86	2,494	-	1,710		46%	1,710	4,204	192	192	32
Injectable 2 Provided	3	3,115	34,874	-	34,427		1%	34,427	69,301	5,812	5,812	897
Non-PSI Injectable 2 Provided	3	3,115	34,874	-	34,427		1%	34,427	69,301	5,812	5,812	897
Injectable 3-IM	-	-	(41)	-	-		0%	-	(41)	(9)	(9)	(1)
(b)PSI Injectable 3 IM Distributed Provided	-	-	(41)	-	-		-%	-	(41)	(9)	(9)	(1)
Injectable 3-IM Provided	80	20,236	206,567	-	224,719		(8)%	224,719	431,286	51,642	51,642	7,969
Non-PSI Injectable 3 IM Provided	80	20,236	206,526	-	224,719		(8)%	224,719	431,245	51,632	51,632	7,968
PSI Injectable 3 IM Provided	-	-	41	-	-		-%	-	41	10	10	2
IUD 10	(20)	(402)	(2,429)	(778)	4,388		(155)%	4,388	1,959	(2,186)	(10,056)	(1,984)
Copper T 380	72	196	4,020	7,000	11,187	7/17	(64)%	11,187	15,207	3,618	16,643	3,284
Copper T 380 Postpartum	-	4	2,066	-	1,084	7/17	91%	1,084	3,150	1,859	8,553	1,688
(b)PSI IUD 10 Distributed Inserted	(92)	(603)	(8,515)	(7,778)	(7,883)		-%	(7,883)	(16,398)	(7,664)	(35,252)	(6,957)
IUD 10 Insertion	144	1,972	16,269	9,133	11,810		38%	11,810	28,079	16,269	74,837	14,768
Non-PSI IUD 10 Inserted	52	1,369	7,754	1,355	3,927		97%	3,927	11,681	7,754	35,668	7,039
PSI IUD 10 Inserted	92	603	8,515	7,778	7,883		8%	7,883	16,398	8,515	39,169	7,730
IUD 5	409	2	415	-	1,002		(59)%	1,002	1,417	374	1,233	259
IUD Slek	409	2	415	-	1,002	7/17	(59)%	1,002	1,417	374	1,233	259
Lubricant	5,630	14,891	81,754	-	136		60013%	136	81,890	-	-	-
Vive Lub (sachet)	2,450	7,833	53,100	-	-		-%	-	53,100	-	-	-
Vive Lub (tube)	1,503	3,798	15,708	-	74	7/17	21,127%	74	15,782	-	-	-
Vive Lub Natural (tube)	1,677	3,260	12,946	-	62	7/17	20,781%	62	13,008	-	-	-
Manual Vacuum Aspiration for PAC	-	396	7,878	4,675	4,901		61%	4,901	12,779	7,878	-	212

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
MVA for PAC	-	396	7,878	4,675	4,901		61%	4,901	12,779	7,878	-	212
Misoprostol for PAC Provided	-	296	5,536	3,275	4,088		35%	4,088	9,624	5,536	-	183
Non-PSI Misoprostol for PAC Provided	-	77	1,061	-	2,240		(53)%	2,240	3,301	1,061	-	35
PSI Misoprostol for PAC Provided	-	219	4,475	3,275	1,848		142%	1,848	6,323	4,475	-	148
Misoprostol for Safe Abortion	10,320	(131)	58,998	59,100	56,728		4%	56,728	115,726	3,097	-	90
Misoprostol for Safe Abortion	10,320	747	76,898	72,200	64,120	3/18	20%	64,120	141,018	4,037	-	117
(b)PSI Misoprostol for Safe Abortion Dist Provided	-	(877)	(17,900)	(13,100)	(7,392)		-%	(7,392)	(25,292)	(940)	-	(27)
OCs	(172,774)	66,510	36,460	-	(1,020)		0%	(1,020)	35,440	2,188	2,188	356
(b)PSI OCs Distributed Provided	(25)	(85)	(1,403)	-	(2,320)		-%	(2,320)	(3,723)	(84)	(84)	(14)
Segura Plus	(172,749)	66,594	37,863	-	1,300	7/17	2,813%	1,300	39,163	2,272	2,272	370
OCs Provided	29	2,874	27,226	-	40,905		(33)%	40,905	68,131	1,815	1,815	295
Non-PSI OCs Provided	4	2,790	25,823	-	38,585		(33)%	38,585	64,408	1,722	1,722	280
PSI OCs Provided	25	85	1,403	-	2,320		(40)%	2,320	3,723	94	94	15
SDM (Cycle Beads) Provided	-	-	4	-	6		(33)%	6	10	4	6	1
Non-PSI SDM (Cycle Beads) Provided	-	-	4	-	6		(33)%	6	10	4	6	1
Tubal Ligation	-	967	8,288	-	9,992		(17)%	9,992	18,280	8,288	82,880	19,863
Tubal Ligation	-	967	8,288	-	9,992		(17)%	9,992	18,280	8,288	82,880	19,863
Vasectomy	-	25	290	-	241		20%	241	531	290	2,900	704
Vasectomy	-	25	290	-	241		20%	241	531	290	2,900	704
Honduras											20,127	9,298
Condom	-	-	1,895,352	4,436,599	4,116,704		(54)%	4,116,704	52,240,120	14,215	14,215	8,450
Combo-Pack Lub Fresa	-	-	4,096	5,355	6,880	2/16	(40)%	6,880	20,144	31	31	18
Combo-Pack Lub Natural	-	-	(736)	-	688	10/10	(207)%	688	26,912	(6)	(6)	(3)
Vive	-	-	394,464	1,082,225	1,088,832	9/00	(64)%	1,088,832	15,815,395	2,958	2,958	1,759

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Vive Amor	-	-	1,075,104	2,593,241	2,348,928	8/04	(54)%	2,348,928	25,213,976	8,063	8,063	4,793
Vive Colors/Mas Colors	-	-	308,880	560,470	455,400	4/02	(32)%	455,400	8,922,718	2,317	2,317	1,377
Vive Mas Fuerte /Retardante	-	-	89,136	154,949	145,680	8/04	(39)%	145,680	1,210,392	669	669	397
Vive Mas Natural /Sensitivo	-	-	23,688	40,359	45,096	8/04	(47)%	45,096	513,506	178	178	106
Vive Mas/Texturizado	-	-	720	-	25,200	8/04	(97)%	25,200	517,077	5	5	3
HIV Testing Services	144	318	3,470	2,407	3,254		7%	3,254	18,587	3,470	-	8
VCT Individual (HIV-Negative)	139	304	3,280	2,271	3,156	4/12	4%	3,156	18,123	3,280	-	7
VCT Individual (HIV-Positive)	5	13	190	136	98	4/14	94%	98	464	190	-	-
Implant 3 Insertion	5	5	57	-	22		159%	22	118	57	143	19
Non-PSI Implant 3 Inserted	5	5	57	-	22		159%	22	118	57	143	19
Injectable 1	-	-	-	3,268	-		0%	-	-	-	-	-
Cyclofem	-	-	-	3,268	-		-%	-	-	-	-	-
Injectable 1 Provided	-	1	12	-	9		33%	9	70	1	1	-
Non-PSI Injectable 1 Provided	-	1	12	-	9		33%	9	70	1	1	-
Injectable 3-IM Provided	3	2	28	-	21		33%	21	106	7	7	1
Non-PSI Injectable 3 IM Provided	3	2	28	-	21		33%	21	106	7	7	1
IUD 10	-	-	(91)	-	(570)		0%	(570)	(664)	(82)	(377)	(48)
(b)PSI IUD 10 Distributed Inserted	-	-	(91)	-	(570)		-%	(570)	(664)	(82)	(377)	(48)
IUD 10 Insertion	7	12	263	-	977		(73)%	977	1,271	263	1,210	153
Non-PSI IUD 10 Inserted	7	12	172	-	407		(58)%	407	607	172	791	100
PSI IUD 10 Inserted	-	-	91	-	570		(84)%	570	664	91	419	53
Lubricant	-	-	53,401	111,654	113,476		(53)%	113,476	960,148	-	-	-
Vive Lub (sachet)	-	-	22,600	64,092	49,802	3/05	(55)%	49,802	602,279	-	-	-
Vive Lub (tube)	-	-	11,675	-	14,051	3/05	(17)%	14,051	106,475	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Vive Lub (tube) 5ml	-	-	-	2,777	-		-%	-	-	-	-	-
Vive Lub Natural (sachet)	-	-	12,676	44,785	37,832	1/10	(66)%	37,832	187,224	-	-	-
Vive Lub Natural (tube)	-	-	6,450	-	11,791	1/10	(45)%	11,791	64,170	-	-	-
OCs Provided	-	-	-	-	2		(100)%	2	15	-	-	-
Non-PSI OCs Provided	-	-	-	-	2		(100)%	2	15	-	-	-
Referral to Implant 3 Insertion	119	216	2,064	-	1,455		42%	1,455	3,519	2,064	2,580	349
Referral to Implant 3 Insertion	119	216	2,064	-	1,455		42%	1,455	3,519	2,064	2,580	349
Referral to Injectable 3	-	-	2	-	-		0%	-	2	2	-	-
Referral to Injectable 3	-	-	2	-	-		-%	-	2	2	-	-
Referral to IUD 10 Insertion	37	133	1,021	-	-		0%	-	1,021	1,021	2,348	297
Referral to IUD 10 Insertion	37	133	1,021	-	-		-%	-	1,021	1,021	2,348	297
Referral to Linkage to HIV Care	2	11	110	-	75		47%	75	281	110	-	69
Referral to Linkage to HIV Care	2	11	110	-	75		47%	75	281	110	-	69
Honduras SA											13,682	8,133
Condom	63,936	310,733	1,824,320	-	-		0%	-	1,824,320	13,682	13,682	8,133
Combo-Pack Lub Fresa	96	757	3,200	-	-		-%	-	3,200	24	24	14
Vive	13,632	86,048	469,632	-	-		-%	-	469,632	3,522	3,522	2,094
Vive Amor	34,800	169,200	1,018,464	-	-		-%	-	1,018,464	7,638	7,638	4,541
Vive Colors/Mas Colors	13,800	40,712	240,792	-	-		-%	-	240,792	1,806	1,806	1,074
Vive Mas Fuerte /Retardante	552	12,824	78,144	-	-		-%	-	78,144	586	586	348
Vive Mas Natural /Sensitivo	1,056	1,192	14,088	-	-		-%	-	14,088	106	106	63
Lubricant	787	11,377	44,462	-	-		0%	-	44,462	-	-	-
Vive Lub (sachet)	-	7,117	23,000	-	-		-%	-	23,000	-	-	-
Vive Lub (tube)	467	2,385	13,594	-	-		-%	-	13,594	-	-	-

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Vive Lub Natural (sachet)	-	867	2,650	-	-		-%	-	2,650	-	-	-
Vive Lub Natural (tube)	320	1,009	5,218	-	-		-%	-	5,218	-	-	-
Kazakhstan											703	1,068
Free Condom	6,285	22,331	93,799	23,000	46,385		102%	46,385	767,349	703	703	102
Generic Male Condom	6,285	22,331	93,799	23,000	46,385	8/16	102%	46,385	767,349	703	703	102
Free Female Condom	-	-	-	-	8,200		(100)%	8,200	32,770	-	-	-
Generic Female Condom	-	-	-	-	8,200	8/16	(100)%	8,200	32,770	-	-	-
HIV Self-Testing Kit	-	38	113	200	-		0%	-	113	102	-	-
HIV Self-Testing Kit (Oral Fluid)	-	-	-	200	-		-%	-	-	-	-	-
INSTI HIVST (Blood based)	-	38	113	-	-		-%	-	113	102	-	-
HIV Testing Services	102	130	1,774	2,298	2,373		(25)%	2,373	7,677	1,774	-	3
VCT Individual (HIV-Negative)	81	105	1,555	2,210	2,219		(30)%	2,219	7,247	1,555	-	3
VCT Individual (HIV-Positive)	21	25	219	88	154		42%	154	430	219	-	-
Referral to HIV Testing Services	-	-	11	-	4		175%	4	5,163	11	-	-
Referral to HIV Testing Services	-	-	11	-	4	12/13	175%	4	5,163	11	-	-
Referral to Linkage to HIV Care	93	101	1,065	590	997		7%	997	2,781	1,065	-	963
Referral to Linkage to HIV Care	93	101	1,065	590	997		7%	997	2,781	1,065	-	963
Referral to Opioid Treatment	6	3	33	-	26		27%	26	126	33	-	-
Referral to Opioid Treatment	6	3	33	-	26		27%	26	126	33	-	-
Referral to TB Screening	-	-	-	-	7		(100)%	7	17	-	-	-
Referrals to TB Screening	-	-	-	-	7		(100)%	7	17	-	-	-
TB Diagnosis	1	3	26	5	11		136%	11	70	26	-	-
TB Diagnosis	1	3	26	5	11		136%	11	70	26	-	-
TB Screening	274	214	2,149	1,086	2,591		(17)%	2,591	7,778	2,149	-	-
TB Screening	274	214	2,149	1,086	2,591		(17)%	2,591	7,778	2,149	-	-

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Kyrgyzstan											273	729
Free Condom	4	4,669	36,412	70,000	30,144		21%	30,144	66,556	273	273	65
Generic Male Condom	4	4,669	36,412	70,000	30,144	11/17	21%	30,144	66,556	273	273	65
Free Female Condom	-	-	-	-	13,000		(100)%	13,000	13,000	-	-	-
Generic Female Condom	-	-	-	-	13,000	11/17	(100)%	13,000	13,000	-	-	-
HIV Self-Testing Kit	1	268	804	5,000	-		0%	-	804	724	-	-
HIV Self-Testing Kit (Oral Fluid)	-	-	-	5,000	-		-%	-	-	-	-	-
ORAQUICK HIV Self-Testing Kit (Saliva based)	1	268	804	-	-		-%	-	804	724	-	-
HIV Testing Services	305	481	12,569	16,165	25,008		(50)%	25,008	51,045	12,569	-	23
VCT Individual (HIV-Negative)	272	444	12,148	15,831	24,608		(51)%	24,608	49,988	12,148	-	22
VCT Individual (HIV-Positive)	33	37	421	334	400		5%	400	1,057	421	-	1
Lubricant	4	2,003	6,012	-	-		0%	-	7,012	-	-	-
Personal lubricants water based 4.5 g	4	2,003	6,012	-	-	7/13	-%	-	7,012	-	-	-
Referral to Linkage to HIV Care	56	68	610	287	456		34%	456	2,128	610	-	640
Referral to Linkage to HIV Care	56	68	610	287	456		34%	456	2,128	610	-	640
Referral to Opioid Treatment	-	-	3	-	44		(93)%	44	193	3	-	-
Referral to Opioid Treatment	-	-	3	-	44		(93)%	44	193	3	-	-
Referral to TB Screening	-	-	-	-	13		(100)%	13	25	-	-	-
Referrals to TB Screening	-	-	-	-	13		(100)%	13	25	-	-	-
TB Diagnosis	-	1	8	10	8		0%	8	46	8	-	-
TB Diagnosis	-	1	8	10	8		-%	8	46	8	-	-
TB Screening	82	285	1,701	1,000	1,418		20%	1,418	8,292	1,701	-	-
TB Screening	82	285	1,701	1,000	1,418		20%	1,418	8,292	1,701	-	-
Laos											84,321	22,541
Condom	-	322,344	3,458,376	3,500,000	3,760,689		(8)%	3,760,689	34,679,847	25,938	25,938	7,391

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
No 1 Condom Grp	-	-	330,624	328,032	628,416	11/10	(47)%	628,416	5,239,492	2,480	2,480	707
No 1 Condom Orange	-	-	-	372,032	-		-%	-	-	-	-	-
No 1 Condom Strw	-	156,240	1,341,792	1,277,856	1,901,232	8/08	(29)%	1,901,232	17,408,904	10,063	10,063	2,867
No 1 Condom Super Thin	-	-	-	148,608	-		-%	-	-	-	-	-
No.1 Orange	-	54,864	256,176	-	-		-%	-	256,176	1,921	1,921	547
No.1 Super Thin	-	18,360	146,664	-	-		-%	-	146,664	1,100	1,100	313
Number One Rose	-	92,880	1,383,120	1,373,472	1,231,041	4/08	12%	1,231,041	11,628,611	10,373	10,373	2,956
Fever Cases Attended	6,446	7,139	73,124	60,000	43,091		70%	43,091	127,276	73,124	-	-
Fever Cases Attended	6,446	7,139	73,124	60,000	43,091		70%	43,091	127,276	73,124	-	-
Fever Cases Tested with Microscopy	-	2,246	6,737	-	-		0%	-	6,737	6,737	-	-
Fever Cases Tested with Microscopy	-	2,246	6,737	-	-		-%	-	6,737	6,737	-	-
Fever Cases Tested with RDTs	6,446	7,139	73,124	60,000	43,075		70%	43,075	127,246	73,124	-	-
Fever Cases Tested with RDTs	6,446	7,139	73,124	60,000	43,075		70%	43,075	127,246	73,124	-	-
HIV Testing Services	461	529	5,953	5,641	5,345		11%	5,345	25,350	5,953	-	4
VCT Individual (HIV-Negative)	458	527	5,922	5,621	5,309	2/10	12%	5,309	25,146	5,922	-	4
VCT Individual (HIV-Positive)	3	2	31	20	36	4/10	(14)%	36	204	31	-	-
Implant 3 Insertion	531	606	9,352	11,031	11,434		(18)%	11,434	33,649	9,352	23,380	5,870
Non-PSI Implant 3 Inserted	531	606	9,352	11,031	11,434	3/16	(18)%	11,434	33,649	9,352	23,380	5,870
Injectable 3-IM	-	-	-	-	(1,586)		0%	(1,586)	(1,586)	-	-	-
(b)PSI Injectable 3 IM Distributed Provided	-	-	-	-	(1,586)		-%	(1,586)	(1,586)	-	-	-
Injectable 3-IM Provided	907	1,217	17,268	17,304	19,748		(13)%	19,748	54,725	4,317	4,317	801
Non-PSI Injectable 3 IM Provided	907	1,217	17,268	17,304	18,162	3/16	(5)%	18,162	53,139	4,317	4,317	801
PSI Injectable 3 IM Provided	-	-	-	-	1,586		(100)%	1,586	1,586	-	-	-
IUD 10	(28)	(40)	(614)	-	(260)		0%	(260)	(874)	(553)	(2,542)	(594)

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
(b)PSI IUD 10 Distributed Inserted	(28)	(40)	(614)	-	(260)		-%	(260)	(874)	(553)	(2,542)	(594)
IUD 10 Insertion	308	368	6,645	10,176	11,005		(40)%	11,005	52,334	6,645	30,567	7,146
Non-PSI IUD 10 Inserted	280	328	6,031	10,176	10,745		(44)%	10,745	51,460	6,031	27,743	6,486
PSI IUD 10 Inserted	28	40	614	-	260		136%	260	874	614	2,824	660
IUD 5	-	-	250	-	800		(69)%	800	2,860	225	742	186
IUD Cu375	-	-	250	-	800	7/12	(69)%	800	2,860	225	742	186
Manual Vacuum Aspiration for PAC	-	-	-	220	-		0%	-	-	-	-	-
Manual Vacuum Aspiration for PAC	-	-	-	220	-		-%	-	-	-	-	-
Manual Vacuum Aspiration for SA	-	-	-	-	81		(100)%	81	81	-	-	-
Manual Vacuum Aspiration for SA	-	-	-	-	81		(100)%	81	81	-	-	-
Misoprostol for PAC Provided	-	-	-	-	70		(100)%	70	70	-	-	-
Non-PSI Misoprostol for PAC Provided	-	-	-	-	52		(100)%	52	52	-	-	-
PSI Misoprostol for PAC Provided	-	-	-	-	18		(100)%	18	18	-	-	-
Misoprostol for Safe Abortion	-	34,033	243,100	172,876	202,928		20%	202,928	839,498	12,763	-	1,159
Misoprostol for Safe Abortion	-	34,033	243,100	172,876	203,000	3/18	20%	203,000	839,570	12,763	-	1,159
(b)PSI Misoprostol for Safe Abortion Dist Provided	-	-	-	-	(72)		-%	(72)	(72)	-	-	-
OCs	-	-	-	-	(2,241)		0%	(2,241)	(2,241)	-	-	-
(b)PSI OCs Distributed Provided	-	-	-	-	(2,241)		-%	(2,241)	(2,241)	-	-	-
OCs Provided	1,510	2,129	28,778	24,784	29,665		(3)%	29,665	82,490	1,919	1,919	376
Non-PSI OCs Provided	1,510	2,129	28,778	24,784	27,424	3/16	5%	27,424	80,249	1,919	1,919	376
PSI OCs Provided	-	-	-	-	2,241		(100)%	2,241	2,241	-	-	-
Positive RDTs	38	34	723	1,500	1,324		(45)%	1,324	2,610	723	-	-
Positive RDTs	38	34	723	1,500	1,324		(45)%	1,324	2,610	723	-	-
Positive RDTs Given First Line Treatment	38	34	723	825	1,324		(45)%	1,324	2,610	723	-	-
Positive RDTs Given First Line Treatment	38	34	723	825	1,324		(45)%	1,324	2,610	723	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
QAACTs Provided after Confirmatory Diagnosis	38	34	723	825	1,324		(45)%	1,324	2,610	723	-	137
Non-PSI QAACTs Provided after Confirmed Diagnosis	38	34	723	825	1,324		(45)%	1,324	2,610	723	-	137
Referral to TB DOTS (completion confirmed)	-	9	81	110	148		(45)%	148	472	81	-	28
Referral to TB DOTS (completion confirmed)	-	9	81	110	148	3/16	(45)%	148	472	81	-	28
Referral to TB DOTS (completion unknown)	-	-	4	-	43		(91)%	43	248	4	-	1
Referral to TB DOTS (completion unknown)	-	-	4	-	43	12/13	(91)%	43	248	4	-	1
TB Diagnosis	-	22	228	370	185		23%	185	1,017	228	-	-
TB Diagnosis	-	22	228	370	185		23%	185	1,017	228	-	-
TB Screening	-	68	918	-	755		22%	755	3,935	918	-	-
TB Screening	-	68	918	-	755		22%	755	3,935	918	-	-
Vivax Treatment after Confirmatory Diagnosis	38	34	201	-	-		0%	-	201	201	-	38
Non-PSI Vivax Treatment after Confirmed Diagnosis	38	34	201	-	-		-%	-	201	201	-	38
Nepal											93,104	30,254
Emergency Contraception	5,400	-	5,400	-	221		2343%	221	5,621	243	243	26
i-pill	5,400	-	5,400	-	221	7/17	2,343%	221	5,621	243	243	26
Free Condom	-	-	-	-	2,148		(100)%	2,148	574,282	-	-	-
Generic Condom	-	-	-	-	2,148	1/16	(100)%	2,148	574,282	-	-	-
Implant 5	2,300	(29)	2,512	-	(34)		0%	(34)	21,849	2,261	8,591	1,601
Jadelle	2,300	-	2,600	-	-	8/09	-%	-	23,314	2,340	8,892	1,657
(b)PSI Implant 5 Distributed Inserted	-	(29)	(88)	-	(34)		-%	(34)	(1,465)	(79)	(301)	(56)
Implant 5 Insertion	57	82	774	428	75		932%	75	2,459	774	2,941	548
Non-PSI Implant 5 Inserted	57	53	686	428	41		1,573%	41	994	686	2,607	486
PSI Implant 5 Inserted	-	29	88	-	34		159%	34	1,465	88	334	62
Injectable 3-IM	3,000	-	3,000	-	-		0%	-	65,000	675	675	96
Depo-Provera	3,000	-	3,000	-	-	6/16	-%	-	65,000	675	675	96

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
IUD 10	2,503	(20)	(336)	3,959	(9,464)		0%	(9,464)	(180,491)	(302)	(1,391)	(245)
OK IUD	550	1,904	14,250	21,141	23,060	5/04	(38)%	23,060	55,560	12,825	58,995	10,391
Pregna T Cu 380A	-	-	555	-	20	7/17	2,675%	20	595	500	2,298	405
(b)PSI IUD 10 Distributed Inserted	(547)	(1,924)	(17,641)	(17,182)	(32,544)		-%	(32,544)	(239,146)	(15,877)	(73,034)	(12,863)
T - CARE IUCD Tcu 380A	2,500	-	2,500	-	-		-%	-	2,500	2,250	10,350	1,823
IUD 10 Insertion	547	1,926	17,734	17,182	33,521		(47)%	33,521	250,659	17,734	81,576	14,368
Non-PSI IUD 10 Inserted	-	2	93	-	977		(90)%	977	11,512	93	428	75
PSI IUD 10 Inserted	547	1,924	17,641	17,182	32,544		(46)%	32,544	239,146	17,641	81,149	14,292
Manual Vacuum Aspiration for PAC	-	3	51	-	12		325%	12	63	51	-	4
Manual Vacuum Aspiration for PAC	-	3	51	-	12		325%	12	63	51	-	4
Manual Vacuum Aspiration for SA	21	56	696	236	170		309%	170	866	696	-	103
Manual Vacuum Aspiration for SA	21	56	696	236	170		309%	170	866	696	-	103
Medical Abortion	16,119	10,793	107,089	99,716	122,575		(13)%	122,575	472,132	96,380	-	13,334
Medabon	16,420	11,085	109,475	104,504	123,798	12/08	(12)%	123,798	475,741	98,528	-	13,631
(b)PSI Medical Abortion Distributed Provided	(301)	(292)	(2,386)	(4,788)	(1,223)		-%	(1,223)	(3,609)	(2,147)	-	(297)
Medical Abortion Provided	305	303	2,518	4,788	1,263		99%	1,263	3,781	2,518	-	348
Non-PSI Medical Abortion Provided	4	12	132	-	40		230%	40	172	132	-	18
PSI Medical Abortion Provided	301	292	2,386	4,788	1,223		95%	1,223	3,609	2,386	-	330
Misoprostol for PAC Provided	-	-	8	-	-		0%	-	8	8	-	1
Non-PSI Misoprostol for PAC Provided	-	-	8	-	-		-%	-	8	8	-	1
OCs	7,800	-	7,800	-	15,134		(48)%	15,134	166,106	468	468	70
Zinnia	-	-	-	-	554	8/15	(100)%	554	143,726	-	-	-
Zinnia - F	7,800	-	7,800	-	14,580	7/17	(47)%	14,580	22,380	468	468	70
STI Screening	-	-	-	-	39		(100)%	39	1,198	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
STI Screening	-	-	-	-	39		(100)%	39	1,198	-	-	-
Nicaragua											81,121	17,728
Condom	366,456	386,161	4,552,683	-	3,880,941		17%	3,880,941	79,349,912	34,145	34,145	9,884
Bodyguard	-	-	-	-	(1,613)	2/04	-%	(1,613)	11,095,477	-	-	-
Combo-Pack Lub Fresa	432	432	3,456	-	14,866	5/11	(77)%	14,866	72,874	26	26	8
Combo-Pack Lub Natural	-	-	-	-	(3,374)	10/10	-%	(3,374)	23,618	-	-	-
Vive	186,000	291,632	3,159,504	-	2,580,363	4/98	22%	2,580,363	51,270,347	23,696	23,696	6,860
Vive Colors/Mas Colors	157,344	46,953	920,403	-	864,750	4/02	6%	864,750	12,524,909	6,903	6,903	1,998
Vive Mas Fuerte /Retardante	16,200	36,528	368,877	-	325,560	6/04	13%	325,560	2,523,491	2,767	2,767	801
Vive Mas Natural /Sensitivo	6,480	10,616	100,539	-	88,989	6/04	13%	88,989	1,089,299	754	754	218
Vive Mas/Texturizado	-	-	(96)	-	11,400	6/04	(101)%	11,400	749,897	(1)	(1)	-
HIV Testing Services	30	62	864	614	687		26%	687	8,582	864	-	1
VCT Individual (HIV-Negative)	28	57	803	578	648	12/09	24%	648	8,390	803	-	1
VCT Individual (HIV-Positive)	2	5	61	36	39	12/09	56%	39	192	61	-	-
Implant 3	109	206	2,188	-	789		177%	789	3,538	1,969	4,923	825
Implanon	203	332	3,364	-	1,506	7/15	123%	1,506	6,379	3,028	7,569	1,269
(b)PSI Implant 3 Distributed Inserted	(94)	(127)	(1,176)	-	(717)	3/16	-%	(717)	(2,841)	(1,058)	(2,646)	(444)
Implant 3 Insertion	164	167	1,610	-	974		65%	974	3,553	1,610	4,025	675
Non-PSI Implant 3 Inserted	70	40	434	-	257		69%	257	712	434	1,085	182
PSI Implant 3 Inserted	94	127	1,176	-	717	3/16	64%	717	2,841	1,176	2,940	493
Implant 5	-	-	(8)	-	474		(102)%	474	2,365	(7)	(27)	(5)
Jadelle	-	-	-	-	1,195	12/08	(100)%	1,195	6,080	-	-	-
(b)PSI Implant 5 Distributed Inserted	-	-	(8)	-	(721)		-%	(721)	(3,715)	(7)	(27)	(5)
Implant 5 Insertion	-	-	8	-	721		(99)%	721	3,715	8	30	5

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
PSI Implant 5 Inserted	-	-	8	-	721		(99)%	721	3,715	8	30	5
Injectable 1 Provided	42	75	636	-	312		104%	312	1,236	49	49	7
Non-PSI Injectable 1 Provided	42	75	636	-	312		104%	312	1,236	49	49	7
Injectable 3-IM Provided	8	35	208	-	62		235%	62	319	52	52	6
Non-PSI Injectable 3 IM Provided	8	35	208	-	62		235%	62	319	52	52	6
IUD 10	(78)	657	3,728	-	2,979		25%	2,979	43,938	3,355	15,434	2,432
Copper T 380	12	787	5,540	-	5,325	12/08	4%	5,325	90,415	4,986	22,936	3,614
Copper-T 380-A IUD	-	53	251	-	84	3/16	199%	84	397	226	1,039	164
(b)PSI IUD 10 Distributed Inserted	(90)	(184)	(2,063)	-	(2,430)		-%	(2,430)	(46,874)	(1,857)	(8,541)	(1,346)
IUD 10 Insertion	90	184	2,063	-	2,430		(15)%	2,430	46,874	2,063	9,490	1,495
PSI IUD 10 Inserted	90	184	2,063	-	2,430		(15)%	2,430	46,874	2,063	9,490	1,495
IUD 5	(5)	994	3,252	-	659		393%	659	4,239	2,927	9,658	1,620
Copper T375 Sleek	1	1,011	3,380	-	732	3/16	362%	732	4,452	3,042	10,039	1,683
(b)PSI IUD 5 Distributed Inserted	(6)	(18)	(128)	-	(73)		-%	(73)	(213)	(115)	(380)	(64)
IUD 5 Insertion	6	18	128	-	73		75%	73	213	128	422	71
PSI IUD 5 Inserted	6	18	128	-	73		75%	73	213	128	422	71
IUS 5 Insertion	3	1	10	-	2		400%	2	13	10	33	6
Non-PSI IUS 5 Inserted	3	1	10	-	2		400%	2	13	10	33	6
Lubricant	13,122	13,379	177,084	-	175,397		1%	175,397	1,208,352	-	-	-
Vive Lub (sachet)	10,800	6,050	77,662	-	74,450	3/05	4%	74,450	544,055	-	-	-
Vive Lub (tube)	1,755	1,900	23,550	-	18,659	3/05	26%	18,659	150,534	-	-	-
Vive Lub Natural (sachet)	-	3,600	55,855	-	63,538	1/10	(12)%	63,538	408,038	-	-	-
Vive Lub Natural (tube)	567	1,829	20,017	-	18,750	1/10	7%	18,750	105,725	-	-	-
Manual Vacuum Aspiration for PAC	27	45	675	-	496		36%	496	2,083	675	-	26

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
MVA for PAC	27	45	675	-	496	5/16	36%	496	2,083	675	-	26
Misoprostol for PAC Provided	7	29	250	-	82		205%	82	380	250	-	12
PSI Misoprostol for PAC Provided	7	29	250	-	82		205%	82	380	250	-	12
Misoprostol for Safe Abortion	(28)	1,250	37,144	-	37,641		(1)%	37,641	82,709	1,950	-	78
Misoprostol for Safe Abortion	-	1,366	38,144	-	37,969	3/18	-%	37,969	84,229	2,003	-	80
(b)PSI Misoprostol for Safe Abortion Dist Provided	(28)	(116)	(1,000)	-	(328)		-%	(328)	(1,520)	(52)	-	(2)
OCs	12	-	12	-	-		0%	-	104,994	1	1	-
Segura Plus	12	-	12	-	-	7/15	-%	-	104,994	1	1	-
OCs Provided	43	50	542	-	300		81%	300	1,014	36	36	5
Non-PSI OCs Provided	43	50	542	-	300		81%	300	1,014	36	36	5
Referral to Linkage to HIV Care	2	4	56	-	2		2700%	2	95	56	-	39
Referral to Linkage to HIV Care	2	4	56	-	2		2,700%	2	95	56	-	39
Tubal Ligation	3	29	285	-	113		152%	113	421	285	2,850	547
Tubal Ligation	3	29	285	-	113		152%	113	421	285	2,850	547
Nicaragua SA												
Condom	-	-	-	4,306,525	-		0%	-	-	-	-	-
Combo-Pack Lub Fresa	-	-	-	15,530	-		-%	-	-	-	-	-
Vive	-	-	-	2,948,290	-		-%	-	-	-	-	-
Vive Colors/Mas Colors	-	-	-	872,758	-		-%	-	-	-	-	-
Vive Mas Fuerte /Retardante	-	-	-	378,032	-		-%	-	-	-	-	-
Vive Mas Natural /Sensitivo	-	-	-	91,915	-		-%	-	-	-	-	-
Implant 3	-	-	-	4,860	-		0%	-	-	-	-	-
Implanon	-	-	-	5,784	-		-%	-	-	-	-	-
(b)PSI Implant 3 Distributed Inserted	-	-	-	(924)	-		-%	-	-	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Implant 3 Insertion	-	-	-	924	-		0%	-	-	-	-	-
PSI Implant 3 Inserted	-	-	-	924	-		-%	-	-	-	-	-
Injectable 1	-	-	-	13,832	-		0%	-	-	-	-	-
Cyclofem	-	-	-	13,832	-		-%	-	-	-	-	-
IUD 10	-	-	-	3,612	-		0%	-	-	-	-	-
Copper T 380	-	-	-	6,000	-		-%	-	-	-	-	-
(b)PSI IUD 10 Distributed Inserted	-	-	-	(2,388)	-		-%	-	-	-	-	-
IUD 10 Insertion	-	-	-	2,388	-		0%	-	-	-	-	-
PSI IUD 10 Inserted	-	-	-	2,388	-		-%	-	-	-	-	-
Lubricant	-	-	-	121,046	-		0%	-	-	-	-	-
Vive Lub (sachet)	-	-	-	64,210	-		-%	-	-	-	-	-
Vive Lub Natural (sachet)	-	-	-	56,836	-		-%	-	-	-	-	-
Manual Vacuum Aspiration for PAC	-	-	-	600	-		0%	-	-	-	-	-
MVA for PAC	-	-	-	600	-		-%	-	-	-	-	-
Misoprostol for PAC Provided	-	-	-	300	-		0%	-	-	-	-	-
PSI Misoprostol for PAC Provided	-	-	-	300	-		-%	-	-	-	-	-
Misoprostol for Safe Abortion	-	-	-	64,920	-		0%	-	-	-	-	-
Misoprostol for Safe Abortion	-	-	-	66,120	-		-%	-	-	-	-	-
(b)PSI Misoprostol for Safe Abortion Dist Provided	-	-	-	(1,200)	-		-%	-	-	-	-	-
OCs	-	-	-	120,000	-		0%	-	-	-	-	-
Segura Plus	-	-	-	120,000	-		-%	-	-	-	-	-
Pakistan											1,705,140	580,103
Condom	15,046,745	14,767,018	99,068,665	106,540,076	133,792,588		(26)%	133,792,588	2,747,176,444	743,015	743,015	169,164
Do	306,360	180,816	1,822,227	2,002,578	1,581,084	8/17	15%	1,581,084	4,572,231	13,667	13,667	3,112
Sathi	13,410,432	11,107,939	75,735,883	89,986,310	116,349,078	1/87	(35)%	116,349,078	2,464,463,396	568,019	568,019	129,322

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Sathi Plus	491,040	559,520	3,516,021	2,550,929	2,133,120	8/17	65%	2,133,120	6,765,141	26,370	26,370	6,004
Touch	577,369	2,227,090	14,342,589	11,226,177	13,002,106	4/96	10%	13,002,106	266,122,091	107,569	107,569	24,491
Touch Delay	258,843	223,038	2,243,400	774,082	727,200	8/17	208%	727,200	3,845,040	16,825	16,825	3,831
Touch Strawberry	2,701	468,615	1,408,545	-	-		-%	-	1,408,545	10,564	10,564	2,405
Emergency Contraception	245,644	296,308	1,835,146	857,425	2,065,123		(11)%	2,065,123	10,740,409	82,582	82,582	14,442
ECP	221,782	223,602	1,610,992	857,425	2,080,232	9/14	(23)%	2,080,232	10,559,148	72,495	72,495	12,678
Levonorgestrel Tablet 0.75 mg x 2's	27,561	75,545	254,196	-	-		-%	-	254,196	11,439	11,439	2,000
(b)PSI Emergency Contraception Distributed Provided	(3,699)	(2,839)	(30,042)	-	(15,109)		-%	(15,109)	(72,935)	(1,352)	(1,352)	(236)
Emergency Contraception Provided	3,699	2,839	30,042	-	15,109		99%	15,109	72,935	1,502	1,502	263
PSI Emergency Contraception Provided	3,699	2,839	30,042	-	15,109		99%	15,109	72,935	1,502	1,502	263
Implant 5	-	1,498	4,796	45	10,646		(55)%	10,646	29,775	4,316	16,402	5,032
Jadelle	-	1,498	4,796	45	10,646	12/11	(55)%	10,646	29,775	4,316	16,402	5,032
Injectable 1	13,484	14,868	129,834	92,496	99,805		30%	99,805	1,833,049	8,989	8,989	2,235
Femi-ject	18,321	18,735	173,972	92,496	122,300	6/03	42%	122,300	1,988,185	12,044	12,044	2,995
(b)PSI Injectable 1 Distributed Provided	(4,837)	(3,867)	(44,138)	-	(22,495)		-%	(22,495)	(155,136)	(3,056)	(3,056)	(760)
Injectable 1 Provided	4,837	3,867	44,138	-	22,495		96%	22,495	155,136	3,395	3,395	844
PSI Injectable 1 Provided	4,837	3,867	44,138	-	22,495		96%	22,495	155,136	3,395	3,395	844
Injectable 2	-	(494)	45,946	19,731	134,028		(66)%	134,028	7,130,029	6,892	6,892	1,582
Novaject	-	-	50,114	19,731	144,514	12/96	(65)%	144,514	7,211,372	7,517	7,517	1,725
(b)PSI Injectable 2 Distributed Provided	-	(494)	(4,168)	-	(10,486)		-%	(10,486)	(81,343)	(625)	(625)	(144)
Injectable 2 Provided	-	494	4,168	-	10,486		(60)%	10,486	81,343	695	695	159
PSI Injectable 2 Provided	-	494	4,168	-	10,486		(60)%	10,486	81,343	695	695	159
Injectable 3-IM	(3,774)	(300)	(14,906)	226,792	406,105		(104)%	406,105	2,875,986	(3,354)	(3,354)	(770)
Depo-Provera	1	-	4,272	226,792	451,716	7/11	(99)%	451,716	3,000,455	961	961	221

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
(b)PSI Injectable 3 IM Distributed Provided	(3,775)	(300)	(19,178)	-	(45,611)		-%	(45,611)	(124,469)	(4,315)	(4,315)	(990)
Injectable 3-IM Provided	3,775	300	19,178	-	45,611		(58)%	45,611	124,469	4,795	4,795	1,101
PSI Injectable 3 IM Provided	3,775	300	19,178	-	45,611		(58)%	45,611	124,469	4,795	4,795	1,101
IUD 10	90	1	59,184	70,778	47,316		25%	47,316	254,443	53,266	245,022	71,870
Safeload	90	1	59,184	70,778	47,316	8/14	25%	47,316	254,443	53,266	245,022	71,870
IUD 5	(5,983)	5,353	6,376	94,294	20,275		(69)%	20,275	3,020,950	5,738	18,937	5,913
Multiloader	4,973	18,241	164,144	-	81,850	12/95	101%	81,850	4,110,670	147,730	487,508	152,227
Protect 5	-	-	-	94,294	-		-%	-	-	-	-	-
(b)PSI IUD 5 Distributed Inserted	(10,956)	(12,889)	(157,768)	-	(61,575)		-%	(61,575)	(1,089,720)	(141,991)	(468,571)	(146,314)
IUD 5 Insertion	10,956	12,889	157,768	-	61,575		156%	61,575	1,089,720	157,768	520,634	162,571
PSI IUD 5 Inserted	10,956	12,889	157,768	-	61,575		156%	61,575	1,089,720	157,768	520,634	162,571
Manual Vacuum Aspiration for PAC	4,312	6,868	76,305	-	27,052		182%	27,052	163,141	76,305	-	3,906
Manual Vacuum Aspiration for PAC	4,312	6,868	76,305	-	27,052		182%	27,052	163,141	76,305	-	3,906
Misoprostol for PAC Provided	9,751	8,729	81,496	-	46,571		75%	46,571	128,067	81,496	-	5,009
PSI Misoprostol for PAC Provided	9,751	8,729	81,496	-	46,571		75%	46,571	128,067	81,496	-	5,009
Misoprostol for Safe Abortion	162,796	64,283	1,319,316	-	982,646		34%	982,646	2,600,762	69,264	-	5,377
Misoprostol for Safe Abortion	201,800	99,200	1,645,300	-	1,168,930	3/18	41%	1,168,930	3,113,030	86,378	-	6,705
(b)PSI Misoprostol for Safe Abortion Dist Provided	(39,004)	(34,917)	(325,984)	-	(186,284)		-%	(186,284)	(512,268)	(17,114)	-	(1,328)
Multivitamin	6,000	6,807	26,420	-	-		0%	-	26,420	132	-	25
Mi-Care	6,000	6,807	26,420	-	-		-%	-	26,420	132	-	25
OCs	128,337	31,326	906,075	475,234	963,276		(6)%	963,276	4,779,348	54,365	54,365	13,164
Novadol	137,010	32,880	925,131	475,234	1,004,634	1/08	(8)%	1,004,634	5,006,511	55,508	55,508	13,441
(b)PSI OCs Distributed Provided	(8,673)	(1,554)	(19,056)	-	(41,358)		-%	(41,358)	(227,163)	(1,143)	(1,143)	(277)
OCs Provided	8,673	1,554	19,056	-	41,358		(54)%	41,358	227,163	1,270	1,270	308
PSI OCs Provided	8,673	1,554	19,056	-	41,358		(54)%	41,358	227,163	1,270	1,270	308

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
TB Diagnosis	2,328	2,516	28,405	-	29,215		(3)%	29,215	107,781	28,405	-	-
TB Diagnosis	2,328	2,516	28,405	-	29,215		(3)%	29,215	107,781	28,405	-	-
TB DOTS	2,289	2,100	25,764	-	26,012		(1)%	26,012	139,239	25,764	-	117,907
TB DOTS	2,289	2,100	25,764	-	26,012	4/05	(1)%	26,012	139,239	25,764	-	117,907
TB Screening	8,306	4,907	58,687	-	65,777		(11)%	65,777	177,985	58,687	-	-
TB Screening	8,306	4,907	58,687	-	65,777		(11)%	65,777	177,985	58,687	-	-
Panama											16,747	4,472
Condom	143,328	131,720	2,232,960	3,696,114	3,308,400		(33)%	3,308,400	45,420,318	16,747	16,747	4,384
Vive	110,928	95,520	1,755,648	2,951,521	2,656,128	7/00	(34)%	2,656,128	37,584,977	13,167	13,167	3,447
Vive Colors/Mas Colors	10,800	19,272	222,864	376,881	263,112	3/05	(15)%	263,112	4,259,796	1,671	1,671	438
Vive Mas Fuerte /Retardante	19,200	16,568	184,872	259,851	240,288	3/05	(23)%	240,288	1,948,159	1,387	1,387	363
Vive Mas Natural /Sensitivo	2,400	368	58,200	107,861	92,832	3/05	(37)%	92,832	917,993	436	436	114
Vive Mas/Texturizado	-	(8)	11,376	-	56,040	3/05	(80)%	56,040	709,393	85	85	22
HIV Testing Services	68	150	2,054	1,731	1,395		47%	1,395	20,831	2,054	-	4
VCT Individual (HIV-Negative)	63	136	1,838	1,564	1,259	12/11	46%	1,259	19,938	1,838	-	3
VCT Individual (HIV-Positive)	5	14	216	167	136	12/11	59%	136	893	216	-	-
Lubricant	2,620	1,194	92,786	26,474	21,742		327%	21,742	559,972	-	-	-
Vive Lub (sachet)	-	533	45,550	20,215	9,200	2/09	395%	9,200	313,776	-	-	-
Vive Lub (tube)	1,170	355	14,491	-	10,843	2/09	34%	10,843	90,774	-	-	-
Vive Lub Natural (sachet)	-	(1,017)	16,350	6,259	(850)	5/11	-%	(850)	75,755	-	-	-
Vive Lub Natural (tube)	1,450	1,322	16,395	-	2,549	5/11	543%	2,549	79,667	-	-	-
Referral to Linkage to HIV Care	5	13	179	-	112		60%	112	441	179	-	84
Referral to Linkage to HIV Care	5	13	179	-	112		60%	112	441	179	-	84
Papua New Guinea											1,634	1,152

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Condom	-	-	-	200,000	62,259		(100)%	62,259	8,050,159	-	-	-
Seif Raida	-	-	-	120,000	59,552	1/08	(100)%	59,552	6,969,005	-	-	-
Seif Raida Orange Plus	-	-	-	80,000	2,707	8/13	(100)%	2,707	1,081,154	-	-	-
Diarrhea Treatment Kit	-	-	-	2,914	-		0%	-	18,236	-	-	-
DTK	-	-	-	2,914	-	2/15	-%	-	18,236	-	-	-
Emergency Contraception	-	-	-	30,000	-		0%	-	-	-	-	-
Emergency Contraception	-	-	-	30,000	-		-%	-	-	-	-	-
Female Condom	-	-	-	-	100		(100)%	100	338,539	-	-	-
Stap Seif	-	-	-	-	100	2/09	(100)%	100	338,539	-	-	-
Free Condom	36,720	54,768	201,312	300,800	-		0%	-	201,312	1,510	1,510	1,042
Generic Male Condom	36,720	54,768	201,312	300,800	-		-%	-	201,312	1,510	1,510	1,042
Free Female Condom	1,000	5,103	16,504	30,000	-		0%	-	16,504	124	124	80
Generic Female Condom	1,000	5,103	16,504	30,000	-		-%	-	16,504	124	124	80
Lubricant	-	85	256	-	-		0%	-	18,241	-	-	-
Glide Lubricant	-	85	256	-	-	2/10	-%	-	18,241	-	-	-
Malaria PPT (ACT)	-	-	-	-	7,782		(100)%	7,782	845,477	-	-	-
Coartem 1x12's for 1-5 years old	-	-	-	-	95	8/15	(100)%	95	125,793	-	-	-
Coartem 1x18's for 6-13 years old	-	-	-	-	4,535	8/15	(100)%	4,535	275,970	-	-	-
Coartem 1x24's for 14+ years old	-	-	-	-	1,490	8/15	(100)%	1,490	259,952	-	-	-
Coartem 1x6's for 2-11 months	-	-	-	-	1,662	8/15	(100)%	1,662	183,762	-	-	-
Malaria RDK	-	-	-	-	4,469		(100)%	4,469	1,361,956	-	-	-
Carestart Malaria HRP2/pLDH (pf/PAN)	-	-	-	-	4,469	10/13	(100)%	4,469	1,361,956	-	-	-
ORS	-	-	2,112	-	-		0%	-	31,346	950	-	26
ORS	-	-	2,112	-	-	12/11	-%	-	31,346	950	-	26
Water Treatment Tablets	4,000	1,417	74,110	80,000	91,160		(19)%	91,160	1,052,893	1,218	-	3

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Aquatab	4,000	1,417	74,110	80,000	91,160	12/11	(19)%	91,160	1,052,893	1,218	-	3
Zinc	-	23	132	-	-		0%	-	32,976	119	-	1
Zinc 20 mg	-	23	132	-	-	12/11	-%	-	32,976	119	-	1
PSI Pakistan											945,604	248,606
Condom	1,044,961	538,949	33,388,650	37,492,943	3,369,589		891%	3,369,589	40,247,112	250,415	250,415	57,013
Do	-	-	519,141	-	-		-%	-	519,141	3,894	3,894	886
Generic Male Condom	1,044,961	538,949	6,359,600	37,492,943	3,369,589	4/16	89%	3,369,589	13,218,062	47,697	47,697	10,859
Sathi	-	-	22,835,062	-	-		-%	-	22,835,062	171,263	171,263	38,992
Sathi Plus	-	-	1,135,731	-	-		-%	-	1,135,731	8,518	8,518	1,939
Touch	-	-	1,943,841	-	-		-%	-	1,943,841	14,579	14,579	3,319
Touch Delay	-	-	595,275	-	-		-%	-	595,275	4,465	4,465	1,016
Emergency Contraception	-	-	641,775	-	-		0%	-	641,775	28,880	28,880	5,051
ECP	-	-	641,775	-	-		-%	-	641,775	28,880	28,880	5,051
Emergency Contraception Provided	-	-	-	1,146,567	-		0%	-	-	-	-	-
Non-PSI Emergency Contraception Provided	-	-	-	1,146,567	-		-%	-	-	-	-	-
Injectable 1	-	-	31,254	-	-		0%	-	31,254	2,164	2,164	538
Femi-ject	-	-	31,254	-	-		-%	-	31,254	2,164	2,164	538
Injectable 1 Provided	-	-	-	44,525	-		0%	-	-	-	-	-
Non-PSI Injectable 1 Provided	-	-	-	44,525	-		-%	-	-	-	-	-
Injectable 2	-	-	78,948	-	-		0%	-	78,948	11,842	11,842	2,718
Novaject	-	-	78,948	-	-		-%	-	78,948	11,842	11,842	2,718
Injectable 2 Provided	-	-	-	132,422	-		0%	-	-	-	-	-
Non-PSI Injectable 2 Provided	-	-	-	132,422	-		-%	-	-	-	-	-
Injectable 3-IM	-	-	78,008	-	(8,571)		0%	(8,571)	69,437	17,552	17,552	4,029

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Depo-Provera	-	-	88,445	-	-		-%	-	88,445	19,900	19,900	4,568
(b)PSI Injectable 3 IM Distributed Provided	-	-	(10,437)	-	(8,571)		-%	(8,571)	(19,008)	(2,348)	(2,348)	(539)
Injectable 3-IM Provided	27,013	25,205	268,725	744,325	280,576		(4)%	280,576	774,636	67,181	67,181	15,421
Non-PSI Injectable 3 IM Provided	27,013	25,205	258,288	744,325	272,005		(5)%	272,005	755,628	64,572	64,572	14,822
PSI Injectable 3 IM Provided	-	-	10,437	-	8,571		22%	8,571	19,008	2,609	2,609	599
IUD 10	-	-	2,697	-	-		0%	-	2,697	2,427	11,166	3,275
Safeload	-	-	2,697	-	-		-%	-	2,697	2,427	11,166	3,275
IUD 10 Insertion	12,903	9,439	78,634	65,609	61,472		28%	61,472	205,616	78,634	361,716	106,099
Non-PSI IUD 10 Inserted	12,903	9,439	78,634	65,609	61,472		28%	61,472	205,616	78,634	361,716	106,099
IUD 5	-	-	30,353	-	-		0%	-	30,353	27,318	90,148	28,149
Multiload	-	-	30,353	-	-		-%	-	30,353	27,318	90,148	28,149
IUD 5 Insertion	-	-	4,319	65,998	1,928		124%	1,928	11,567	4,319	14,253	4,450
Non-PSI IUD 5 Inserted	-	-	4,319	65,998	1,928		124%	1,928	11,567	4,319	14,253	4,450
OCs	-	-	83,939	-	(33,625)		0%	(33,625)	50,314	5,036	5,036	1,220
Novadol	-	-	144,168	-	-		-%	-	144,168	8,650	8,650	2,095
(b)PSI OCs Distributed Provided	-	-	(60,229)	-	(33,625)		-%	(33,625)	(93,854)	(3,614)	(3,614)	(875)
OCs Provided	141,080	114,999	1,278,755	1,576,577	773,098		65%	773,098	2,499,722	85,250	85,250	20,643
Non-PSI OCs Provided	141,080	114,999	1,218,526	1,576,577	739,473		65%	739,473	2,405,868	81,235	81,235	19,671
PSI OCs Provided	-	-	60,229	-	33,625		79%	33,625	93,854	4,015	4,015	972
Tajikistan											1,330	14,367
Free Condom	13,581	7,423	177,383	219,360	1,137,682		(84)%	1,137,682	1,636,717	1,330	1,330	744
Generic Male Condom	13,581	7,423	177,383	219,360	1,137,682	8/16	(84)%	1,137,682	1,636,717	1,330	1,330	744
HIV Self-Testing Kit	527	17	579	2,000	-		0%	-	579	521	-	-
HIV Self-Testing Kit (Oral Fluid)	-	-	-	2,000	-		-%	-	-	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
ORAQUICK HIV Self-Testing Kit (Saliva based)	527	17	579	-	-		-%	-	579	521	-	-
HIV Testing Services	556	578	15,421	18,627	16,547		(7)%	16,547	47,215	15,421	-	49
VCT Individual (HIV-Negative)	484	513	14,759	18,094	16,076		(8)%	16,076	45,703	14,759	-	47
VCT Individual (HIV-Positive)	72	66	662	533	471		41%	471	1,512	662	-	2
Naloxone	-	167	1,995	3,089	2,570		(22)%	2,570	18,708	1,796	-	2,722
Naloxone	-	167	1,995	3,089	2,570	1/11	(22)%	2,570	18,708	1,796	-	2,722
Needle & Syringe	-	92,933	796,800	1,085,760	689,065		16%	689,065	3,654,818	2,780	-	10,001
Needle/Syringe	-	92,933	796,800	1,085,760	689,065	1/11	16%	689,065	3,654,818	2,780	-	10,001
Referral to HIV Testing Services	-	-	3	6	4		(25)%	4	15,110	3	-	-
Referral to HIV Testing Services	-	-	3	6	4	12/13	(25)%	4	15,110	3	-	-
Referral to Linkage to HIV Care	102	88	1,069	731	691		55%	691	2,672	1,069	-	851
Referral to Linkage to HIV Care	102	88	1,069	731	691		55%	691	2,672	1,069	-	851
Referral to Opioid Treatment	2	2	48	37	65		(26)%	65	237	48	-	-
Referral to Opioid Treatment	2	2	48	37	65		(26)%	65	237	48	-	-
Referral to TB Screening	-	-	-	-	1		(100)%	1	8	-	-	-
Referrals to TB Screening	-	-	-	-	1		(100)%	1	8	-	-	-
TB Diagnosis	-	-	3	-	-		0%	-	21	3	-	-
TB Diagnosis	-	-	3	-	-		-%	-	21	3	-	-
TB Screening	351	205	1,786	2,000	1,892		(6)%	1,892	8,767	1,786	-	-
TB Screening	351	205	1,786	2,000	1,892		(6)%	1,892	8,767	1,786	-	-
Viet Nam											6,768	2,252
Emergency Contraception	-	-	-	-	(52)		0%	(52)	(104)	-	-	-
(b)PSI Emergency Contraception Distributed Provided	-	-	-	-	(52)		-%	(52)	(104)	-	-	-
Emergency Contraception Provided	-	50	150	-	225		(33)%	225	1,036	8	8	-
Non-PSI Emergency Contraception Provided	-	50	150	-	173		(13)%	173	932	8	8	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
PSI Emergency Contraception Provided	-	-	-	-	52		(100)%	52	104	-	-	-
Fever Cases Tested with RDTs	2,544	4,204	28,120	20,000	15,898		77%	15,898	44,018	28,120	-	-
Fever Cases Tested with RDTs	2,544	4,204	28,120	20,000	15,898		77%	15,898	44,018	28,120	-	-
HIV Testing Services	-	-	552	552	6,827		(92)%	6,827	12,603	552	-	1
VCT Individual (HIV-Negative)	-	-	527	527	6,402		(92)%	6,402	11,753	527	-	1
VCT Individual (HIV-Positive)	-	-	25	25	425		(94)%	425	850	25	-	-
Hypertension Diagnosis	-	-	7,961	14,572	26,102		(70)%	26,102	60,396	7,961	-	-
Hypertension Diagnosis	-	-	7,961	14,572	26,102		(70)%	26,102	60,396	7,961	-	-
Hypertension Screening	-	-	191,916	150,000	413,475		(54)%	413,475	807,605	191,916	-	-
Hypertension Screening	-	-	191,916	150,000	413,475		(54)%	413,475	807,605	191,916	-	-
Hypertension_Controlled Condition	-	-	12,035	13,009	30,443		(60)%	30,443	62,586	4,814	-	-
Hypertension_Controlled Condition	-	-	12,035	13,009	30,443		(60)%	30,443	62,586	4,814	-	-
Implant 3	82	99	706	60	892		(21)%	892	1,899	635	1,589	61
Implanon NXT	82	99	752	300	1,147	2/17	(34)%	1,147	2,235	677	1,692	65
(b)PSI Implant 3 Distributed Inserted	-	-	(46)	(240)	(255)		-%	(255)	(336)	(41)	(104)	(4)
Implant 3 Insertion	-	49	192	240	267		(28)%	267	539	192	480	18
Non-PSI Implant 3 Inserted	-	49	146	-	12		1,117%	12	203	146	365	14
PSI Implant 3 Inserted	-	-	46	240	255		(82)%	255	336	46	115	4
Implant 5 Insertion	-	-	15	-	-		0%	-	15	15	57	2
Non-PSI Implant 5 Inserted	-	-	15	-	-		-%	-	15	15	57	2
Injectable 1	-	-	-	-	(2)		0%	(2)	(4)	-	-	-
(b)PSI Injectable 1 Distributed Provided	-	-	-	-	(2)		-%	(2)	(4)	-	-	-
Injectable 1 Provided	-	-	2	-	2		0%	2	46	-	-	-
Non-PSI Injectable 1 Provided	-	-	2	-	-		-%	-	42	-	-	-
PSI Injectable 1 Provided	-	-	-	-	2		(100)%	2	4	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Injectable 3-IM	60	52	2,470	-	440		461%	440	3,143	556	556	16
Depoteron	60	467	3,784	-	712	2/17	431%	712	4,967	851	851	24
(b)PSI Injectable 3 IM Distributed Provided	-	(415)	(1,314)	-	(272)		-%	(272)	(1,824)	(296)	(296)	(8)
Injectable 3-IM Provided	-	415	1,368	-	735		86%	735	2,925	342	342	10
Non-PSI Injectable 3 IM Provided	-	-	54	-	463		(88)%	463	1,101	14	14	-
PSI Injectable 3 IM Provided	-	415	1,314	-	272		383%	272	1,824	329	329	9
Injectable 3-SC	-	(34)	(102)	1,400	-		0%	-	(102)	(23)	(23)	(1)
(b)PSI Injectable 3 SC Distributed Provided	-	(34)	(102)	(5,600)	-		-%	-	(102)	(23)	(23)	(1)
Sayana Press	-	-	-	7,000	-		-%	-	-	-	-	-
Injectable 3-SC Provided	-	256	769	5,600	-		0%	-	769	192	192	5
Non-PSI Injectable 3 SC Provided	-	222	667	-	-		-%	-	667	167	167	5
PSI Injectable 3 SC Provided	-	34	102	5,600	-		-%	-	102	26	26	1
IUD 10	-	164	492	-	50		884%	50	611	443	2,037	73
Copper-T 380-A IUD	-	165	494	-	50	9/16	888%	50	644	445	2,045	74
(b)PSI IUD 10 Distributed Inserted	-	(1)	(2)	-	-		-%	-	(33)	(2)	(8)	-
IUD 10 Insertion	-	85	329	-	396		(17)%	396	951	329	1,513	54
Non-PSI IUD 10 Inserted	-	84	327	-	396		(17)%	396	918	327	1,504	54
PSI IUD 10 Inserted	-	1	2	-	-		-%	-	33	2	9	-
LLIN (Hammock net)	-	-	781	1,350	1,259		(38)%	1,259	2,085	703	-	-
Tana Nets	-	-	781	1,350	1,259		(38)%	1,259	2,085	703	-	-
Malaria PPT (ACT)	-	-	-	-	(210)		0%	(210)	(210)	-	-	-
(b)PSI QAACTs Distributed Provided after Diagnosis	-	-	-	-	(210)		-%	(210)	(210)	-	-	-
Malaria PPT (Non-ACT)	-	-	-	-	(141)		0%	(141)	(141)	-	-	-
(b)PSI Vivax Tx Distributed Provided after Diagnosis	-	-	-	-	(141)		-%	(141)	(141)	-	-	-
Malaria RDK	6,920	3,497	35,300	25,000	24,220		46%	24,220	59,520	31,770	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
On-site Malaria Pf/Pv Ag Rapid Test	250	1,260	5,690	-	24,220	10/17	(77)%	24,220	29,910	5,121	-	-
SD Bioline Malaria Ag Pf/Pv Rapid Test	6,670	2,237	29,610	25,000	-		-%	-	29,610	26,649	-	-
Needle & Syringe	-	-	270,100	270,100	5,126,150		(95)%	5,126,150	22,921,150	942	-	1,900
B-braun Omnican 40 (U-40 Insulin/40I.U.)	-	-	270,100	270,100	4,610,150	9/13	(94)%	4,610,150	22,405,150	942	-	1,900
Co-pack LDS	-	-	-	-	516,000		(100)%	516,000	516,000	-	-	-
OCs	-	-	-	-	(70)		0%	(70)	(187)	-	-	-
(b)PSI OCs Distributed Provided	-	-	-	-	(70)		-%	(70)	(187)	-	-	-
OCs Provided	-	89	268	-	568		(53)%	568	1,786	18	18	1
Non-PSI OCs Provided	-	89	268	-	498		(46)%	498	1,599	18	18	1
PSI OCs Provided	-	-	-	-	70		(100)%	70	187	-	-	-
Positive RDTs	50	91	854	690	634		35%	634	1,666	854	-	-
Positive RDTs	50	91	854	690	634		35%	634	1,666	854	-	-
Positive RDTs Given First Line Treatment	30	47	569	550	403		41%	403	1,037	569	-	-
Positive RDTs Given First Line Treatment	30	47	569	550	403		41%	403	1,037	569	-	-
QAACts Provided after Confirmatory Diagnosis	21	36	230	330	253		(9)%	253	545	230	-	43
Non-PSI QAACts Provided after Confirmed Diagnosis	21	36	230	330	43		435%	43	335	230	-	43
PSI QAACts Provided after Confirmed Diagnosis	-	-	-	-	210		(100)%	210	210	-	-	-
Referral to Linkage to HIV Care	-	-	19	19	-		0%	-	19	19	-	11
Referral to Linkage to HIV Care	-	-	19	19	-		-%	-	19	19	-	11
TB Diagnosis	-	-	-	-	434		(100)%	434	5,371	-	-	-
TB Diagnosis	-	-	-	-	434		(100)%	434	5,371	-	-	-
Toilets Sold	-	175	1,113	750	4,405		(75)%	4,405	7,416	4,675	-	39
Toilet Type 1, Direct Sales	-	175	1,113	-	4,405		(75)%	4,405	7,416	4,675	-	39
Toilets Sold	-	-	-	750	-		-%	-	-	-	-	-
Toilets Sold - All	-	175	1,113	-	4,159		(73)%	4,159	5,272	4,675	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 12

Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	^(a) YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Toilets Sold - All	-	175	1,113	-	4,159		(73)%	4,159	5,272	4,675	-	-
Vivax Treatment after Confirmatory Diagnosis	9	12	92	248	156		(41)%	156	257	92	-	17
Non-PSI Vivax Treatment after Confirmed Diagnosis	9	12	92	248	15		513%	15	116	92	-	17
PSI Vivax Treatment after Confirmed Diagnosis	-	-	-	-	141		(100)%	141	141	-	-	-

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

^(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

Foundation Market Group

POPULATION SERVICES INTERNATIONAL
CYPs, Cases, and Deaths by Country
1/2019 - 12/2019

	<u>New HIV Infections</u>	<u>STI Deaths</u>	<u>PWID Deaths</u>	<u>TB Deaths</u>	<u>CYP*</u>	<u>Maternal Deaths</u>	<u>Unintended Pregnancies</u>	<u>Malaria Deaths</u>	<u>Diarrhea Deaths</u>	<u>Pneumonia Deaths</u>	<u>Cervical Cancer Death</u>	<u>Sum of All Deaths</u>
Foundation Market Group	3,394	2	-	677	1,600,475	1,878	625,204	61,220	239	881	2	77,362
Haiti	707	-	-	677	29,345	14	8,843	372	85	-	-	1,245
Liberia	89	-	-	-	7,934	10	2,234	-	1	-	-	47
Madagascar	2,580	2	-	-	1,107,857	900	404,021	4,512	26	655	-	11,647
Mali	15	-	-	-	449,801	889	207,515	35,270	2	-	1	41,563
Somaliland	4	-	-	-	5,539	65	2,589	13	125	226	-	1,807
South Sudan	-	-	-	-	-	-	-	21,054	-	-	-	21,054

* Using USAID CYP conversion factors

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Market Group and Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE SALES	YTD USERS REACHED ^(a) 2019	YTD CYP 2019	YTD DALY 2019
Foundation Market Group										1,600,475	6,338,408
Acute Malnutrition Screening_CU5	21	-	410	-	619,055	(100)%	619,055	619,465	410	-	-
Antiretroviral Treatment (Currently Enrolled)	34,562	34,824	139,035	29,957	216,577	(36)%	216,577	625,610	11,586	-	23,619
Antiretroviral Treatment (Newly Enrolled)	266	2,114	6,702	3,317	3,898	72%	3,898	14,901	6,702	-	-
Cervical Cancer-Pap and Cryotherapy	-	-	-	-	4	(100)%	4	4	-	-	-
Cervical Cancer-VIA and Cryotherapy	13	16	156	700	189	(17)%	189	1,498	156	-	48
Cervical Cancer-VIA/VILI Screening	3,072	4,329	25,479	35,000	13,295	92%	13,295	99,179	25,479	-	-
Chlorhexidine	300	5,015	31,731	9,000	107,120	(70)%	107,120	464,575	28,558	-	1,857
Condom	79,536	292,240	1,828,764	2,920,716	3,347,338	(45)%	3,347,338	71,126,776	13,716	13,716	16,365
Counseling & Tx for Moderate Acute Malnutrition	545	2,096	19,252	20,942	20,332	(5)%	20,332	39,584	19,252	-	60,218
Diarrhea Treatment Kit	9,060	1	91,713	264,416	179,738	(49)%	179,738	2,355,137	82,542	-	8,103
Diarrhea Treatment Kit Provided	635	-	635	-	1,812	(65)%	1,812	12,909	635	-	69
Emergency Contraception	(4)	(6)	44,760	15,700	40,018	12%	40,018	83,721	2,014	2,014	547
Emergency Contraception Provided	4	6	123	-	282	(56)%	282	1,462	6	6	2
Fever Cases Attended	28,033	18,106	204,513	202,868	86,150	137%	86,150	670,672	204,513	-	-
Fever Cases Tested with Microscopy	4,030	2,818	37,419	30,340	56,797	(34)%	56,797	221,661	37,419	-	-
Fever Cases Tested with RDTs	33,268	24,799	297,762	172,438	274,829	8%	274,829	1,434,601	297,762	-	-
Free Condom	4,813,306	4,461,068	23,328,462	21,468,907	28,342,179	(18)%	28,342,179	59,039,590	174,963	174,963	199,393
Free Female Condom	-	-	-	-	253	(100)%	253	21,253	-	-	-
HIV Testing Services	81,256	105,183	583,801	191,074	395,037	48%	395,037	1,999,487	583,801	-	3,380
Hypertension Diagnosis	59	-	59	-	-	-%	-	59	59	-	-
Implant 3	3,862	2,509	15,454	1,560	8,075	91%	8,075	25,935	13,909	34,772	29,405

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Market Group and Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE SALES	YTD USERS REACHED ^(a) 2019	YTD CYP 2019	YTD DALY 2019
Implant 3 Insertion	4,843	5,278	58,002	62,393	48,078	21%	48,078	157,340	58,002	145,005	107,860
Implant 4	(1)	(1)	(97)	-	(14)	-%	(14)	(2,625)	(87)	(279)	(267)
Implant 4 Insertion	1	1	182	-	14	1,200%	14	2,710	182	582	569
Implant 5	(1)	1,600	20,434	-	5,334	283%	5,334	134,693	18,391	69,884	79,433
Implant 5 Insertion	6,291	4,793	45,724	50,000	38,472	19%	38,472	152,410	45,724	173,751	197,046
Injectable 1 Provided	-	-	270	-	-	-%	-	270	21	21	17
Injectable 3-IM	241,325	228,903	2,150,139	1,988,500	1,669,487	29%	1,669,487	22,026,395	483,781	483,781	216,424
Injectable 3-IM Provided	10,814	7,559	80,561	35,040	77,146	4%	77,146	325,843	20,140	20,140	14,057
Injectable 3-SC	394	6,669	509,958	618,160	535,592	(5)%	535,592	1,926,752	114,741	114,741	51,277
Injectable 3-SC Provided	329	184	1,774	-	175	914%	175	1,949	444	444	277
IPTp2	206	595	5,919	291,388	81,911	(93)%	81,911	291,271	5,919	-	662
Iron Folic Acid Tablet	-	-	-	19,843	-	-%	-	-	-	-	-
IUD 10	1,381	2,055	12,638	7,000	7,568	67%	7,568	57,851	11,374	52,321	59,730
IUD 10 Insertion	2,797	3,430	37,004	46,654	40,411	(8)%	40,411	305,048	37,004	170,218	140,570
IUD 5 Insertion	27	24	265	311	299	(11)%	299	564	265	874	876
IUS 3	87	(12)	51	2,500	98	(48)%	98	149	46	115	65
IUS 3 Insertion	88	136	1,131	-	135	738%	135	1,266	1,131	2,828	1,611
IUS 5	-	10	(11)	-	-	-%	-	(11)	(10)	(33)	(81)
IUS 5 Insertion	-	-	82	-	-	-%	-	82	82	271	276
LLIN	1,038,941	1,105,848	6,377,414	11,942,257	19,624,561	(68)%	19,624,561	77,350,014	10,331,411	-	2,113,544
Lubricant	197,340	265,160	3,676,834	2,500,000	1,223,813	200%	1,223,813	5,619,488	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Market Group and Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE SALES	YTD USERS REACHED ^(a) 2019	YTD CYP 2019	YTD DALY 2019
Malaria PPT (ACT)	3,089,456	473,470	5,930,040	6,053,942	6,990,357	(15)%	6,990,357	31,322,969	5,337,036	-	1,787,919
Malaria PPT (Non-ACT)	7,000	40,633	220,800	80,000	-	-%	-	537,040	198,720	-	23,936
Malaria RDK	985,450	593,767	3,675,250	3,650,121	10,954,467	(66)%	10,954,467	29,267,008	3,307,725	-	-
Manual Vacuum Aspiration for PAC	872	672	7,505	5,784	6,247	20%	6,247	21,391	7,505	-	3,633
Micronutrient Powder	-	-	-	-	5,797,980	(100)%	5,797,980	16,505,640	-	-	-
Misoprostol for PAC Provided	1,398	1,610	16,306	15,430	12,741	28%	12,741	41,866	16,306	-	8,327
Misoprostol for PPH	-	2,833	15,500	4,500	30,800	(50)%	30,800	210,208	4,650	-	101
Misoprostol for Safe Abortion	15,224	13,533	106,820	119,780	81,047	32%	81,047	170,627	5,608	-	1,897
Multivitamin	-	-	-	24,202	-	-%	-	-	-	-	-
OCs	167,144	142,346	2,317,388	1,777,420	2,094,239	11%	2,094,239	43,308,371	139,043	139,043	65,406
OCs Provided	1,735	1,155	12,988	7,495	16,628	(22)%	16,628	111,567	866	866	602
ORS	79,104	1,080	299,226	300,000	1,249,743	(76)%	1,249,743	15,906,568	134,652	-	7,507
ORS Provided	3,538	2,150	29,095	13,914	13,509	115%	13,509	42,604	29,095	-	1,516
Pneumonia PPT	12,610	17,677	152,525	96,000	738,319	(79)%	738,319	2,991,637	137,273	-	55,974
Pneumonia PPT Provided	3,006	1,320	16,712	-	11,575	44%	11,575	28,287	16,712	-	19,309
Positive RDTs	5,190	2,933	28,743	8,000	17,054	69%	17,054	181,936	28,743	-	-
QAACs Provided after Confirmatory Diagnosis	87	170	1,748	1,928	1,872	(7)%	1,872	3,620	1,748	-	393
Referral to HIV Testing Services	-	-	-	-	5	(100)%	5	607	-	-	-
Referral to Linkage to HIV Care	-	-	-	300	-	-%	-	-	-	-	-
Safe Water Solution	24	2,813	370,393	31,680	1,345,883	(72)%	1,345,883	23,928,568	429,053	-	1,452
SDM (Cycle Beads)	(4)	(15)	(185)	-	5,121	(104)%	5,121	143,332	(167)	(250)	(160)

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Market Group and Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE SALES	YTD USERS REACHED ^(a) 2019	YTD CYP 2019	YTD DALY 2019
SDM (Cycle Beads) Provided	26	20	247	-	503	(51)%	503	5,404	247	371	289
Seasonal Malaria Chemoprevention	-	-	-	-	1,665,225	(100)%	1,665,225	4,076,234	-	-	-
Seasonal Malaria Chemoprevention_children reac	1,992,077	-	1,992,077	1,771,537	-	-%	-	1,992,077	1,992,077	-	938,488
Skilled Birth Attendance	2,070	1,764	18,979	17,196	16,695	14%	16,695	35,674	18,979	-	27,042
STI Screening	871	740	9,330	83,325	142,852	(93)%	142,852	623,412	9,330	-	-
TB Diagnosis	-	-	10,115	12,000	18,240	(45)%	18,240	49,245	10,115	-	-
TB DOTS	-	-	11,108	9,960	22,400	(50)%	22,400	54,142	11,108	-	38,021
TB Screening	-	-	38,860	14,000	76,668	(49)%	76,668	139,061	38,860	-	-
Toilets Sold	6	3	93	4,000	27	239%	27	6,390	529	-	20
Toilets Sold - All	127	81	1,908	-	1,515	26%	1,515	3,423	10,876	-	-
Treatment for Inguinal Bubo	1	1	26	-	53	(51)%	53	162	26	-	-
Treatment for Lower Abdominal Pain	35	38	494	-	800	(38)%	800	2,591	494	-	-
Treatment for Nonherpetic Genital Ulcer	47	53	686	-	5,172	(87)%	5,172	14,276	686	-	77
Treatment for Pre-Eclampsia (with MgSO4)	87	34	410	353	343	20%	343	753	410	-	1,423
Treatment for Severe Acute Malnutrition	362	746	6,999	9,888	12,893	(46)%	12,893	61,538	6,999	-	26,679
Treatment for Urethral Discharge (Men)	401	276	3,705	-	5,596	(34)%	5,596	16,922	7,270	-	21
Treatment for Urethral Discharge (Women)	282	-	282	-	15	1,780%	15	297	282	-	-
Treatment for Vaginitis	212	266	3,213	-	4,978	(35)%	4,978	15,246	3,213	-	28
Tubal Ligation	1	4	31	-	42	(26)%	42	147	31	310	142
Type 2 Diabetes Diagnosis	26	-	26	-	-	-%	-	26	26	-	-
Water Treatment Tablets	44,200	436,433	4,854,942	6,710,250	10,958,880	(56)%	10,958,880	151,379,984	79,807	-	600

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Market Group and Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE SALES	YTD USERS REACHED ^(a) 2019	YTD CYP 2019	YTD DALY 2019
Zinc	-	850	2,690	-	512,836	(99)%	512,836	1,908,926	2,421	-	61
Zinc Provided	3,650	2,152	28,688	12,189	11,834	142%	11,834	40,522	28,688	-	752

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Foundation Market Group											1,600,475	6,338,408
Haiti											29,345	126,628
Antiretroviral Treatment (Currently Enrolled)	34,562	34,760	138,841	29,957	216,577		(36)%	216,577	625,416	11,570	-	23,567
Antiretroviral Treatment (Currently Enrolled)	34,562	34,760	138,841	29,957	216,577		(36)%	216,577	625,416	11,570	-	23,567
Antiretroviral Treatment (Newly Enrolled)	266	1,929	6,054	3,317	3,561		70%	3,561	13,916	6,054	-	-
Antiretroviral Treatment (Newly Enrolled)	266	1,929	6,054	3,317	3,561		70%	3,561	13,916	6,054	-	-
Cervical Cancer-VIA and Cryotherapy	-	-	1	-	5		(80)%	5	124	1	-	-
Cervical Cancer-VIA and Cryotherapy	-	-	1	-	5		(80)%	5	124	1	-	-
Cervical Cancer-VIA/VILI Screening	-	-	7	-	31		(77)%	31	820	7	-	-
Cervical Cancer-VIA/VILI Screening	-	-	7	-	31		(77)%	31	820	7	-	-
Emergency Contraception	-	-	44,880	15,700	40,300		11%	40,300	85,180	2,020	2,020	549
Levonorgestrel 1.5 mg Tablet	-	-	44,880	-	40,300	9/17	11%	40,300	85,180	2,020	2,020	549
Pronta1	-	-	-	15,700	-	3/17	-%	-	-	-	-	-
Emergency Contraception Provided	-	-	3	-	-		0%	-	3	-	-	-
Non-PSI Emergency Contraception Provided	-	-	3	-	-		-%	-	3	-	-	-
Fever Cases Attended	926	486	5,003	202,868	9,014		(44)%	9,014	51,572	5,003	-	-
Fever Cases Attended	926	486	5,003	202,868	9,014		(44)%	9,014	51,572	5,003	-	-
Fever Cases Tested with Microscopy	2,754	1,844	29,938	30,340	54,725		(45)%	54,725	205,173	29,938	-	-
Fever Cases Tested with Microscopy	2,754	1,844	29,938	30,340	54,725		(45)%	54,725	205,173	29,938	-	-
Fever Cases Tested with RDTs	10,812	11,041	144,954	172,438	221,408		(35)%	221,408	912,794	144,954	-	-
Fever Cases Tested with RDTs	10,812	11,041	144,954	172,438	221,408		(35)%	221,408	912,794	144,954	-	-
Free Condom	180,000	84,144	3,054,510	2,000,000	8,256,538		(63)%	8,256,538	11,311,048	22,909	22,909	16,795
Generic Condom	180,000	84,144	3,054,510	2,000,000	8,256,538	3/17	(63)%	8,256,538	11,311,048	22,909	22,909	16,795
HIV Testing Services	13,158	83,929	264,946	136,153	127,117		108%	127,117	931,904	264,946	-	2,136
VCT Individual (HIV-Negative)	12,897	82,048	259,040	133,702	122,702	4/10	111%	122,702	892,681	259,040	-	2,089

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
VCT Individual (HIV-Positive)	261	1,882	5,906	2,451	4,415	4/10	34%	4,415	39,223	5,906	-	48
Implant 3	-	-	-	1,200	2,016		(100)%	2,016	4,032	-	-	-
Implanon NXT	-	-	-	1,200	2,016	7/17	(100)%	2,016	4,032	-	-	-
Implant 3 Insertion	5	7	120	120	465		(74)%	465	807	120	300	146
Non-PSI Implant 3 Inserted	5	7	120	120	465		(74)%	465	807	120	300	146
Injectable 3-IM Provided	-	-	-	-	949		(100)%	949	1,137	-	-	-
Non-PSI Injectable 3 IM Provided	-	-	-	-	949		(100)%	949	1,137	-	-	-
Injectable 3-SC	-	-	-	10,560	12,500		(100)%	12,500	12,500	-	-	-
Sayana Press	-	-	-	10,560	12,500	3/17	(100)%	12,500	12,500	-	-	-
Injectable 3-SC Provided	70	55	804	-	175		359%	175	979	201	201	72
Non-PSI Injectable 3 SC Provided	70	55	804	-	175		359%	175	979	201	201	72
IUD 10	-	-	450	-	50		800%	50	2,747	405	1,863	854
Confiance Plus IUD	-	-	450	-	50	12/13	800%	50	2,747	405	1,863	854
IUD 10 Insertion	7	4	72	900	125		(42)%	125	396	72	331	152
Non-PSI IUD 10 Inserted	7	4	72	900	125		(42)%	125	396	72	331	152
IUD 5 Insertion	-	3	9	-	-		0%	-	9	9	30	14
Non-PSI IUD 5 Inserted	-	3	9	-	-		-%	-	9	9	30	14
IUS 5	-	10	30	-	-		0%	-	30	27	89	43
LNG IUS - Bayer	-	10	30	-	-		-%	-	30	27	89	43
LLIN	-	-	226,310	272,770	36,486		520%	36,486	3,931,636	366,622	-	12,373
LLIN Free	-	-	226,310	272,770	36,486	1/08	520%	36,486	3,931,636	366,622	-	12,373
Lubricant	60,000	173,333	2,230,072	500,000	223,000		900%	223,000	2,453,072	-	-	-
Lube Sachet Free	60,000	173,333	2,230,072	500,000	223,000	3/17	900%	223,000	2,453,072	-	-	-
Malaria PPT (Non-ACT)	7,000	40,633	220,800	80,000	-		0%	-	537,040	198,720	-	23,936
Chloroquine	7,000	40,633	220,800	80,000	-	3/12	-%	-	537,040	198,720	-	23,936

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
OCs	-	-	25,532	21,120	76,322		(67)%	76,322	101,854	1,532	1,532	577
MEURI	-	-	25,532	21,120	76,322	3/17	(67)%	76,322	101,854	1,532	1,532	577
OCs Provided	165	107	1,053	-	1,413		(25)%	1,413	2,808	70	70	26
Non-PSI OCs Provided	165	107	1,053	-	1,413		(25)%	1,413	2,808	70	70	26
ORS	79,104	80	296,146	300,000	-		0%	-	10,343,484	133,266	-	7,366
Sel Lavi	79,104	80	296,146	300,000	-	10/99	-%	-	10,343,484	133,266	-	7,366
Positive RDTs	1,052	564	5,620	8,000	8,354		(33)%	8,354	45,304	5,620	-	-
Positive RDTs	1,052	564	5,620	8,000	8,354		(33)%	8,354	45,304	5,620	-	-
STI Screening	-	-	-	80,737	127,773		(100)%	127,773	535,770	-	-	-
STI Screening	-	-	-	80,737	127,773		(100)%	127,773	535,770	-	-	-
TB Diagnosis	-	-	10,115	12,000	18,240		(45)%	18,240	49,245	10,115	-	-
TB Diagnosis	-	-	10,115	12,000	18,240		(45)%	18,240	49,245	10,115	-	-
TB DOTS	-	-	11,108	9,960	22,400		(50)%	22,400	54,142	11,108	-	38,021
TB DOTS	-	-	11,108	9,960	22,400		(50)%	22,400	54,142	11,108	-	38,021
TB Screening	-	-	38,860	14,000	76,668		(49)%	76,668	139,061	38,860	-	-
TB Screening	-	-	38,860	14,000	76,668		(49)%	76,668	139,061	38,860	-	-
Treatment for Nonherpetic Genital Ulcer	-	-	-	-	4,007		(100)%	4,007	10,724	-	-	-
Treatment for Nonherpetic Genital Ulcer	-	-	-	-	4,007		(100)%	4,007	10,724	-	-	-
Liberia											7,934	7,836
Antiretroviral Treatment (Currently Enrolled)	-	65	194	-	-		0%	-	194	16	-	52
Antiretroviral Treatment (Currently Enrolled)	-	65	194	-	-		-%	-	194	16	-	52
Antiretroviral Treatment (Newly Enrolled)	-	185	648	-	337		92%	337	985	648	-	-
Antiretroviral Treatment (Newly Enrolled)	-	185	648	-	337		92%	337	985	648	-	-
Condom	-	-	132,672	-	1,042,072		(87)%	1,042,072	6,628,730	995	995	952
STAR	-	-	132,672	-	1,042,072	7/09	(87)%	1,042,072	6,628,730	995	995	952

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Free Condom	-	105,600	925,200	3,758,480	606,240		53%	606,240	1,680,581	6,939	6,939	6,640
Generic Condom	-	105,600	925,200	3,758,480	606,240	5/17	53%	606,240	1,680,581	6,939	6,939	6,640
Free Female Condom	-	-	-	-	253		(100)%	253	21,253	-	-	-
Generic Female Condom	-	-	-	-	253	5/17	(100)%	253	21,253	-	-	-
HIV Testing Services	1,688	3,048	16,543	17,084	12,049		37%	12,049	30,848	16,543	-	101
VCT Individual (HIV-Negative)	1,660	2,902	15,863	17,084	11,479	5/14	38%	11,479	29,521	15,863	-	97
VCT Individual (HIV-Positive)	28	146	680	-	570	5/14	19%	570	1,327	680	-	4
Lubricant	-	80,000	1,259,000	2,000,000	431,750		192%	431,750	1,860,891	-	-	-
Lube Sachet Free	-	80,000	1,259,000	2,000,000	431,750	5/17	192%	431,750	1,860,891	-	-	-
Referral to HIV Testing Services	-	-	-	-	5		(100)%	5	607	-	-	-
Referral to HIV Testing Services	-	-	-	-	5	12/13	(100)%	5	607	-	-	-
Referral to Linkage to HIV Care	-	-	-	300	-		0%	-	-	-	-	-
Referral to Linkage to HIV Care	-	-	-	300	-		-%	-	-	-	-	-
Safe Water Solution	24	680	25,798	31,680	37,800		(32)%	37,800	798,487	21,204	-	91
WaterGuard	24	680	25,798	31,680	37,800	7/09	(32)%	37,800	798,487	21,204	-	91
STI Screening	-	-	-	-	63		(100)%	63	64	-	-	-
STI Screening	-	-	-	-	63		(100)%	63	64	-	-	-
Treatment for Lower Abdominal Pain	-	-	-	-	48		(100)%	48	48	-	-	-
Treatment for Lower Abdominal Pain	-	-	-	-	48		(100)%	48	48	-	-	-
Treatment for Urethral Discharge (Women)	-	-	-	-	15		(100)%	15	15	-	-	-
Treatment for Urethral Discharge (Women)	-	-	-	-	15		(100)%	15	15	-	-	-
Madagascar											1,107,857	1,093,857
Cervical Cancer-Pap and Cryotherapy	-	-	-	-	4		(100)%	4	4	-	-	-
Cervical Cancer-PAP and Cryotherapy	-	-	-	-	4		(100)%	4	4	-	-	-
Cervical Cancer-VIA and Cryotherapy	2	1	26	-	63		(59)%	63	206	26	-	9

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Cervical Cancer-VIA and Cryotherapy	2	1	26	-	63		(59)%	63	206	26	-	9
Cervical Cancer-VIA/VILI Screening	39	54	631	-	899		(30)%	899	3,063	631	-	-
Cervical Cancer-VIA/VILI Screening	39	54	631	-	899		(30)%	899	3,063	631	-	-
Chlorhexidine	300	5,015	31,731	9,000	107,120		(70)%	107,120	464,575	28,558	-	1,857
Arofoitra	300	5,015	31,731	9,000	107,120	9/15	(70)%	107,120	464,575	28,558	-	1,857
Condom	79,536	292,240	1,696,092	2,920,716	2,305,266		(26)%	2,305,266	64,498,046	12,721	12,721	15,413
Protector Plus	79,536	292,240	1,426,992	2,680,416	573,456	1/08	149%	573,456	59,794,226	10,702	10,702	12,967
YES	-	-	269,100	240,300	1,731,810	9/14	(84)%	1,731,810	4,703,820	2,018	2,018	2,445
Diarrhea Treatment Kit	9,060	1	11,713	44,000	49,568		(76)%	49,568	1,166,907	10,542	-	245
Hydrazinc	-	-	-	-	13,754	1/10	(100)%	13,754	701,539	-	-	-
ORS-Zinc	9,060	1	11,713	44,000	37,626	8/14	(69)%	37,626	477,642	10,542	-	245
(b)PSI Diarrhea Treatment Kit Distributed Provided	-	-	-	-	(1,812)		-%	(1,812)	(12,274)	-	-	-
Diarrhea Treatment Kit Provided	-	-	-	-	1,812		(100)%	1,812	12,274	-	-	-
PSI Diarrhea Treatment Kit Provided	-	-	-	-	1,812		(100)%	1,812	12,274	-	-	-
Emergency Contraception	(4)	(6)	(120)	-	(282)		0%	(282)	(1,459)	(5)	(5)	(2)
(b)PSI Emergency Contraception Distributed Provided	(4)	(6)	(120)	-	(282)		-%	(282)	(1,459)	(5)	(5)	(2)
Emergency Contraception Provided	4	6	120	-	282		(57)%	282	1,459	6	6	2
PSI Emergency Contraception Provided	4	6	120	-	282		(57)%	282	1,459	6	6	2
Fever Cases Attended	27,052	17,620	199,455	-	77,136		159%	77,136	619,045	199,455	-	-
Fever Cases Attended	27,052	17,620	199,455	-	77,136		159%	77,136	619,045	199,455	-	-
Fever Cases Tested with Microscopy	1,276	974	7,481	-	2,072		261%	2,072	16,488	7,481	-	-
Fever Cases Tested with Microscopy	1,276	974	7,481	-	2,072		261%	2,072	16,488	7,481	-	-
Fever Cases Tested with RDTs	22,456	13,758	152,808	-	53,421		186%	53,421	521,807	152,808	-	-
Fever Cases Tested with RDTs	22,456	13,758	152,808	-	53,421		186%	53,421	521,807	152,808	-	-
Free Condom	4,633,306	4,254,124	19,237,152	15,510,427	19,479,201		(1)%	19,479,201	45,936,161	144,279	144,279	174,810

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Generic Condom	-	-	-	-	15,700	10/16	(100)%	15,700	7,235,508	-	-	-
KPOTY	4,633,306	4,254,124	19,237,152	15,510,427	19,463,501	1/18	(1)%	19,463,501	38,700,653	144,279	144,279	174,810
HIV Testing Services	62,781	16,729	282,110	24,117	243,365		16%	243,365	1,004,027	282,110	-	951
VCT Individual (HIV-Negative)	62,591	16,681	281,299	23,065	242,688	12/09	16%	242,688	1,001,512	281,299	-	948
VCT Individual (HIV-Positive)	190	49	811	1,052	677	12/09	20%	677	2,515	811	-	3
Implant 3	3,832	2,174	8,423	-	4,681		80%	4,681	13,027	7,581	18,952	11,497
Implanon	-	-	-	-	2,007	7/06	(100)%	2,007	35,127	-	-	-
Implanon NXT	7,065	6,240	51,579	44,320	36,178	5/17	43%	36,178	91,284	46,421	116,053	70,403
(b)PSI Implant 3 Distributed Inserted	(3,233)	(4,066)	(43,156)	(44,320)	(33,504)		-%	(33,504)	(113,384)	(38,840)	(97,101)	(58,906)
Implant 3 Insertion	3,233	4,066	43,156	44,320	33,504		29%	33,504	113,384	43,156	107,890	65,451
PSI Implant 3 Inserted	3,233	4,066	43,156	44,320	33,504		29%	33,504	113,384	43,156	107,890	65,451
Implant 4	(1)	(1)	(12)	-	(14)		0%	(14)	(2,540)	(11)	(35)	(21)
(b)PSI Implant 4 Distributed Inserted	(1)	(1)	(12)	-	(14)		-%	(14)	(2,540)	(11)	(35)	(21)
Implant 4 Insertion	1	1	12	-	14		(14)%	14	2,540	12	38	23
PSI Implant 4 Inserted	1	1	12	-	14		(14)%	14	2,540	12	38	23
Implant 5	(1)	(7)	(67)	-	(265)		0%	(265)	1,439	(60)	(229)	(136)
Jadelle	-	-	-	-	20	7/14	(100)%	20	3,703	-	-	-
(b)PSI Implant 5 Distributed Inserted	(1)	(7)	(67)	-	(285)		-%	(285)	(2,264)	(60)	(229)	(136)
Implant 5 Insertion	1	7	67	-	285		(76)%	285	2,264	67	255	152
PSI Implant 5 Inserted	1	7	67	-	285		(76)%	285	2,264	67	255	152
Injectable 3-IM	241,325	228,653	2,147,544	1,985,000	1,664,193		29%	1,664,193	21,995,547	483,197	483,197	215,937
Confiance Injectable	-	603	384,066	1,985,000	1,702,545	10/98	(77)%	1,702,545	20,435,562	86,415	86,415	38,618
(b)PSI Injectable 3 IM Distributed Provided	(2,016)	(2,339)	(29,673)	-	(38,352)		-%	(38,352)	(233,166)	(6,676)	(6,676)	(2,984)
Triclofem Injection 150 mg/mL	243,341	230,389	1,793,151	-	-		-%	-	1,793,151	403,459	403,459	180,302

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Injectable 3-IM Provided	2,016	2,339	29,673	-	38,352		(23)%	38,352	233,166	7,418	7,418	3,315
PSI Injectable 3 IM Provided	2,016	2,339	29,673	-	38,352		(23)%	38,352	233,166	7,418	7,418	3,315
Injectable 3-SC	394	6,669	509,958	607,600	523,092		(3)%	523,092	1,914,252	114,741	114,741	51,277
Sayana Press	394	6,669	509,958	607,600	523,092	9/15	(3)%	523,092	1,914,252	114,741	114,741	51,277
IPTp2	-	-	-	287,518	78,153		(100)%	78,153	281,594	-	-	-
IPTp2	-	-	-	287,518	78,153		(100)%	78,153	281,594	-	-	-
IUD 10	1,219	250	(1,865)	-	1,979		(194)%	1,979	16,478	(1,679)	(7,721)	(4,384)
Copper T	172	293	2,340	17,754	4,320	5/06	(46)%	4,320	200,092	2,106	9,688	5,500
IUD 1 x 5	-	-	-	-	25	8/11	(100)%	25	5,285	-	-	-
Pregna T Cu 380A	2,135	1,600	14,332	-	15,143	7/17	(5)%	15,143	34,632	12,899	59,334	33,687
(b)PSI IUD 10 Distributed Inserted	(1,088)	(1,643)	(18,537)	(17,754)	(17,509)		-%	(17,509)	(223,531)	(16,683)	(76,743)	(43,571)
IUD 10 Insertion	1,088	1,643	18,537	17,754	17,509		6%	17,509	223,531	18,537	85,270	48,412
PSI IUD 10 Inserted	1,088	1,643	18,537	17,754	17,509		6%	17,509	223,531	18,537	85,270	48,412
IUS 3	87	(12)	51	2,500	98		(48)%	98	149	46	115	65
Avibela (52 mg levonorgestrel)	175	124	1,182	2,500	233	2/18	407%	233	1,415	1,064	2,660	1,516
(b)PSI IUS 3 Distributed Inserted	(88)	(136)	(1,131)	-	(135)		-%	(135)	(1,266)	(1,018)	(2,545)	(1,450)
IUS 3 Insertion	88	136	1,131	-	135		738%	135	1,266	1,131	2,828	1,611
PSI IUS 3 Inserted	88	136	1,131	-	135		738%	135	1,266	1,131	2,828	1,611
LLIN	312,880	52,107	1,060,856	2,377,984	13,921,182		(92)%	13,921,182	34,334,459	1,718,587	-	41,960
Dawa Plus Blue	-	-	-	-	1,161,814		(100)%	1,161,814	1,161,814	-	-	-
Dawa Plus White	-	-	131,050	-	6,891,750	4/18	(98)%	6,891,750	7,022,800	212,301	-	5,183
Generic net "PERMANET WHITE"	-	-	130	-	1,760	5/15	(93)%	1,760	9,216,166	211	-	5
Interceptor White	-	-	-	1,000,000	-	5/09	-%	-	1,099,951	-	-	-
PermaNet	-	33	39,150	-	2,216,858	3/07	(98)%	2,216,858	4,705,781	63,423	-	1,548

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Royal Sentry White	26,100	-	26,100	-	-		-%	-	26,100	42,282	-	1,032
Safe Net Blue	-	-	8,650	-	1,732,600		(100)%	1,732,600	1,741,250	14,013	-	342
Safe Net White	-	-	363,400	-	495,650		(27)%	495,650	859,050	588,708	-	14,373
Super Moustiquaire	286,780	52,073	460,726	450,000	482,572	9/01	(5)%	482,572	4,121,330	746,376	-	18,223
Yorkool Blue (Generic Net)	-	-	-	927,984	313,000	7/15	(100)%	313,000	1,378,824	-	-	-
Yorkool White (Generic Net)	-	-	31,650	-	625,178	9/13	(95)%	625,178	3,001,393	51,273	-	1,252
Lubricant	137,340	11,827	187,762	-	569,063		(67)%	569,063	1,305,525	-	-	-
Gel Lubricant 5 mL	137,340	11,827	187,762	-	569,063	12/16	(67)%	569,063	1,305,525	-	-	-
Malaria PPT (ACT)	-	172,645	1,325,195	1,403,822	3,507,514		(62)%	3,507,514	8,003,914	1,192,676	-	336,444
ACT 100 mg (1x3's)	-	-	-	-	331,575	7/15	(100)%	331,575	574,532	-	-	-
ACT 100 mg (1x6's)	-	-	-	-	318,325	7/15	(100)%	318,325	560,050	-	-	-
ACT 25 mg (1x3's)	-	-	-	-	280,575	7/15	(100)%	280,575	520,199	-	-	-
ACT 50 mg (1x3's)	-	-	-	-	773,650	7/15	(100)%	773,650	1,454,575	-	-	-
AL for Adolescent, 20/120mg, 18's	-	-	-	-	20,581	7/16	(100)%	20,581	67,103	-	-	-
AL for Adult, 20/120mg, 24's	-	-	-	-	28,330	7/16	(100)%	28,330	98,705	-	-	-
AL for Infant, 20/120mg, 6's	-	-	-	-	11,097	7/16	(100)%	11,097	43,625	-	-	-
AL for Toddler, 20/120mg, 12's	-	-	-	-	37,176	7/16	(100)%	37,176	100,505	-	-	-
ASAQ for Adolescent, 100/270mg, 3's	-	-	146,247	-	503,415	7/16	(71)%	503,415	1,034,823	131,622	-	37,130
ASAQ for Adult, 100/270mg, 6's	-	-	196,332	-	542,613	7/16	(64)%	542,613	1,196,686	176,699	-	49,845
ASAQ for Infant, 25/67.5mg, 3's	-	23,638	125,758	-	69,596	7/16	81%	69,596	371,787	113,182	-	31,928
ASAQ for Toddler, 50/135mg, 3's	-	14	263,628	-	590,581	7/16	(55)%	590,581	1,388,094	237,265	-	66,931
PRIVATE - AS/AQ 100mg+270mg (base) - 3 - Blister-3	-	-	-	46,149	-		-%	-	-	-	-	-
PRIVATE - AS/AQ 100mg+270mg (base) - 3 - Blister-6	-	-	-	127,100	-		-%	-	-	-	-	-
PRIVATE - AS/AQ 25mg+67.5mg (base) - 3 - Blister-3	-	-	-	35,331	-		-%	-	-	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
PRIVATE - AS/AQ 50mg+135mg (base) - 3 - Blister-3	-	-	-	145,989	-		-%	-	-	-	-	-
PRIVATE A/L(20/120mg,FDC,24's,Indiv)	-	-	-	30,501	-		-%	-	-	-	-	-
PRIVATE A/L(20/120mg,FDC,6x1,Indiv)	-	-	-	11,602	-		-%	-	-	-	-	-
PRIVATE A/L(20/120mg,FDC,6x2,Indiv)	-	-	-	21,214	-		-%	-	-	-	-	-
PRIVATE A/L(20/120mg,FDC,6x3,Indiv)	-	-	-	15,839	-		-%	-	-	-	-	-
PUBLIC - AS/AQ 100mg+270mg (base) - 3 - Blister-3	-	9,445	28,335	144,112	-		-%	-	28,335	25,502	-	7,194
PUBLIC - AS/AQ 100mg+270mg (base) - 3 - Blister-6	-	-	-	138,865	-		-%	-	-	-	-	-
PUBLIC - AS/AQ 25mg+67.5mg (base) - 3 - Blister-3	-	45,892	157,925	157,923	-		-%	-	157,925	142,133	-	40,094
PUBLIC - AS/AQ 50mg+135mg (base) - 3 - Blister-3	-	93,657	406,970	407,046	-		-%	-	406,970	366,273	-	103,323
PUBLIC A/L(20/120mg,FDC,6x1,Indiv)	-	-	-	12,217	-		-%	-	-	-	-	-
PUBLIC A/L(20/120mg,FDC,6x2,Indiv)	-	-	-	31,424	-		-%	-	-	-	-	-
PUBLIC A/L(20/120mg,FDC,6x3,Indiv)	-	-	-	19,574	-		-%	-	-	-	-	-
PUBLIC A/L(20/120mg,FDC,6x4,Indiv)	-	-	-	58,936	-		-%	-	-	-	-	-
Malaria RDK	1,650	495,525	2,113,625	2,374,725	7,698,425		(73)%	7,698,425	19,213,488	1,902,263	-	-
RDT Malaria	1,650	495,525	2,113,625	2,374,725	7,698,425	8/11	(73)%	7,698,425	19,213,488	1,902,263	-	-
Manual Vacuum Aspiration for PAC	318	306	3,055	2,334	2,719		12%	2,719	9,231	3,055	-	964
MVA for PAC	318	306	3,055	2,334	2,719	12/16	12%	2,719	9,231	3,055	-	964
Micronutrient Powder	-	-	-	-	5,797,980		(100)%	5,797,980	16,505,640	-	-	-
ZAZATOMADY (ZZT)	-	-	-	-	5,797,980	2/13	(100)%	5,797,980	16,505,640	-	-	-
Misoprostol for PAC Provided	709	912	9,055	4,430	6,438		41%	6,438	20,403	9,055	-	3,356
PSI Misoprostol for PAC Provided	709	912	9,055	4,430	6,438		41%	6,438	20,403	9,055	-	3,356
Misoprostol for Safe Abortion	15,224	13,533	106,820	69,780	81,047		32%	81,047	168,227	5,608	-	1,897
Misoprostol 200 mcg Tablet	18,060	17,180	143,040	87,500	106,799	3/18	34%	106,799	249,839	7,510	-	2,540
(b)PSI Misoprostol for Safe Abortion Dist Provided	(2,836)	(3,647)	(36,220)	(17,720)	(25,752)		-%	(25,752)	(81,612)	(1,902)	-	(643)

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
OCs	167,144	142,346	2,291,856	1,730,300	1,994,828		15%	1,994,828	43,056,477	137,511	137,511	64,829
Combination 3	500	2,816	742,940	-	-		-%	-	742,940	44,576	44,576	21,015
Microgynon	166,985	127,428	1,343,466	-	1,471,355	2/18	(9)%	1,471,355	2,814,821	80,608	80,608	38,002
Pilplan	-	12,453	209,745	1,730,300	531,113	10/98	(61)%	531,113	39,591,072	12,585	12,585	5,933
(b)PSI OCs Distributed Provided	(341)	(351)	(4,295)	-	(7,640)		-%	(7,640)	(92,356)	(258)	(258)	(121)
OCs Provided	341	351	4,295	-	7,640		(44)%	7,640	92,356	286	286	135
PSI OCs Provided	341	351	4,295	-	7,640		(44)%	7,640	92,356	286	286	135
ORS	-	-	80	-	39,368		(100)%	39,368	39,448	36	-	1
SRO Generique	-	-	80	-	39,368	4/18	(100)%	39,368	39,448	36	-	1
Pneumonia PPT	12,610	17,677	152,525	96,000	157,872		(3)%	157,872	943,939	137,273	-	55,974
Pneumox 250 (10's)	12,610	17,677	152,525	-	-		-%	-	152,525	137,273	-	55,974
Pneumox 250 (10's) for Children under 12 months	-	-	-	96,000	157,872	7/16	(100)%	157,872	791,414	-	-	-
Positive RDTs	4,138	2,369	23,123	-	8,700		166%	8,700	136,632	23,123	-	-
Positive RDTs	4,138	2,369	23,123	-	8,700		166%	8,700	136,632	23,123	-	-
Safe Water Solution	-	2,133	344,595	-	1,308,083		(74)%	1,308,083	23,130,081	407,849	-	1,361
Sur Eau Vaovao	-	2,133	344,595	-	1,308,083	9/04	(74)%	1,308,083	23,130,081	407,849	-	1,361
SDM (Cycle Beads)	(4)	(15)	(185)	-	5,121		(104)%	5,121	143,332	(167)	(250)	(160)
(b)PSI SDM (Cycle Beads) Distributed Provided	(4)	(15)	(187)	-	(467)		-%	(467)	(5,298)	(168)	(252)	(162)
Rojo	-	-	2	-	5,588	3/12	(100)%	5,588	148,630	2	3	2
SDM (Cycle Beads) Provided	4	15	187	-	467		(60)%	467	5,298	187	281	180
PSI SDM (Cycle Beads) Provided	4	15	187	-	467		(60)%	467	5,298	187	281	180
STI Screening	566	643	8,085	-	12,714		(36)%	12,714	84,031	8,085	-	-
STI Screening	566	643	8,085	-	12,714		(36)%	12,714	84,031	8,085	-	-
Treatment for Inguinal Bubo	1	1	26	-	53		(51)%	53	162	26	-	-
Treatment for Inguinal Bubo	1	1	26	-	53		(51)%	53	162	26	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Treatment for Lower Abdominal Pain	35	38	494	-	752		(34)%	752	2,543	494	-	-
Treatment for Lower Abdominal Pain	35	38	494	-	752		(34)%	752	2,543	494	-	-
Treatment for Nonherpetic Genital Ulcer	47	53	686	-	1,165		(41)%	1,165	3,552	686	-	77
Treatment for Nonherpetic Genital Ulcer	47	53	686	-	1,165		(41)%	1,165	3,552	686	-	77
Treatment for Severe Acute Malnutrition	-	-	-	-	187		(100)%	187	187	-	-	-
Treatment for Severe Acute Malnutrition	-	-	-	-	187		(100)%	187	187	-	-	-
Treatment for Urethral Discharge (Men)	261	276	3,565	-	5,596		(36)%	5,596	16,782	7,130	-	21
Treatment for Urethral Discharge (Men)	261	276	3,565	-	5,596		(36)%	5,596	16,782	7,130	-	21
Treatment for Vaginitis	212	266	3,213	-	4,978		(35)%	4,978	15,246	3,213	-	28
Treatment for Vaginitis	212	266	3,213	-	4,978		(35)%	4,978	15,246	3,213	-	28
Tubal Ligation	1	4	31	-	42		(26)%	42	147	31	310	142
Tubal Ligation	1	4	31	-	42		(26)%	42	147	31	310	142
Water Treatment Tablets	44,200	268,767	3,002,980	3,600,000	6,183,000		(51)%	6,183,000	31,292,610	49,364	-	165
SUR'EAU PILINA (67mg tablet)	44,200	268,767	3,002,980	3,600,000	6,183,000	10/14	(51)%	6,183,000	31,292,610	49,364	-	165
Zinc	-	-	140	-	13,132		(99)%	13,132	13,272	126	-	1
Zinc	-	-	140	-	13,132	1/08	(99)%	13,132	13,272	126	-	1
Mali											449,801	3,231,077
Cervical Cancer-VIA and Cryotherapy	11	14	129	700	121		7%	121	1,168	129	-	39
Cervical Cancer-VIA and Cryotherapy	11	14	129	700	121	12/13	7%	121	1,168	129	-	39
Cervical Cancer-VIA/VILI Screening	3,033	4,275	24,841	35,000	12,365		101%	12,365	95,296	24,841	-	-
Cervical Cancer-VIA/VILI Screening	3,033	4,275	24,841	35,000	12,365		101%	12,365	95,296	24,841	-	-
Free Condom	-	17,200	111,600	200,000	200		55700%	200	111,800	837	837	1,148
Generic Condom	-	17,200	111,600	200,000	200		55,700%	200	111,800	837	837	1,148
Implant 3	-	-	5,936	-	1,336		344%	1,336	7,472	5,342	13,356	15,397
Implanon NXT	-	-	5,936	-	1,336	2/16	344%	1,336	7,472	5,342	13,356	15,397

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Implant 3 Insertion	1,445	1,174	14,195	17,600	13,564		5%	13,564	41,722	14,195	35,488	40,911
Non-PSI Implant 3 Inserted	1,445	1,174	14,195	17,600	13,564		5%	13,564	41,722	14,195	35,488	40,911
Implant 5	-	1,607	20,501	-	5,599		266%	5,599	133,254	18,451	70,113	79,569
Jadelle	-	1,607	20,501	-	5,599	7/09	266%	5,599	133,254	18,451	70,113	79,569
Implant 5 Insertion	6,290	4,786	45,657	50,000	38,187		20%	38,187	150,146	45,657	173,497	196,895
Non-PSI Implant 5 Inserted	6,290	4,786	45,657	50,000	38,187		20%	38,187	150,146	45,657	173,497	196,895
Injectable 3-IM	-	250	2,275	-	927		145%	927	3,202	512	512	433
Depo-Provera	-	250	2,275	-	927	1/08	145%	927	3,202	512	512	433
Injectable 3-IM Provided	8,535	5,179	49,970	34,000	36,909		35%	36,909	89,686	12,493	12,493	10,569
Non-PSI Injectable 3 IM Provided	8,535	5,179	49,970	34,000	36,909		35%	36,909	89,686	12,493	12,493	10,569
Injectable 3-SC Provided	259	128	970	-	-		0%	-	970	243	243	205
Non-PSI Injectable 3 SC Provided	259	128	970	-	-		-%	-	970	243	243	205
IUD 10	162	1,806	14,053	7,000	5,539		154%	5,539	38,626	12,648	58,179	63,259
Copper-T 380-A with inserter	-	-	-	7,000	112		(100)%	112	112	-	-	-
IUD Copper T 380A	162	1,522	11,803	-	5,302	12/13	123%	5,302	36,139	10,623	48,864	53,131
PPIUD Cu T380A	-	283	2,250	-	125		1,700%	125	2,375	2,025	9,315	10,128
IUD 10 Insertion	1,702	1,783	18,395	28,000	22,777		(19)%	22,777	81,121	18,395	84,617	92,005
Non-PSI IUD 10 Inserted	1,702	1,783	18,395	28,000	22,777		(19)%	22,777	81,121	18,395	84,617	92,005
LLIN	723,923	959,258	4,258,834	4,343,735	4,911,866		(13)%	4,911,866	23,797,071	6,899,311	-	1,783,941
MILD - (G)	990	702,446	2,108,334	4,343,735	3,685,706	10/14	(43)%	3,685,706	13,306,486	3,415,501	-	883,139
MILD - (O)	-	-	36	-	45	9/16	(20)%	45	1,125,719	58	-	15
MILD - (U)	479,003	22,322	1,203,064	-	1,226,115	12/14	(2)%	1,226,115	8,417,466	1,948,964	-	503,940
Yorkool White (Generic Net)	243,930	234,490	947,400	-	-		-%	-	947,400	1,534,788	-	396,847
Malaria PPT (ACT)	-	-	-	-	460,404		(100)%	460,404	4,646,729	-	-	-
Coartem 12 tabs	-	-	-	-	138,127	5/10	(100)%	138,127	1,694,442	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Coartem 6 tabs	-	-	-	-	322,277	5/10	(100)%	322,277	2,952,287	-	-	-
Manual Vacuum Aspiration for PAC	554	366	4,450	3,450	3,528		26%	3,528	12,160	4,450	-	2,669
MVA for PAC	554	366	4,450	3,450	3,528	7/15	26%	3,528	12,160	4,450	-	2,669
Misoprostol for PAC Provided	689	698	7,251	11,000	6,303		15%	6,303	21,463	7,251	-	4,971
Non-PSI Misoprostol for PAC Provided	689	698	7,251	11,000	6,303		15%	6,303	21,463	7,251	-	4,971
Misoprostol for Safe Abortion	-	-	-	50,000	-		0%	-	2,400	-	-	-
Misoprostol for Safe Abortion	-	-	-	50,000	-		-%	-	2,400	-	-	-
OCs Provided	889	602	5,653	5,500	5,695		(1)%	5,695	12,536	377	377	336
Non-PSI OCs Provided	889	602	5,653	5,500	5,695		(1)%	5,695	12,536	377	377	336
SDM (Cycle Beads) Provided	22	6	60	-	36		67%	36	106	60	90	110
Non-PSI SDM (Cycle Beads) Provided	22	6	60	-	36		67%	36	106	60	90	110
Seasonal Malaria Chemoprevention	-	-	-	-	1,665,225		(100)%	1,665,225	4,076,234	-	-	-
SMC for Children ages 12-59 months	-	-	-	-	1,361,725		(100)%	1,361,725	3,333,317	-	-	-
SMC for Infants ages 3-11 months	-	-	-	-	303,500	3/17	(100)%	303,500	742,917	-	-	-
Seasonal Malaria Chemoprevention_children reache	1,992,077	-	1,992,077	1,771,537	-		0%	-	1,992,077	1,992,077	-	938,488
SMC for Children ages 12-59 months	1,662,685	-	1,662,685	1,771,537	-		-%	-	1,662,685	1,662,685	-	783,308
SMC for Infants ages 3-11 months	329,392	-	329,392	-	-		-%	-	329,392	329,392	-	155,180
Toilets Sold	6	3	93	4,000	27		239%	27	6,390	529	-	20
Toilet Type 1, Direct Sales	6	3	93	4,000	27	12/16	239%	27	6,390	529	-	20
Toilets Sold - All	127	81	1,908	-	1,515		26%	1,515	3,423	10,876	-	-
Toilets Sold - All	127	81	1,908	-	1,515		26%	1,515	3,423	10,876	-	-
Water Treatment Tablets	-	122,667	787,200	1,248,000	262,400		200%	262,400	44,311,670	12,940	-	111
Aquatab	-	122,667	787,200	1,248,000	262,400	2/09	200%	262,400	44,311,670	12,940	-	111
Somaliland											5,539	152,264
Acute Malnutrition Screening_CU5	21	-	410	-	-		0%	-	410	410	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Acute Malnutrition Screening_CU5	21	-	410	-	-		-%	-	410	410	-	-
Counseling & Tx for Moderate Acute MalnutritionCU!	545	2,096	19,252	20,942	20,332		(5)%	20,332	39,584	19,252	-	60,218
Counseling & Tx for Moderate Acute MalnutritionCU5	545	2,096	19,252	20,942	20,332		(5)%	20,332	39,584	19,252	-	60,218
Diarrhea Treatment Kit	-	-	80,000	220,416	128,358		(38)%	128,358	1,175,956	72,000	-	7,857
SD OFLV-DTK	-	-	80,000	-	128,358	9/11	(38)%	128,358	1,030,435	72,000	-	7,857
Shuban Daweeye_DTK	-	-	-	220,416	-	6/11	-%	-	145,521	-	-	-
Diarrhea Treatment Kit Provided	635	-	635	-	-		0%	-	635	635	-	69
Non-PSI Diarrhea Treatment Kit Provided	635	-	635	-	-		-%	-	635	635	-	69
Fever Cases Attended	55	-	55	-	-		0%	-	55	55	-	-
Fever Cases Attended	55	-	55	-	-		-%	-	55	55	-	-
HIV Testing Services	3,629	1,477	20,202	13,720	12,506		62%	12,506	32,708	20,202	-	193
VCT Individual (HIV-Negative)	3,629	1,477	20,202	13,720	12,506		62%	12,506	32,708	20,202	-	193
Hypertension Diagnosis	59	-	59	-	-		0%	-	59	59	-	-
Hypertension Diagnosis	59	-	59	-	-		-%	-	59	59	-	-
Implant 3	30	335	1,095	360	42		2507%	42	1,404	986	2,464	2,511
Nasiye Implant (Implanon)	30	335	1,149	360	236	12/15	387%	236	1,968	1,034	2,585	2,634
(b)PSI Implant 3 Distributed Inserted	-	-	(54)	-	(194)		-%	(194)	(564)	(49)	(122)	(124)
Implant 3 Insertion	160	32	531	353	545		(3)%	545	1,427	531	1,328	1,353
Non-PSI Implant 3 Inserted	160	32	477	353	351		36%	351	863	477	1,193	1,215
PSI Implant 3 Inserted	-	-	54	-	194		(72)%	194	564	54	135	138
Implant 4	-	-	(85)	-	-		0%	-	(85)	(77)	(245)	(246)
(b)PSI Implant 4 Distributed Inserted	-	-	(85)	-	-		-%	-	(85)	(77)	(245)	(246)
Implant 4 Insertion	-	-	170	-	-		0%	-	170	170	544	546
Non-PSI Implant 4 Inserted	-	-	85	-	-		-%	-	85	85	272	273
PSI Implant 4 Inserted	-	-	85	-	-		-%	-	85	85	272	273

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Injectable 1 Provided	-	-	270	-	-		0%	-	270	21	21	17
Non-PSI Injectable 1 Provided	-	-	270	-	-		-%	-	270	21	21	17
Injectable 3-IM	-	-	320	3,500	4,367		(93)%	4,367	27,646	72	72	54
Nasiye - Inj 3	-	-	320	3,500	4,367	6/11	(93)%	4,367	27,646	72	72	54
Injectable 3-IM Provided	263	41	918	1,040	936		(2)%	936	1,854	230	230	172
Non-PSI Injectable 3 IM Provided	263	41	918	1,040	936		(2)%	936	1,854	230	230	172
IPTp2	206	595	5,919	3,870	3,758		58%	3,758	9,677	5,919	-	662
IPTp2	206	595	5,919	3,870	3,758		58%	3,758	9,677	5,919	-	662
Iron Folic Acid Tablet	-	-	-	19,843	-		0%	-	-	-	-	-
Iron Folic Acid Tablet	-	-	-	19,843	-		-%	-	-	-	-	-
IUD 5 Insertion	27	21	256	311	299		(14)%	299	555	256	845	861
Non-PSI IUD 5 Inserted	27	21	256	311	299		(14)%	299	555	256	845	861
IUS 5	-	-	(41)	-	-		0%	-	(41)	(37)	(122)	(124)
(b)PSI IUS 5 Distributed Inserted	-	-	(41)	-	-		-%	-	(41)	(37)	(122)	(124)
IUS 5 Insertion	-	-	82	-	-		0%	-	82	82	271	276
Non-PSI IUS 5 Inserted	-	-	41	-	-		-%	-	41	41	135	138
PSI IUS 5 Inserted	-	-	41	-	-		-%	-	41	41	135	138
Misoprostol for PPH	-	2,833	15,500	4,500	30,800		(50)%	30,800	210,208	4,650	-	101
Ummul-gargaar	-	2,833	15,500	4,500	30,800	3/10	(50)%	30,800	210,208	4,650	-	101
Multivitamin	-	-	-	24,202	-		0%	-	-	-	-	-
Multivitamin	-	-	-	24,202	-		-%	-	-	-	-	-
OCs	-	-	-	26,000	23,089		(100)%	23,089	150,040	-	-	-
Nasiye - OC	-	-	-	26,000	23,089	3/12	(100)%	23,089	150,040	-	-	-
OCs Provided	340	95	1,987	1,995	1,880		6%	1,880	3,867	132	132	105
Non-PSI OCs Provided	340	95	1,987	1,995	1,880		6%	1,880	3,867	132	132	105

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
ORS	-	1,000	3,000	-	-		0%	-	3,000	1,350	-	141
Orasel ORS Sachet	-	1,000	3,000	-	-		-%	-	3,000	1,350	-	141
ORS Provided	3,538	2,150	29,095	13,914	13,509		115%	13,509	42,604	29,095	-	1,516
Non-PSI ORS Provided	3,538	2,150	29,095	13,914	13,509		115%	13,509	42,604	29,095	-	1,516
Pneumonia PPT	-	-	-	-	14,500		(100)%	14,500	53,213	-	-	-
Pneumox 125mg tablet (Amoxicillin) x 20's	-	-	-	-	2,900	11/14	(100)%	2,900	10,716	-	-	-
Pneumox 250mg tablet (Amoxicillin) x 20's	-	-	-	-	11,600	11/14	(100)%	11,600	42,497	-	-	-
Pneumonia PPT Provided	3,006	1,320	16,712	-	11,575		44%	11,575	28,287	16,712	-	19,309
Non-PSI Pneumonia PPT Provided	3,006	1,320	16,712	-	11,575		44%	11,575	28,287	16,712	-	19,309
QAACTs Provided after Confirmatory Diagnosis	87	170	1,748	1,928	1,872		(7)%	1,872	3,620	1,748	-	393
Non-PSI QAACTs Provided after Confirmed Diagnosis	87	170	1,748	1,928	1,872		(7)%	1,872	3,620	1,748	-	393
Skilled Birth Attendance	2,070	1,764	18,979	17,196	16,695		14%	16,695	35,674	18,979	-	27,042
Skilled Birth Attendance	2,070	1,764	18,979	17,196	16,695		14%	16,695	35,674	18,979	-	27,042
STI Screening	305	98	1,245	2,588	2,302		(46)%	2,302	3,547	1,245	-	-
STI Screening	305	98	1,245	2,588	2,302		(46)%	2,302	3,547	1,245	-	-
Treatment for Pre-Eclampsia (with MgSO4)	87	34	410	353	343		20%	343	753	410	-	1,423
Treatment for Pre-Eclampsia (with MgSO4)	87	34	410	353	343		20%	343	753	410	-	1,423
Treatment for Severe Acute Malnutrition	362	746	6,999	9,888	9,600		(27)%	9,600	16,599	6,999	-	26,679
Treatment for Severe Acute Malnutrition	362	746	6,999	9,888	9,600		(27)%	9,600	16,599	6,999	-	26,679
Treatment for Urethral Discharge (Men)	140	-	140	-	-		0%	-	140	140	-	-
Treatment for Urethral Discharge (Men)	140	-	140	-	-		-%	-	140	140	-	-
Treatment for Urethral Discharge (Women)	282	-	282	-	-		0%	-	282	282	-	-
Treatment for Urethral Discharge (Women)	282	-	282	-	-		-%	-	282	282	-	-
Type 2 Diabetes Diagnosis	26	-	26	-	-		0%	-	26	26	-	-
Type 2 Diabetes Diagnosis	26	-	26	-	-		-%	-	26	26	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Water Treatment Tablets	-	45,000	1,064,762	1,862,250	4,513,480		(76)%	4,513,480	75,775,704	17,503	-	325
Aquatab	-	45,000	672,602	864,000	334,000	9/10	101%	334,000	36,581,392	11,056	-	205
Biyosifeeye	-	-	392,160	998,250	4,179,480	7/08	(91)%	4,179,480	39,194,312	6,446	-	120
Zinc	-	850	2,550	-	-		0%	-	2,550	2,295	-	60
Shuban Daweeye_Zinc	-	850	2,550	-	-	6/11	-%	-	2,550	2,295	-	60
Zinc Provided	3,650	2,152	28,688	12,189	11,834		142%	11,834	40,522	28,688	-	752
Non-PSI Zinc Provided	3,650	2,152	28,688	12,189	11,834		142%	11,834	40,522	28,688	-	752
South Sudan											-	1,726,746
Acute Malnutrition Screening_CU5	-	-	-	-	619,055		(100)%	619,055	619,055	-	-	-
Acute Malnutrition Screening_CU5	-	-	-	-	619,055		(100)%	619,055	619,055	-	-	-
LLIN	2,138	94,483	831,414	4,947,768	755,027		10%	755,027	15,286,848	1,346,891	-	275,270
Free Permanet Mesh	2,138	94,483	831,414	4,947,768	724,734	4/08	15%	724,734	9,402,141	1,346,891	-	275,270
Mass LLIN - WES	-	-	-	-	30,293	6/14	(100)%	30,293	5,884,707	-	-	-
Malaria PPT (ACT)	3,089,456	300,825	4,604,845	4,650,120	3,022,439		52%	3,022,439	18,672,326	4,144,361	-	1,451,475
ACTs for Adult (14+ years)	818,917	99,000	1,364,000	1,257,791	641,055	2/13	113%	641,055	4,415,095	1,227,600	-	429,941
ACTs for Child (6-14 years)	614,884	75,000	1,008,537	918,479	479,609	2/13	110%	479,609	2,785,207	907,683	-	317,897
ACTs for Infant (2-12 months)	470,085	30,017	589,069	882,296	692,193	2/13	(15)%	692,193	4,076,453	530,162	-	185,678
ACTs for Toddler (1-5 years)	987,388	82,500	1,335,575	1,232,271	1,139,058	2/13	17%	1,139,058	7,017,383	1,202,018	-	420,981
Artemether Tabs – Adult	72,960	5,690	142,200	139,755	36,350		291%	36,350	178,550	127,980	-	44,822
Artemether Tabs - Child	75,822	5,938	107,100	102,053	26,276		308%	26,276	133,376	96,390	-	33,759
Artemether Tabs - Infant	8,800	900	11,764	49,016	2,022		482%	2,022	13,786	10,588	-	3,708
Artemether Tabs - Toddler	40,600	1,780	46,600	68,459	5,876		693%	5,876	52,476	41,940	-	14,689
Malaria RDK	983,800	98,242	1,561,625	1,275,396	3,256,042		(52)%	3,256,042	10,053,520	1,405,463	-	-
Malaria Rapid Diagnostic Kit	983,800	98,242	1,561,625	1,275,396	3,256,042	9/14	(52)%	3,256,042	10,053,520	1,405,463	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.
(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	^(a) YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
ORS	-	-	-	-	1,210,375		(100)%	1,210,375	5,520,636	-	-	-
ORS	-	-	-	-	1,210,375	9/08	(100)%	1,210,375	5,520,636	-	-	-
Pneumonia PPT	-	-	-	-	565,947		(100)%	565,947	1,994,485	-	-	-
Amoxicillin for Children (1-5 years)	-	-	-	-	361,615	10/12	(100)%	361,615	1,358,695	-	-	-
Amoxicillin for Infant (2-12 months)	-	-	-	-	204,332	10/12	(100)%	204,332	635,790	-	-	-
Treatment for Severe Acute Malnutrition	-	-	-	-	3,106		(100)%	3,106	44,752	-	-	-
Treatment for Severe Acute Malnutrition	-	-	-	-	3,106		(100)%	3,106	44,752	-	-	-
Zinc	-	-	-	-	499,704		(100)%	499,704	1,893,104	-	-	-
Zinc	-	-	-	-	499,704	1/08	(100)%	499,704	1,893,104	-	-	-

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

^(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

Social Enterprise Market Group

POPULATION SERVICES INTERNATIONAL
CYPs, Cases, and Deaths by Country
1/2019 - 12/2019

	<u>New HIV Infections</u>	<u>STI Deaths</u>	<u>PWID Deaths</u>	<u>TB Deaths</u>	<u>CYP*</u>	<u>Maternal Deaths</u>	<u>Unintended Pregnancies</u>	<u>Malaria Deaths</u>	<u>Diarrhea Deaths</u>	<u>Pneumonia Deaths</u>	<u>Cervical Cancer Death</u>	<u>Sum of All Deaths</u>
Social Enterprise	18,683	-	-	-	1,233,886	1,234	431,636	-	313	-	-	3,788
India LLC	3,094	-	-	-	936,113	1,170	344,466	-	313	-	-	3,236
Paraguay	389	-	-	-	81,283	15	26,213	-	-	-	-	89
PSI South Africa	15,200	-	-	-	216,490	48	60,957	-	-	-	-	463
Total	174,022	30	48	6,006	16,227,308	16,468	6,537,688	72,101	1,795	1,004	60	189,585

* Using USAID CYP conversion factors

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Market Group and Product
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE SALES	YTD USERS REACHED ^(a) 2019	YTD CYP 2019	YTD DALY 2019
Social Enterprise										1,233,886	1,011,719
Condom	14,419,555	4,656,703	98,181,497	202,585,322	159,709,190	(39)%	159,709,190	806,993,596	736,347	736,347	828,627
Emergency Contraception	35,132	37,270	418,892	1,240,030	553,951	(24)%	553,951	3,484,995	18,850	18,850	1,909
Injectable 3-IM	9,595	(1,882)	39,544	20,736	129,729	(70)%	129,729	238,354	8,897	8,897	1,489
IUD 10	(5)	(7)	10	-	65,510	(100)%	65,510	65,520	9	41	9
IUD 3	(125)	(20)	(57)	-	6,953	(101)%	6,953	6,896	(51)	(128)	(27)
IUD 5	95	254	130,659	111,600	79,621	64%	79,621	310,994	117,593	388,057	87,975
IUS 5	-	(51)	419	5,184	-	-%	-	419	377	1,244	282
Lubricant	23,241	552	49,209	93,942	37,944	30%	37,944	173,577	-	-	-
Male Vasodilator	80,000	5,467	1,766,180	3,029,400	-	-%	-	1,766,180	13,246	-	-
Medical Abortion	35,908	16,145	571,512	1,656,000	1,139,134	(50)%	1,139,134	2,225,582	514,361	-	53,118
Misoprostol for Safe Abortion	-	-	-	250,000	-	-%	-	-	-	-	-
Multivitamin	120,780	117,180	1,410,030	2,232,000	1,974,210	(29)%	1,974,210	38,419,590	7,050	-	241
OCs	206,702	46,079	1,342,940	7,097,180	4,758,355	(72)%	4,758,355	17,426,340	80,576	80,576	11,023
ORS	(3,799)	(16,263)	1,349,277	1,320,000	1,144,506	18%	1,144,506	2,820,211	607,175	-	27,074
Pregnancy Test	21,082	21,401	313,592	1,188,000	575,675	(46)%	575,675	889,267	-	-	-
Vaginal Wash	(39)	45	18,625	71,280	-	-%	-	18,625	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Social Enterprise											1,233,886	1,011,719
India LLC											936,113	372,241
Condom	9,918,357	3,248,528	66,179,492	160,842,000	121,087,377		(45)%	121,087,377	327,478,721	496,346	496,346	195,048
Masti 10's - Banana & Chocolate	295,200	55,280	817,440	-	-		-%	-	817,440	6,131	6,131	2,409
Masti 10's - Strawberry & Banana	-	18,800	1,011,120	-	-		-%	-	1,011,120	7,583	7,583	2,980
Masti Banana Dotted 3's	626,400	18,040	680,520	-	-		-%	-	680,520	5,104	5,104	2,006
Masti Banana Dotted 4's	-	40	1,998,600	-	-		-%	-	1,998,600	14,989	14,989	5,890
Masti Cherry 2's	7,230	1,393,130	5,019,300	-	-		-%	-	5,019,300	37,645	37,645	14,793
Masti Chocolate 4's	140,520	121,240	3,954,360	-	-		-%	-	3,954,360	29,658	29,658	11,654
Masti Chocolate Dotted 3's	687,600	18,040	741,720	-	-		-%	-	741,720	5,563	5,563	2,186
Masti Classic 10's	283,707	118,000	5,054,907	-	12,641,730	10/17	(60)%	12,641,730	22,129,437	37,912	37,912	14,898
Masti Classic 10's (Flavoured)	347,000	(115,917)	8,252,860	-	12,638,400	6/17	(35)%	12,638,400	30,100,900	61,896	61,896	24,323
Masti Classic 2's Orange	(1,905)	166,707	1,666,597	-	7,334,310	4/18	(77)%	7,334,310	9,000,907	12,499	12,499	4,912
Masti Classic 3's Cool Mint	(1,732)	(15,533)	(48,760)	-	1,000,080	4/18	(105)%	1,000,080	951,320	(366)	(366)	(144)
Masti Classic 3's	2,565,876	218,440	16,260,216	-	43,947,594	12/16	(63)%	43,947,594	125,373,637	121,952	121,952	47,923
Masti Classic 3's (Flavoured)	976,150	(332,496)	5,545,468	-	22,653,043		(76)%	22,653,043	42,284,871	41,591	41,591	16,344
Masti Classic 6's	-	-	-	-	960	12/16	(100)%	960	27,094,440	-	-	-
Masti Green Apple 2's	108,000	(49,260)	(39,780)	-	4,018,980		(101)%	4,018,980	3,979,200	(298)	(298)	(117)
Masti Lemon 2's	1,616,730	1,110,420	5,001,990	-	-		-%	-	5,001,990	37,515	37,515	14,742
Masti Long Innings 2's	888,990	387,800	2,502,870	-	-		-%	-	2,502,870	18,772	18,772	7,377
Masti Mix 10's Chocolate & Strawberry	(7,080)	(39,440)	1,886,280	-	-		-%	-	1,886,280	14,147	14,147	5,559
Masti Night Queen (Raat Ki Rani) 2's	171,720	300,370	3,007,110	-	-		-%	-	3,007,110	22,553	22,553	8,863
Masti Premium 10's (Flavoured)	416,008	(142,883)	(1,452)	-	6,531,960		(100)%	6,531,960	10,780,428	(11)	(11)	(4)
Masti Premium 2's Chocolate	-	-	-	-	134,910		(100)%	134,910	134,910	-	-	-

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Masti Premium 2's Strawberry	-	-	-	-	134,824		(100)%	134,824	134,824	-	-	-
Masti Premium 3's	-	-	-	-	23,656	12/16	(100)%	23,656	8,984,681	-	-	-
Masti Premium 3's Cool Mint	(847)	(160)	(1,327)	-	913,200	4/18	(100)%	913,200	911,873	(10)	(10)	(4)
Masti Premium 3's (Flavoured)	6,790	(170)	9,253	-	9,113,730		(100)%	9,113,730	16,135,783	69	69	27
Masti Standard 10's	-	-	-	85,536,000	-		-%	-	-	-	-	-
Masti Standard 3's	-	-	-	49,896,000	-		-%	-	-	-	-	-
Masti Strawberry Dotted 3's	792,000	18,040	846,120	-	-		-%	-	846,120	6,346	6,346	2,494
Masti Strawberry Dotted 4's	-	40	2,014,080	-	-		-%	-	2,014,080	15,106	15,106	5,936
Premium Condom (ONE)	-	-	-	25,410,000	-		-%	-	-	-	-	-
Emergency Contraception	(3,537)	1,666	35,412	594,000	212,227		(83)%	212,227	247,639	1,594	1,594	203
Pronta	-	-	-	-	18,500		(100)%	18,500	18,500	-	-	-
Pronta1	(5,337)	(1,371)	(6,742)	-	178,469	4/18	(104)%	178,469	171,727	(303)	(303)	(39)
Pronta-72	1,800	3,037	42,154	594,000	15,258		176%	15,258	57,412	1,897	1,897	242
Injectable 3-IM	9,595	(1,882)	39,544	20,736	129,729		(70)%	129,729	238,354	8,897	8,897	1,489
Freedom Inject (3-month)	9,595	(1,882)	39,544	20,736	129,729	12/16	(70)%	129,729	238,354	8,897	8,897	1,489
IUD 10	(5)	(7)	10	-	65,510		(100)%	65,510	65,520	9	41	9
Freedom 10	(5)	(7)	10	-	65,510	12/16	(100)%	65,510	65,520	9	41	9
IUD 3	(125)	(20)	(57)	-	6,953		(101)%	6,953	6,896	(51)	(128)	(27)
Freedom 3	(125)	(20)	(57)	-	6,953	1/18	(101)%	6,953	6,896	(51)	(128)	(27)
IUD 5	95	254	130,659	111,600	79,621		64%	79,621	310,994	117,593	388,057	87,975
Freedom 5	(385)	(28)	124,953	64,800	70,638	12/16	77%	70,638	296,305	112,458	371,110	84,133
Freedom 5 – Sleek	500	324	5,424	-	6,909	1/18	(21)%	6,909	12,333	4,882	16,109	3,652
Freedom 5 (PPIUCD) Cu 375	(20)	(42)	282	46,800	2,074		(86)%	2,074	2,356	254	838	190
IUS 5	-	(51)	419	5,184	-		0%	-	419	377	1,244	282

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Freedom LNG-IUS	-	-	-	5,184	-	1/18	-%	-	-	-	-	-
Sabatica – LNG IUS	-	(51)	419	-	-		-%	-	419	377	1,244	282
Male Vasodilator	80,000	5,467	1,766,180	3,029,400	-		0%	-	1,766,180	13,246	-	-
Masti Super 100 - 100 mg Tab	80,000	5,467	1,766,180	3,029,400	-		-%	-	1,766,180	13,246	-	-
Medical Abortion	35,908	16,145	571,512	1,656,000	1,139,134		(50)%	1,139,134	2,225,582	514,361	-	53,118
Mifeso	-	-	9,000	72,000	-		-%	-	9,000	8,100	-	836
Safe Abort kit	35,908	16,145	562,512	1,584,000	1,139,134	12/16	(51)%	1,139,134	2,216,582	506,261	-	52,282
Misoprostol for Safe Abortion	-	-	-	250,000	-		0%	-	-	-	-	-
Avertiso	-	-	-	250,000	-		-%	-	-	-	-	-
OCs	142,151	(7,623)	667,680	6,376,560	4,052,619		(84)%	4,052,619	8,390,259	40,061	40,061	7,071
Freedom 28	-	(67)	(656)	1,134,000	42,146		(102)%	42,146	41,490	(39)	(39)	(7)
MEURI	3,504	1,903	34,414	216,000	37,645		(9)%	37,645	72,059	2,065	2,065	364
Pearl	138,647	(9,460)	633,922	5,026,560	3,972,828	12/16	(84)%	3,972,828	8,276,710	38,035	38,035	6,713
ORS	(3,799)	(16,263)	1,349,277	1,320,000	1,144,506		18%	1,144,506	2,820,211	607,175	-	27,074
Neotral Orange 1000ml	(3,799)	(16,263)	1,349,277	1,320,000	1,144,506	12/16	18%	1,144,506	2,820,211	607,175	-	27,074
Pregnancy Test	21,082	21,401	313,592	1,188,000	575,675		(46)%	575,675	889,267	-	-	-
Pronta (PTK)	21,082	21,401	313,592	1,188,000	575,675	4/18	(46)%	575,675	889,267	-	-	-
Vaginal Wash	(39)	45	18,625	71,280	-		0%	-	18,625	-	-	-
Pronta Intimate Wash – 100 ml bottle	(39)	45	18,625	71,280	-		-%	-	18,625	-	-	-
Paraguay											81,283	24,842
Condom	445,294	326,663	3,409,365	3,317,080	3,450,963		(1)%	3,450,963	46,797,392	25,570	25,570	19,579
Pantera	235,857	155,222	1,651,691	1,628,902	1,641,868	8/98	1%	1,641,868	38,432,846	12,388	12,388	9,485
Pantera Banana	18,412	17,030	163,747	154,498	168,808	9/16	(3)%	168,808	565,547	1,228	1,228	940
Pantera Chocolate	21,546	20,174	204,079	219,757	231,222	2/14	(12)%	231,222	1,228,001	1,531	1,531	1,172

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Pantera Neon	2,634	1	2,637	-	-		-%	-	2,637	20	20	15
Pantera Retardant	71,004	51,241	577,683	536,632	562,869	2/14	3%	562,869	2,839,352	4,333	4,333	3,317
Pantera Ribbed	12,936	13,173	127,327	136,806	165,502	2/14	(23)%	165,502	924,033	955	955	731
Pantera Strawberry	46,488	32,417	336,707	293,511	313,950	2/14	7%	313,950	1,617,228	2,525	2,525	1,934
Pantera Tachas	14,385	13,258	127,324	130,508	147,059	9/16	(13)%	147,059	483,964	955	955	731
Pantera Tutti Frutti	19,878	24,145	216,013	216,466	219,685	9/16	(2)%	219,685	701,627	1,620	1,620	1,240
Pantera XL	2,154	1	2,157	-	-		-%	-	2,157	16	16	12
Emergency Contraception	29,280	28,907	337,851	358,605	338,724		0%	338,724	3,188,727	15,203	15,203	1,071
Pronta	27,098	25,000	304,584	241,605	338,634	2/04	(10)%	338,634	3,155,370	13,706	13,706	966
Pronta1	2,182	3,907	33,267	117,000	90		36,863%	90	33,357	1,497	1,497	105
Lubricant	9,657	-	9,657	-	-		0%	-	9,657	-	-	-
Pantera sachet classic	8,485	-	8,485	-	-		-%	-	8,485	-	-	-
Pantera sachet strawberry	1,170	-	1,170	-	-		-%	-	1,170	-	-	-
Pantera tube classic	1	-	1	-	-		-%	-	1	-	-	-
Pantera tube strawberry	1	-	1	-	-		-%	-	1	-	-	-
Multivitamin	120,780	117,180	1,410,030	2,232,000	1,974,210		(29)%	1,974,210	38,419,590	7,050	-	241
VitalDia	120,780	117,180	1,410,030	2,232,000	1,974,210	11/00	(29)%	1,974,210	38,419,590	7,050	-	241
OCs	64,452	53,702	675,161	720,620	705,736		(4)%	705,736	9,035,982	40,510	40,510	3,951
Segura	61,325	49,752	627,692	690,020	667,753	4/01	(6)%	667,753	8,745,064	37,662	37,662	3,673
Segura Plus	3,127	3,950	47,469	30,600	37,983	3/11	25%	37,983	290,918	2,848	2,848	278
PSI South Africa											216,490	614,636
Condom	4,055,904	1,081,512	28,592,640	38,426,242	35,170,850		(19)%	35,170,850	432,717,483	214,431	214,431	614,000
Lovers Plus	382,608	93,696	2,702,160	4,207,083	3,350,719	6/93	(19)%	3,350,719	50,435,920	20,265	20,265	58,051
Lovers Plus C&F	-	-	137,016	2,785,260	3,238,511	1/05	(96)%	3,238,511	38,586,190	1,028	1,028	2,938

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 12
Year: 2019

	DISTRIBUTION 12/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	^(a) YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Lovers Plus C&S	516,096	95,856	2,099,736	-	-		-%	-	2,099,736	15,746	15,746	45,190
Lovers Plus Climax Delay	95,112	(24,600)	304,776	-	-		-%	-	304,776	2,285	2,285	6,663
Lovers Plus Extra Play	-	-	63,072	831,317	610,748	3/16	(90)%	610,748	3,790,718	473	473	1,352
Lovers Plus R&S	339,552	85,512	1,799,928	2,282,405	2,216,556	11/12	(19)%	2,216,556	24,576,437	13,498	13,498	38,527
Lovers Plus UltraThin	131,616	(65,496)	318,384	429,981	634,392		(50)%	634,392	952,776	2,387	2,387	7,022
Trust	649,800	259,392	8,278,344	15,041,017	9,253,073	5/01	(11)%	9,253,073	148,642,176	62,085	62,085	177,107
Trust Extra C&S	162,432	48,648	720,648	865,152	705,528		2%	705,528	1,426,176	5,404	5,404	15,311
Trust Extra Thin	207,648	73,464	1,090,224	1,049,252	692,496		57%	692,496	1,782,720	8,176	8,176	23,362
Trust Studded	1,571,040	515,040	11,078,352	10,934,775	14,468,827		(23)%	14,468,827	160,119,858	83,082	83,082	238,477
Emergency Contraception	9,389	6,697	45,629	287,425	3,000		1421%	3,000	48,629	2,053	2,053	635
Escapelle	9,389	-	9,389	-	-		-%	-	9,389	423	423	68
Pronta1	-	6,697	36,240	287,425	3,000		1,108%	3,000	39,240	1,631	1,631	566
Lubricant	13,584	552	39,552	93,942	37,944		4%	37,944	163,920	-	-	-
Lovers Plus Lube Natural (100mL)	13,008	536	35,064	93,942	37,944	1/13	(8)%	37,944	159,432	-	-	-
Lovers Plus Lubricant 2-in-1, 100 ml tube	96	4	1,068	-	-		-%	-	1,068	-	-	-
Lovers Plus Lubricant Strawberry, 100 ml tube	240	8	2,220	-	-		-%	-	2,220	-	-	-
Lovers Plus Lubricant Warming, 100 ml tube	240	4	1,200	-	-		-%	-	1,200	-	-	-
OCs	99	-	99	-	-		0%	-	99	6	6	1
Novynette	99	-	99	-	-		-%	-	99	6	6	1

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.